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 Prostate cancer is the most frequently diagnosed cancer among American men, 
and is second only to lung cancer in malignancy-related deaths. In Singapore, it is 
now the third commonest malignancy among all men. Current diagnostic tools are not 
powerful enough to accurately predict the clinical outcome, and more biomarkers are 
in need to warrant better prediction and treatment plans for each patient. In addition, 
understanding the complexities of this disease at a molecular level may aid in the 
identification and subsequent development of potential therapeutics.  
Glycosaminoglycans and proteoglycans have been found to be important 
regulators of cellular growth and metastasis. In this study, the expression of 
chondroitin sulphate (CS) and heparan sulphate (HS) in prostate cancer tissues was 
determined and their possible uses as potential biomarkers of prostate cancer 
progression were explored. To search for plausible novel therapeutic targets, the 
functional implications of CS and HS synthesis enzymes that were differently 
expressed in prostate cancer were identified and determined. 
 Genome-wide expression profiling of six prostate adenocarcinoma tissues 
compared to six benign hyperplasia tissues was performed. It was found that 
CSGalNAcT-1, HS3ST3A1 and HS6ST2 were differentially expressed in prostate 
cancer. Immunohistochemistry was also performed and it was found that CS was 
upregulated in prostate cancer and high CS expression augurs poor prognosis.  
 Since CSGalNAcT-1, a gene involved in chondroitin sulphate/dermatan 
sulphate synthesis, is upregulated in both prostate cancer tissues and prostate cancer 
cell lines, as compared to their benign counterparts, this gene was silenced in PC-3 
prostate cancer cells. The upregulation of this gene could possibly explain the 





immunohistochemistry. Silencing CSGalNAcT-1 inhibited cell proliferation and 
invasion, and promoted apoptosis via suppression of MAPRE-1, TPX2 and HIPK3. 
These results point to a potential role of CSGalNAcT-1 and chondroitin sulphate as a 
novel therapeutic target.       
 Immunohistochemistry was also performed using monoclonal 10E4 that 
recognizes mixed HS domains containing N-acetylated and N-sulphated disaccharide 
units. 10E4-specific heparan sulphate epitopes were not found to be differentially 
expressed in the prostate adenocarcinoma tissues as compared to the benign 
hyperplastic prostate tissues. However, strong 10E4 staining in the prostate cancer 
cells is associated with higher clinical stage.  
 HS3ST3A1 and HS6ST2, both heparan sulphotransferases, were downregulated 
in prostate cancer and silencing either of these genes in normal prostate epithelial cell, 
RWPE-1, led to growth inhibition and reduced motility. These indicated the 
importance of HS3ST3A1 and HS6ST2 in normal prostate cell physiology, but perhaps 
suggested these genes to demonstrate different roles after the acquisition of tumour 
cell characteristics.  
On the whole, my findings reiterated the importance of CS and HS in cellular 
growth and behaviour, and essentially, suggested CS to be a promising biomarker of 
prostate cancer progression and established the role of CSGalNAcT-1 as a pro-tumour 
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Chapter 1  
 Introduction 
1.1 Prostate Gland and Prostate Cancer   
1.1.1 The Anatomy of the Prostate Gland 
The prostate gland is composed of a large series of independently branching ducts, 
all of which open into the prostatic urethra that the prostate gland surrounds. The 
somewhat conical-shaped prostate has a base, which lies against the bladder neck 
situated above the gland and also has an apex, which lies against the urogenital 
diaphragm below. Located superiorly to the prostate base are the seminal vesicles. 
The seminal vesicles join the vas deferens on each side to form the ejaculatory ducts. 
The two ejaculatory ducts penetrate the upper part of the posterior surface of the 
prostate to join the prostatic urethra at the verumontanum [Snell RS, 2008].  
Traditionally, the topography of prostatic disorders is related to prostate lobes 
[Lowsley O, 1912; Hammerich et al, 2009]. The prostate is incompletely divided into 
five lobes: anterior lobe, median lobe, posterior lobe, right lateral lobe and left lateral 
lobe. The non-glandular anterior lobe lies in front of the urethra while the glandular-
rich median lobe is situated between the urethra and the ejaculatory ducts. The 
posterior lobe sits behind the urethra and below the ejaculatory ducts; glands are also 
present in the posterior lobe. On the sides of the urethra lie the right and left lateral 
lobes of the prostate, in which there are many glands present. This lobular system was 
used even though there was no distinct lobes observable in human. Subsequently, 
McNeal established the current and most widely accepted concept of the zonal 
anatomy of the prostate [McNeal et al, 1980 & 1988].  
The zonal anatomy of the prostate includes a peripheral zone, a central zone, a 





all of the prostatic glandular tissue at the apex and the tissue located posteriorly near 
the capsule; the central zone is a cone-shaped area of the adult gland, extending from 
the apex of the cone at the confluence of the ejaculatory ducts and the prostatic 
urethra at the verumontanum. The transition zone consists of 2 equal portions of 
glandular tissue lateral to the urethra in the mid gland. The anterior fibromuscular 
stroma extends downward from the bladder neck over the anteromedial surface of the 
prostate, narrowing to join the urethra at the prostate apex. The apical half of the 
anterior fibromuscular stroma consists of striated muscles that blend into the glands 
and the muscles of the pelvic diaphragm while towards the base, there are more 
smooth muscle cells which blend into the fibres of the bladder neck [McNeal JE, 
1972].  
These zones of the prostate are usually associated with certain pathology of the 
prostate; prostate carcinoma and inflammation usually occurs in the peripheral region 
while the transition zone is involved in benign prostatic hyperplasia (BPH) and less 
commonly, prostate adenocarcinoma. The central zone is resistant to both carcinoma 
and inflammation [Hammerich et al, 2009].  
The prostatic capsule mainly consists of smooth muscle fibres and collagenous 
tissues, where the relative and absolute amounts of fibrous and muscular tissue vary 
from area to area; there is no clear separation between the periacinar smooth muscle 
and the smooth muscle at the inner capsular border. In addition, the distance of the 
terminal acini to the prostate surface is highly variable at different areas within the 
same prostate. Even more so, there is inconsistency in the proportion and arrangement 
of the collagenous tissue at different areas of the same prostate. As a result, the 
prostate capsule cannot be regarded as a well defined anatomical structure. In 





with perforation through the capsule surface may be related to prognosis in prostate 
carcinoma [McNeal JE, 1990]. There is a defect in the capsule anteriorly and 
anterolaterally at the apex; the distal fibres of the anterior fibromuscular stroma and 
the striated sphincter together often mingle with the prostatic glandular tissue 
anterolateral to the urethra; the relative extent of these tissues vary considerably inter-
individually. As a result, it is hard to determine the extent of invasion if carcinoma of 
the prostate apex invades anteriorly [Ayala et al, 1989].  
The prostate receives its blood supply from the inferior vesical and middle rectal 
arteries. Veins of the prostate form the prostatic venous plexus which also receives the 
deep dorsal vein of the penis and numerous vesical veins. The plexus drains into the 
internal iliac nodes [Brooks JD, 2007].  
Innervation of the prostate gland is accomplished by two neurovascular bundles 
located posterolaterally adjacent to the gland. The prostate receive sympathetic and 
parasympathetic innervations from the peripheral hypogastric ganglion, and the 
hypogastric and pelvic nerves respectively. Prostate stroma consists of both 
cholinergic and noradrenergic fibres while the smooth muscle of the capsule and the 
space around the blood vessels consist of cholinergic nerves which helps the secretory 
function of the epithelial part. During ejaculation, excitation of the sympathetic nerves 
closes the bladder neck and assists in the discharge of the seminal fluid into the 
urethra [Snell RS, 2008]. 
1.1.2 Functions of the prostate gland 
The secretory glandular cells synthesize and secrete prostate specific antigen 
(PSA), citric acid, spermine, prostate-specific acid phosphatase (PAP) into the 
glandular lumen, contributing 20% to 25% of the ejaculate volume [Veltri and 





glands responsible for the secretions of the semen too. Also, this prostatic secretion is 
alkaline and helps neutralize the acidity in the vagina.  
1.1.3 The Histology and Histopathology of the Prostate Gland  
1.1.3.1 Normal Prostate Histology 
The architecture of the normal prostate consists of branched ducts embedded in a 
mixture of smooth muscle and connective tissue. The glandular epithelium, resting on 
a thin basement membrane, consists of two cell layers: a luminal secretory columnar 
cell layer and an underlying flattened cuboidal basal cell layer. The stroma of the 
prostate gland consists of fibroblasts, smooth muscles, blood vessels and nerve cells.  
Corpora amylacea, composed largely of protein and nucleic acid that are formed 
from desquamated epithelial cells, can be found in the lumen of the prostatic glands. 
They are oftenly seen as concentric lamellae which also consists of inspissated 
prostatic secretions that accumulate because of partial ductal obstruction. These may 
further block the ducts with dilatation and further inspissations of secretions, resulting 
in inflammation and subsequent deposition of calcium salts to form 
microcalcifications [Moore and Hanzel, 1936].  
1.1.3.2 Histopathology of Benign Prostatic Hyperplasia (BPH)  
BPH, also known as nodular hyperplasia, is the benign enlargement of the 
prostate usually occurring in older men. The prostatic stromal and epithelial cells 
undergo uncontrolled proliferation, leading to large nodules formation in the 
periurethral region of the prostate. Consequently, this may lead to compression of the 
urethra resulting in urinary obstruction, dysuria and increased risk of urinary retention 
and infection. Absence of cytologic atypia is observed, with the basal cell layer still 





nodules and normal prostate are not significantly different [Mao et al, 1965; Fisher 
and Jeffrey, 1965]. Nodular expansion is more readily apparent macroscopically, 
where the gross appearance is that of well–defined clustered nodules with variable 
cystic and solid compositions [Petersen et al, 2009].  
1.1.3.3 Histopathology of Prostatic Intraepithelial Neoplasia (PIN) 
PIN refers to the pre-invasive stage of the uncontrolled proliferation of the 
prostatic ducts and acini. PIN can be classified into low grade PIN (LGPIN) and high 
grade PIN (HGPIN), based on the cytologic characteristics of the cell [Petersen et al, 
2009]. Histologic features of LGPIN include intact basal cell layer, enlarged nuclei of 
variable sizes, normal or slightly increased chromatin content and presence of small 
or inconspicuous nucleoli. In HGPIN, there is enlargement of nuclei with uniform 
sizes, prominent nucleoli, increased chromatin content and disruptions in the basal 
cell layer. HGPIN has been linked as the pre-malignant precursor to prostate cancer in 
many morphologic, immunohistochemical, molecular and genetic studies. HGPIN has 
been found in higher frequencies in prostate with cancers than prostates without 
cancer. The value of HGPIN is that it serves as a strong predictive marker of 
adenocarcinoma, and that its presence in biopsy specimens necessitates further search 
for invasive carcinoma [Petersen et al, 2009].  
1.1.3.4 Histopathology of Prostate Adenocarcinoma 
Prostate adenocarcinoma is the malignant transformation of the epithelial cells 
lining the prostate glands. The microscopic features of prostate adenocarcinoma are 
seen both architecturally and cytologically, as shown in Table 1.1. The light 
microscopic features are usually sufficient for diagnosis of prostate cancer, but in 





high molecular weight keratin (36βE12) and p63, could prove the presence of prostate 
adenocarcinoma more definitively in suspicious foci [Montironi et al, 2007]. PSA is 
useful in distinguishing high grade prostate cancer from other prostate diseases like 
granulomatous prostatitis and other cancers such as urothelial cancer, colon cancer 
and lymphoma. It is also useful in identifying prostate tumour origin in metastatic 
sites [Petersen et al, 2009]. In suspicious foci, positively stained basal cell layer with 
36βE12 or p63 could confirm the non-malignancy of the foci (as adenocarcinoma 
cells have a lack of basal cell layer); the diagnosis of malignancy should be based also 
on architectural and cytological features. 
 
Table 1.1 Histology of prostate adenocarcinoma tissues 
Architectural features Cytologic features 
• Infiltrative pattern • Nuclear enlargement 
• Irregular and haphazard arrangement • Prominent nucleoli 
• Variation in spacing between acini • Mitotic figures 
• Variation in acini sizes • Nuclear hyperchromasia 
• Irregular contour  
• Absent basal cell layer  
 
1.1.4  Clinical symptoms and diagnosis of prostate cancer 
Most prostate cancer cases are asymptomatic, and are detected by digital rectal 
examination. If symptoms do present, they include urinary problems such as dysuria, 
urinary obstruction, erectile difficulties, hematuria and frequent pain in the lower 
back, hips, or upper thighs. However, other disease conditions such as benign prostate 
hyperplasia (BPH) can also be presented with such symptoms.  
In addition, laboratory test like prostate specific antigen (PSA) test are available 
for prostate cancer diagnosis and early prostate cancer detection. PSA is found 





However, both benign prostatic hyperplasia (BPH) and prostate adenocarcinoma 
conditions can result in elevated PSA levels, thus limiting its use as a good diagnostic 
and prognostic marker. Nevertheless, PSA screening is still widely used as it 
highlights a diseased condition that warrants further investigation, and enables early 
detection of prostate cancer [Diamandis EP, 2000].  
Prostate biopsies are often necessary for the diagnosis of prostate cancer. The 
current standard method for detection is by transrectal ultrasound guided core biopsies 
(TRUS) while transurethral resection of the prostate (TURP) can also be performed. 
Microscopic features of the prostate biopsy tissue are then analyzed to confirm the 
diagnosis of prostate cancer [Montironi et al, 2007].  
1.1.5 Gleason grading of prostate cancer   
The Gleason grading system of prostate cancer which is based on pattern of 
glandular growth and differentiation is divided into 5 grades [Gleason DF, 1966] 
(Table 1.2). The Gleason sum, obtained from the addition of the primary grade 
(dominant pattern) and the secondary grade (second most prevalent pattern), remains 
one of the most significant prognostic markers of prostate cancer [Bostwick DG, 
1994].   
 
Table 1.2 Features of prostate cancer tissues with different Gleason grades 
Gleason grade Features 
Grade 1 single, separate, closely packed acini 
Grade 2 single, more loosely arranged, less uniformed acini 
Grade 3 single acini of variable size and separation, cribriform and papillary 
patterns 
Grade 4 irregular masses of acini and fused epithelium, presence of clear 
cells 
Grade 5 almost complete loss of glandular lumen; epithelium are in solid 






1.1.6 Prognostic markers for prostate cancer 
Gleason sum is one of the most powerful predictor of progression; patients 
with Gleason sum 5-6 are cured after radical prostatectomy while those with Gleason 
sum of 8-10 have highly aggressive tumours with advanced stage. In these patients, 
more aggressive treatment is required [Epstein et al, 2005; Mian et al, 2002].  
The TNM staging system, as recommended by the American Joint Committee 
on Cancer (AJCC) and International Union Against Cancer (IUAC), assesses the 
cancer according to the tumour features (T), regional lymph node metastasis (N) and 
distant metastasis (M). Clinical classification (cTNM) is carried out during initial 
evaluation of patient or when pathologic classification is not possible. Pathological 
classification (pTNM) is based on gross and microscopic examination (Table 1.3).  
Extent of local invasion includes extraprostatic extension and seminal vesicle 
involvement. Seminal vesicle involvement is defined as cancer invading into the 
muscular coat of the seminal vesicle. Extraprostatic extension is the presence of 
cancer cells in extraprostatic fat tissue. 
Positive surgical margins are indicated when cancer cells are found at the 
margins of the resected prostate. Presence of cancer cells at surgical margins could 
indicate that not all cancer cells are surgically removed and there may be residual 
cancer cells left in the patient. Surgical margin positivity has been significantly 
associated with increased risk of progression as compared to those with negative 









Table 1.3 Prostate cancer - TNM staging (AJCC/IUAC) 
Primary tumour, pathologic (pT) Regional lymph nodes (N) 
pT2 - Organ confined NX - Regional lymph nodes cannot be assessed 
pT2a - Unilateral N0 - No regional lymph node metastasis 
pT2b - Bilateral N1 - Metastasis in regional lymph node or nodes 
pT3 - Extraprostatic extension Distant metastasis (M) 
pT3a - Extraprostatic extension MX - Distant metastasis cannot be assessed 
pT3b -  Seminal vesicle invasion M0 - No distant metastasis 
pT4 - Invasion of bladder, rectum M1-  Distant metastasis 
*No pT1 stage in pT staging 
 
Primary tumour (T), Clinical 
TX - Primary tumour cannot be assessed 
T0 - No evidence of primary tumour 
T1 - Clinically inapparent tumour not palpable or visible by imaging 
T1a - Tumour incidental histologic finding in 5% or less of tissue resected 
T1b - Tumour incidental histologic finding in more than 5% of tissue resected 
T1c - Tumour identified by needle biopsy (e.g. because of elevated PSA) 
T2 - Palpable tumour confined within prostate 
T2a - Tumour involves one lobe 
T2b - Tumour involves both lobes 
T3 - Tumour extends through the prostatic capsule 
T3a - Extracapsular extension (unilateral or bilateral) 
T3b - Tumour invades seminal vesicle(s) 
T4 - Tumour is fixed or invades adjacent structures other than seminal vesicles, e.g bladder 
 
Perineural invasion is present when prostate cancer cells are seen adjacent or 
within a nerve. It has been found to correlate with extraprostatic extension and 
recently, reported to be an important predictor of lymph node metastasis [Quinn et al, 
2003; Vargas et al, 1999].  
Lymphovascular invasion is the presence of cancer cells within endothelial-
lined spaces; vascular and lymphatic channels are difficult to differentiate and there is 
also lack of reproducibility among different observers by light microscopic 
examination. It has been found to correlate with lymph node metastasis, biochemical 
recurrence and distant metastasis [Shariat et al, 2004]. 
 The natural history of prostate carcinoma is complex and not fully understood. 





others. Better prognostic markers that can stratify the different types of prostate 
cancer will be helpful. One way is to identify molecular biomarkers that can 
differentiate between quiescent cancers and aggressive ones. In fact, there is immense 
research in finding new molecular markers for prostate cancer, such as several recent 
studies reporting on the use of Pin1, Akt-1 and cyclin D1 as predictive factors of 
clinical outcome in prostate cancer [Ayala et al, 2003; Le Page et al, 2006; Drobnjak 
et al, 2000]. 
1.1.7 Treatment   
Various treatment options are available for prostate cancer such as active 
surveillance, surgery, radiation therapy, hormone therapy and chemotherapy. 
Treatment plan for each patient usually depends on various factors, such as age, 
Gleason grade, cancer stage, symptoms and health status of individual.  
For patients with early stage prostate cancer that appears to be slow growing, 
active surveillance (watchful waiting) may appear to be a ‘treatment plan’ if the risks 
and side effects of other treatments appear to outweigh the benefits; such scenarios 
could include very old age or implications from other serious health problems.  
Radical prostatectomy which includes open radical retropubic prostatectomy 
(RRP) (entire prostate removed through a cut in abdomen), open radical perineal 
prostatectomy (RPP) (entire prostate removed through a cut between scrotum and 
anus), laparoscopic prostatectomy (entire prostate removed through small cuts made 
in abdomen, using a laparoscope) and robotic laparoscopic surgery, remains the ‘gold 
standard’ for treatment of localized prostate cancer [Catalona and Han, 2007]. For 
patients with advanced cancer, transurethral resection of the prostate (TURP) can be 





Radiation therapy and/or hormone therapy can be performed for any stage of 
prostate cancer. Radiation therapy consists of external beam radiation therapy and 
internal beam radiation therapy (brachytherapy) [Catalona and Han, 2007]. Radiation 
therapy makes use of high energy waves that can damage the DNA of cells and 
focuses that energy onto targeted cancer cells. Briefly, external beam radiation 
accelerates electrons to generate waves of high energy photon radiation while 
brachytherapy involves planting radioactive substances in the prostate to eliminate the 
cancer cells over a period of time.  
Hormone therapy involves the use of drugs that will deprive the prostate 
cancer of androgens like testosterone, which the cancer cells are dependent on for 
growth. Anti-androgen drugs include flutamide and bicalutamide. Gonadotrophin-
releasing hormone agonists such as leuprolide, goserelin, triptorelin can also inhibit 
testosterone production in the testicles. Ketoconazole prevents testosterone production 
in the adrenal gland. Sometimes, orchiectomy (surgery to remove testicles) is also 
performed [Nelson JB, 2007]. These measures aim to limit testosterone supply to the 
prostate so as to curb the growth of the prostate cancer cells. However, prostate cancer 
cells could eventually progress to be androgen-independent and will continue to grow 
and spread, resulting in hormone therapy failure. This is commonly seen during the 
advanced stages of prostate cancer and is known as hormone refractory prostate 
cancer.  
Chemotherapy may be used for hormone refractory prostate cancer. Docetaxel, 
a drug that disrupts microtubules and induces apoptosis, is currently the standard of 
care for metastatic hormone-refractory prostate cancer [Hadaschik and Gleave, 2007]. 






1.1.8  Current Challenges in Prostate Cancer 
Carcinoma of the prostate is the most frequently diagnosed cancer among 
American men, and is second only to lung cancer in malignancy-related deaths. 
[Jemal et al, 2009] While comparatively less common in Asian populations [Hsing et 
al, 2000] prostate cancer has seen a rise of 118% from 6.6 to 14.4 per 100000 person-
years among Chinese men in Singapore [Sim and Cheng, 2005], where it is now the 
3rd commonest malignancy among all Singapore men [Seow et al, 2009]. PSA 
detection, digital rectal examination and transrectal ultrasonography are current 
procedures used in the initial diagnosis of prostate cancer, and they are not specific to 
and cannot confirm prostate cancer diagnosis. Moreover, heterogeneity in disease 
manifestations of prostate cancer, in which some prostate cancers remain latent while 
others may progress to clinically significant metastatic forms poses a huge prognostic 
and treatment challenge. It remains a clinical challenge to decide treatment plans for 
prostate cancer patients, so as to ensure that there is no over-treatment for those 
whose cancer will not become life threatening, nor to under-treat aggressive cancers 
with conservative treatment [Yao and Lu-Yao, 2002]. More biomarkers are in need to 
warrant better prediction and treatment plans for each patient. In addition, 
understanding the complexities of this disease at a molecular level may aid in the 
identification and subsequent development of potential therapeutics for localized and 
metastatic prostate cancer.  
 
1.1.9 Genome-wide expression profiling of prostate cancer  
Genome-wide expression profiling is a high throughput method that generates 
comprehensive descriptions of the transcriptional state of cancer cells and allows the 





addition, such distinct gene signatures may allow the classification of different 
tumours into different tumour subtypes, which could potentially have prognostic 
values. For example, the use of gene expression profiling has been used to demarcate 
various breast tumours into clinically relevant groups based on their molecular profile. 
Perou and co-workers revealed that breast tumours could be clearly delineated into 4 
distinct subgroups: luminal, normal breast-like, human epidermal growth factor 
receptor 2 (Her2) and basal-like [Perou et al, 2000]. Notably, this classification of 
breast cancer has key clinical implications, where it has been associated with 
significantly different clinical outcomes. Luminal tumours tend to have better 
prognosis than Her2/basal-like breast carcinomas. [Sørlie et al, 2001 and 2003; 
Sotiriou et al, 2003] This has driven much research into the potential use of such 
classification in a clinical setting. For instance, immunohistochemical surrogates have 
been actively investigated to replace the high cost and expertise required for the 
microarray profiling.  
In prostate cancer, many microarray studies have been previously performed in 
different populations, albeit using different platforms [Welsh et al, 2001; 
Dhanasekaran et al, 2001; Luo et al, 2001; Lapointe et al, 2004; Chandran et al, 
2005]. Several genes have been commonly observed to be differentially expressed 
across different microarray datasets, such as AMACR, HPN and FASN. The 
identification of some of these genes in microarray studies has led to their use as 
potential diagnostic markers. AMACR is an enzyme that plays important roles in the 
peroxisomal and mitochondrial β-oxidation pathways [Lloyd et al, 2008] and was 
upregulated in malignant prostate tissues. AMACR protein analysis, in combination 
with the basal cell marker p63, has become a useful immunohistochemical aid in the 





In addition, Lapointe et al has identified three classes of prostate tumours based on 
their distinct gene signature that was profiled through microarray studies. Subtype I 
prostate tumours is the clinically least aggressive subclass while subtype II and III 
represent the clinically aggressive tumour classes. Notably, subtype III tumours share 
features of gene expression with lymph node metastases. MUC1, encoding mucin 1 
transmembrane protein, is a gene highly expressed in subgroup II and III. MUC1 was 
found to associate with higher recurrence risk. On the contrary, AZGP1 encoding 
zinc-α-2-glycoprotein, characterized subtype I tumours and was associated with 
longer time to recurrence [Lapointe et al, 2004]. These data demonstrated the 
potential utility and benefits expression profiling can offer, where identification of 
distinct gene signatures and candidate genes may provide a basis for improved 
prognostication and treatment stratifications. 
1.2 Glycosaminoglycans (GAG) and Proteoglycans (PG) – An introduction 
1.2.1 Structure  
Glycosaminoglycans are unbranched polysaccharides composed of repeating 
units of alternating amino sugars and uronic acid. Heparan sulphate, heparin, 
chondroitin sulphate, dermatan sulphate, keratan sulphate and hyaluronan are 
different types of glycosaminoglycans. Different glycosaminoglycans (except 
hyaluronan) are found attached to different core proteins, giving rise to structurally 
diverse molecular entities known as proteoglycans. Glycosaminoglycans are usually 
attached to a serine residue in a core protein through a tetrasaccharide linkage region 
made up of xylose-galactose-galactose-glucuronic acid [Yip et al, 2006] (Figure 1.1). 
Chondroitin sulphate (CS) and dermatan sulphate (DS) are composed of 
repeating disaccharide units of N-acetyl-D-galactosamine (GalNAc) and uronic acid. 





glucuronic acid (GlcA) while in dermatan sulphate, epimerization of the C5 position 
of the uronic acid moiety results in a mixture of α-L-iduronic acid (IdoA) and GlcA 
[Yip et al, 2006]. Sulphate modifications frequently occur at various positions of the 
CS and DS sugar chains; O-sulphation can occur at the C4 and/or C6 position of 
GalNAc and/or C2 position of GlcA and IduA [Kusche-Gullberg and Kjellén, 2003].  
Heparan sulphate / heparin are composed of repeating disaccharide units of N-
acetyl-D-glucosamine (GlcNAc) and uronic acid (glucuronic acid or iduronic acid) 
(Figure 1.2C). Heparan sulphate/heparin are modified at several positions; the first 
being the N-deacetylation and N-sulphation of the GlcNAc, which is the prerequisite 
for all other modifications such as C5-epimerization of glucuronic acid to iduronic 
acid, sulphate modifications at C2 position of the uronic acids, 6-O-sulphation and 3-
O-sulphation of the C6 and C3 positions of the glucosamine residues respectively 
[Carlsson et al, 2008].   
The classification of proteoglycans can be on the basis of their location 
(cellular surface, extracellular matrix or basement membrane), GAG-chain 
composition and amino acid homology of their core protein. GAG representations on 
protein cores are not necessarily homogenous; different GAG types can be found on 
one protein core and the number of GAGs attached to each protein core could differ. 
For example, syndecan-1, a cell-surface proteoglycan, consists of heparan sulphate 
and chondroitin sulphate chains. Table 1.4 shows a list of proteoglycans classified 
accordingly to location, namely, cell surface proteoglycans and extracellular matrix 
proteoglycans, as compiled in the Kyoto Encyclopedia of Genome and Genes 





Figure 1.1 Structure of proteoglycans and glycosaminoglycans 
 
Figure 1.2 Structure of glycosaminoglycans. [A] CS [B] DS [C] HS/heparin. The 





Table 1.4  List of proteoglycans, classified according to location. 
Gene Symbol Proteoglycan name Types of GAG 
on proteoglycan 
Cell surface proteoglycans 
Syndecan family (transmembrane HSPG) 
SDC1 syndecan 1 HS / CS  
SDC2 syndecan 2 (fibroglycan) HS 
SDC3 syndecan 3 (N-syndecan) HS 
SDC4 syndecan 4 (amphiglycan, ryudocan) HS / CS 
   
Glypican family (GPI-anchored HSPG) 
GPC1  glypican 1 HS 
GPC2  glypican 2 (cerebroglycan) HS 
GPC3  glypican 3 (OCI-5) HS 
GPC4  glypican 4 (K-glypican) HS  
GPC5  glypican 5 HS / CS 
GPC6  glypican 6 HS 
   
Others 
PTPRZ protein tyrosine phosphatase, receptor-
type, Z polypeptide 
CS / KS 
TGFBR3  transforming growth factor, beta 
receptor III 
HS / CS 
CSPG4 chondroitin sulphate proteoglycan 4 CS 
CSPG5  chondroitin sulphate proteoglycan 5 
(neuroglycan C) 
CS 
CD44  CD44 antigen CS / DS 
APP amyloid beta (A4) precursor protein 
(protease nexin-II, Alzheimer disease) 
CS 
   
Extracellular matrix (ECM) proteoglycans 
Small leucine-rich proteoglycan (SLRP) family 
Class I   
BGN biglycan CS / DS 
DCN decorin CS / DS 
Class II   
FMOD fibromodulin KS 
LUM lumican KS 
KERA keratocan KS  
OMD osteomodulin KS 
Class III   
OGN osteoglycin (osteoinductive factor, 
mimecan) 
KS 
DSPG3 dermatan sulphate proteoglycan 3 
(epiphycan) 
CS / DS 
 
Aggrecan/Versican family 
AGC1, CSPG1 aggrecan 1 CS / KS 






NCAN chondroitin sulphate proteoglycan 3 
(neurocan) 
CS 
BCAN brevican CS 
 
Basement membrane proteoglycans  
HSPG2 heparan sulphate proteoglycan 2 
(perlecan) 
HS / CS 
AGRN agrin HS 
COL18A collagen, type XVIII, alpha HS 
SMC3 (CSPG6) structural maintenance of chromosome 
3 (chondroitin sulphate proteoglycan 6)
CS 
LEPRE leucine proline-enriched proteoglycan 
(leprecan) 
CS 
COL15A collagen, type XV, alpha CS 
   
Others   
SRGN serglycin Heparin / CS 
SPOCK1 sparc / osteonectin, cwcv and kazal-
like domeins 
CS / HS 
SPOCK2 sparc / osteonectin, cwcv and kazal-
like domeins 





1.2.2 Biosynthesis of chondroitin sulphate/dermatan sulphate and heparan 
sulphate  
With such a diverse structural repertoire of the glycosaminoglycans, many 
biosynthetic enzymes are co-ordinately involved in the generation of these chains. A 
summary of all genes involved in the synthesis of CS/DS and HS is shown in Table 
1.5. Briefly, the common tetrasaccharide linkage is first synthesised by the addition of 
xylose to the serine residue via Xylotransferases 1 (Xyl1) and Xylotransferases 2 
(Xyl2) [Götting et al, 2000]. Two subsequent galactoses are added sequentially to the 
xylose via the action of 2 different galactosyltransferases coded by Xylosylprotein 
beta 1,4-galactosyltransferase, polypeptide 7 (galactosyltransferase I) (B4GalT7) 
[Almeida et al, 1999] and UDP-Gal:betaGal beta 1,3-galactosyltransferase 
polypeptide 6 (B3GalT6) [Bai et al, 2001] respectively. The glucuronic acid is added 
via glucuronyltransferase I coded by Beta-1,3-glucuronyltransferase 3 (B3GAT3) 
[Kitagawa et al, 1998].  
The addition of a galactosamine to the linkage region via Chondroitin sulphate 
N-acetylgalactosaminyltransferase 1 (CSGalNAcT-1) will thus initiate the synthesis of 
the CS/DS instead of HS/heparin [Uyama et al, 2002; Gotoh et al, 2002; Sato et al, 
2003]. The subsequent polymerisation of the CS/DS chain is aided by the 
galactosaminyltransferases and glucuronyltransferases, Chondroitin sulphate N-
acetylgalactosaminyltransferase 2 (CSGalNAcT-2) [Sato et al, 2003; Uyama et al, 
2003], Chondroitin synthase I (CHSY1) [Kitagawa et al, 2001], Chondroitin synthase 
3 (CHSY3) [Yada et al, 2003], Chondroitin polymerising factor (CHPF) [Kitagawa et 
al, 2003] and Chondroitin sulphate glucuronyltransferase (CSGlcAT) [Gotoh et al, 
2002; Izumikawa et al, 2008]. Epimerisation of glucuronic acid to iduronic acid is 





Sulphate modifications to the CS/DS chain are added via the different 
sulphotransferases, Carbohydrate (chondroitin 4) sulphotransferase 13 (CHST13 
/C4ST1) [Yamauchi et al, 2000; Hiraoka et al, 2000], Carbohydrate (chondroitin 4) 
sulphotransferase 11 (CHST11/C4ST2) [Hiraoka et al, 2000]  , Carbohydrate 
(chondroitin 4) sulphotransferase 12 (CHST12/C4ST3) [Kang et al, 2002], 
Carbohydrate (N-acetylglucosamine 6-O) sulphotransferase 7 (CHST7/C6ST1) 
[Fukuta et al, 1998], Carbohydrate (chondroitin 6) sulphotransferase 3 
(CHST3/C6ST2) [Kitagawa et al, 2000], B cell RAG associated protein (GalNAcT4S-
6ST) [Ohtake et al, 2001], Carbohydrate (N-acetylgalactosamine 4-0) 
sulphotransferase 14 (CHST14/D4ST1) [Evers et al, 2001] and Uronyl-2-
sulphotransferase (UST) [Kobayashi et al, 1999]. 
The transfer of GlcNAc by N-acetyl-glucosaminyltransferase I (GlcNAcT-I) to 
the tetrasaccharide linkage region will initiate heparan sulphate/heparin formation. 
This GlcNAcT-I reaction is catalysed by two EXT gene family members, EXTL2 and 
EXTL3 [Fritz et al, 1994; Kitagawa et al, 1999; Kim et al, 2001]. Elongation of the 
heparan sulphate/heparin chains is further performed by the N-acetyl-
glucosaminyltransferase II (GlcNAcT-II) coded by EXTL1 and EXTL3 and the 
heparan sulphate polymerases (GlcA/GlcNAc transferases) coded by EXT1 and EXT2, 
which are bifunctional enzymes that have both GlcNAcT-II and glucuronyltransferase 
activities [Lind et al, 1998; McCormick et al, 2000; Senay et al, 2000]. Following 
heparan sulphate/heparin chain elongation, HS/heparin GlcNAc N-deacetylase/N-
sulphotransferase (NDST1-4) catalyzes N-deacetylation and N-sulphation of GlcNAc 
residue of HS and heparin [Aikawa et al, 2001; Kjellén L, 2003], which are 
prerequisites for all of other modifications such as C5-epimerization of GlcA to 





uronic acids, and 6-O- and 3-O-sulphation of glucosamine residues, which are 
catalyzed by uronyl C5-epimerase (GLCE), 2-O-sulphotransferase (HS2ST1), 6-O-
sulphotransferase (HS6ST1-3), and 3-O-sulphotransferase (HS3ST1-5), respectively 





Table 1.5 Genes coding for enzymes involved in the synthesis of CSPG/DSPG and HSPG. 
Gene Gene name Function 
Tetrasaccharide Linkage Region Synthesis 
XylTI xylosyltransferase I Xylosylation of core protein 
XylTII xylosyltransferase  II Xylosylation of core protein 
B4GalT7 xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7 
(galactosyltransferase I) 
Addition of first galactose in linkage region 
B3GalT6 UDP-Gal:betaGal beta 1,3-galactosyltransferase polypeptide 6 Addition of second galactose in linkage region 
B3GAT3 beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) Transfer GlcA to linkage region 
   
Chondroitin/Dermatan Sulphate Synthesis 
CSGalNAcT-1 chondroitin sulphate N-acetylgalactosaminyltransferase 1 Initiates biosynthesis of CS/DS biosynthesis by adding the 
first GalNAc 
CSGalNAcT-2 chondroitin sulphate N-acetylgalactosaminyltransferase 2 Transfer GalNAc to growing oligosaccharide chain 
CSGLCA-T chondroitin sulphate glucuronyltransferase Transfer of GlcA to growing oligosaccharide chain 
CHPF chondroitin polymerising factor Chain polymerization: alternate addition of GlcA and 
GalNAc 
CHSY1 chondroitin synthase I Chain polymerization: alternate addition of GlcA and 
GalNAc 
CHSY3 chondroitin synthase 3 Chain polymerization: alternate addition of GlcA and 
GalNAc 
DSE, SART2 dermatan sulphate epimerase Epimerization of GlcA to IdoA 
CHST13 carbohydrate (chondroitin 4) sulphotransferase 13 Sulphates GalNAc in CS at 4-O-position 
CHST11 carbohydrate (chondroitin 4) sulphotransferase 11 Sulphates GalNAc in CS at 4-O-position 





CHST7 carbohydrate (N-acetylglucosamine 6-O) sulphotransferase 7 Sulphates GalNAc in CS at 6-O-position 
CHST3 carbohydrate (chondroitin 6) sulphotransferase 3 Sulphates GalNAc in CS at 6-O-position 
GALNAC4S-6ST B cell RAG associated protein Sulphates GalNAc4S at 6-O-position 
CHST14, D4ST1 carbohydrate (N-acetylgalactosamine 4-0) sulphotransferase 14 Sulphates GalNAc in DS at 4-O-position 
UST uronyl-2-sulphotransferase Sulphates GlcA in GlcA-GalNAc6S or IdoA in IdoA-
GalNAc or IdoA-GalNAc4S 
   
Heparan Sulphate Synthesis 
EXTL2 exostoses (multiple)-like 2 Chain polymerization: alternate addition of GlcA and 
GlcNAc 
EXTL3 exostoses (multiple)-like 3 Chain polymerization: alternate addition of GlcA and 
GlcNAc 
EXTL1 exostoses (multiple)-like 1 Chain polymerization: alternate addition of GlcA and 
GlcNAc 
EXT1 exostoses (multiple) 1 Chain polymerization: alternate addition of GlcA and 
GlcNAc 
EXT2 exostoses (multiple) 2 Chain polymerization: alternate addition of GlcA and 
GlcNAc 
NDST1 N-deacetylase/N-sulphotransferase (heparan glucosaminyl) 1 N-deacetylation and N-sulphation of GlcNAc units 
NDST2 N-deacetylase/N-sulphotransferase (heparan glucosaminyl) 2 N-deacetylation and N-sulphation of GlcNAc units 
NDST3 N-deacetylase/N-sulphotransferase (heparan glucosaminyl) 3 N-deacetylation and N-sulphation of GlcNAc units 
NDST4 N-deacetylase/N-sulphotransferase (heparan glucosaminyl) 4 N-deacetylation and N-sulphation of GlcNAc units 
GLCE glucuronic acid epimerase Epimerisation of GlcA to IdoA 
HS2ST1 heparan sulphate 2-O-sulphotransferase 1 Sulphates GlcA in HS at 2-O-position 
HS6ST1 heparan sulphate 6-O-sulphotransferase 1 Sulphates GlcNAc in HS at 6-O-position 
HS6ST2 heparan sulphate 6-O-sulphotransferase 2 Sulphates GlcNAc in HS at 6-O-position 





HS3ST1 heparan sulphate (glucosamine) 3-O-sulphotransferase 1 Sulphates GlcNAc in HS at 3-O-position 
HS3ST2 heparan sulphate (glucosamine) 3-O-sulphotransferase 2 Sulphates GlcNAc in HS at 3-O-position 
HS3ST3A1 heparan sulphate (glucosamine) 3-O-sulphotransferase 3A1 Sulphates GlcNAc in HS at 3-O-position 
HS3ST3B1 heparan sulphate (glucosamine) 3-O-sulphotransferase 3B1 Sulphates GlcNAc in HS at 3-O-position 
HS3ST5 heparan sulphate (glucosamine) 3-O-sulphotransferase 4 Sulphates GlcNAc in HS at 3-O-position 
HS3ST5 heparan sulphate (glucosamine) 3-O-sulphotransferase 5 Sulphates GlcNAc in HS at 3-O-position 
SULF1  sulphatase 1 Heparan sulphate 6-O-endosulphatases 
SULF2  sulphatase 2 Heparan sulphate 6-O-endosulphatases 
HPSE  heparanase Cleaves heparan sulphate chains 
HPSE2  heparanase 2 Cleaves heparan sulphate chains 
   
CS/HS/DS modifications 
PAPSS1  3'-phosphoadenosine 5'-phosphosulphate synthase 1 Sulphate donor cosubstrate for all sulphotransferase 
enzymes 







1.2.3  Enzymatic remodelling of chondroitin/dermatan sulphate and heparan 
sulphate chains 
Physiologically, heparanase coded by the HPSE gene, is an endo-beta-D-
glucuronidase that can cleave heparan sulphate side chains of heparan sulphate 
proteoglycans on cell surfaces and the extracellular matrix [Nasser NJ, 2008]. The 
degradation of heparan sulphate chains by heparanase at the cell surface and in the 
extracellular matrix results in the release of bound growth factors and induces tumour 
growth and angiogenesis. Expression of heparanase in tumour cells have been found 
to correlate with increased metastatic potential [Vlodavsky et al, 2002; Ilan et al, 
2006].  
Sulphatases are heparan-6-O-endosulphatases that are found localised to the 
cell surface or secreted into the extracellular matrix, and selectively remove the 6-O-
sulphates from heparan sulphate. The heparan-6-O-endosulphatases are encoded by 
HSulf1 and HSulf2. Similarly, HSulf1 and HSulf2 have been implicated in cancer 
growth [Dai et al, 2005]. 
Microbial-derived heparan sulphate and chondroitin/dermatan sulphate lyases 
include the heparinases and the chondroitinases. Heparinases have been classified as 
heparinase I acting primarily on heparin, heparinase II acting on both heparin and 
heparan sulphate, and heparinase III, which acts exclusively on heparan sulphate 
[Ernst et al, 1995].  The chondroitinases include the chondroitinase AC (degrades 
chondroitin-4-sulphate and chondroitin-6-sulphate), chondroitinase B (degrades 
dermatan sulphate), chondroitinase C (degrades chondroitin-6-sulphate) and 
chondroitinase ABC (degrades chondroitin-4-sulphate, chondroitin-6-sulphate and 
dermatan sulphate). These enzymes are frequently used and commercially available, 





1.2.4 Functions of chondroitin/dermatan sulphate and heparan sulphate and/or 
proteoglycans in cancer  
The huge repertoire of structurally diverse chondroitin/dermatan sulphate 
proteoglycans and heparan sulphate proteoglycans is generated by different protein 
cores, post translational modifications of the protein backbone, the number and types 
of glycosaminoglycan on the protein cores and post translational modifications of the 
GAG chains.  Important biological functions of the proteoglycans derive primarily 
from those of the attached glycosaminoglycan chains, protein component of the 
molecule and/or possibly function as a whole structural entity. Different sulphate 
moieties at different positions in the GAG/PG give rise to different structural 
characteristics of the GAG/PG, leading to specific functional properties of that 
GAG/PG.  
Being ubiquitously present on the cellular surface and in the ECM and 
basement membrane, chondroitin/dermatan sulphates and heparan sulphate/heparin 
are well positioned to elicit many cell-cell, cell-ECM and cell-BM signalling events, 
regulating homeostatic cellular behaviour. Numerous biologically active molecules 
(e.g growth factors like FGF, HGF, PDGF, VEGF and chemokines) can bind to 
HSPGs, which then function as co-receptors to elicit downstream signalling. HSPGs 
can also bind to HS/heparin binding molecules, where they accumulate and 
concentrate, and are released when appropriate signalling mechanisms are detected 
[Sanderson RD, 2001]. For instance, the binding of FGF to HSPG and FGFR induces 
receptor dimerization, activation and autophosphorylation of multiple tyrosine 
residues in the cytoplasmic domain of the receptor. This leads to phosphorylation of 





proliferation, cell differentiation, cell migration and cell survival [Eswarakumar et al, 
2005].  
Chondroitin/dermatan sulphates have also been reported to be able to interact 
with various growth factors such as heparin binding growth factors like FGF-2, 
pleiotrophin and midkine, and thus play important roles in cell signaling [Delehedde 
et al, 2001]. The CSPG, protein-tyrosine phosphatase zeta (PTPzeta), is a receptor for 
midkine and pleiotrophin, and upon binding, induce downstream signalling that 
includes ERK and PI3 kinase, thus promote the growth, survival, and migration of 
various cells [Qi et al, 2001].  The DSPG, decorin, modulates epidermal growth 
factor, insulin-like growth factor signalling and thus controls cell proliferation and 
angiogenesis.  
Dysregulation of these molecules has thus important functional repercussions, 
as they could play many roles in diseases such as cancer. Indeed, many studies on the 
altered composition and structure of glycosaminoglycans and proteoglycans in 
numerous cancers such as gastric carcinoma, melanoma, rectum carcinoma, breast 
cancer, squamous cell laryngeal carcinoma and pancreatic cancer have been reported 
[Pirinen et al, 2005; Pukkila et al, 2007; Pukkila et al, 2004; Suwiwat et al, 2004; 
Voutilainen et al, 2003; Yang et al, 2004]. 
1.2.4.1 Heparan sulphate in cancer biology 
The heparan sulphate proteoglycan syndecans consist of four family members, 
syndecan 1-4. Syndecan-1 has been more widely studied; elevated expression of 
syndecan-1 has been reported in breast cancer [Loussouarn et al, 2008], gall bladder 
cancer [Roh et al, 2008] and in the extracellular matrix of ovarian tumours [Davies et 





interact with heparin-binding growth factors, such as fibroblast growth factors, in the 
stromal milieu to stimulate carcinoma development and tumour angiogenesis 
[Mundhenke et al, 2002]. 
Syndecan-1 expression in prostate adenocarcinoma cases was found to 
correlate with established features of biologically aggressive cancer such as higher 
PSA levels, higher Gleason sum and occurrence of lymph nodes metastases [Shariat 
et al, 2008; Chen et al, 2004; Kiviniemi et al, 2004). In addition, syndecan-1 
expression was also associated with significantly greater risk of PSA-progression after 
surgery [Shariat et al, 2008]. 
Glypicans, GPI-anchored cellular membrane proteoglycans, consist of 6 
family members, glypican 1-6. Glypican-1 and glypican-3 are the more widely 
reported glypicans in cancer expression and biomarker studies; glypican-1 was 
reported to be highly expressed in breast cancer [Matsuda et al, 2001], gliomas [Su et 
al, 2006], pancreatic cancer [Kleef et al, 1998], and its expression is a poor prognostic 
factor for survival. The differential expression of glypican-3 could be tissue-specific, 
as glypican-3 was found to be overexpressed in hepatocellular carcinoma [Nakatsura 
et al, 2003] and malignant melanoma [Ikuta et al, 2005] while downregulated in 
breast cancer [Xiang et al, 2001], ovarian [Lin et al, 1999] and gastric cancer [Zhu et 
al, 2002]. As a member of the HSPG family, glypican -1 and -3 can modulate the 
mitogenic effects of the heparin-binding growth factors such as FGF2 and TGFβ – 
dependent signalling. Glypican-3 has also been shown to inhibit growth and invasion 
in breast cancer cells by activating the Wnt signalling pathway [Stigliano et al, 2009]. 
However, what remains to be clarified is whether there are tissue-specific functions of 





or perhaps there could be differences in importance of glypican-3 functions in 
different cancer progression.  
Increased heparanase has also been detected in many malignant tumours like 
renal cell carcinoma [Mikami et al, 2008], endometrial cancer [Inamine et al, 2008] 
and head and neck cancers [Doweck et al, 2006], and these have been significantly 
correlated with metastatic potential. Heparanase is a heparan sulphate (HS) degrading 
endoglycosidase that regulates extracellular matrix degradation and remodelling. The 
secretion of heparanase by tumour cells will allow the malignant cells to degrade 
heparan sulphate and penetrate the basement membrane and ECM. Heparanase can 
also release bioactive cell-surface HS fragments that can stimulate cell migration and 
angiogenesis, thus contributing to aggressive cancer phenotype [Roy and Marchetti, 
2009]. Interestingly, besides enzymatically cleaving heparan sulphate chains, 
heparanase was noted to exert other biological functions. Nonenzymatic functions of 
heparanase include enhanced cell adhesion [Goldshmidt et al, 2003] and induction of 
p38 and Akt phosphorylation [Gingis-Velitski et al, 2004; Ben-Zaken et al, 2007]. In 
addition, enzymatically active and inactive heparanase were noted to induce VEGF 
expression and enhance EGFR phosphorylation, resulting in angiogenesis and 
increased cell migration and cell proliferation [Cohen-Kaplan et al, 2008]. 
Upregulation of heparanase can accelerate the shedding of syndecan-1 from the cell 
surface thus influencing the expression and localization of syndecan-1. Recently, 
Chen and Sanderson, 2009, discovered that heparanase also alters the level of nuclear 
syndecan-1 [Chen and Sanderson, 2009]. Although the function of nuclear heparan 
sulphate is not well understood, there is emerging evidence that it may act to repress 





to transcriptional expression of MMP-9, VEGF and other effectors that condition the 
tumour microenvironment to promote an aggressive cancer phenotype. 
Human prostatic adenocarcinoma cells are reported to have increased 
heparanase production due to promoter hypomethylation and upregulation of the 
transcriptional factor early growth response-1 [Ogishima et al, 2005; de Mestre et al, 
2005]. There was a strong correlation between tumour grade and heparanase 
expression. Overexpression of heparanase in PC-3 cells results in dramatic five-fold 
increase in the metastatic potential [Lerner et al, 2008]. The degradation of the 
basement membrane by heparanase could be a potential factor in its increased 
metastatic potential [Kosir et al, 1999].  
The heparin-degrading endosulphatases, SULF1 and SULF2, have also been 
reported to be differentially expressed in several cancers (ovarian, hepatocellular, 
gastric, breast cancer) [Narita et al, 2007; Lai et al, 2008b; Chen et al, 2009]. SULF1 
was found downregulated in many cancers, and was postulated to be a tumour 
suppressor gene; overexpression of SULF1 in cancer cells lead to reduced sulphation 
of the HSPGS and subsequent diminished phosphorylation of receptor tyrosine 
kinases that require sulphated HSPGs as co-receptors for their cognate ligands [Lai et 
al, 2008a]. Consequently, downstream signaling through the extracellular signal-
regulated kinase pathway is impeded and this results in reduced proliferation. In 
addition, this decreased heparin-binding growth factor signalling promotes apoptosis 
and inhibits angiogenesis. On the other hand, HSULF2 was reported to be upregulated 
in breast and hepatocellular carcinoma (HCC) [Morimoto-Tomita et al, 2005; Lai et 
al, 2008b]. Expression of SULF2 activates MAPK and Akt pathways and promotes 





Perlecan, a heparan sulphate proteoglycan found in basement membranes, is 
highly expressed in prostate cancer cell lines, including androgen insensitive cell lines 
and cell lines selected for metastatic properties [Datta et al, 2006]. Perlecan 
expression in prostate cancer tissues also correlates with high tumour grade (high 
Gleason score). Perlecan was reported to regulate prostate cell growth via the sonic 
hedgehog pathway [Datta et al, 2006], as well as activating heparin-binding growth 
factor receptors such as FGF2 and VEGF [Savorè et al, 2005]. 
1.2.4.2 Chondroitin/dermatan sulphate in cancer biology 
Structural modifications to chondroitin sulphate chains could be a means by 
which cancer cells employ in their quest to invade and spread. Highly sulphated 
chondroitin sulphate, CS-E, was found in higher proportions in highly metastatic 
Lewis lung carcinoma cells than in cells with low metastatic potential [Li et al, 2008]. 
Inhibition of the CSE epitopes strongly inhibited the invasiveness of the metastatic 
cell line. In a separate study, Sugahara et al, 2008, reported that CSE fragments 
enhance CD44 cleavage and promote CD44-mediated cell motility [Sugahara et al, 
2008]. Fthenou et al, 2006, reported the role of chondroitin sulphate A in the 
regulation of fibrosarcoma cell adhesion and motility via the JNK and tyrosine kinase 
pathways and also enhances the PDGF-mediated signalling in fibrosarcoma cells 
[Fthenou et al, 2006]. Melanoma chondroitin sulphate proteoglycan has also been 
found to enhance FAK and extracellular signal regulated signalling pathways [Yang 
et al, 2004].  
Decorin, a dermatan sulphate proteoglycan found to be downregulated in 
many cancers (e.g colon adenocarcinoma [Adany and Iozzo, 1991]; breast cancer 





angiogenesis through down-regulation of vascular endothelial growth factor 
production by cancer cell transduction [Grant et al, 2002]. In addition, decorin caused 
cell cycle arrest through mitogen-activated protein (MAPK) kinase signal pathway, 
which led to endogenous p21 activation, a potent inhibitor of cyclin-dependent 
kinases [Moscatello et al, 1998; Ständer et al, 1999]. It has also been reported that 
decorin can result in EGFR degradation by endocytosis of the EGFR, thus resulting in 
attenuation of its signaling pathway [Seidler et al, 2006]. Downregulation of decorin 
in tumours promotes malignant characteristics in tumours. 
High performance liquid chromatography analysis of glycosaminoglycans 
extracted from prostate cancer samples revealed that chondroitin-6-sulphate and 
dermatan sulphate were the predominantly upregulated components [Iida et al, 1997]. 
Moreover, elevated levels of sulphated chondroitin were reported to be associated 
with poorer disease outcome in early stage prostate cancer [Ricciardelli et al, 1997 
and 1999]. In patients with metastatic disease, chondroitin sulphate is upregulated but 
the increased expression does not predict survival. Moreover, Sakko et al, 2008, have 
recently shown the importance of non-sulphated chondroitin as an independent 
predictor of PSA relapse [Sakko et al, 2008].  
Previous studies have shown that expression of versican, a chondroitin 
sulphate proteoglycan, is increased in prostate cancer and inhibits cancer cell adhesion 
to fibronectin in the stromal matrix [Ricciardelli et al, 1998; Sakko et al, 2003]. 
Increased versican expression is also associated with increased risk of PSA relapse in 
early-stage prostate cancer [Ricciardelli et al, 1998]. TENB2, a chondroitin sulphate 
proteoglycan, has been found upregulated in prostate adenocarcinoma, with particular 





EGF and two follistatin domains in TENB2 points to a role of this CSPG in growth 
factor signalling.  
A heparan sulphate and chondroitin sulphate proteoglycan, TGFβ receptor 
type III (TGFβR3, betaglycan), was reported to have decreased expression in the 
majority of human prostate cancers as compared with benign prostate tissue at both 
the mRNA and protein level [Sharifi et al, 2007; Turley et al, 2007]. Loss of 
betaglycan expression correlates with advancing tumour stage and a higher 
probability of prostate-specific antigen (PSA) recurrence. There were decreased cell 
motility and cell invasion through Matrigel in vitro and prostate tumourigenicity in 
vivo when betaglycan was overexpressed in prostate cancer cells [Turley et al, 2007; 
Bandyopadhyay et al, 2005].  
It appears that proteoglycans play significant roles in prostate cancer cell 
behaviour and progression. However, the vast functional repertoire of different 
chondroitin sulphates, heparan sulphates and their proteoglycans in prostate cancer 
are not completely investigated and understood. Delineating specific chondroitin 
sulphate and heparan sulphate structures that are involved in prostate cancer 
progression will provide more avenues to identify potential biomarkers and 
therapeutic targets. 
1.3 Objectives of project 
 Identifying biomarkers for improved detection of aggressive prostate cancer 
will improve the management of malignancy. In addition, identification of new 
molecular targets could facilitate innovation of novel therapies that could halt 
progression of localized prostate cancer towards metastasis or that could target 





1. Establish the application of different chondroitin sulphate and heparan 
sulphate subtypes as biomarkers of prostate cancer progression, by first 
determining their expression patterns and levels in prostate cancer tissues via 
immunohistochemistry, and then further determining whether they are 
associated with current prognostic markers.  
2. Identify genes coding for chondroitin sulphate and heparan sulphate 
biosynthesis enzymes that are deregulated in prostate cancer by microarray 
profiling and real-time polymerase chain reaction, and then determine their 
functional significance in prostate cancer phenotype using silencing RNAs.  




Chapter 2   
Materials and Methods 
2.1 Genome-wide expression profiling of prostate adenocarcinoma tissues 
2.1.1 Collection of prostate adenocarcinoma tissues 
Prostate adenocarcinoma samples and control benign prostatic hyperplasia tissue 
specimens were obtained from 11 patients who underwent open radical retropubic 
prostatectomy (RRP) or transurethral resection of the prostate (TURP) from 2005 to 2006 
at the Department of Urology, Tan Tock Seng Hospital. Ethics approval was obtained 
from the Institutional Review Board, Tan Tock Seng Hospital. The tissue samples were 
snap-frozen in liquid nitrogen and stored at -80oC.  
2.1.2  Haematoxylin and eosin staining of prostate tissues 
The frozen prostate tissue sections collected (in Section 2.1.1) were sectioned using a 
cryostat. The slide sections were then fixed in 4% paraformaldehyde overnight, washed 
thrice in 1X PBS and stained in Shandon’s haematoxylin for 5 minutes. After washing in 
deionized water, the sections were immersed in differentiating fluid (70% alcohol with 
HCl), blued in tap water for 5 minutes, washed in deionized water and eosin-stained for 5 
minutes. Dehydration of the sections was done in 3 changes of absolute ethanol followed 
by 3 changes of Histoclear.  
2.1.3  RNA isolation, yield and quality from prostate tissues 
Total RNA was isolated from each prostate adenocarcinoma and benign prostatic 
hyperplasia tissue using the RNeasy Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany),




as per the manufacturer’s protocol. RNA yield was quantified using Nanodrop while 
RNA purity was determined using the absorbance ratio of A260/A280. The ratio of the 
absorbance values measured at 260nm (A260) to absorbance values measured at 280nm 
(A280) provides an estimate of RNA purity, in consideration of contaminants that absorb 
in the UV spectrum. As pH changes can affect the absorbance, the guideline is that pure 
RNA has an A260/A280 ratio of 1.9–2.1 in 10 mM Tris·Cl, pH 7.5 [Wilfinger et al, 1997]. 
RNA quality was checked using the Agilent RNA 6000 Nano Kit (Agilent Technologies 
Inc, California, United States of America) on the Agilent 2100 Bioanalyzer System. 
Quality of the RNA was assessed based on the electrophoretic trace of the RNA sample 
and the RNA integrity number (RIN). For the electrophoregram, 2 distinct peaks 
representing the 18S and 28S ribosomal subunits should be present in intact total RNA. 
The RIN is assigned through the Agilent Bioanalyzer, where it determines the integrity of 
the RNA; RIN of ‘10’ stands for a totally undegraded perfect RNA sample while a RIN 
of ‘1’ represents a completely degraded sample [Schroeder et al, 2006].  
2.1.4 Microarray Analysis 
RNA labeling and hybridization on the Affymetrix Genechip U133 Plus 2 chips 
(Affymetrix Inc, California, United States of America) were performed according to the 
manufacturer’s protocol. Briefly, the two-cycle target labeling protocol was used to 
synthesize biotin-labeled cRNA from 100ng of total RNA starting material. The 
biotinylated cRNA targets are then cleaned up, fragmented, and hybridized to Affymetrix 
Genechip U133 Plus 2 expression arrays. Washing and staining of the chips was 
performed using the Fluidics Station 450 where it is operated using the GeneChip 




operating software (GCOS). Scanning of the probe arrays was done using Affymetrix 
GeneChip Scanner 3000. 
2.1.5 Analysis of microarray data 
Microarray data was analyzed using 4 different softwares: GeneChip Operating Software 
(GCOS), dCHIP, Robust Multi-array Average (RMA) and Genespring. Raw data were 
normalized according to the algorithms in the software (Table 2.1). Fold changes were 
calculated based on mean values. Genes that were found to be common in all gene lists, 
as determined by the criteria used in individual software, were merged. 
2.1.6 cDNA synthesis and quantitative real-time polymerase chain reaction  
Total RNA was converted into cDNA using the SuperScript III First-strand cDNA 
synthesis kit (Invitrogen Corporation, California, United States of America) according to 
manufacturer’s protocol. The cDNA was then used for real-time PCR using the 
QuantiTect SYBR Green PCR Kit (Qiagen) on the Roche LightCycler 2 machine (Roche 
Diagnostics Corporation, Roche Applied Science, Indianapolis, United States of 
America). The programme settings used for the real-time PCR (qPCR) run is shown in 









Table 2.1  Methods of normalization and criteria for determining genes differentially 
expressed using different microarray analysis software, for microarray work involving 
human prostate tissues. 
 
 Software Normalization and Expression 
values 
Criteria 
GCOS 1. One array was chosen as 
baseline array, to which 
other arrays are normalized 
against. Thus, for 6 control 
BPH samples and 6 prostate 
adenocarcinoma samples, 
there were a total of 36 
different comparisons. 
1. Change calls (i.e 
normalized expression of 
genes that are 
differentially expressed as 
compared to the baseline 
array – increase or 
decrease) are the same in 
at least 50% of the 36 
different comparisons. 
2. Fold change ≥ 2 
3. P-value < 0.05 
dCHIP 1. Array with the median 
overall intensity was used as 
the baseline array against 
which other arrays are 
normalized (Li and Wong, 
2001).  
2. PM/MM difference model-
based expression values 
were calculated. (Li and 
Wong, 2001). 
1. Detection ‘P’ call present 
in at least 50% of either 
control BPH group or 
prostate adenocarcinoma 
group.  
2. Fold change ≥ 2 
3. P-value < 0.05 
RMA 1. RMA does not use a base 
line array, but "quantile 
normalization", based on the 
complete data set (Wu and 
Irizarry, 2004) 
1. Fold change ≥ 2 
2. P-value < 0.05 
Genespring 1. Methods as in ‘RMA’ 
software 
1. Fold change ≥ 2 










Table 2.2  Programme settings for qPCR 
 
Program Temperature Duration Ramp rate Cycle(s) 
Initial Activation 95oC 15 min 20oC/sec 1 
3-step cycling    45 
   Denaturation 94oC 15 sec 20oC/sec  
   Annealing 60oC 25 sec 20oC/sec  
   Extension 72oC 12 sec 20oC/sec  
Melting Curve 95 oC 0 sec 20oC/sec 1 
 65 oC 15 sec 20oC/sec  
 95 oC 0 sec 0.1 oC/sec  
Cooling 40 oC 30 sec 20oC/sec 1 




Table 2.3  Primer sequences used in real-time PCR (qPCR) for microarray data verification 
Gene Symbol Gene Name Gene 
ID 
Forward primer (5’-3’) Reverse primer (5’-3’) Amplicon 
Size 
ALDH1A2 aldehyde dehydrogenase 1 family, 
member A2 
8854 ccattggagtgtgtggacag gatgagggctcccatgtaga 152 
AMACR alpha-methylacyl-coA racemase 23600 gcatgtgaggaaggggtaga caccttcctcttgcgattgt 145 
B3GALT6 UDP-Gal:betaGal beta 1,3-
galactosyltransferase polypeptide 6 
126792 gcctctactggggcttcttc cgcgtagggcaggtagtagt 101 
CHST2 carbohydrate (N-acetylglucosamine-6-
O) sulphotransferase 2 
9435 aagttcgagagcatggagga agttgggcgaagtactggtg 146 
COL4A6 collagen, type IV, alpha 6 1288 cagacccagattccccagta gcagtgtgcatgaggaaaga 152 
CSGalNAcT-1 chondroitin beta1,4 N-
acetylgalactosaminyltransferase  
55790  gagatgtgcattgagcagga gaagttggcagctttggaag 114 
CXCL13 chemokine (C-X-C motif) ligand 13 (B-
cell chemoattractant) 
10563 aatgagcctggactcagagc gacctccagaacaccttgga 126 
CYP3A5 cytochrome P450, family 3, subfamily 
A, polypeptide 5 
1577 taggcccagtgggatttatg caatgatggggaacatctcc 126 
CYP4B1 cytochrome P450, family 4, subfamily 
B, polypeptide 1 
1580 cctaaggcccctgatgtgta cagtgaacacggccacatag 151 
DCN decorin 1634 gcccagaagttcctgatgac gagttgtgtcagggggaaga 144 
EFEMP2 EGF-containing fibulin-like 
extracellular matrix protein 2 
30008 gcccaaacctgtgtcaactt atgaaggctgctctcgacat 136 
FASN fatty acid synthase  2194 tcatccccctgatgaagaag actccacaggtgggaacaag 120 
FBP1 fructose-1,6-bisphosphatase 1 2203 tcatcgcactctggtctacg gccctctggtgaatgtctgt 186 
FLRT3 fibronectin leucine rich transmembrane 
protein 3 
23767 accctcaatcgagagcaaga tgagaagagcgatccattcc 147 








51809 gcacgaagtattggtgctca ctataagcggcacagtgcaa 145 
GATA3 GATA binding protein 3 2625 aaggcagggagtgtgtgaac cttcgcttgggcttaatgag 142 
GJA1 gap junction protein, alpha 1, 43kDa 
(connexin 43) 
2697 gtgcctgaacttgccttttc ccctccagcagttgagtagg 166 
GLYATL1 glycine-N-acyltransferase-like 1 92292 ttctcacctggagccttgat ggtaaccccgtctttcccta 147 
HOXC6 homeobox C6 3223 ccaggaccagaaagccagta ggtctggtaccgcgagtaga 121 
HPN hepsin 3249 gctgtgtggcattgtgagtt tggcttcggagtgagtcttt 122 
HS3ST3A1 heparan sulphate (glucosamine) 3-O-
sulphotransferase 3A1 
9955 cagtgccctctccacctc gccaggcagtagaagacgtaa 108 
HS6ST2 heparan sulphate 6-O-sulphotransferase 
2 
90161 ccctggtaggctgctacaac aaactcagtgaggccgaaga 116 
KRT15 keratin 15 3866 taccagaagcagaccccaac gcattgtcgatctccaggat 131 
LAMB3 laminin, beta 3 3914 caagcctgagacctactgcac ctgcagagagacagggttcac 172 
LTF lactotransferrin /// similar to 
lactotransferrin 
4057 ccctacaaactgcgacctgt ctgtgtggcaggacttcaga 142 
MAL2 mal, T-cell differentiation protein 2 114569 gacatcctgcggacctactc gctgtcacggacacaaacat 137 
MYC v-myc myelocytomatosis viral 
oncogene homolog (avian) 
4609 ttcgggtagtggaaaaccag cctcctcgtcgcagtagaaa 120 
MYO6 myosin VI 4646 gcagtcgctggaagaaagtt aatgcgaggtttgtgtctcc 143 
PCA3 prostate cancer specific antigen 3  50652 caaaggcagggaacctcata ctaaagcgcactcaccatga 145 
PDGFC platelet derived growth factor C 56034 gccaggttgtctcctggtta ctgacaccggtctttggtct 141 
PDLIM5 PDZ and LIM domain 5 10611 aatccttgcccagatcactg cgtgctgaaacttcatggtg 144 
PPAP2B phosphatidic acid phosphatase type 2B 8613 ctgtctcgcgtatcagacca cagggagagcgtcgtcttag 132 
RARRES2 retinoic acid receptor responder 5919 ttaagctgcagcagacaagc ccgcagaacttgggtctcta 167 




(tazarotene induced) 2 
SCUBE2 signal peptide, CUB domain, EGF-like 
2 
57758 ctggtcgaacttcctgcttc caggctggtatgttcccact 165 
SDC1 syndecan 1 6382 gggactcagccttcagacag ctcgtcaatttccaggagga 128 
SGEF Src homology 3 domain-containing 
guanine nucleotide exchange factor 
26084 gatgtctgtgaggcaagcaa ggtcaaatgtggatgctgtg 118 
SLC14A1 solute carrier family 14 (urea 
transporter), member 1 (Kidd blood 
group) 
6563 ccagtgggagttggtcagat aagactgagtcccgctgcta 144 
SLC2A5 solute carrier family 2 (facilitated 
glucose/fructose transporter), member 5 
6518 ccaagaaagccctacagacg aacagcttcagcacggagat 118 
SPOCK3 sparc/osteonectin, cwcv and kazal-like 
domains proteoglycan (testican) 3 
50859 cagggaagtggcaaacagat acatccagccaagtgagtcc 152 
SRD5A2 steroid-5-alpha-reductase, alpha 
polypeptide 2 (3-oxo-5 alpha-steroid 
delta 4-dehydrogenase alpha 2) 
6716 tgaataccctgatgggtggt acaagccaccttgtggaatc 155 
SRPRB signal recognition particle receptor, B 
subunit 
58477 cgttgctctttgtcaggttg gggaaggtcaatcaaggtca 125 
STEAP4 STEAP family member 4 79689 ttgccttccttcatgtcctc gctgaggaggtgctaaatgg 127 
SULF2 sulphatase 2 55959 gagctgcaagggttacaagc cttcccacagttgtcccagt 158 
TCEAL2 transcription elongation factor A (SII)-
like 2 
140597 acagaaaacacgggcaagag tctttgatcctccctgcatc 130 
TGFB3 transforming growth factor, beta 3 7043 ggatcaccacaaccctcatc gcagttctcctccaagttgc 133 
TGFBR3 transforming growth factor, beta 
receptor III (betaglycan, 300kDa) 
7049 ccaagatgaatggcacacac ccatctggccaaccactact 151 
TP73L tumour protein p73-like 8626 gaggttgggctgttcatcat gaggagaattcgtggagctg 174 
TPD52 tumour protein D52 7163 cacagagaccctctcggaag ccaagtttccgcttgatctc 135 




TRIM29 tripartite motif-containing 29 23650 acatcataccagccctcgtc agcctttcagggagaaggag 184 
TRIM36 tripartite motif-containing 36 55521 gccagtttgccatctgtgta cacctggctttccttaccaa 136 
UAP1 UDP-N-acteylglucosamine 
pyrophosphorylase 1 
6675 gactgtggagcaaaggtggt gtccgtctgagcttcgtttt 139 
VCAN chondroitin sulphate proteoglycan 2 
(versican) 
1462 ggtgcactttgtgagcaaga ttcgtgagacaggatgcttg 159 
VSNL1 visinin-like 1 7447 tgagcatgaactcaagcagtg tgaactctcggaagtcaatgg 188 
WIF1 WNT inhibitory factor 1 11197 tgctttaatggagggacctg ccctggtaacctttggaaca 158 




2.2 Expression analysis of chondroitin sulphate and heparan sulphate in prostate 
adenocarcinoma tissues using immunohistochemistry 
2.2.1 Clinical samples and patient data collection 
Archival prostate adenocarcinoma samples and paired benign prostatic tissue specimens 
from corresponding patients were obtained from the Department of Pathology, Singapore 
General Hospital. The samples were collected from 163 patients who underwent radical 
prostatectomy from 2001 to 2004. Targeted areas of the specimens were identified and 
used for tissue microarray construction using the Beecher arrayer as previously described 
[Tan et al, 2005], with a minimum of two cores of tissue taken from each formalin-fixed 
paraffin-embedded sample block. Clinicopathological data were collected for statistical 
analysis. Ethics approval was obtained from the Institutional Review Board, Singapore 
General Hospital. 
2.2.2 Immunohistochemical staining 
Monoclonal antibodies targeting heparan sulphate and various chondroitin sulphate 
subtypes were used, as shown in Table 2.4. After deparaffinization and rehydration of the 
tissues, endogenous peroxidase activity was quenched with 3% aqueous hydrogen 
peroxide for 30 min and washed in Tris-buffered saline, pH7.6 thereafter. For the 
monoclonals 1B5 and 3B3, the sections were treated with 0.025 units/ml chondroitinase 
ABC (Sigma-Aldrich) and incubated for 2 h at 37oC. Thereafter, the tissue sections were 
washed thrice with 1X PBS, and then blocked with serum (from the species in which the 
secondary antibody is made. For 1B5, 3B3, CS56, F58-10E4 staining, horse serum is 
used while for LY111 staining, goat serum is used) for 1 hr at room temperature. For the 
monoclonals LY111, CS56 and F58-10E4, the sections were blocked with serum for 1 h 




at room temperature, without the need for chondroitinase ABC treatment. All sections 
were then incubated at 4°C overnight with the respective primary antibodies (at their 
optimal primary antibody dilution, Table 2.4) after blocking. After 3 washes, biotinylated 
secondary antibody was added and incubated for 1 h at room temperature, followed by 
visualization of the staining by the avidin-biotin-complex technique using 
diaminobenzidine as the substrate (ABC kit, Vector Laboratories). The sections were 
counterstained with haematoxylin. Control sections were processed using the same 
protocol, but the chondroitinase ABC incubation step was omitted (for 3B3 and 1B5) 
while the primary antibodies were not added (for LY111, CS56 and F58-10E4). 
Table 2.4 Antibodies and optimal conditions used for immunohistochemistry 












































1:100 or 1:800 a 1:200 15 min 
a Different batches of antibodies were used – different optimization conditions have to be used to 
detect similar immunohistochemical staining. 




2.2.3 Immunohistochemical evaluation 
Sections were assessed for expression of chondroitin sulphate or heparan sulphate in 
secretory and basal cells of benign prostatic tissue, in cancerous cells of adenocarcinoma 
specimens, and in the stromal components of both groups. The intensity of staining was 
noted as absent (0), weak (1+), moderate (2+) or strong (3+). The percentage of cells 
stained was also recorded. For a tissue section stained heterogeneously with different 
intensities, a weighted average intensity was computed as follows: Σ(intensityx x 
percentage of cells stained with intensityx) ÷ total percentage of cells stained. An 
immunoreactivity score (IRS) was calculated for each section by multiplying the 
weighted average staining intensity by the percentage of cells stained. Sections from 
different cores of the same specimen were independently scored, and average values for 
staining intensity, percentage of cells stained and IRS calculated for each sample.  
2.2.4 Statistical analysis 
Statistical analysis was performed using SPSS for Windows Version 12.0. Paired T-test 
or one-way ANOVA was used to compare the means between variables. Associations 
between the immunohistochemical staining data and clinicopathological parameters were 
determined using Fisher’s exact test. A P-value of < 0.05 was considered to be 
statistically significant.  




2.3 In vitro cell culture 
2.3.1 Cell lines 
RWPE-1 cell line was purchased from ATCC and was propagated in Keratinocyte-serum 
free medium, supplemented with 0.05mg/ml bovine pituitary extract and 5ng/ml 
recombinant epidermal growth factor (Invitrogen Corporation). The LNCaP and PC-3 
human prostate cancer cell lines were kind gifts from A/P Marie Veronique Clement 
(Department of Biochemistry, National University of Singapore) Both LNCaP and PC-3 
cells were cultured in RPMI-1640 (Invitrogen Corporation) supplemented with 10% Fetal 
Bovine Serum (FBS) (Hyclone, Thermo Fisher Scientific Inc, Massachusetts, United 
States of America), 2mM L-glutamine (Hyclone, Thermo Fisher Scientific Inc) and 1mM 
sodium pyruvate (Hyclone, Thermo Fisher Scientific Inc). All cell lines were incubated in 
a humidified incubator at 37oC in a 5% CO2, 95% air atmosphere.   
2.3.2 Storage of cells 
The cryopreservation medium used for LNCaP and PC-3 comprised of complete growth 
medium (see section 2.3.1) supplemented with an additional 20% FBS and 5% 
cryoprotective agent dimethylsulfoxide (DMSO) (Sigma-Aldrich, Missouri, United States 
of America). The cryopreservation medium used for RWPE-1 is complete growth 
medium (see section 2.3.1) supplemented with 15% FBS and 10% DMSO. The cell 
suspensions were then stored at -80 oC freezer overnight to ensure gradual freezing before 
storing in liquid nitrogen. 
 
 




2.3.3  Antibodies used 
Antibodies against CSGalNacT-1 (ChGn MaxPab polyclonal antibody B01) and HIPK3 
(H-80, rabbit polyclonal IgG) were purchased from Abnova Corporation, Taipei, Taiwan 
and Santa Cruz Biotechnologies, California, United States of America respectively. 
Antibodies recognizing MAPRE-1 (1A11/4, mouse monoclonal IgG) and TPX2 (18D5-1, 
mouse monoclonal IgG) were obtained from Abcam Inc, Cambridge, Massachusetts, 
United States of America. β-actin monoclonal antibody, horseradish peroxidise 
conjugated anti-mouse IgG secondary antibody, FITC-conjugated anti-mouse IgG 
secondary antibody were purchased from Sigma-Aldrich, Missouri, United States of 
America. Alexa-Fluor 488 conjugated anti-rabbit immunoglobulins secondary antibody 
was purchased from Invitrogen Corporation, California, United States of America.  
  
2.3.4 RNA Extraction, cDNA synthesis, qPCR of prostate tumour cell lines 
Total RNA was isolated from the prostate cell lines, RWPE-1, LNCaP and PC-3 using 
the RNeasy Mini Kit or RNeasy Micro Kit (Qiagen, Hilden, Germany), as according to 
the manufacturer’s protocol. RNA yield was quantified using Nanodrop while RNA 
purity was determined using the absorbance ratio of A260/A280. Total RNA was converted 
into cDNA using the SuperScript III First-strand cDNA synthesis kit (Invitrogen 
Corporation) according to manufacturer’s protocol. The cDNA was then used for real-
time PCR using the QuantiTect SYBR Green PCR Kit (Qiagen) on the Roche 
LightCycler 2 machine (Roche Diagnostics Corporation, Roche Applied Science). 
Primers used for real-time PCR are as shown in Table 2.5. Programme settings used for 
the real-time PCR run are the same as Section 2.1.6, as shown in Table 2.2.  




Table 2.5  Primer sequences used in real-time PCR, for in vitro work involving prostate cancer cell lines. 
 
Gene Symbol Gene Name Gene 
ID 
Forward primer (5’-3’) Reverse primer (5’-3’) Amplicon 
Size 
ACAN aggrecan 176 gaatcaactgctgcagacca atgctgctcaggtgtgactg 143 
ACTB beta-actin 60 ggcatgggtcagaaggatt aggtgtggtgccagattttc  133 
B3GalT6  UDP-Gal:betaGal beta 1,3-
galactosyltransferase polypeptide 6 
126792 gcctctactggggcttcttc cgcgtagggcaggtagtagt 101 
B3GAT3 beta-1,3-glucuronyltransferase 3 
(glucuronosyltransferase I) 
26229 ccacctggagagcagtcttc ctcctcctgcttcatcttgg 127 
B4GalT7  xylosylprotein beta 1,4-
galactosyltransferase, polypeptide 7 
(galactosyltransferase I) 
11285 caggtggaccacttcaggtt cagcctcaggaaagccatag 145 
CHPF chondroitin polymerising factor 79586 gaacgcacgtaccaggagat ggatggtgctggaataccc 114 
CHST11 carbohydrate (chondroitin 4) 
sulphotransferase 11 
50515 atcaaccaccgcttgaaaag ttgatgatcttggtgccgta 140 
CHST12 carbohydrate (chondroitin 4) 
sulphotransferase 12 
55501 gtgtccttcgccaacttcat ttccccacgaagtcgtagtc 131 
CHST13 carbohydrate (chondroitin 4) 
sulphotransferase 13 






113189 attccccgagttcctgagat cagcctccagcctctcatag 139 
      




CHST3 carbohydrate (chondroitin 6) 
sulphotransferase 3 
9469 acgcccttttcttggttttt agagcttggggaatctgctt 106 
CHST7 carbohydrate (N-acetylglucosamine 
6-O) sulphotransferase 7 
56548 ggggcaatctgtcacactct aggatgccttgttgaaatgg 236 
CHSY1 chondroitin synthase 1 22856 ccctccttcatgaggtttca acaatgtcgtccaaggcttc 149 
CHSY3 chondroitin synthase 3 337876 gaggacggctcattgacttc tgctgaagataggcatgacg 158 
CPOX coproporphyrinogen oxidase 1371 ggcatcagctgtgtacttcaa ataacagagctcacgcccata 176 
CSGalNAcT-1 chondroitin sulphate N-
acetylgalactosaminyltransferase 1 
55790  gagatgtgcattgagcagga gaagttggcagctttggaag 114 
CSGalNAcT-2 chondroitin sulphate N-
acetylgalactosaminyltransferase 2 
55454  tccccttggagagaaactga cggaagagggtcacatgtct 141 
CSGLCA-T chondroitin sulphate 
glucuronyltransferase 
54480 cccaacaagccctacaagaa agtgtagctcgggaggtcag 104 
CSPG4 chondroitin sulphate proteoglycan 4 1464 cagtatgggcatctcctggt cattgacacccctagccagt 148 
CSPG5 chondroitin sulphate proteoglycan 5 
(neuroglycan C) 
10675 gctgcgtaggaccaacaaat cctctttcaggcaggacttg 150 
EXT1 exostoses (multiple) 1 2131 cacatcaaagtggacgaacg ttggtccaccatgttcttca 121 
EXT2 exostoses (multiple) 2 2132 cgtgttagcccatttgaggt ccaccaagatgtttggcttt 131 
EXTL1 exostoses (multiple)-like 1 2134 ggtcgtgtcgtgtccttttc gttctgtctctccgctcacc 136 
EXTL2 exostoses (multiple)-like 2 2135 cgtctgtgtttcacccattg gggaaaggaggagaaagagaa 105 
EXTL3 exostoses (multiple)-like 3 2137 ggacattgccatgaacttcc atcatgagacagggcctgag 113 
GALNAC4S-
6ST 
B cell RAG associated protein 52363 tgagttcacgaccagacagc cgtaccaacaggggctctta 116 
GPC1 glypican 1 2817 gatggctgtctggatgacct agccgaggtcttctgtcctt 120 
GPC2 glypican 2 221914 aggagggagtgtggtttcct cccacttccaacttccttca 135 
GPC3 glypican 3 2719 aactccgaaggacaacgaga gcaccaggaagaagaagcac 113 




GPC4 glypican 4 2239 ctcccccaaaccatgttaaa aggcgagatcacagttggaa 149 
GPC5 glypican 5 2262 tctcagaagccaagctgaaa ctgtgcccttcacatcttca 143 
GPC6 glypican 6 10082 ggaccatgccacaaaaactt ggtccccacagatagctgaa 136 
HIPK3 homeodomain interacting protein 
kinase 3 
10114 gctttcagcaccgtaaccat tggcttgagatcagcatgaa 185 
HPSE heparanase 10855 gagaagtgattgattcagttac gcctggtgctctcaaccacctgga 144 
HPSE2 heparanase 2 60495 gcagttacctggcaacattgc gtcccgtcgtccaccatcac 600+ 
HS2ST1 heparan sulphate 2-O-
sulphotransferase 1 
9653 cgaagtccgagaaattgagc aatgaagtgcttgccgtttt 123 
HS3ST1 heparan sulphate (glucosamine) 3-O-
sulphotransferase 1 
9957 gaacgaggtccacttcttcg ttctccactgtgagctggtg 105 
HS3ST2 heparan sulphate (glucosamine) 3-O-
sulphotransferase 2 
9956 agtcggtccctgtcattgtc taaggtctgaggagggctga 137 
HS3ST3A1 heparan sulphate (glucosamine) 3-O-
sulphotransferase 3A1 
9955 cagtgccctctccacctc gccaggcagtagaagacgtaa 108 
HS3ST3B1 heparan sulphate (glucosamine) 3-O-
sulphotransferase 3B1 
9953 ctggcttcaggcaaggagat gacccactgaaaaagctgga 104 
HS3ST4 heparan sulphate (glucosamine) 3-O-
sulphotransferase 4 
9951 ggagcagtcagcattcttcc cagctttctcgccactacct 101 
HS3ST5 heparan sulphate (glucosamine) 3-O-
sulphotransferase 5 
222537  atcattgtcagggagccaac agggtctatggccagcttct 114 
HS6ST1 heparan sulphate 6-O-
sulphotransferase 1 
9394 ggcccttcatgcagtacaat tacagctgcatgtccaggtc 103 
HS6ST2 heparan sulphate 6-O-
sulphotransferase 2 
90161 ccctggtaggctgctacaac aaactcagtgaggccgaaga 116 
HS6ST3 heparan sulphate 6-O-
sulphotransferase 3 
266722 catctcccccttcacacagt ctcgtaaagctgcatgtcca 112 




HSPG2 heparan sulphate proteoglycan 2 / 
perlecan 
429806 gggcaccttgtcttcaggta gacttggatggaacctctgc 129 
LIFR leukaemia inhibitory factor receptor 3977 gcctgcatttacaaggtggt accaatgactgggctttcac 186 
MAPRE-1 microtubule associated protein, 
RP/EB family, member 1 
22919 
 
cttacagggctgcttgaacc catctcagggctgaaacaca 166 
NCAN neurocan 1463 ggatcccaggtgtttgaaga gcttgaggagcccagtgtag 146 
NDST1 N-deacetylase/N-sulphotransferase 
(heparan glucosaminyl) 1 
3340 aaggattttggtgccaactg ttggagagctcgatgttgtg 142 
NDST2 N-deacetylase/N-sulphotransferase 
(heparan glucosaminyl) 2 
8509 ctacacacggaccctcaggt ggaaaagacgggactcagtg 134 
NDST3 N-deacetylase/N-sulphotransferase 
(heparan glucosaminyl) 3 
9348 aatgccttggaaagagcaaa tgtgcagcagctttgagagt 114 
NDST4 N-deacetylase/N-sulphotransferase 
(heparan glucosaminyl) 4 
64579 agccaagatcatcaccatcc aagtcagatggagcccaatg 144 
PAPSS1 3'-phosphoadenosine 5'-
phosphosulphate synthase 1 
9061 tcctttgatgtggcgtatga gacctcagttggtccagcat 121 
PAPSS2 3'-phosphoadenosine 5'-
phosphosulphate synthase 2 
9060 cacccggtcctcctactaca gacggaaagatggcaacaat 125 
RCBTB1 regulator of chromosome 
condensation (RCC1) and BTB 
(POZ) domain containing protein 1 
55213  tctgaacctggagcctgaat   ggggctcctaggcttgtatc 177 
RPLPO ribosomal protein, large, P0 6175 ctgttgcatcagtaccccatt gccttgaccttttcagcaag 103 
SDC1 syndecan 1 6382 gggactcagccttcagacag ctcgtcaatttccaggagga 128 
SDC2 syndecan 2 6383 ctgctccaaaagtggaaacc tgggtccattttcctttctg 126 
SDC3 syndecan 3 9672 accccaactccagagacctt cccacagctaccacctcatt 141 
SDC4 syndecan 4 6385 cattagctcccgtcaccact agaggaggtgctcactccaa 104 




SMC3 structural maintenance of 
chromosomes 3 
9162 aagagtatggagcgctggaa tggggaagtgatccaagttc 158 
SULF1 sulphatase 1 23213 aagtgacgggttcttggttg ggcaaggtcaaatgaggtgt 117 
SULF2A sulphatase 2A 55959 tggccagaaatgaagagacc ggaaatcacccacatggttt 147 
SULF2B sulphatase 2B 55959 gaggtggacctccaaaaaca ttgactgagagtgcgtgctt 130 
TPX2 TPX, microtubule associated protein 
homologue (Xenopus laevis) 
22974 ttcccttgcctcattttgac gcttccaagtctgtgccttc 123 
UST uronyl-2-sulphotransferase 10090 gcaaagctgaacgtgaatga ttccaagcttcctgtgctct 148 
VCAN versican 1462 ggtgcactttgtgagcaaga ttcgtgagacaggatgcttg 159 
XylTI xylosyltransferase I 64131 ctctggatccacacccaagt ctttggggacagagttctcg 121 
XylTII xylosyltransferase  II 64132 ctacatgctggtggttcacg caggtagtcggaacgcttgt 116 
 




2.3.5 Silencing of prostate cell lines 
3 x 105 PC-3 cells in 6 well plates were seeded and allowed to adhere overnight. 
Following this, 40 nM of ON-TARGETplus SMARTpool CSGalNAcT-1 siRNA 
(Dharmacon Inc, Colorado, United States of America) was added to the cells, together 
with 3ul of DharmaFECT 2 siRNA transfection reagent (Dharmacon Inc), according to 
protocol recommended by the manufacturer. ON-TARGETplus siCONTROL Non-
targeting SMARTpool siRNAs (Dharmacon Inc) were used as negative controls while 
ON-TARGETplus siCONTROL GAPD SMARTpool siRNAs (Dharmacon, Inc) were used 
as positive controls. Silencer Cy3 labeled Negative Control #1 siRNA (Ambion, Inc / 
Applied Biosystems, Texas, United States of America) were used to monitor the 
transfection efficiency. The sequences for the various siRNAs are listed in Table 2.6. The 
siRNA-transfection reagent complexes were removed 24 hours later and replaced with 
complete growth medium.  
Table 2.6. ON-TARGETplus SMARTpool CSGalNAcT-1 siRNA sequences 
 
Sequence Anti-sense Sense 
1 5’-PUGACACGAUAUUUAUGGUUUU  AACCAUAAAUAUCGUGUCAUU 
2 5’-PUAUUGAUGAAGUCUGACCGUU CGGUCAGACUUCAUCAAUAUU 
3 5’PAUACCUUCUUCCCUGGCUGUU CAGCCAGGGAAGAAGGUAUUU
4 5’PAUACUUGCGAUAAAGGUGCUU GCACCUUUAUCGCAAGUAUUU 
 
5 x 104 RWPE-1 cells were seeded in 24 well plates and allowed to adhere overnight. 2ul 
of Oligofectamine transfection reagent (Invitrogen Corporation) and a final concentration 
of 100nM of HS3ST3A1 siRNA (Ambion, Inc / Applied Biosystems) or HS6ST2 siRNA 
(Ambion, Inc / Applied Biosystems) were added to each well. Table 2.7 shows the 




sequences of the siRNA used. Ambion’s Silencer siRNA Negative Control #1 was used 
as negative controls while Ambion’s Silencer GAPD siRNA was used as positive 
controls. Silencer Cy3 labeled Negative Control #1 siRNA (Ambion, Inc / Applied 
Biosystems) Complete growth medium with 2% FBS was added 4 hours after 
transfection and transfection medium was replaced with complete growth medium 24 
hours post-transfection. 
 
Table 2.7  Ambion Silencer siRNA sequences 
siRNA Anti-sense (5’ -> 3’) Sense  (5’ -> 3’) 
HS3ST3A1 UAGAAGACGUAAAGGGACGtg CGUCCCUUUACGUCUUCUAtt 
HS6ST2 CAGAUAUUGGGUCUUCCGCtg GCGGAAGACCCAAUAUCUGtt 
 
2.3.6  Western blot 
Proteins were extracted using M-PER Mammalian Protein Extraction Reagent (Thermo 
Fisher Scientific, Massachusetts, United States of America) and resolved by SDS-PAGE 
and transferred onto polyvinylidene difluoride membrane (Immun-Blot PVDF 
membrane, Bio-Rad Laboratories, California, United States of America) using the semi-
dry method. The membranes were blocked in Tris-buffered saline containing 0.2% 
Tween 20 (Bio-Rad Laboratories) and 5% fat-free dry milk (Bio-Rad Laboratories). The 
blot was then incubated with the primary antibody and then with horseradish peroxidise-
conjugated secondary antibody. Visualisation of the proteins was determined via 
chemiluminescence detection using SuperSignal West Femto Maximun Sensitivity 
Substrate (Thermo Fisher Scientific).   
 




2.3.7 GAG extraction and quantification 
Glycoaminoglycans were purified from sonicated boiled cellular extracts using 3 volumes 
of 1.3% potassium acetate in 95% ethanol at -20oC overnight. The precipitates were 
collected by centrifugation at 14000g for 15min, treated with pronase at 55oC overnight 
and reboiled. GAGs were further extracted from the supernatant by using 3 volumes of 
1.3% potassium acetate in 95% ethanol at -20oC overnight. The precipitates were 
collected by centrifugation at 14000g for 15min and resuspended in deionized water. The 
total GAGs were quantified using Blyscan Glycosaminoglycan Assay (Biocolor Ltd, 
United Kingdom). Chondroitinase B (Sigma-Aldrich, Missouri, United States of 
America) and chondroitinase AC (Sigma-Aldrich) was used to remove dermatan sulphate 
and chondroitin-4-sulphate and chondroitin-6-sulphate respectively and total GAG was 
requantified after enzymatic digestion – dermatan sulphate and chondroitin sulphate 
levels can be quantified by subtraction of total GAG after digestion from total GAG 
before digestion. 
2.3.8 Proliferation assay 
Proliferation assays were performed using the CellTiter 96 AQueous One Solution Cell 
Proliferation Assay (Promega Corporation, Madison, Wisconsin, USA) according to 
manufacturer’s protocol. The CellTiter 96® AQueous One Solution Reagent contains a 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt; MTS] which is bioreduced by NADPH or 
NADH produced by metabolically active cells via dehydrogenase enzymes into a colored 
formazan product that is soluble in tissue culture medium. The quantity of formazan 
product is directly proportional to the number of viable living cells. 




2.3.9 Migration assay 
 Transwell Inserts (Corning Incorporated, New York, United States of America) of 
6.5mm diameter, polycarbonate membrane with 8.0μm pore size were used for the assay. 
The inserts were first hydrated by adding serum-free medium to the 24-well plate well 
and then to the Transwell inserts. The plate was then incubated for 2 hours at 37oC with 
5% CO2. This initial equilibrium period was used to improve cell attachment.     
 0.6ml of 20% FBS complete growth medium was added to the lower chamber. 8 x 
104 RWPE-1 cells resuspended in 0.2ml serum-free medium were added to the inside of 
the Transwell inserts. Migration of the cells was allowed to occur at 37oC in 5% CO2 
conditions for 48 hours.  
The medium was carefully removed from the upper and lower chambers of the Transwell 
Inserts. The inserts were then washed with 1X PBS and fixed with 0.6ml of 4% 
paraformaldehyde for 10min. Subsequently, the inserts were rinsed with 1X PBS again 
and left to air dry. The inserts were then stained with 0.6ml of aqueous crystal violet 
(0.5% w/v) for 30 minutes. The excess stain was then washed out by immersion of the 
inserts in a beaker of clean tap water. A cotton swab was used to clean the insides of the 
inserts so as to remove the unmigrated / uninvaded cells. The inserts were then air-dried 
and viewed under a microscope (Nikon SMZ 1500). Five different field views of each 
insert were taken and the cells were counted using an image analysis software, 
AxioVision Release 4.6. 
2.3.10 Invasion assay 
BD BioCoat™ Matrigel™ Invasion Chambers (BD Biosciences, California, United 
States of America) were used for the conduct of the invasion assay. The Falcon Cell 




Culture Inserts contain an 8.0μm pore size polyethylene terephthalate (PET) membrane 
with a thin layer of Matrigel Basement Membrane Matrix. The Matrigel Matrix serves as 
a reconstituted basement membrane in vitro. The layer occludes the pores of the 
membrane, blocking non-invasive cells from migrating through the membrane. In 
contrast, invasive cells are able to detach themselves from and invade through the 
Matrigel Matrix and the 8.0μm membrane pores.  
The Cell Culture inserts were first hydrated overnight at 4oC by adding serum-free 
medium to the 24-well plate well and then to the cell culture inserts. The plate was then 
incubated for 2 hours at 37oC with 5% CO2 prior to the start of the invasion proper. This 
initial equilibrium period was used to improve cell attachment.     
 A total of 0.5ml of 20% FBS complete growth medium was added to the lower 
chamber. 1 x 105 PC-3 cells resuspended in 0.5ml of serum-free medium were added to 
the inside of the Falcon cell culture inserts. Invasion of the cells was allowed to occur at 
37oC in 5% CO2 conditions for 48 hours. Staining and counting of the invaded cells were 
performed as in Section 2.3.11, Migration Assay.  
2.3.11  Adhesion assay 
 2X104 transfected PC-3 or RWPE-1 cells were seeded into pre-collagen type 1-
coated ((BD Biosciences) 96 well plates. The cells were then incubated at humified 37oC, 
5% CO2 level incubator for 30 mins. Unadhered cells were then removed and washed 
thrice with 1X PBS. Unwashed wells of cells were used as loading controls. Thereafter, 
CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega Corporation) was 
added to quantify the number of cells that adhered to the collagen type I substrate.  




2.3.12  Cell cycle assay 
 Cell cycle analysis was performed on ethanol-fixed PC-3 cells and stained using 
20ug/ml propidium iodide (PI) (Sigma-Aldrich) with 0.01% Triton X (Bio-Rad 
Laboratories) and 0.2mg/ml DNase-free RNase A (Roche Diagnostics Corporation, 
Roche Applied Science) for 30 mins. Thereafter, the PI-stained cells were put through the 
Dako Cytomation Cyan LX (Dako, Denmark) and fluorescence data was collected and 
analysed using Dako Summit version 4.3 software (Dako). 
2.3.13 Cell apoptosis assay 
Apoptosis assay was conducted using the Guava Nexin Reagent (Millipore Corporation, 
Massachusetts, United States of America) on the EasyCyte Mini Flow Cytometer (Guava 
Technologies, Inc, California, United States of America), according to the manufacturer’s 
protocol. The Guava Nexin Assay contains 2 dyes, Annexin V-PE and 7-AAD. Annexin 
V binds with high affinity to phosphatidylserine which externalizes to the outer cellular 
surface in the early stages of apoptosis [Vermes et al, 1995]. 7-AAD is a cell impermeant 
dye and is used as an indicator of cell membrane structural integrity, which in late stages 
of apoptosis, there is loss of membrane integrity [Schmidt et al, 1992]. 
2.3.14 Flow cytometry 
Transfected PC-3 cells were fixed in cold methanol (for MAPRE-1 staining) or 95% 
ethanol with 5% acetic acid (for TPX-2 and HIPK3 staining) at -20oC for 10min. The 
cells were then washed in 1X PBS and permeabilized in 0.5% Tween-20 for 10min. Cell 
pellet was collected and the primary antibody, diluted in 3% BSA/PBS was added and 
incubated at room temperature for 1 hour. MAPRE-1 antibody was diluted 1:400, TPX2 
antibody was diluted 1:200 and HIPK3 antibody was diluted 1:100. The cells were 




washed thrice in 1X PBS and cell pellet was again collected by centrifugation at 1000rpm 
for 5min. Respective secondary antibodies were added and incubated at room 
temperature for 1 hour. The cells were washed thrice in 1X PBS and cell pellet was again 
collected by centrifugation at 1000rpm for 5min. The cells were then resuspended in 1X 
PBS and 5000 stained cells were used for fluorescence analysis, performed on the 
EasyCyte Mini Flow Cytometer (Guava Technologies, Inc) using the Guava Express Pro 
Software (Guava Technologies, Inc).  
2.3.15 Microarray analysis 
RNA was isolated from the transfected PC-3 cells using the RNeasy Micro Kit (Qiagen) 
and the RNA quality was checked using the Agilent RNA 6000 Nano Kit (Agilent 
Technologies Inc) on the Agilent 2100 Bioanalyzer System. RNA labeling and 
hybridization on the Affymetrix Genechip U133 Plus 2 chips (Affymetrix Inc, California, 
United States of America) were performed, as in Section 2.1.4, except that the one-cycle 
target labeling protocol was used to synthesize biotin-labeled cRNA from 2.5ug of total 
RNA starting material (from the non-targeting or CSGalNAcT-1 silenced PC-3 cells). 
Microarray data was analyzed as shown in Table 2.8. Genes that were found to be 
common in all gene lists, as determined by the criteria used in individual software, were 
merged. 




Table 2.8  Methods of normalization and criteria for determining genes differentially expressed using different microarray 
analysis software, for microarray work involving CSGalNAcT-1 silenced PC-3 cells. 
Software Normalization and Expression values Criteria 
GCOS 1. One array was chosen as baseline array, to which 
other arrays are normalized against. Thus, for 6 
control BPH samples and 6 prostate 
adenocarcinoma samples, I have a total of 36 
different comparisons. 
1. Change calls (i.e normalized expression of genes that 
are differentially expressed as compared to the 
baseline array – increase or decrease) are the same in 
at least 50% of the 36 different comparisons. 
2. Fold change ≥ 2 
3. P-value < 0.05 
dCHIP 1. Array with the median overall intensity was used as 
the baseline array against which other arrays are 
normalized (Li and Wong 2001a).  
2. PM/MM difference model-based expression values 
were calculated. (Li and Wong 2001a). 
1. Detection ‘P’ call present in at least 50% of either 
control BPH group or prostate adenocarcinoma 
group.  
2. Fold change ≥ 2 
3. P-value < 0.05 
Genespring 1. Five different algorithms were used in Genespring 
to generate 5 different lists – GC-RMA, RMA, 
dCHIP, GCOS and PLIER 
1. Fold change ≥ 2 
2. P-value < 0.05 
 




Chapter 3  
 
Expression Profiling of Prostate Adenocarcinoma Tissues 
 
 The expression of most of the genes in the human genome can be analyzed 
simultaneously through the application of expression microarray technology. This has 
enabled the discovery of molecular biomarkers that can serve as diagnostic and 
prognostic markers of prostate cancer, and also permitted the identification of novel 
therapeutic targets. In this study, genome wide expression profiling of prostate cancer 
tissues and benign hyperplastic prostate tissues were performed so as to identify 
potential biomarkers and therapeutic targets of prostate cancer. 
3.1 Selection of tissues to be used for study 
Six benign prostatic hyperplasia tissue sections and six prostate 
adenocarcinoma tissue sections were histologically checked using haematoxylin-eosin 
stain (Figure 3.1 and Figure 3.2) and subsequently used for the microarray study. The 
tissue sections used for the study were all obtained from Chinese patients. 
Clinicopathological data of the samples used are listed in Table 3.1. The mean age of 
diagnosis for patients with benign prostatic hyperplasia is 68.3 while for patients with 
prostate adenocarcinoma is 77.5 years. All the samples used belong to patients of 
Chinese ethnicity. Three of the six cancer patients have bone metastasis. 
3.2 RNA quality of tissue samples used for Affymetrix GeneChip microarrays 
Total RNA was extracted from all the twelve prostate tissues to be used for the 
microarray study. The mean A260/A280 and mean RIN numbers of BPH and 
adenocarcinoma samples are shown in Table 3.2 and the electrophoregrams are shown 
in Figure 3.3. As seen, all samples used for the microarray study were of good purity 




with mean A260/A280 of 2.04 (BPH samples) and of 2.01 (Cancer samples). The mean 
RIN for BPH samples is 7.7 and is 7.5 for cancer samples. 
Labelled cRNA was fragmented prior to hybridization to Affymetrix U133 
plus2 Genechips. cRNA is usually fragmented to sizes ranging from 50 to 200 bases 
to improve target specificity [Affymetrix, Inc, 2007]. The fragmented cRNA was 
checked using the Agilent Bioanalyzer and the electrophoregrams are shown in Figure 
3.4. The electrophoregrams show that all the cRNA was successfully fragmented to 
sizes ranging from 50 to 200 bases.  
 




Figure 3.1 Haematoxylin and eosin staining of BPH prostate samples used for microarray study. Scale bar represents 100µm. 
 




Figure 3.2 Haematoxylin and eosin staining of prostate adenocarcinoma samples used for microarray study. Scale bar represents 100µm.




Table 3.1 Clinical features of prostate adenocarcinoma cases used for expression profiling.  
















Benign Sample 1 80 34.3 N/A N/A Benign prostatic 
hyperplasia 
N/A TURP  N/A N/A 
Benign Sample 2 / 
Cancer Sample 2a 
61 16 No No Gleason 3+4 T2cN0M0 Open RRP <0.01 No 
Benign Sample 3 74 5.7 N/A N/A Benign prostatic 
hyperplasia 
N/A TURP  N/A N/A 
Benign Sample 4 59 N/A N/A N/A Benign prostatic 
hyperplasia 
N/A TURP  N/A N/A 
Benign Sample 5b 68 25.1 No No Gleason 3+4 T1cN0M0 Open RRP <0.1 No 
Benign Sample 6 68 N/A N/A N/A Benign prostatic 
hyperplasia 
N/A TURP  N/A N/A 
Cancer Sample 1 69 235.8 Yes (bone) No Gleason 5+5 T1cNxM1 TURP  N/A N/A 
Cancer Sample 3 80 587.8 Yes (bone) No Gleason 4+3 T1cNxM1 TURP 10.41 Yes  
Cancer Sample 4c 90 16.2 N/A N/A Benign prostatic 
hyperplasia 
N/A TURP  N/A N/A 
Cancer Sample 5 83 22.8 No No Gleason 4+3 T1bN0M0 TURP  <0.1 N/A 
Cancer Sample 6 82 127.6 Yes (bone) No Gleason 5+5 T1bNxM1 TURP  7.9 Yes 
a Benign sample 2 and Cancer sample 2 were 2 different prostate tissue types taken from the same patient, and the 2 different tissue types were 
used as separate samples. 
b Patient had prostate adenocarcinoma but no prostate adenocarcinoma tissue were seen in the prostatic chips collected from the patient. Only BPH 
sections were obtained. 
cCancer tissues were found in the prostatic chips that were collected, but were not sampled when the chips were collected for pathologic diagnosis. 
See Figure 3.2. 




Figure 3.3  Electrophoregrams of RNA samples extracted from six BPH sections and six cancer sections, as determined by Agilent 
Bioanalyzer. Good quality RNA samples are typified by intact 18S and 28S ribosomal subunit peaks, flat baseline throughout 
electrophoregrams and no well-defined peaks between 18S and 28S peaks. Y-axis represents ‘FU’, which stands for fluorescence units 
while x-axis represents time in seconds. 




Figure 3.4 Electrophoregrams of fragmented cRNA samples. A distinct peak should be observed from approximately 20 to 30 
seconds on the x-axis. Y-axis represents ‘FU’, which stands for fluorescence units while x-axis represents time in seconds. 




Table 3.2  RNA purity and quality of samples used for microarray study 
Samples A260/A280 RIN 
 Mean (± SD) Mean (± SD) 
BPH  (n=6) 2.04 ± 0.02 7.7 ± 0.3 
Adenocarcinoma (n=6) 2.01 ± 0.07 7.5 ± 0.8 
 
3.3  Quality control of microarray data 
Staining, washing and scanning of the microarray chips were performed on 
Fluidics Station 450 and the Affymetrix GeneChip Scanner 3000. The presence of 
housekeeping genes, spike control cRNAs, background scaling factor and noise (raw 
Q) were checked to ensure the quality of the assays done.  
On the Genechips, a number of housekeeping genes are controlled for by 
using a set of 3 probes directed against the 5’, middle, and 3’ region of the gene 
transcript. 3'/5' ratio, which is the signal intensity ratio of the 3' probe set over the 5' 
probe set, can be used to indicate the efficacy of the whole cRNA labelling process, 
from integrity of the starting RNA, efficiency of first strand cDNA synthesis to in 
vitro transcription of cRNA. In an ideal situation with total intact RNA, efficient 
oligo-dT based first strand cDNA synthesis and efficient hybridization, the 3'/5' ratio 
will be 1:1. However, it has been noted that a two-cycle cRNA synthesis and labelling 
process could be biased towards the 3’ region, resulting in higher 3'/5' ratio 
[Affymetrix, Inc, 2007].  It may be more appropriate to detect any sample whose 3'/5' 
ratios deviates from the mean of the group within a particular study, which could 
highlight an unusual sample that deserves further investigation. The 3’/5’ ratios for 
GAPDH gene lies from 2.59 to 3.92 for all samples.  




The scaling factor provides a measure of the ‘brightness’ of the array.  
‘Brightness’, a measure of the image intensity, varies from array to array due to 
experimental variation. Hence, it is necessary to normalize intensities of all arrays to 
same level to prevent confounding by non-biological errors.  The intensity values of 
all probe sets on the array, except the top and bottom 2% of the probe set intensities, 
were averaged in GCOS, giving rise an overall intensity. This overall intensity is then 
multiplied by a scaling factor to bring it to an arbitrary target intensity value i.e 500.  
In a particular set of experiments, the scaling factor value for all the arrays should be 
very close to each other (within two-fold of each other) [Affymetrix, Inc, 2007]. The 
scaling factors for all the samples are within two-fold of each other, the smallest 
factor being 6.4 while the largest factor is 11.0, with a mean factor of 8.0. 
 Controls are needed to detect hybridization efficiency and Bio-B, C, D and 
CRE serve as such controls and are spiked at the following concentrations: BioB: 1.5 
pM, BioC: 5.0 pM, BioD: 25.0 pM, CRE: 100 pM.  All controls are expected to be 
called present at all times, with increasing signal values (BioC, BioD, and CRE, 
respectively), with the exception of BioB, which at the lowest concentration, is 
anticipated to be called present at least 70% of the time [Affymetrix, Inc, 2007]. All 
the spiked in controls were detected as present in all arrays; in addition, there was 
increasing average intensity values from BioB to CRE for all samples.  
 Small variations in the digitized signal can happen due to sampling of probe 
array surface by the scanner, leading to noise (Q value). Examining pixel-to-pixel 
variations in background intensities allows us to measure noise. The noise value for 
all the arrays in one experiment should be very similar to each other [Affymetrix, Inc, 
2007], and the Q values for all our samples are similar to one another, with a range of 
1.1 to 1.7 only. 




3.4  Differential expression of genes in prostate adenocarcinoma 
Several softwares such as GCOS, dCHIP, RMA and Genespring were used to 
analyze the microarray data. The data was normalized and expression intensities of 
different genes were derived using each of the above software. Genes that were 
commonly identified by the four softwares as differentially expressed in the prostate 
cancer sections using the criteria set in Table 2.1 were identified and merged. From 
this selection criterion, 192 genes were found to be upregulated and 673 genes to be 
downregulated.  
 Using Database for Annotation, Visualization, and Integrated Discovery 
(DAVID) 2008, the 865 genes that were differentially expressed were functionally 
annotated and categorised, and the Gene Ontology (GO) biological process enriched 
terms associated with the genes are represented in Table 3.3.  Gene enrichment 
analysis, i.e the association of the input genes with GO terms, is statistically measured 
by Fisher’s Exact Statistics in DAVID, as represented by an EASE score. Due to 
repeated representation of similar annotations, DAVID has also developed a new tool 
termed Functional Annotation Clustering, which groups similar annotations together. 
This allows the reader to have a clearer idea of the functional categorization of the 
gene list. In addition, the Group Enrichment Score, obtained after Functional 
Annotation Clustering, is a measure of the particular annotation cluster’s biological 
significance. Thus, the bigger the group enrichment score, the more statistically 
significant is the genes in the group associated with GO terms. [Huang et al, 2009; 
Dennis et al, 2003]. 
 As seen in Table 3.3, the top-ranked annotation cluster contains genes relating 
to development process and cell differentiation. A total of 243 genes are represented 
in this cohort. Other functional annotation clusters include genes involved in cell 




migration (41 genes), proliferation (69 genes), carbohydrate binding (26 genes), 
cellular response to stress (126 genes), homeostasis (59 genes), cell communication 
(212 genes), metabolism (87 genes), of which 46 genes are involved in lipid 
metabolism, cell cycle (37 genes) and cell death (73 genes). Due to functional 
overlaps of some genes, one gene may be represented more than once in several 
annotation groups.  
Table 3.4 shows a list of some genes that are aberrantly expressed in the 
prostate cancer tissues, grouped according to their functional annotations. This list is 
not exhaustive but serves to highlight certain genes that are frequently reported to be 
involved in tumourigenesis, and also genes that code enzymes involved in GAG 
synthesis or those that code for proteoglycans. For instance, it was noted that many 
genes involved in Wnt signalling, Hedgehog signalling, TGFβ signalling and 
homeobox genes are differently expressed in prostate cancer; and all of these 
signalling pathway molecules are known to be involved in development and 
differentiation. Genes that code for GAG synthesis enzymes such as CSGalNAcT-1 
and CHST2, and genes coding for protein cores of proteoglycans such as DCN, VCAN 
and TGFBR3 are also differentially expressed and known to be involved in 
development and differentiation.  
It has been reported that chondroitin sulphate and heparan sulphate can bind 
other proteins to elicit a concerted effect on cellular signalling [Deepa et al, 2004]. 
Interestingly, transcripts coding for proteins known to be able to bind GAGs have 
been identified to be aberrantly expressed in prostate cancer (Table 3.4). It can also be 
observed that many of the GAG synthetic and editing genes are dysregulated in 
prostate adenocarcinoma tissues, such as B3GalT6, CSGalNAcT-1, GALNAC4S-6ST, 




HS6ST2, HS3ST3A1, HS3ST3B1 and SULF2. In addition, CSPG, DSPG and HSPG 
such as syndecan-1 (SDC1), decorin (DCN), versican (VCAN) and transforming 
growth factor beta receptor 3 (TGFβR3) are found to be differentially expressed in 
prostate adenocarcinoma cases as compared to benign hyperplastic tissues.  
There are also many genes that are drastically upregulated or downregulated in 
prostate adenocarcinoma tissues but are not present in the gene enrichment analysis 
table in Table 3.4. However, these genes may potentially be used as biomarkers or 
could be important functionally as well. For such reasons, I have included in the 
whole list of the 865 genes found to be more than 2 fold differentially expressed in 
prostate adenocarcinoma tissue, without any functional classification but in terms of 
its fold change value, in Appendix I. 
  




Table 3.3 Gene Ontology (GO) annotation terms and clusters that the 865 filtered genes are associated with.  
Gene Ontology Annotations Number of genes Percentage of genes (n=865) EASE score  
(p-value) 
Annotation Cluster  – Development and differentiation  Total genes: 243 Group Enrichment Score: 15.4  
anatomical structure development 184 21.27% 3.79E-24 
developmental process 241 27.86% 1.22E-23 
multicellular organismal development 192 22.20% 5.23E-23 
system development 144 16.65% 1.97E-16 
multicellular organismal process 243 28.09% 8.71E-16 
organ development 106 12.25% 2.40E-12 
cell differentiation 117 13.53% 7.73E-07 
cellular developmental process 117 13.53% 7.73E-07 
    
Annotation Cluster  – Cell motility Total genes: 41 Group Enrichment Score: 5.03  
localization of cell 40 4.62% 1.61E-06 
cell motility 40 4.62% 1.61E-06 
cell migration 25 2.89% 3.17E-04 
    
Annotation Cluster  – Cell proliferation Total genes: 69 Group Enrichment Score: 4.01  
cell proliferation 57 6.59% 4.79E-05 
negative regulation of cell proliferation 25 2.89% 5.57E-05 
regulation of cell proliferation 38 4.39% 3.46E-04 
    
Annotation Cluster - Carbohydrate binding Total genes: 26 Group Enrichment Score : 3.82  
polysaccharide binding 16 1.85% 2.49E-05 
glycosaminoglycan binding 15 1.73% 6.58E-05 




pattern binding 16 1.85% 7.78E-05 
heparin binding 12 1.39% 4.12E-04 
carbohydrate binding 26 3.01% 0.001497 
    
Annotation Cluster – Cellular response to stress Total genes: 126 Group Enrichment Score : 2.94  
inflammatory response 35 4.05% 7.82E-08 
response to wounding 40 4.62% 2.84E-06 
response to external stimulus 49 5.66% 4.15E-05 
defence response 43 4.97% 2.09E-04 
response to stress 62 7.17% 0.006162 
immune response 39 4.51% 0.544508 
immune system process 47 5.43% 0.617306 
response to stimulus 121 13.99% 0.71586 
    
Annotation Cluster  - Homeostasis Total genes: 59 Group Enrichment Score: 2.71  
cellular cation homeostasis 20 2.31% 1.55E-04 
cation homeostasis 20 2.31% 1.67E-04 
cellular di-, tri-valent inorganic cation homeostasis 18 2.08% 2.94E-04 
di-, tri-valent inorganic cation homeostasis 18 2.08% 3.16E-04 
regulation of biological quality 58 6.71% 3.72E-04 
cellular chemical homeostasis 20 2.31% 0.001254 
cellular ion homeostasis 20 2.31% 0.001254 
ion homeostasis 20 2.31% 0.003802 
chemical homeostasis 22 2.54% 0.004482 
cellular homeostasis 24 2.77% 0.00484 
metal ion homeostasis 13 1.50% 0.00692 
cellular metal ion homeostasis 13 1.50% 0.00692 




calcium ion homeostasis 12 1.39% 0.010591 
cellular calcium ion homeostasis 12 1.39% 0.010591 
homeostatic process 26 3.01% 0.036701 
    
Annotation Cluster  – Cell communication Total genes: 212 Group Enrichment Score: 2.68  
cell communication 212 24.51% 7.25E-05 
signal transduction 185 21.39% 0.002471 
cell surface receptor linked signal transduction 91 10.52% 0.051529 
    
Annotation Cluster   – Lipid metabolism Total genes: 46 Group Enrichment Score: 2.12  
fatty acid metabolic process 17 1.97% 0.00219 
lipid metabolic process 46 5.32% 0.008691 
cellular lipid metabolic process 37 4.28% 0.023393 
    
Annotation Cluster - Metabolism Total genes: 52 Group Enrichment Score: 1.83  
monocarboxylic acid metabolic process 22 2.54% 0.001061 
fatty acid metabolic process 17 1.97% 0.00219 
amine metabolic process 31 3.58% 0.007742 
carboxylic acid metabolic process 36 4.16% 0.011448 
organic acid metabolic process 36 4.16% 0.012118 
nitrogen compound metabolic process 32 3.70% 0.012476 
amino acid and derivative metabolic process 20 2.31% 0.199456 
amino acid metabolic process 15 1.73% 0.369168 
    
Annotation Cluster – Amine metabolism Total genes: 6 Group Enrichment Score: 1.78  
amino sugar metabolic process 6 0.69% 0.010263 
N-acetylglucosamine metabolic process 5 0.58% 0.020122 




glucosamine metabolic process 5 0.58% 0.022879 
    
Annotation Cluster - Cell cycle Total genes: 37 Group Enrichment Score: 1.05  
negative regulation of progression through cell cycle 18 2.08% 0.005422 
regulation of progression through cell cycle 30 3.47% 0.063881 
regulation of cell cycle 30 3.47% 0.06594 
cell cycle process 33 3.82% 0.426408 
cell cycle 37 4.28% 0.559598 
    
Annotation Cluster – Cell death Total genes: 73 Group Enrichment Score: 0.88  
cell development 73 8.44% 0.00157 
regulation of apoptosis 30 3.47% 0.078811 
regulation of programmed cell death 30 3.47% 0.086461 
death 42 4.86% 0.123836 
cell death 42 4.86% 0.123836 
anti-apoptosis 11 1.27% 0.153858 
programmed cell death 39 4.51% 0.169792 
apoptosis 38 4.39% 0.200731 
negative regulation of apoptosis 13 1.50% 0.234682 
positive regulation of apoptosis 14 1.62% 0.24354 
negative regulation of programmed cell death 13 1.50% 0.244507 
positive regulation of programmed cell death 14 1.62% 0.248142 
induction of apoptosis 11 1.27% 0.371252 
induction of programmed cell death 11 1.27% 0.376754 
 




Table 3.4  A highlight of some genes that are differentially expressed in prostate adenocarcinoma tissues (n=6) as compared to BPH tissues 
(n=6), grouped by their functions. 
Gene Symbol Gene Name Gene ID Relative fold changea 
 Developmental and Differentiation   
 Wnt signalling pathway   
DIXDC1 Dix domain containing 1 85458 -2.1 
DKK3 Dickkopf Homolog 3 (Xenopus Laevis) 27122 -2.3 
FZD1 Frizzled Homolog 1 (Drosophila)  8321 -2.2 
FZD10 Frizzled Homolog 10 (Drosophila) 11211 -9.5 
FZD2 Frizzled Homolog 2 (Drosophila) 2535 -2.4 
FZD7 Frizzled Homolog 7 (Drosophila) 8324 -2.4 
PPAP2B Phosphatidic acid phosphatase Type 2B 8613 -2.9 
ROR2 Receptor tyrosine kinase-like orphan receptor 2 4920 -5.0 
RSPO3 R-spondin 3 homolog (Xenopus laevis) 84870 -3.9 
SFRP1 Secreted Frizzled-Related Protein 1 6422 -3.8 
TCF7L1 Transcription factor 7-Like 1 (T-cell specific, HMG-Box) 83439 -2.7 
TGFB1/1 Transforming growth factor beta 1 induced transcript 1 7041 -3.3 
TLE2 Transducin-like enhancer of split 2 (E(Sp1) Homolog, Drosophila) 7089 -2.4 
WIF1 WNT inhibitory factor 1 11197 -36.7 
WNT2 Wingless-type MMTV integration site family member 2 7472 -2.8 
WNT4 Wingless-type MMTV integration site family member 4 54361 -3.1 
WNT5B Wingless-type MMTV integration site family member 5B 81029 -2.0 
    
 Hedgehog signalling pathway   
BMP4 Bone morphogenetic protein 4 652 -2.9 
BMP5 Bone morphogenetic protein 5 653 -2.7 
GAS1 Growth arrest specific 1 2619 -2.5 




HHIP Hedgehog interacting protein  64399 -2.9 
WNT2 Wingless-type MMTV integration site family member 2 7472 -2.8 
WNT4 Wingless-type MMTV integration site family member 4 54361 -3.1 
WNT5B Wingless-type MMTV integration site family member 5B 81029 -2.0 
ZIC2 Zic family member 2 (Odd-paired Homolog, Drosophila)  7546 21.7 
    
 TGFβ signalling pathway   
BMP4 Bone morphogenetic protein 4 652 -2.9 
BMP5 Bone morphogenetic protein 5 653 -2.7 
COMP Cartilage oligomeric matrix protein 1311 4.4 
DCN Decorin 1634 -2.0 
FST Follistatin 10468 -3.9 
TGFB3 Transforming growth factor, beta 3 7043 -5.1 
    
 Homeobox genes   
HOXC6 Homeobox C6 3223 12.3 
HOXC4 Homeobox C4 3221 4.8 
HOXB3 Homeobox B3 3213 -2.5 
HOXB2 Homeobox B2 3212 -2.6 
HOXD10 Homeobox D10 3236 -3.2 
DLX1 Distal-less Homeobox 1 1745 7.8 
NKX2-3 NK2 tanscription factor homolog C (Drosophila) 159296 6.6 
    
 GAG enzyme synthesis genes/proteoglycans   
CSGALNACT-1 Chondroitin beta 1,4 N-acetylgalactosaminyltransferase 55790 2.0 
DCN Decorin 1634 -2.0 
VCAN Chondroitin sulphate proteoglycan 2 (versican) 1462 -2.7 




TGFBR3 Transforming growth factor , beta receptor III (Betaglycan, 300kDa) 7049 -2.8 
CHST2 Carbohydrate (N-Acetylglucosamine-6-O) Sulphotransferase 2 9435 -4.4 
    
 Cell proliferation   
MYC V-MYC Myelocytomatosis viral oncogene homolog (Avian) 4609 4.1 
CSGALNACT-1 Chondroitin beta 1,4 N-acetylgalactosaminyltransferase 55790 2.0 
FGFR1 Fibroblast growth factor receptor 1 2260 -2.0 
PDGFC Spinal cord derived growth factor; Secretory growth factor-like protein 
fallotein 
56034 -2.3 
PTN Pleiotrophin   5764 -3.3 
PGF Placental growth factor 5228 -3.6 
FGFR2 Fibroblast growth factor receptor 2 2263 -4.7 
TGFB3 Transforming growth factor, beta 3 7043 -5.1 
    
 Glycosaminoglycan binding proteins   
ABP1 Amiloride binding protein 1 (amine oxidase (Copper containing) 26 -27.8 
ANG Angiogenin, ribonuclease, RNase A family, 5 283 -2.2 
APOE Apolipoprotein E 348 2.1 
BMP4 Bone morphogenetic protein 4 652 -2.9 
COL13A1 Collagen, type XIII, alpha 1 1305 -4.6 
CXCL6 Chemokine (C-X-C Motif) Ligand 6 (Granulocyte chemotactic protein 
2) 
6372 -6.7 
FGFR1 Fibroblast growth factor receptor 1 2260 -2.0 
FGFR2 Fibroblast growth factor receptor 2 2263 -4.7 
HMMR Hyaluronan-mediated motility receptor (RHAMM) 3161 2.4 
PGF Placental growth factor 5228 -3.6 
PTN Pleiotrophin   5764 -3.3 




RSPO3 R-spondin 3 homolog (Xenopus laevis) 84870 -3.9 
SERPINE2 Serpin peptidase inhibitor, Clade E (Nexin, Plasminogen activator 
inhibitor type I), member 2 
5270 -2.1 
TGFBR3 Transforming growth factor , beta receptor III (Betaglycan, 300kDa) 7049 -2.8 
VCAN Chondroitin sulphate proteoglycan 2 (versican) 1462 -2.7 
    
 Metabolism   
APOE Apolipoprotein E 348 2.1 
B3GALT6 UDP-Gal:BetaGal Beta 1,3-Galactosyltransferase Polypeptide 6 126792 2.2 
CHST2 Carbohydrate (N-Acetylglucosamine-6-O) sulphotransferase 2 9435 -4.4 
CHST9 Carbohydrate (N-Acetylgalactosamine-4-O) sulphotransferase 9 83539 -11.3 
CSGALNACT-1 Chondroitin beta 1,4 N-acetylgalactosaminyltransferase 55790 2.0 
FABP5 Fatty acid  binding protein 5 (Psoriasis-associated) 2171 4.4 
FASN Fatty acid synthase 2194 4.5 
FBP1 Fructose-1,6-bisphosphatase 1 2203 4.1 
GALNAC4S-6ST BRAG 51363 -4.0 
HK2 Hexokinase 2 3099 3.8 
HS3ST3B1 Heparan sulphate-3-O-sulphotransferase 3B1 5593 -2.2 
SULF2 Sulphatase 2 55959 -2.7 
    
 GAG synthesis / Proteoglycan   
B3GALT6 UDP-Gal:BetaGal Beta 1,3-Galactosyltransferase Polypeptide 6  126792 2.2 
CHST2 Carbohydrate (N-Acetylglucosamine-6-O) sulphotransferase 2 9435 -4.4 
CHST9 Carbohydrate (N-Acetylgalactosamine-4-O) sulphotransferase 9 83539 -11.3 
CSGALNACT-1 Chondroitin beta 1,4 N-acetylgalactosaminyltransferase 55790 2.0 
DCN Decorin 1634 -2.0 
GALNAC4S-6ST BRAG 51363 -4.0 




HS3ST3A1 Heparan sulphate-3-O-sulphotransferase 3A1 9955 -2.5 
HS3ST3B1 Heparan sulphate-3-O-sulphotransferase 3B1 5593 -2.2 
HS6ST2 Heparan sulphate 6-O-sulphotransferase 2 90161 -3.6 
SDC1 Syndecan 1 6382 -2.8 
SULF2 Sulphatase 2 55959 -2.7 
TGFBR3 Transforming growth factor , beta receptor III (Betaglycan, 300kDa) 7049 -2.8 
VCAN Chondroitin sulphate proteoglycan 2 (versican) 1462 -2.7 
aRelative fold changes listed are those determined by dCHIP. 
  




3.5 Hierarchical clustering of microarray data 
Unsupervised sample clustering using the 865 filtered genes was used to identify 
novel sample clusters and their associated gene signature. This allows checking of the quality 
of the microarray data to determine if similar samples cluster together and to identify 
unexpected clustering (e.g of samples processed in the same batch cluster together.) A 
dendrogram shown in Figure 3.5 illustrates the overall gene expression profile across the 
samples (genes-horizontal, samples-vertical). This analysis revealed a major division between 
the benign prostate sections and the cancerous tissue sections. 
3.6 Principal component analysis (PCA) of microarray expression data 
Principal component analysis (PCA) is a useful method to determine sample classes 
based on the gene expression profiles. PCA maps samples in high N dimensions (N is the 
number of genes) to two dimensions, identifying clusters of samples that are more similar to 
one another in terms of gene expression. Using PCA, it can be clearly seen that the cancer 
samples are separated distinctly from the BPH samples (Figure 3.6). The cancer samples are 
observed to be further apart from one another, demonstrating a more heterogeneous genetic 
makeup.  





Figure 3.5  Hierarchical clustering of differentially expressed genes (n=865) in 
prostate cancer tissues (n=6) compared to BPH (n=6) tissues. Rows: individual genes; 
columns: individual samples. Each cell in the matrix represents expression level of a 
single gene in a single sample. Red: transcripts above the median for that gene across 
all samples. Green: transcripts below the median for that gene across all samples. The 
dendrogram on the left represents genes grouped by similarity. Inset: BPH samples 
clustered separately from prostate cancer samples. 
 
  




Figure 3.6 Principal component analysis (PCA) of the six BPH samples and six 
prostate adenocarcinoma samples used in the study. PCA was generated in two-
dimension and presented here, showing difference and similarities between samples. 
The BPH samples and cancer samples were distinctly separated from each other. 
 




3.7  Quantitative real-time polymerase chain reaction (qPCR) verification of 
microarray results 
For the purpose of verification of the microarray data, quantitative real-time 
polymerase chain reaction was performed on the human prostate tissue samples used 
for the microarray study. Fifty-three random genes were quantified, in which all 53 
genes (100%) were found to be differentially changed in the same direction as 
determined from the microarray study (i.e both upregulated or downregulated through 
microarray study and real-time PCR) (Table 3.5). From the microarray, 865 genes 
from our gene list are genes determined to be differentially expressed by at least 2 
fold change with a significant p-value <0.05. However, from real-time PCR, 5 of the 
53 genes (about 9%) did not demonstrate a statistically significant p-value (p>0.05) 
albeit revealing a trend in the same differential direction as the microarray result. 
Nevertheless, these data represent that approximately 91% of the genes from the 
microarray data are true positives.  
  




Table 3.5 Verification of several genes from microarray list, as determined by real-time PCR 










ALDH1A2 aldehyde dehydrogenase 1 family, member A2 8854 -5.22 -4.65 0.0003 
AMACR alpha-methylacyl-CoA racemase 23600 28.94 59.58 <0.0001 
B3GALT6c UDP-Gal:betaGal beta 1,3-galactosyltransferase 
polypeptide 6 
126792 2.32 2.47 0.0158 
CHST2 c carbohydrate (N-acetylglucosamine-6-O) 
sulphotransferase 2 
9435 -4.38 1.31 0.496 
CSGalNAcT-1 c chondroitin beta1,4 N-acetylgalactosaminyltransferase 55790 2.75 4.27 0.0161 
COL4A6 collagen, type IV, alpha 6 1288 -6.38 -4.51 0.0016 
CXCL13 chemokine (C-X-C motif) ligand 13 (B-cell 
chemoattractant) 
10563 -27.09 -33.01 0.0002 
CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5 1577 -29.34 N.Db <0.05 
CYP4B1 cytochrome P450, family 4, subfamily B, polypeptide 1 1580 -24.84 -37.57 <0.0001 
DCN c decorin 1634 -2.03 -4.55 0.07 
EFEMP2 EGF-containing fibulin-like extracellular matrix protein 
2 
30008 -2.90 -1.96 0.0113 
FASN fatty acid synthase 2194 4.30 7.87 0.0002 
FBP1 fructose-1,6-bisphosphatase 1 2203 4.27 13.25 <0.0001 
FLRT3 fibronectin leucine rich transmembrane protein 3 23767 -6.06 -4.85 0.0003 
GALNT7 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 7 (GalNAc-T7) 
51809 2.74 10.82 0.0006 
GATA3 GATA binding protein 3 2625 -9.67 -8.11 0.0003 




GJA1 gap junction protein, alpha 1, 43kDa (connexin 43) 2697 -3.23 -3.90 0.0007 
GLYATL1 glycine-N-acyltransferase-like 1 92292 7.62 19.23 0.0002 
HOXC6 homeobox C6 3223 12.08 30.03 0.0008 
HPN hepsin (transmembrane protease, serine 1) 3249 6.19 6.39 0.22 
HS3ST3A1c heparan sulphate (glucosamine) 3-O-sulphotransferase 
3A1 
9955 -2.52 -2.32 0.035 
HS6ST2 c heparan sulphate 6-O-sulphotransferase 2 90161 -3.54 -3.59 0.0293 
KRT15 keratin 15 3866 -43.86 0.01 0.0012 
LAMB3 laminin, beta 3 3914 -11.79 -28.64 0.0022 
LTF lactotransferrin 4057 -188.70 -70.36 <0.0001 
MAL2 mal, T-cell differentiation protein 2 114569 4.66 10.33 0.0002 
MYC v-myc myelocytomatosis viral oncogene homolog 
(avian) 
4609 3.86 13.91 <0.0001 
MYO6 myosin VI 4646 3.56 8.39 0.0021 
PCA3 prostate cancer antigen 3 50652 19.36 140.07 0.047 
PDGFC platelet derived growth factor C 56034 -1.97 -2.45 0.0093 
PDLIM5 PDZ and LIM domain 5 10611 3.42 2.22 0.09 
PPAP2B phosphatidic acid phosphatase type 2B 8613 -2.86 -1.75 0.0258 
RARRES2 retinoic acid receptor responder (tazarotene induced) 2 5919 -4.23 -1.66 0.1991 
SDC1 c syndecan 1 6382 -2.94 -2.92 0.063 
SGEF Src homology 3 domain-containing guanine nucleotide 
exchange factor 
26084 4.89 2.71 0.0025 
SLC14A1 solute carrier family 14 (urea transporter), member 1 
(Kidd blood group) 
6563 -30.8 -41.79 0.0003 
SLC2A5 solute carrier family 2 (facilitated glucose/fructose 
transporter), member 5 
6518 -14.67 -60.13 0.0043 
SPOCK3  sparc/osteonectin, cwcv and kazal-like domains 50859 -2.11 -3.69 0.0418 




proteoglycan (testican) 3 
SRD5A2 steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 
alpha-steroid delta 4-dehydrogenase alpha 2) 
6716 -8.63 -26.85 0.0297 
SRPRB signal recognition particle receptor, B subunit 58477 2.14 5.62 0.0004 
STEAP4 STEAP family member 4 79689 3.01 11.50 0.0001 
SULF2 c sulphatase 2 55959 -2.49 -2.05 0.0154 
TCEAL2 transcription elongation factor A (SII)-like 2 140597 -3.83 -3.09 0.0304 
TGFB3 transforming growth factor, beta 3 7043 -4.20 -2.87 0.0333 
TGFBR3 c transforming growth factor, beta receptor III 
(betaglycan, 300kDa) 
7049 -2.55 -2.08 0.0362 
TP73L tumour protein p73-like 8626 -53.81 -753.95 0.0151 
TPD52 tumour protein D52 7163 2.38 4.93 0.0011 
TRIM29 tripartite motif-containing 29 23650 -5.54 -102.66 0.0182 
TRIM36 tripartite motif-containing 36 55521 3.92 12.79 <0.0001 
UAP1 UDP-N-acteylglucosamine pyrophosphorylase 1 6675 3.45 7.26 0.0013 
VCAN c chondroitin sulphate proteoglycan 2, versican 1462 -2.59 -2.26 0.0442 
VSNL1 visinin-like 1 7447 -4 -157.04 0.0021 
WIF1 Wnt inhibitory factor 1 11197 -38.85 -45.10 0.0006 
aFor relative fold changes of genes, as derived from microarray study, p-values are all <0.05. 
bNot detectable in 45 cycles of real-time PCR in prostate adenocarcinoma tissues, but detectable within 45 cycles for BPH tissues. 
cGenes highlighted in bold are genes coding for CS/DS/HS enzymes or genes coding for CSPG/DSPG/HSPG. 
dRelative fold changes are calculated using BPH tissues as control sections.    






3.8.1 Aberrant expression of genes in prostate adenocarcinoma  
Genome-wide expression profiling of human tissues using microarray platforms 
have been very beneficial in studies aimed at elucidating molecular pathways that 
have gone awry in diseases. Due to its high-throughput nature, thousands of genes can 
be screened in a short matter of time, giving rise to molecular pictures illustrating 
many genes that are differentially expressed in diseased conditions such as cancer, as 
compared to normal controls. This molecular picture obtained can then be applied in 
the field of cancer diagnosis and prognosis, such as the one developed in breast 
cancer, where the molecular patterns of thousands of gene expression have been used 
as prognostic markers of breast cancer outcome [Perou et al, 2000; Zajchowski et al, 
2001]. 
The prerequisite of such a study for prognostic purposes would be to have a big 
sample population size and long-term follow up data. Prostate cancer incidence in 
Singapore for the Chinese population occurs at a rate of 24.3 for every 100000 
persons per year, from 2002-2006 [Seow et al, 2009]. From our experience with 
prostate tissue sample collection at Tan Tock Seng Hospital, we managed to collect 
prostate tissues from 62 different patients (of different races) with BPH or prostate 
cancer, over a span of approximately 2 years (2005 and 2006), out of which, after 
haematoxylin and eosin staining (to check for presence of cancer tissues) and RNA 
quality check using Agilent Bioanalyzer 2000 (only good quality RNA can be used 
for downstream microarray analysis), only 6 prostate adenocarcinoma tissue sections 
were found suitable for use in the microarray study. Long-term post-surgery follow up 
data for the prostate cancer patients are still in midst of acquisition. As such, the small 
sample sizes (n=6 for each of  BPH control group and prostate cancer group) and lack 




of long term follow up data in this study currently do not allow delineation of 
predictive models for prostate cancer progression.  
Nevertheless, this study gives insight into some of the molecules that are 
dysregulated in prostate adenocarcinoma, which thereafter permits us to conduct 
further studies to determine which of these molecules are important players in the 
prostate adenocarcinoma phenotype. In addition, molecules that are highly 
differentially expressed can act as potential markers for prostate cancer diagnosis 
and/or prognosis.  Our study has provided insights into prostate carcinogenesis in a 
Singapore Chinese population using the Affymetrix GeneChip microarray platform. 
Interestingly, some genes that have been reported to be differentially expressed in 
previous studies [Welsh et al, 2001; Dhanasekaran et al, 2001; Luo et al, 2001; 
Lapointe et al, 2004; Chandran et al, 2005], have also been found to be differentially 
expressed in our study. This suggests that these genes could be important factors in 
prostate cancer regardless of genetic makeup, geographic locality and technical 
operating issues. Due to difficulties in obtaining raw microarray data from most of 
those previous studies except those from Welsh et al, 2001, it was only possible to 
compare our filtered gene list with theirs. Welsh et al, 2001 compared the expression 
profiles of 25 prostate cancer tissues with 9 nonmalignant prostate tissues using the 
Affymetrix GeneChip microarray platform. It was revealed that 247 genes (28.6% of 
my gene list) were found common to be differently expressed by 2 fold change in 
both their study and my study. Considering genes that were highlighted to be 
differentially expressed in prostate cancer from the other studies where raw data was 
not easily available, alpha-methylacyl-CoA-racemase (AMACR), hepsin (HPN) and 
fatty acid synthase (FASN) were found to be consistently upregulated in prostate 
cancer across all studies including those of mine.  




Using DAVID and based on the Gene Ontology Biological Function categories, 
the list of differentially expressed genes could be divided into different functional 
groups. As seen from the results above, the top-ranked annotation cluster in our gene 
list are the genes relating to development process and cell differentiation. A total of 
243 genes are represented in this cohort. This is followed by, in decreasing group 
enrichment scores, genes involved in cell migration (41 genes), proliferation (69 
genes), carbohydrate binding (26 genes), cellular response to stress (126 genes), 
homeostasis (59 genes), cell communication (212 genes), metabolism (87 genes), of 
which 46 genes are involved in lipid metabolism, cell cycle (37 genes) and cell death 
(73 genes). Due to functional overlaps of some genes, one gene may be represented 
more than once in several annotation groups.  
3.8.2 Prostate cancer as a result of development gone wrong? 
It has long been hypothesized that the biology of cancer cell is a recapitulation of 
the biology of normal development and tissue renewal. Observational studies by 
Pierce and Speers, 1988, described the similarities seen in both developing tissues and 
tumours, that both tissue types had numerous undifferentiated cells with high 
proliferative capacity and the presence of post-mitotic differentiated cells. This led to 
the proposal that both tissues types are sustained by a population of self-renewing 
stem cells that first give rise to undifferentiated, highly proliferative daughter cells 
and in the case of the developing and renewing tissue, the daughter cells will 
subsequently differentiate and remain growth quiescent.  What is different in the 
tumour tissue is the inability of the progeny cells to undergo proper differentiation, 
resulting in the accumulation of a heterogeneous mass of undifferentiated cancer stem 
cells with great proliferative ability, as well as more differentiated cancer cells with 
limited proliferative capacity [Pierce and Speers, 1988]. The suggestion that the 




mechanisms regulating cell proliferation and differentiation in tumours is 
fundamentally similar to the mechanisms regulating those of the developing and 
renewing tissues is thus put forth; dysregulation of the normal stem cell self-renewal 
pathway could result in unregulated control of cell proliferation and leads to 
neoplastic transformation [Marker PC, 2008]. It has also been proposed that mutations 
could cause the de-differentiation of mature differentiated cells and subsequent 
acquisition of cancer stem cell-like properties. 
Evidence for the existence of normal stem cells in prostate gland have been 
identified:  by using cell surface markers integrin α2β1 and CD133 [Collins et al, 
2005; Gu et al, 2007; Patrawala et al, 2007], stem cells are found to be randomly 
distributed throughout the acini and ductal regions, usually at the base of branching 
points [Collins et al, 2001; Hudson et al, 2001; Richardson et al, 2004]. The adult 
prostate epithelial stem cells have been shown to sit on and be anchored to the 
basement membrane by integrin α2β1 [Collins et al, 2001].  
Cancer stem cells do not necessarily originate from normal stem cells; the origins 
of the cancer stem cell are still not well-established but many postulations are made. 
These include the ideas that cancer stem cells can arise from aberrant mutated stem 
cells, or due to accumulations of mutations in progeny daughter cells and perhaps 
even as a result of acquisition of stem-cell like properties of well-differentiated 
progeny cells that are undergoing de-differentiation [Moltzahn et al, 2008]. In the case 
of prostate cancer, prostate cancer stem cells are postulated to arise from the normal 
prostate stem cells; Collins et al, 2005, isolated cell populations from primary prostate 
cancers and found that only cells expressing α2β1/ CD133+/ CD44+ , which were 
identical to normal prostate stem cells, could self-renew in vitro [Lang et al, 2009; 
Collins et al, 2005]. Transcript levels of α2β1, CD133 and CD44 were not differently 




expressed in the prostate adenocarcinoma tissues as compared to BPH sections, which 
could possibly indicate that there are no higher numbers of prostate cancer stem cells 
in prostate tumours, but rather support the view that prostate cancer stem cells arise 
from the normal prostate stem cells and hence, possibly hint at the dysregulation of 
the normal stem cell self-renewal mechanisms, leading to prostate tumourigenesis and 
progression. 
Several pathways have been shown to regulate a balance between normal stem 
cell self-renewal and apoptosis.  These include the WNT signalling pathway, TGFβ 
pathway, Sonic hedgehog and Notch signalling pathway [Lang et al, 2009; Moltzahn 
et al, 2008]. Interestingly, these same signal transduction pathways have been 
acknowledged to be able to trigger epithelial-mesenchymal transition (EMT) 
programmes. EMT refers to “a complex molecular programme in which epithelial 
cells sheds their well-differentiated characteristics, including cell-cell adhesion, planar 
apical-basal polarity, lack of motility, and acquire mesenchymal features such as 
motility, invasion and apoptosis resistance” [Polyak and Weinberg, 2009]. EMTs are 
crucial in embryonic development and increasingly acknowledged to be important in 
carcinogenesis as well, where they contribute to invasive properties, and generates 
stem cell-like cells [Hugo et al, 2007; Yang & Weinberg, 2008; Mani et al, 2008].  
Therefore, it appears that dysregulation of these pathways have significant 
repercussions, from disrupting homeostatic balance of normal stem cell self renewal, 
differentiation and apoptosis to triggering EMTs, resulting in neoplastic 
transformation and subsequent metastasis. In short, carcinogenesis appears to be 
development of the organ that has gone awry. 
  Indeed, results from my study appear to agree with the idea that cancer could be 
a dysregulated recapitulation of development and differentiation and due to activation 




of EMT programmes. Two hundred and forty-three genes in our differentially 
expressed gene list are genes involved in development and differentiation. These 
perhaps suggest that the genes regulating development and differentiation are 
dysregulated resulting in tumourigenesis or from another view, these genes may be 
selected for use during prostate cancer progression. Many of the genes in our list 
belong to the WNT signalling pathway, hedgehog signalling pathway and TGFβ 
pathway, and in addition to that, many of these genes are homeobox genes, all of 
which are established to be implicated in organogenesis, tumourigenesis and EMTs.  
3.8.2.1 Dysregulation of Wnt signalling pathway  
The WNT signalling pathway is a highly conserved pathway, crucial in 
embryonic development in many animal species and continues to be important in the 
regeneration of many adult tissues [Klaus and Birchmeier, 2008]; dysregulation of 
WNT pathway has been implicated in many cancers to date [Akiri et al, 2009; Bisson 
and Prowse, 2009; Bandapalli et al, 2009] and in addition, specification and 
maintenance of precursor cell and stem cell lineages have been shown to involve the 
Wnt signalling pathway too [Bisson and Prowse, 2009; Evans T, 2009; Goessling et 
al, 2009]. From our gene list, 17 genes, known to be involved in the WNT signalling 
pathway, have been found to be differentially expressed in prostate adenocarcinoma 
as compared to benign prostate hyperplastic tissues. These 17 genes include WNT 
inhibitory factor 1 (WIF1), frizzled homolog 10 (Drosophila) (FZD10), frizzled 
homolog 2 (Drosophila) (FZD2), frizzled homolog 7 (Drosophila) (FZD7), frizzled 
homolog 1 (Drosophila) (FZD1), wingless-type MMTV integration site family, 
member 4 (WNT4), wingless-type MMTV integration site family member 2 (WNT2), 
wingless-type MMTV integration site family, member 5B (WNT5B), secreted 
frizzled-related protein 1 (SFRP1), dickkopf homolog 3 (Xenopus laevis) (DKK3), R-




spondin 3 homolog (Xenopus laevis) (RSPO3), DIX domain containing 1 (DIXDC1), 
receptor tyrosine kinase-like orphan receptor 2 (ROR2), transforming growth factor 
beta 1 induced transcript 1 (TGFB1/1), phosphatidic acid phosphatase type 2B 
(PPAP2B), transcription factor 7-like 1 (T-cell specific, HMG-box) (TCF7L1), 
transducin-like enhancer of split 2 (E(sp1) homolog, Drosophila) (TLE2).  
It is interesting to note that all 17 genes are downregulated in prostate 
adenocarcinoma tissues, the most prominent gene being WIF1, which is 
downregulated by approximately 37 fold.  WIF1 encodes a secreted protein that binds 
and inhibits WNT proteins and have been reported to be a tumour suppressor gene 
that is frequently silenced in tumours [Chim et al, 2008; Kansara et al, 2009; Licchesi 
et al, 2008; Elston et al, 2008]. RNA and protein levels of WIF1 were also found to be 
reduced in prostate cancers, in a separate study conducted by Wissman et al. 
[Wissmann et al, 2003]. In addition, SFRP1 and DKK, soluble WNT antagonists, are 
oftenly found downregulated in several tumours and suggested to be potential tumour 
suppressor genes [Gauger et al, 2009; Chung et al, 2009; Maehata et al, 2008; Suzuki 
et al, 2008]. Loss of DKK3 has been reported to result in loss of prostate glandular 
architecture and overproliferation of prostate epithelial cells, a hallmark of prostate 
cancer progression [Kawano et al, 2006].  
Frizzled (FZD) are cell surface receptors of WNT ligands, and both receptors and 
ligands encompass a huge family of variants; there are 10 known frizzled (FZD) and 
12 known WNT ligands in the pathway, but exact roles and interplay between each 
FZD and WNT ligands in the activation or repression of the WNT transduction signal 
remains to be elucidated. MYC, a well-known proto-oncogene, is a target of the WNT 
signalling pathway [He et al, 1998], and this gene has been shown to be upregulated 
by 4 folds in the cohort of prostate adenocarcinomas studied here. All in, these results 




have clearly demonstrated that many components of the WNT signalling pathway is 
dysregulated in prostate adenocarcinoma, and this dysregulation could potentially 
disturb the balance between stem cell renewal, differentiation and apoptosis 
ultimately resulting in neoplastic transformation of the prostate gland. 
3.8.2.2 Dysregulation of homeobox genes   
Homeobox genes encode nuclear proteins that act as transcription factors, which 
are important in regulating morphogenesis and cell differentiation during embryonic 
development [Nunes et al, 2003]. Homeobox genes are categorized into clustered (or 
HOX genes) and non-clustered genes. HOX genes are organized in 4 genomic 
clusters, HOX-A, HOX-B, HOX-C and HOX-D, located at different genomic loci 
while non-clustered homeobox genes are dispersed everywhere at different positions 
on different chromosomes [Cillo et al, 2001]. From our study, several homeobox 
genes that are differentially expressed in prostate adenocarcinomas, that includes 
homeobox C6 (HOXC6), distal-less homeobox 1 (DLX1), homeobox C4 (HOXC4), 
homeobox B2 (HOXB2), homeobox B3 (HOXB3), homeobox D10 (HOXD10) and 
NK2 transcription factor related, locus 3 (Drosophila) (NKX2-3) have been identified. 
HOXC6 was upregulated by nearly 12 fold in prostate adenocarcinoma tissues used in 
our study, and other studies have also reported the overexpression of HOXC6 in 
prostate cancers that correlated with cancer progression [McCabe et al, 2008]. Loss of 
HOXC6 was found to induce apoptosis in prostate cancer cells, which infers that a 
high expression of HOXC6 could confer apoptosis resistance in prostate 
adenocarcinoma [Ramachandran et al, 2005]. In addition, HOXC6 was found to 
indirectly regulate Notch and WNT signalling pathways in prostate cancer in vivo 
[McCabe et al, 2008]. HOXC4 was also shown to be upregulated in prostate cancers 
in our study, consistent with another study performed by Miller GJ et al. [Miller et al, 




2003]. However, the other HOX genes found in a different cluster from HOX-C, 
namely HOXB2, HOXB3, HOXD10 were downregulated in our prostate 
adenocarcinoma tissues. The expression and functions of these HOX genes in prostate 
cancer have rarely been reported to date. Again, differential expression of these 
homeobox genes in prostate adenocarcinoma could result in aberrations in cell 
differentiation and apoptosis, piloting the way for carcinogenesis. 
3.8.3 Prostate cancer – sustaining growth and motility while evading death 
signals 
The hallmarks of cancer cells are to sustain cell growth and proliferation, evade 
apoptosis, detach from cell-cell adhesions, invade into the surrounding stroma and 
migrate to metastatic sites [Hanahan and Weinberg, 2000]. Malignant transformation 
is viewed as a multistep process comprising of the above processes, and these steps 
reflect genetic alterations that drive the cells to malignancy. As anticipated, many 
genes known to be involved in cell cycle, proliferation, migration and apoptosis, were 
observed to be differentially expressed in the prostate adenocarcinoma tissues used in 
our study. Delineating the functional significance of the differential expression of 
these genes will be important though, so as to demarcate genes that could play central 
roles, not necessarily causative factors, in prostate tumourigenesis, from genes that are 
differentially expressed as a consequence of the transformation process. In doing so, 
these could provide us potential novel therapeutic targets that could impede the 
progression of prostate cancer. 
3.8.4 Prostate cancer as a result of aberration of metabolic processes? 
Cancer has hardly been recognized as a disease due to aberration in metabolic 
pathways but until recently, tumour bioenergetics has been thrown into the spotlight. 
Certainly, the Warburg effect, exemplified by the dependence of cancer cells on 




glycolysis (anaerobic breakdown of glucose into ATP) even in the presence of 
oxygen, has long been recognized since nearly 80 years ago. Otto Warburg thought 
that this phenomenon was a main cause of cancer, which has subsequently been 
discredited over the years due to identification of cancers that do not rely heavily on 
aerobic glycolysis for energy [Zhivotovsky and Orrenius, 2009]. However, in recent 
years, reports were made linking metabolic changes to malignant transformation, but 
this comes with controversy and debate [Gatenby and Gillies, 2004; Bernards and 
Weinberg, 2002; Garber K, 2006]. Some refute that metabolic changes are 
consequences of cancer rather than as contributors to it. No doubt such metabolic 
changes could provide cancer cells with growth and survival advantages in the tumour 
microenvironment, as glycolysis gives an added boost of energy to cancer cells and 
provides sustenance and autonomy. Hence, it will be valuable to target components of 
the metabolic pathway for anti-tumour therapeutics. 
From our gene list, 104 genes associated with various metabolic pathways have 
been shown to be differentially expressed in prostate adenocarcinoma. The 
upregulation of fructose-1,6-bisphosphatase (FBP1) and hexokinase 2 (HEX2) seems 
to highlight the prominence of high glucose utilization in the prostate tumour cells; 
fructose-1,6-bisphosphatase is an enzyme that converts fructose-1,6-bisphosphate to 
fructose during gluconeogenesis [Marcus et al, 1987], and increased expression of this 
gene implies increased glucose synthesis. Moreover, hexokinases phosphorylate 
glucose to yield glucose-6-phosphate (Glc-6-P), which is the first essential step of 
glucose metabolism. This allows glucose entry into the cells through maintaining a 
concentration gradient, and is fundamental to all major pathways of glucose 
utilization, including glycolysis, the pentose phosphate pathway (PPP) and 




glycogenesis [Mathupala et al, 2009]. Again, this emphasizes the high glucose 
requirement of the tumour cells. 
Of significance too, is the huge representation of lipid metabolism genes (46 
genes) in our differentially expressed gene list, with the prominent upregulation of 
fatty acid synthase (FASN) in the prostate adenocarcinoma tissues. FASN is a 
lipogenic enzyme catalyzing the terminal steps in the de novo synthesis of fatty acids; 
the endogenous fatty acid production could be an important source of energy supply 
for tumour growth, or a crucial source of structural constituents of the membrane for 
actively proliferating cells, and/or to synthesize lipid-based factors that could act as 
autocrine/paracrine factors, all of which could confer growth advantage and survival 
for the tumour cells [Menendez and Lupu, 2006]. Many tumours were observed to 
undergo exacerbated fatty acid synthesis with a concomitant FASN overexpression 
[Innocenzi et al, 2003; Takahiro et al, 2003; Wang et al, 2004; Visca et al, 2004]. In 
prostate cancer, this FASN increase was associated with a four-fold increase risk of 
disease recurrence and with higher Gleason sum [van de Sande et al, 2005]. Inhibition 
of FASN leading to reduced FA synthesis has resulted in cell cycle arrest, reduced 
growth and induced apoptosis [Migita et al, 2009], suggesting that FASN may play a 
role that integrates metabolism and cell survival signalling pathways. This positions 
FASN as a potential drug target for cancer therapy.   
3.8.5 Aberrant expression of GAGs and PGs genes in prostate cancer 
Essentially, we have also identified many genes coding for glycosaminoglycan 
biosynthetic and editing enzymes and proteoglycans that are differentially expressed 
in prostate adenocarcinomas. The genes coding for GAG synthesis and modifying 
enzymes that are significantly upregulated (p<0.05) by more than 2 folds include 
UDP-Gal:betaGal beta 1,3-galactosyltransferase polypeptide 6 (B3GalT6), 




chondroitin sulphate N-acetylgalactosaminyltransferase 1 (CSGalNAcT1) and 
sulphatase 2 (SULF2) while those downregulated by more than 2 fold are B cell RAG 
associated protein (GalNAcT4S-6ST), heparan sulphate 6-O-sulphotransferase 2 
(HS6ST2), heparan sulphate (glucosamine) 3-O-sulphotransferase 3A1 (HS3ST3A1) 
and heparan sulphate (glucosamine) 3-O-sulphotransferase 3B1 (HS3ST3B1). 
Proteoglycans like syndecan-1 (SDC1), decorin (DCN), versican (VCAN) and 
transforming growth factor beta receptor type III (TGFBR3) are downregulated by at 
least 2 fold from the microarray result.   
B3GalT6 codes galactosyltransferase II, which is responsible for the addition of 
the second galactose in the tetrasaccharide linkage region of the GAG chain to the 
core protein. The increased expression of B3GalT6 could represent the increased 
synthesis and attachment of various glycosaminoglycans to the protein core. 
CSGalNAcT-1, on the other hand, is required for the initiation of chondroitin sulphate 
biosynthesis after the formation of the linkage region, which is common in HSPG, 
CSPG and DSPG. Again, the upregulation of CSGalNAcT-1 could represent increased 
biosynthesis of chondroitin sulphate chains on the proteoglycan. Expression changes 
and their roles in cancer biology have rarely been reported to date. 
Specific sulphation motifs have been known to function as molecular 
recognition elements for various growth factors and this functional information 
encoded by glycosaminoglycans is analogous to the information provided by DNA, 
RNA and proteins [Gama et al, 2006]. For instance, chondroitin-4,6-sulphate has been 
shown to be highly expressed by highly metastatic lung carcinoma cells and involved 
in cell proliferation, migration and invasion while chondroitin-4-sulphate did not 
appear to be crucial [Li et al, 2008]. Different sulphation patterns of heparan sulphate 
had different binding properties with different members of the fibroblast growth 




family too [Ashikari-Hada S et al, 2004 and 2009; Sugaya et al, 2008]. In our study, 
only one chondroitin sulphotransferase, the GalNAcT4S-6ST, was found to be 
downregulated by at least 2 fold. In fact, GalNAcT4S-6ST was downregulated by 4 
fold in the prostate adenocarcinoma tissue as compared to benign prostate tissues. 
Interestingly, the expression of GalNAcT4S-6ST was found overexpressed in other 
tumour types: highly metastatic lung carcinoma cells compared to low metastatic 
cells, colorectal cancer [Ito et al, 2007], pancreatic ductal adenocarcinoma [Sugahara 
et al, 2008] and ovarian adenocarcinoma [ten Dam et al, 2007]. It remains to be 
elucidated the exact tissue-specific function of GalNAcT4S-6ST and chondroitin-4,6-
sulphate moieties in different tumours.  
The heparan sulphotransferases differentially expressed in our prostate 
adenocarcinoma tissues belong mainly to 2 families: the heparan-3-O-
sulphotransferases (HS3ST3A1 and HS3ST3B1) and the heparan-6-O-
sulphotransferases (HS6ST2). Notably, sulphatase 2 (SULF2), an enzyme that 
selectively removes the 6-O-sulphate groups from heparan sulphate, was upregulated 
in prostate adenocarcinoma. This, combined with a downregulation of the HS6ST2 
gene, could indicate that the expression of heparan-6-O-sulphate moiety is reduced in 
prostate adenocarcinoma and perhaps play an important role in carcinogenesis, thus 
warrants further investigation. HS3ST3A1 and HS3ST3B1 are both downregulated in 
prostate adenocarcinoma tissues and these merit further investigation into their roles 
and their corresponding heparan-3-O-sulphate motifs in prostate tumourigenesis.    
Syndecan-1 (SDC1) is a proteoglycan containing both heparan sulphate and 
chondroitin sulphate chains.  From our microarray study, SDC-1 demonstrated nearly 
3 fold downregulation in the prostate adenocarcinoma tissues with p<0.05; however, 
real-time PCR verification showed also a similar 3 fold downregulation albeit this did 




not reach statistical significance (P=0.063). This could result from a small sample size 
(n=6 per group) and inherent variation of SDC-1 expression in different prostate 
tumours, resulting in sampling variation. This is actually consistent with previous 
studies, in which they found that syndecan-1 is altered, but not uniformly absent in 
prostate adenocarcinomas. Shariat et al, 2008, reported that although SDC-1 is found 
expressed only in a small percentage of prostate adenocarcinoma tissues (37.1%), it 
has prognostic value. Patients with SDC-1 expression were at significantly greater risk 
of aggressive progression after surgery [Chen et al, 2004; Kiviniemi et al, 2004]. Most 
recently, Shimada et al, 2009, have found that SDC-1 was found at higher levels in 
androgen-independent cell lines, DU145 and PC-3, as compared to androgen-
dependent LNCaP, and yet the expression of SDC-1 was increased in LNCaP after 
long-term androgen deprivation. Using siRNA studies, SDC-1 repression resulted in 
increased apoptosis and reduced angiogenesis, indicating that SDC-1 might participate 
in the progression from androgen-dependent to androgen-independent status. Since 
SDC1 expression appears to favour aggressive progression of cancer cells, it would 
perhaps be interesting to investigate further why only a small percentage of prostate 
cancers (37.1%) express SDC1. SDC1 expression could possibly be temporal and 
switched on only after a certain tumour progression phase, which allows the 
progression of androgen-dependent cancer to an androgen-independent one. If so, 
these results suggest a role for SDC-1 in prostate cancer progression to hormone-
resistant cancer, and could prove to be a valuable therapeutic target, especially in late 
stage prostate cancer. 
Decorin (DCN) and versican (VCAN), both proteoglycans containing 
chondroitin sulphate and dermatan sulphate chains, were found to be downregulated 
in prostate adenocarincoma tissues in our study. Likewise, Banerjee et al, 2003, 




reported that stromal areas of BPH stained intensively for DCN and decreased with 
advancing stages of prostate cancer [Banerjee et al, 2003]. They also reported on 
versican expression to be moderate in all BPH tissues, but weak in most of the 
moderately differentiated prostate cancer, yet moderately focal in poorly-
differentiated prostate cancer. In contrary to the above study, Ricciardelli et al, 1998, 
reported the increased expression of versican and decorin in the peritumoural 
fibromuscular stroma in the prostatic tissue of men with early-stage prostate cancer 
compared with tissue from men without cancer. The increase in versican 
concentration but not that of decorin was associated with increased risk of prostate-
specific antigen (PSA) progression [Ricciardelli et al, 1998]. Variation of versican 
and decorin expression across different studies could be attributed to the different 
patient cohort used and the inherent highly variable nature of VCAN and DCN 
expression in prostate tumours. Decorin has been known to modulate signalling 
mechanisms in the tumour microenvironment [Wegrowski and Maquart, 2004; 
Goldoni and Iozzo, 2008]. Decorin binds to and modulates the signalling of the 
epidermal growth factor receptor and other members of the ErbB family of receptor 
tyrosine kinases [Santra et al, 2000]. p21, an inhibitor of cyclin-dependent kinases, is 
also upregulated as a result of decorin-induced signalling, leading to growth 
suppression [Ständer et al, 1999; de Luca et al, 1996]. Consequently, decorin 
suppresses angiogenesis and metastatic spreading, and can enhance apoptosis through 
caspase-3 activation as well. The role of versican in cancer biology appears more 
complex. It has been reported to cause both apoptotic resistance and sensitivity 
[LaPierre et al, 2007], and is generally found to be overexpressed in many cancers 
such as laryngeal cancer [Vynios et al, 2008], cervical cancer [Kodama et al, 2007] 
and endometrial cancer [Kodama et al, 2007]. Versican upregulation has often been 




associated with worse prognosis in such studies too. However, post translational 
modifications in versican might add another dimension of complexity in tumour 
progression as well. Post-translational modifications, such as the type, length and the 
sulphation pattern of the GAG chains on versican, were found to be different in 
human colon adenocarcinoma versus human normal colon and pancreatic cancer 
versus normal pancreas [Theocharis AD, 2002]. These specific structural alterations 
of versican may influence the biology of cancer cells too, in addition to transcript 
changes and more study is necessitated to understand the complex biology of versican 
in cancer. 
The transforming growth factor-beta (TGFβ) pathway has been implicated in 
the progression of prostate adenocarcinoma [Jones et al, 2009; Bello-DeOcampo and 
Tindall, 2003]. This pathway has been paralleled to a double edge sword, where it 
inhibits tumour growth in early stages of prostate tumourigenesis but subsequently 
promotes tumour capabilities in metastatic prostate cancer [Bello-DeOcampo and 
Tindall, 2003]. This pathway is known to inhibit prostate cell proliferation, 
differentiation and induce apoptosis but when growth inhibitory signals are lost, it 
promotes invasion and metastasis. From our study, we observed a loss of TGFβRIII 
(betaglycan) and TGFβIII in prostate adenocarcinomas as compared to BPH samples, 
while there were no other observable changes in the expression of other members of 
the TGFβ family such as TGFβRI and TGFβRII. This result can be supported with 
findings from other studies. Kim et al, 1996 and 1998, and Guo et al, 1997, reported 
loss of TGFβRI and TGFβRII expression in only 30% of prostate tumours [Kim et al, 
1996 & 1998; Guo et al, 1997] but the TGFβRIII is the most commonly perturbed 
member of the TGFβ pathway in prostate cancer [Sharifi et al, 2007; Turley et al, 
2007]. Loss of TGFβRIII correlates with increased tumour grade and PSA relapse. 




Functional studies revealed that TGFβRIII downregulation impedes tumour cell 
motility and invasiveness [Mythreye and Blobe, 2009]. Future work could be done to 
investigate the mechanisms by which TGFβRIII regulate prostate cancer cell 
behaviour. 
Heparanase transcript levels (both HPSE and HPSE2) were not observed to be 
differentially expressed in the prostate adenocarcinomas studied here. This is in 
contrast to a study by Lerner et al, 2008, in which they report heparanase 
overexpression in prostate cancers using immunohistochemistry, and the 
overexpression of heparanase was associated with high tumour grade [Lerner et al, 
2008]. Functional studies using prostate cancer cell lines showed that heparanase 
regulates tumour growth and faciliatates angiogenesis [Zhou et al, 2008; Kosir et al, 
1999]. The discrepancy of our findings with those in literature is not surprising, as 
heparanase is not unanimously overexpressed in all prostate cancers. 14% of the 
prostate tumours studied by Lerner et al, 2008, had no heparanase staining as well. 
The small sample size in our study could attribute to the incongruity as well, as our 
samples could represent the small percentage of tumours that did not express 
heparanase.  
3.8.6  Conclusions 
This study has allowed the identification of 865 candidate genes that are altered in 
malignant prostate tissues obtained from a local Singapore Chinese population. This 
will set the stage for future work on identifying good prognostic markers, especially 
pertaining to a local context. In addition, the delineation of prostate tumours into 
different subclasses can potentially be achieved in the future with the collection of 
more prostate tissues for a bigger sample size.  




Chapter 4   
Expression and Functional Analysis of Chondroitin Sulphate in Prostate 
Cancer 
4.1  Expression analysis of chondroitin sulphate in prostate cancer 
4.1.1 Clinical and demographic data 
A total of one hundred and sixty-three prostate tissue samples (consisting of both 
benign hyperplastic prostatic tissue and prostate adenocarcinoma tissue specimens) were 
used for immunohistochemical evaluation. The age of the patients ranged from 45 to 90 
years, with a mean of 65.5 years and a median of 64 years. The study cohort 
predominantly consisted of Chinese patients (127 cases), while the remaining cases 
included Malays (20 cases), Indians (4 cases) and other minor ethnic groups (7 cases). 
Clinicopathological features of the cancer samples used are shown in Table 4.1. Due to 
loss of tissue sections during immunohistochemical processing, the number of cases used 
to determine the expression of the various chondroitin sulphate subtypes in prostate 
adenocarcinoma could vary and is detailed in the corresponding sections.   




Table 4.1  Clinical features of prostate adenocarcinoma cases used for immunohistochemistry 
Clinicopathological parameter Frequency distribution 












At least T2ca 4 
Not available 1 
Core biopsies 71 
  
Extraprostatic extension  
Yes 38 
No 48 
Cannot be assessedb 4 
Not available 2 
Core biopsies 71 
  
Clinicopathological parameter Frequency distribution 
  
Maximum tumour dimension  
<2.5cm 46 
≥2.5cm 40 
Not available 6 
Core biopsies 71 
  
Tumour volume  
<4.0 cm3                  37 
≥4.0 cm3 32 
Not available 23 
Core biopsies 71 
  
Gleason sum  
Gleason sum 3 6 
Gleason sum 4 19 
Gleason sum 5 5 
Gleason sum 6 36 
Gleason sum 7 44 
Gleason sum 8 2 
Gleason sum 9 44 
Gleason sum 10 7 
  




Clinicopathological parameter Frequency distribution 
Lymphovascular invasion  
Present 18 
Absent 138 
Not available 7 
 
Obturator  lymph node metastasis 
Yes 0 
No 49 
Not sampled 43 
Core biopsies 71 
  
Seminal vesicle involvement  
Yes 8 
No 82 
Not available 2 
Core Biopsies 71 
  
Perineural invasion  
Seen 93 
Not seen 68 
Not available 2 
  
Preoperative PSA  
≤ 8 ng/ml 27 
> 8 ng/ml 25 
Not available 111 
  
Clinicopathological parameter Frequency distribution 
Apex (distal) margin involvement 
Involved 41 
Not involved 49 
Not available 2 
Core Biopsies 71 
  
Bladder base (proximal) margin involvement 
Involved 10 
Not involved 81 
Not available 1 
Core Biopsies 71 
  






Not available 38 
Core Biopsies 71 
  
Lobe occurence  
Both lobes 77 
Single lobe 12 
Not available 3 
Core Biopsies 71 
  




Clinicopathological parameter Frequency distribution 
Resection margin involvement (other than at apex and 
bladder base/proximal margin) 
Involved 38 
Not involved 53 
Not available 1 






aPathological T staging is classified as ‘at least T2c’ due to inability to ascertain the capsular status of the tumour. 
bCapsular integrity cannot be ascertained as the site where the positive surgical margin is does not disclose the capsule of the gland.




4.1.2  Expression analysis of non-sulphated chondroitin in prostate 
adenocarcinoma 
4.1.2.1 Localization of non-sulphated chondroitin in prostatic tissues 
Expression analysis of the non-sulphated chondroitin was examined in a total 
of 116 cases of benign prostatic hyperplastic tissues and 142 cases of prostate 
adenocarcinoma cases, in which 95 of these cases are matched cases (i.e both BPH 
samples and prostate adenocarcinoma tissues were taken from the same patient).    
In benign prostatic tissue, non-sulphated chondroitin was expressed at 
moderate to high intensity in basal cells and in the periglandular stroma (Figure 
4.1A). Weaker staining intensity was detected in the cytoplasm of secretory cells and 
in the stromal connective tissue away from the immediate periglandular zones. In 
prostate cancer, immunohistochemical staining for non-sulphated chondroitin was 
seen in the cytoplasm of malignant cells and in the surrounding stroma (Figure 4.1B 
to 4.1D). The expression data of non-sulphated chondroitin in the 116 cases of benign 
prostatic tissues and 142 cases of prostate adenocarcinoma samples are shown in 
Table 4.2. 
4.1.2.2 Comparison of non-sulphated chondroitin expression in benign prostatic 
and adenocarcinoma tissues 
As shown in Figure 4.2 and Table 4.3, when the staining differences in the 
means of 95 cases of matched benign and prostate adenocarcinoma tissues were 
compared, it was found that cancer cells were more intensely stained compared 
against benign secretory cells (P=0.0008). Furthermore, an average of 40.11% of 
cancer cells were positively stained for non-sulphated chondroitin, in contrast to an 
average of 24.90% of secretory cells in the benign prostatic group (P=0.0016). The 
immunoreactivity score (IRS) of the prostate adenocarcinoma cells were also 




significantly higher (mean of 71.77) than the benign hyperplastic prostates (mean of 
36.18). However, no significant changes in staining intensity or percentage of cells 
stained in the peritumoural stroma, as compared to the periglandular stroma were 
observed. 




Figure 4.1 Non-sulphated chondroitin expression in prostate tissues. [A] BPH [B] Gleason sum 4 Section [C] Gleason sum 7 section [D] Gleason 
sum 10 section [E] Negative Control ‘BL’ represents basal cell layer, ‘Epi’ represents benign epithelial cell, ‘CaP’ represents cancer cells and 
‘SM’ represents stromal cells. 












Number of cases stained 
Weighted Average Intensity 
(WAI) 
Percentage of cells 
stained (%) Immunoreactivity Score (IRS) 
≤1 1<I<2 ≥2 ≤50 >50 ≤100 100<IRS<200 ≥200 
BPH 
Secretory 
epithelial cells 116 46 32 12 26 49 21 58 10 2 
39.66% 27.59% 10.34% 22.41% 42.24% 18.10% 50.00% 8.62% 1.72% 
Periglandular 
Stromal cells 116 49 23 17 27 44 23 50 9 8 
42.24% 19.83% 14.66% 23.28% 37.93% 19.83% 43.10% 7.76% 6.90% 
Adenocarcinoma 
Cancerous cells 142 52 26 22 42 50 40 54 28 8 
36.62% 18.31% 15.49% 29.58% 35.21% 28.17% 38.03% 19.72% 5.63% 
Peritumoural 
Stromal cells 142 40 41 20 41 53 49 59 23 20 
28.17% 28.87% 14.08% 28.87% 37.32% 34.51% 41.55% 16.20% 14.08% 
  




Figure 4.2  Comparisons of non-sulphated chondroitin expression in prostate adenocarcinoma samples (n=95) against matched BPH samples 
(n=95). [A] Weighted Average Intensity [B] Percentage of cells positively stained [C] Immunoreactivity Score ‘**’ represents p<0.01; ‘***’ 
represents p<0.001. P-values were determined by Paired T-test.  
 




Table 4.3 Mean values of non-sulphated chondroitin staining in prostate adenocarcinoma samples (n=95) versus paired BPH samples (n=95). 
  
  
Weighted Average Intensity Percentage of cells stained (%) IRS 
Mean SEM P-value Mean SEM p-value Mean SEM P-value 
Epithelial / Cancer cell region 
Benign secretory epithelial 
cells 0.83 0.09 0.0008 24.90 3.18 0.0016 36.18 5.07 0.0001 
Adenocarcinoma cells 1.28 0.10 40.11 3.82 71.77 7.74 
Stromal region 
Periglandular stromal cells 0.95 0.10 0.7377 26.84 3.60 0.212 46.48 7.24 0.7323 
Peritumoural stromal cells 0.91 0.09 32.30 3.81 49.59 6.99   
   




 4.1.2.3 Comparison of non-sulphated chondroitin expression in different 
grades of prostate adenocarcinoma tissues 
To take a step further, the expression levels of non-sulphated chondroitin in 
both the cytoplasm of the prostate adenocarcinoma cells and the peritumoural stroma 
were associated with different tumour grades of prostate adenocarcinoma. The tumour 
grades were classified into 3 groups: Gleason sum ≤5, Gleason sum 6 and 7 and 
Gleason sum ≥8 and the means of chondroitin sulphate staining of each group were 
compared.  
 As seen from Figure 4.3, a decreasing expression of non-sulphated chondroitin 
staining (in terms of staining intensity, percentage of cells positively stained and 
immunoreactivity score) in the prostate adenocarcinoma cells were observed with 
increasing tumour grade while there was an increasing non-sulphated chondroitin 
expression (increased staining intensity, percentage of cells positively stained and 
immunoreactivity score) in the peritumoural stroma with increasing tumour grade. 
The mean values of non-sulphated chondroitin staining in the various groups of 
tumour grade are shown in Table 4.4. By using One-way ANOVA, it was 
demonstrated that the means are significantly different. These results suggest a 
potential role of non-sulphated chondroitin involvement in prostate cancer 
progression and warrants further investigation. 
 





Figure 4.3  Comparisons of non-sulphated chondroitin expression in different grades of prostate adenocarcinoma tissues: Gleason sum 3,4 & 
5 (n=22) vs Gleason sum 6 & 7 (n=68) vs Gleason sum 8, 9 & 10 (n=52), in both [A,B,C] cytoplasm of cancer cell and [D,E,F] peritumoural 
stroma. [A,D] Weighted Average Intensity [B,E] Percentage of cells positively stained [C,F] Immunoreactivity score. ‘*’ represents p< 0.05;  
‘**’ represents p<0.01; ‘***’ represents p<0.001. P-values were determined by One-way ANOVA with Bonferroni’s Multiple Comparison Post 
test.  




Table 4.4  Mean values of non-sulphated chondroitin staining in different grades of prostate adenocarcinoma tissues: Gleason sum 3,4 & 5 
(n=22) vs Gleason sum 6 & 7 (n=68) vs Gleason sum 8, 9 & 10 (n=52). P-values were determined by One-way ANOVA with Bonferroni’s 
Mulitple Comparison Post test. 
Gleason Sum Weighted Average Intensity Percentage of cells positively stained Immunoreactivity Score 
Mean SEM P-value Mean SEM P-value Mean SEM P-value 
Adenocarcinoma          
3,4 & 5 1.26 0.16 0.0092 54.09 8.82 <0.0001 82.02 16.12 0.0063 
6 & 7 1.30 0.11  39.01 4.17  70.26 8.83  
8, 9 & 10 0.77 0.15  17.47 4.18  34.96 8.45  
          
Peritumoural Stroma         
3,4 & 5 0.47 0.15 <0.0001 24.35 8.02 0.0001 33/04 14.13 <0.0001 
6 & 7 1.08 0.10  33.86 4.40  56.07 8.99  
8, 9 & 10 1.70 0.14  59.90 5.65  124.4 13.75  




4.1.3  Expression analysis of chondroitin-4-sulphate in prostate 
adenocarcinoma.  
4.1.3.1 Localization of chondroitin-4-sulphate in prostate tissues 
Expression analysis of the chondroitin-4-sulphate was examined in a total of 
117 cases of benign prostatic hyperplastic tissues and 146 cases of prostate 
adenocarcinoma cases, in which 100 of these cases are matched cases (i.e both BPH 
samples and prostate adenocarcinoma tissues were taken from the same patient).    
Chondroitin-4-sulphate was not detected in the benign secretory epithelial 
cells in about 71.79% of benign prostate hyperplastic cases; while those that 
expressed cytoplasmic staining in the benign epithelial cells, intensity of staining 
varied from weak to strong (Figure 4.4A). Strong (WAI ≥ 2) periglandular stroma 
staining was observed in about 45.30% of the benign prostate tissues. 56.41% of the 
BPH cases had more than 50% of the periglandular stroma tissue stained. In prostate 
cancer, immunohistochemical staining for chondroitin-4-sulphate was observed more 
prominently in the peritumoural stroma while there was some staining in the 
cytoplasm of the malignant cells for about 20.55% of the adenocarcinoma tissues, 
with a majority of adenocarcinoma cells (63.01%) not expressing any chondroitin-4-
sulphate in the cytoplasm of the cancer cells (Figure 4.4B to 4.4D). The expression 
data of chondroitin-4-sulphate in the 117 cases of benign prostatic tissues and 146 
cases of prostate adenocarcinoma samples are shown in Table 4.5. 




Figure 4.4 Chondroitin-4-sulphate expression in BPH tissue and prostate adenocarcinoma sections. [A] BPH [B] Gleason sum 4 section [C] 
Gleason sum 7 section [D] Gleason sum 9 section [E] Negative control ‘BL’ represents basal cell layer, ‘Epi’ represents benign epithelial cell, 
‘CaP’ represents cancer cells and ‘SM’ represents stromal cells. 












Number of cases stained 
Weighted Average Intensity 
(WAI) 
Percentage of cells 
stained (%) Immunoreactivity Score (IRS) 
≤1 1<I<2 ≥2 ≤50 >50 ≤100 100<IRS<200 ≥200 
BPH 
Secretory epithelial 
cells 117 84 12 5 16 23 10 23 6 4 
71.79% 10.26% 4.27% 13.68% 19.66% 8.55% 19.66% 5.13% 3.42% 
Periglandular 
Stromal cells 117 11 34 19 53 40 66 60 21 25 
9.40% 29.06% 16.24% 45.30% 34.19% 56.41% 51.28% 17.95% 21.37%
Adenocarcinoma 
Cancerous cells 146 92 30 9 15 31 23 41 9 4 
63.01% 20.55% 6.16% 10.27% 21.23% 15.75% 28.08% 6.16% 2.74% 
Peritumoural 
Stromal cells 146 19 59 23 45 58 69 90 16 21 
13.01% 40.41% 15.75% 30.82% 39.73% 47.26% 61.64% 10.96% 14.38%




4.1.3.2 Comparison of chondroitin-4-sulphate expression in benign prostatic and 
adenocarcinoma tissues 
Although the majority of the benign epithelial cells and adenocarcinoma cells 
demonstrated negative chondroitin-4-sulphate staining, comparing the means of 100 
cases of matched benign and prostate adenocarcinoma tissues revealed that cancer 
cells were more intensely stained compared against benign secretory cells (P=0.003). 
Furthermore, an average of 23.5% of cancer cells were positively stained for 
chondroitin-4-sulphate, in contrast to an average of 10.5% of secretory cells in the 
benign prostatic group (P=0.0002). The immunoreactivity score (IRS) of the prostate 
adenocarcinoma cells were also significantly higher (mean of 35.9) than the benign 
epithelial cells (mean of 19.8).  (Figure 4.5 and Table 4.6) 
In addition, chondroitin-4-sulphate was found to be downregulated in the 
peritumoural stroma tissue compared to the periglandular stroma region. The mean 
staining intensity of the periglandular stroma was 1.61 while the mean staining 
intensity of the peritumoural stroma was 1.27 (P=0.002). There was no significant 
difference in the percentage of periglandular cells and the peritumoural cells 
positively stained.  
  




Figure 4.5  Comparisons of chondroitin-4-sulphate expression in prostate adenocarcinoma samples (n=100) against matched BPH samples 
(n=100). [A] Weighted Average Intensity [B] Percentage of cells positively stained [C] Immunoreactivity Score ‘*’ represents p<0.05; ‘**’ 
represents p<0.01; ‘***’ represents p<0.001. P-values were determined by Paired T-test. 




Table 4.6 Mean values of chondroitin-4-sulphate staining in prostate adenocarcinoma samples (n=100) versus paired BPH samples (n=100). P-
values were determined by Paired T-test. 
  
  
Weighted Average Intensity Percentage of cells stained (%) IRS 
Mean SEM P-value Mean SEM p-value Mean SEM P-value 
Epithelial / Cancer cell region 
Benign secretory epithelial 
cells 0.40 0.08 0.003 10.50 2.50 0.0002 19.78 5.38 0.018 
Adenocarcinoma cells 0.68 0.08 23.53 3.47 35.87 6.00 
Stromal region 
Periglandular stromal cells 1.61 0.08 0.002 62.20 3.83 0.229 104.30 7.79 0.049 








4.1.3.3 Comparison of chondroitin-4-sulphate expression in different grades of 
prostate adenocarcinoma tissues 
Following this, the expression levels of chondroitin-4-sulphate in both the 
cytoplasm of the prostate adenocarcinoma cells and the peritumoural stroma were 
associated with different tumour grades of prostate adenocarcinoma. Due to technical 
difficulties encountered as a result of different batches of antibodies employed for use 
for the prostate TMAs (Gleason sum 6 and 7) and the core biopsies (Gleason sum 3 to 
5 and 8 to 10), only the 2 extreme grades of prostate adenocarcinoma cases were 
compared (i.e Gleason sum 3 to 5 versus Gleason sum 8 to 10) since 
immunohistochemical staining was performed at the same time and using the same 
batch of antibodies for this set of tissues.  
 As seen from Figure 4.6, there was very weak mean staining in the cytoplasm 
of the adenocarcinoma tissues of Gleason sum 3 to 5 and 8 to 10, and there was no 
significant difference between the two extreme grades. There was also a very small 
percentage of adenocarcinoma cells positively stained for chondroitin-4-sulphate in 
both Gleason sum 3 to 5 and Gleason sum 8 to 10 groups, and there was no significant 
difference between the two extreme grades either. Conversely, there was stronger 
staining in the peritumoural stroma than the cytoplasmic adenocarcinoma cells; in the 
Gleason sum 3 to 5 group, the mean staining in the peritumoural stroma was 0.95 and 
this mean was increased to 1.65 in the Gleason sum 8 to 10 group (P=0.003). No 
significant difference was observed in the percentage of peritumoural stroma cells 
positively stained between the Gleason sum 3 to 5 group and Gleason sum 8 to 10 
group (Table 4.7).  




Figure 4.6 Comparisons of chondroitin-4-sulphate expression in different grades of prostate adenocarcinoma tissues: Gleason sum 3, 4 & 5 
(n=26) vs Gleason sum 8,9 & 10 (n=51), in both [A,B,C] cytoplasm of cancer cell and [D,E,F] peritumoural stroma. [A,D] Weighted Average 
Intensity [B,E] Percentage of cells positively stained [C,F] Immunoreactivity score. ‘**’ represents p<0.01; P-values were determined by One-
way ANOVA with Bonferroni’s Multiple Comparison Post test. 
 




Table 4.7 Mean values of chondroitin-4-sulphate staining in different grades of prostate adenocarcinoma tissues: Gleason sum 3, 4 & 5 
(n=26) vs Gleason sum 8,9 & 10 (n=51). P-values were determined by One-way ANOVA with Bonferroni’s Mulitple Comparison Post Test. 
Gleason Sum 
Weighted Average Intensity Percentage of cells positively stained  Immunoreactivity Score 
Mean SEM P-value Mean SEM P-value Mean SEM P-value 
Adenocarcinoma          
3,4 & 5 0.12 0.06 0.829 5.00 3.89 0.925 5.00 3.89 0.461 
8, 9 & 10 0.14 0.08  5.49 3.12  13..33 7.75  
          
Peritumoural Stroma         
3,4 & 5 0.95 0.19 0.003 30.77 7.36 0.469 51.92 14.14 0.388 
8, 9 & 10 1.65 0.13  37.00 4.83  66.35 9.44  




4.1.4 Expression analysis of chondroitin-6-sulphate in prostate 
adenocarcinoma. 
 4.1.4.1 Localization of chondroitin-6-sulphate in prostate tissues 
Expression analysis of chondroitin-6-sulphate was examined in a total of 120 
cases of benign prostatic hyperplastic tissues and 128 cases of prostate 
adenocarcinoma cases, in which 89 of these cases are matched cases (i.e both BPH 
samples and prostate adenocarcinoma tissues were taken from the same patient).    
In benign prostatic tissue, weak staining intensity was detected in the 
cytoplasm of secretory cells and in the periglandular stroma region. In prostate cancer, 
weak immunohistochemical staining for chondroitin-6-sulphate was seen in the 
cytoplasm of malignant cells while strong expression of chondroitin-6-sulphate was 
observed in the surrounding peritumoural stroma (Figure 4.7). The expression data of 
chondroitin-6-sulphate in the 120 cases of benign prostatic tissues and 128 cases of 
prostate adenocarcinoma samples are shown in Table 4.8. 
4.1.4.2  Comparison of chondroitin-6-sulphate expression in benign 
prostatic and adenocarcinoma tissues 
Staining differences in the means of 89 cases of matched benign and prostate 
adenocarcinoma tissues were compared. It was found that a higher percentage of 
peritumoural stroma cells (approximate mean of 60.47%) were stained for 
chondroitin-6-sulphate compared against periglandular stroma cells (approximate 
mean of 46.85%) (P=0.002). (Figure 4.8) The immunoreactivity score (IRS) of the 
peritumoural stroma cells were also significantly higher (mean of 89.89) than the 
benign hyperplastic prostates (mean of 57.99). However, there were no significant 
changes in staining intensity or percentage of cells stained in the adenocarcinoma 
cells, as compared to the benign epithelial cells (Figure 4.8 and Table 4.9). 




Figure 4.7 Chondroitin-6-sulphate expression in BPH tissue and prostate adenocarcinoma sections. [A] BPH [B] Gleason sum 4 section [C] 
Gleason sum 7 section [D] Gleason sum 9 section [E] Negative control ‘BL’ represents basal cell layer, ‘Epi’ represents benign epithelial cell, 
‘CaP’ represents cancer cells and ‘SM’ represents stromal cells.  












Number of cases stained 
Weighted Average Intensity 
(WAI) 
Percentage of 
cells stained (%) Immunoreactivity Score (IRS) 
≤1 1<I<2 ≥2 ≤50 >50 ≤100 100<IRS<200 ≥200 
BPH 
Secretory 
epithelial cells 120 13 72 21 14 37 70 86 15 6 
10.83% 60.00% 17.50% 11.67% 30.83% 58.33% 71.67% 12.50% 5.00% 
Periglandular 
stromal cells 120 22 64 15 19 61 37 83 12 3 
18.33% 53.33% 12.50% 15.83% 50.83% 30.83% 69.17% 10.00% 2.50% 
Adenocarcinoma 
Cancerous cells 128 46 44 23 15 27 55 55 22 5 
35.94% 34.38% 17.97% 11.72% 21.09% 42.97% 42.97% 17.19% 3.91% 
Peritumoural 
stromal cells 128 10 49 21 47 43 89 63 26 28 
7.81% 38.28% 16.41% 36.72% 33.59% 69.53% 49.22% 20.31% 21.88% 
  




Figure 4.8 Comparisons of chondroitin-6-sulphate expression in prostate adenocarcinoma samples (n=89) against BPH samples (n=89). [A] 
Weighted Average Intensity [B] Percentage of cells positively stained [C] Immunoreactivity Score ‘**’ represents p<0.01; ‘***’ represents 
p<0.001. P-values were determined by Paired T-test. 




Table 4.9 Mean values of chondroitin-6-sulphate staining in prostate adenocarcinoma samples (n=89) versus paired BPH samples (n=89). 
P-values were determined by Paired T-test. 
  
  
Weighted Average Intensity Percentage of cells stained (%) IRS 
Mean SEM P-value Mean SEM p-value Mean SEM P-value 
Epithelial / Cancer cell region 
Benign secretory epithelial 
cells 1.07 0.06 0.585 67.36 4.27 0.087 80.18 5.69 0.937 
Adenocarcinoma cells 1.12 0.08 59.16 4.43 79.57 6.95 
Stromal region 
Periglandular stromal cells 1.06 0.07 0.177 46.85 3.98 0.002 57.99 5.91 <0.0001 
Peritumoural stromal cells 2.00 0.68 60.47 4.00 89.89 7.98 




4.1.4.3  Comparison of chondroitin-6-sulphate expression in different 
grades of prostate adenocarcinoma tissues 
The expression levels of chondroitin-6-sulphate in both the cytoplasm of the 
prostate adenocarcinoma cells and the peritumoural stroma are also associated with 
different tumour grades of prostate adenocarcinoma. The tumour grades were 
classified into 3 groups: Gleason sum ≤5, Gleason sum 6 and 7 and Gleason sum ≥8 
and the means of chondroitin sulphate staining of each group were compared.  
 With increasing tumour grade, there was increasing chondroitin-6-sulphate 
expression in the peritumoural stroma (P<0.0001) but decreasing chondroitin-6-
sulphate expression in the cytoplasm of the adenocarcinoma cells (P<0.0001). (Figure 
4.9) The mean values of non-sulphated chondroitin staining in the various groups of 
tumour grade are shown in Table 4.10. One-way ANOVA with Bonferroni’s post-test 
was performed to determine statistical significance. These results suggest a potential 
role of chondroitin-6-sulphate involvement in prostate cancer progression and 









Figure 4.9 Comparisons of chondroitin-6-sulphate expression in different grades of prostate adenocarcinoma tissues: Gleason sum 3,4 & 5 
(n=19) vs Gleason sum 6 & 7 (n=65) vs Gleason sum 8,9 & 10 (n=44), in both [A,B,C] cytoplasm of cancer cell and [D,E,F] peritumoural 
stroma. [A,D] Weighted Average Intensity [B,E] Percentage of cells positively stained [C,F] Immunoreactivity score. ‘**’ represents p<0.01; 
‘***’ represents p<0.001. P-values were determined by One-way ANOVA with Bonferroni’s Multiple Comparison Post test. 




Table 4.10 Mean values of chondroitin-6-sulphate staining in different grades of prostate adenocarcinoma tissues: Gleason sum 3, 4 & 5 
(n=19) vs Gleason sum 6 & 7 (n= 65) vs Gleason sum 8, 9 & 10 (n=44). P-values were determined by One-way ANOVA with Bonferroni’s 
Mulitple Comparison Post Test. 
Gleason Sum 
Weighted Average Intensity Percentage of cells positively stained Immunoreactivity Score 
Mean SEM P-value Mean SEM P-value Mean SEM P-value 
Adenocarcinoma          
3,4 & 5 1.48 0.28 <0.0001 52.11 9.66 <0.0001 99.47 21.78 <0.0001 
6 & 7 1.11 0.05  69.38 4.67  83.05 6.41  
8, 9 & 10 0.32 0.12  9.66 3.96  16.44 6.21  
          
Peritumoural Stroma         
3,4 & 5 1.16 0.24 <0.0001 32.11 7.59 <0.0001 47.37 10.78 <0.0001 
6 & 7 1.18 0.07  65.41 4.55  85.56 8.30  
8, 9 & 10 2.35 0.10  81.16 4.49  194.90 13.28  




4.1.5  Expression analysis of chondroitin-2,6-sulphate in prostate 
adenocarcinoma  
4.1.5.1 Localization of chondroitin-2,6-sulphate in prostate tissues 
Expression analysis of the chondroitin-2,6-sulphate was examined in a total of 
115 cases of benign prostatic hyperplastic tissues and 142 cases of prostate 
adenocarcinoma cases, in which 95 of these cases are matched cases (i.e both BPH 
samples and prostate adenocarcinoma tissues were taken from the same patient).    
Approximately 50.43% of the benign cases did not show chondroitin-2,6-
sulphate staining in the benign epithelial cells; while the other 49.57% of the cases 
demonstrated chondroitin-2,6-sulphate in the cytoplasm of the benign epithelial cells, 
the intensity of staining varied from weak to strong staining. Chondroitin-2,-6-
sulphate was observed to be expressed in the periglandular stroma in 95.65% of the 
cases, with 77.39% of the cases demonstrating moderate to strong staining. 74.78% of 
the cases had positive chondroitin-2,6-sulphate staining in more than 50% of the 
periglandular stroma cells as well. In prostate adenocarcinoma tissues, we observed a 
similar staining pattern for chondroitin-2,6-sulphate. Approximately 58.45% of the 
cases had no staining in the cytoplasm of the prostate adenocarcinoma cells, while 
those that showed cytoplasmic staining was in the range of weak to moderate. About 
61.97% of the cases revealed strong chondroitin-2,6-sulphate staining in the 
peritumoural stroma, with 86.62% of the cases showing positive staining in more than 
50% of the peritumoural stroma cells. (Figure 4.10 and Table 4.11)   




Figure 4.10 Chondroitin-2,6-sulphate expression in BPH and prostate adenocarcinoma tissues.[A] BPH [B] Gleason sum 4 section [C] 
Gleason sum 8 section [D] Gleason sum 9 section [E] Negative control ‘BL’ represents basal cell layer, ‘Epi’ represents benign epithelial cell, 
‘CaP’ represents cancer cells and ‘SM’ represents stromal cells. 















Number of cases stained 
Weighted Average Intensity 
(WAI) 
Percentage of 
cells stained (%) Immunoreactivity Score (IRS) 
≤1 1<I<2 ≥2 ≤50 >50 ≤100 100<IRS<200 ≥200 
BPH 
Secretory epithelial 
cells 115 58 20 7 30 39 18 43 7 7 
50.43% 17.39% 6.09% 26.09% 33.91% 15.65% 37.39% 6.09% 6.09% 
Periglandular 
Stromal cells 115 5 21 37 52 24 86 30 37 43 
4.35% 18.26% 32.17% 45.22% 20.87% 74.78% 26.09% 32.17% 37.39%
Adenocarcinoma 
Cancerous cells 142 83 26 4 29 34 25 39 15 5 
58.45% 18.31% 2.82% 20.42% 23.94% 17.61% 27.46% 10.56% 3.52% 
Peritumoural 
Stromal cells 142 2 17 35 88 17 123 31 29 80 
1.41% 11.97% 24.65% 61.97% 11.97% 86.62% 21.83% 20.42% 56.34%




4.1.5.2 Comparison of chondroitin-2,6-sulphate expression in benign prostatic 
and adenocarcinoma tissues 
 The expression levels of chondroitin-2,6-sulphate in 95 cases of matched 
benign prostate hyperplastic tissues and prostate adenocarcinoma tissues were 
compared. There were no significant difference in terms of staining intensity, 
percentage of cells positively stained and immunoreactivity score in the 
adenocarcinoma cells and in the peritumoural stroma (Figure 4.11). However, if the 
expression levels of chondroitin-2,6-sulphate in matched benign and adenocarcinoma 
were compared based on the Gleason sum of the adenocarcinoma tissue, we observed 
that adenocarcinoma tumours of Gleason sum 6 and 7 had increased expression of 
chondroitin-2,6-sulphate in the cytoplasmic adenocarcinoma cells as compared to 
their matched benign epithelial cells (n=60). However, decreased expression of 
chondroitin-2,6-sulphate in the cytoplasmic adenocarcinoma cells as compared to the 
matched benign epithelial cells was observed in Gleason sum 3 to 5 tumours (n=16) 
and Gleason sum 8 to 10 tumours (n=18), albeit without statistical significance. None 
of the prostate adenocarcinoma cells with Gleason sum 8, 9 and 10 were stained 
positively for chondroitin-2,6-sulphate. Therefore, to analyze the difference in 
chondroitin-2,6-sulphate expression in all the adenocarcinoma tissues collectively as a 
whole, regardless of Gleason sum as compared to their matched benign tissues, results 
in insignificant difference in terms of staining intensity, percentage of cells positively 
stained and immunoreactivity score.   
 A trend of increased chondroitin-2,6-sulphate expression in the peritumoural 
stroma as compared to matched periglandular stroma was revealed, although this did 
not reach statistical significance of  p<0.05; the mean IRS of periglandular stroma 




staining is 159.80 while the mean IRS of peritumoural stroma is 180.20 (P=0.07) 
(Table 4.12). 




Figure 4.11 Comparisons of chondroitin-2,6-sulphate expression in prostate adenocarcinoma samples (n=95) against paired BPH samples 
(n=95). [A,D] Weighted Average Intensity [B,C] Percentage of cells positively stained [C,F] Immunoreactivity Score [D,E,F] Tumours in 
different Gleason sum group were compared against their matched BPH samples, giving rise to various differential expression patterns of 
chondroitin-2,6-sulphate. No expression of chondroitin-2,6-sulphate were detected in all prostate adenocarcinoma cells with Gleason sum >8. ‘*’ 
represents p<0.05; P-value was determined using Paired T-test. 




 Table 4.12 Mean values of chondroitin-2,6-sulphate staining in prostate adenocarcinoma samples (n=95) versus paired BPH samples (n=95). 
P-values were determined by Paired T-test. 
  
  
Weighted Average Intensity Percentage of cells stained  IRS 
Mean SEM P-value Mean SEM p-value Mean SEM P-value 
Epithelial / Cancer cell region 
Benign secretory epithelial cells 0.78 0.10 0.34 22.87 3.27 0.58 39.99 6.41 0.41 
Adenocarcinoma cells 0.90 0.11  25.32 3.55  47.03 7.51  
          
Stromal region 
Periglandular stromal cells 1.83 0.08 0.11 81.73 2.99 0.07 159.80 9.23 0.07 
Peritumoural stromal cells 1.99 0.07  88.26 2.62  180.20 8.95  
   




4.1.5.3 Comparison of chondroitin-2,6-sulphate expression in different grades of 
prostate adenocarcinoma tissues  
Subsequently, the expression levels of chondroitin-2,6-sulphate in both the 
cytoplasm of the prostate adenocarcinoma cells and the peritumoural stroma were 
associated with different tumour grades of prostate adenocarcinoma. We have 
classified the tumour grades into 3 groups: Gleason sum ≤5, Gleason sum 6 and 7 and 
Gleason sum ≥8 and compared the means of chondroitin-2,6-sulphate staining of each 
group (Figure 4.12). 
 Interestingly, we observed that the expression of chondroitin-2,6-sulphate was 
highest in adenocarcinoma cells of Gleason sum 6 and 7 (mean IRS = 62.58) while 
tumours of Gleason sum 8 to 10 had the lowest expression of chondroitin-2,6-sulphate 
in the cytoplasm of the adenocarcinoma cells (mean IRS = 11.18) (P<0.0001). In the 
peritumoural stroma region, it was shown that chondroitin-2,6-sulphate staining was 
increased with increasing tumour grades, with the highest expression in Gleason sum 
8 to 10 tumours (Table 4.13). 





Figure 4.12 Comparisons of chondroitin-2,6-sulphate expression in different grades of prostate adenocarcinoma tissues: Gleason sum 3,4 & 5 
(n=22) vs Gleason sum 6 & 7 (n=69) vs Gleason sum 8,9 & 10 (n=51), in both [A,B,C] cytoplasm of cancer cell and [D,E,F] peritumoural 
stroma. [A,D] Weighted Average Intensity [B,E] Percentage of cells positively stained [C,F] Immunoreactivity score. ‘*’ represents p<0.05; ‘**’ 
represents p<0.01; ‘***’ represents p<0.001. P-values were determined by One-way ANOVA with Bonferroni’s Multiple Comparison Post test 




Table 4.13 Mean values of chondroitin-2,6-sulphate staining in different grades of prostate adenocarcinoma tissues: Gleason sum 3, 4 & 5 
(n=22) vs Gleason sum 6 & 7 (n= 69) vs Gleason sum 8, 9 & 10 (n=51). P-values were determined by One-way ANOVA with Bonferroni’s 
Multiple Comparison Post Test. 
Gleason Sum Weighted Average Intensity Percentage of cells positively stained  Immunoreactivity Score 
Mean SEM P-value Mean SEM P-value Mean SEM P-value 
Adenocarcinoma          
3,4 & 5 0.55 0.17 <0.0001 16.36 6.36 0.0028 23.18 10.64 <0.0001 
6 & 7 1.23 0.13  33.70 4.23  62.58 8.93  
8, 9 & 10 0.12 0.07  5.39 3.06  11.18 7.03  
          
Peritumoural Stroma         
3,4 & 5 1.70 0.18 0.001 71.59 8.56 0.001 141.8 22.05 0.0003 
6 & 7 1.91 0.09  90.07 2.88  174.6 9.93  
8, 9 & 10 2.31 0.09  94.90 2.28  223.1 10.56  




4.1.6  Comparisons of chondroitin sulphate staining amongst each subtype  
Correlations in the immunohistochemical staining amongst the different 
chondroitin sulphate subtypes in the adenocarcinoma tissues were determined. 
Association studies were performed using the Fisher’s Exact Test and it was revealed 
that there were significant associations between different chondroitin sulphate subtype 
staining; both in the cytoplasm of adenocarcinoma cells and in the peritumoural 
stroma. 
   From Table 4.14, it can be seen that higher non-sulphated chondroitin 
staining in the cytoplasmic adenocarcinoma cells is correlated with higher 
chondroitin-4-sulphate expression, chondroitin-6-sulphate expression and 
chondroitin-2,6-sulphate expression in the cytoplasm of the adenocarcinoma cells.  
Similarly, higher chondroitin-2,6-sulphate expression is associated with higher 
chondroitin-4-sulphate and chondroitin-6-sulphate expression in the adenocarcinoma 
cells; the same association is observed for chondroitin-4-sulphate and chondroitin-6-
sulphate expression too.  
Likewise, different chondroitin sulphate subtypes staining in the peritumoural 
stroma were associated with one another (Table 4.15). With a higher expression of 
non-sulphated chondroitin in the peritumoural stroma, chondroitin-4-sulphate, 
chondroitin-6-sulphate and chondroitin-2,6-sulphate were also highly expressed. 
Chondroitin-2,6-sulphate expression was also associated with chondroitin-4-sulphate 
and chondroitin-6-sulphate expression in the peritumoural stroma. Although there was 
no statistical significance, it can be seen that high levels of chondroitin-6-sulphate in 
the peritumoural stroma is correlated with high chondroitin-4-sulphate expression. 




Table 4.14  Comparisons of chondroitin sulphate staining amongst each subtype in the adenocarcinoma cells 
 
Adenocarcinoma Cell 
Chondroitin-4-sulphate Chondroitin-6-sulphate Chondroitin-2,6-sulphate 


















IRS ≤ 100 104 100 4 0.00 92 84 8 0.00 101 94 7 0.00 
100.0% 96.2% 3.8% 100.0% 91.3% 8.7% 100.0% 93.1% 6.9% 
IRS > 100 33 24 9 33 14 19 33 21 12 
100.0% 72.7% 27.3% 100.0% 42.4% 57.6% 100.0% 63.6% 36.4% 
Chondroitin-2,6-sulphate 
IRS ≤ 100 117 114 3 0.00 105 88 17 0.001 - - - - 
100.0% 97.4% 2.6% 100.0% 83.8% 16.2% - -  - 
IRS > 100 19 9 10 18 8 10 - -  - 
100.0% 47.4% 52.6% 100.0% 44.4% 55.6% - -  - 
Chondroitin-6-sulphate 
IRS ≤ 100 99 93 6 0.006 - - - - - - - - 
100.0% 93.94% 6.06% - -  - - -  - 
IRS > 100 26 19 7 - -  - - -  - 








Table 4.15  Comparisons of chondroitin sulphate staining amongst each subtype in the peritumoural stroma 
 
Peritumoural Stroma 
Chondroitin-4-sulphate Chondroitin-6-sulphate Chondroitin-2,6-sulphate 


















IRS ≤ 100 95 78 17 0.005 87 65 22 0.00 92 28 64 0.003 
100.0% 82.1% 17.9% 100.0% 74.7% 25.3% 100.0% 30.4% 69.6% 
IRS > 100 41 24 17 38 7 31 41 3 38 
100.0% 58.5% 41.5% 100.0% 18.4% 81.6% 100.0% 7.3% 92.7% 
Chondroitin-2,6-sulphate 
IRS ≤ 100 31 30 1 0.00 29 25 4 0.00 - - - - 
100.0% 96.8% 3.2% 100.0% 86.2% 13.8% - - - 
IRS > 100 105 70 35 93 45 48 - - - 
100.0% 66.7% 33.3% 100.0% 48.4% 51.6% - - - 
Chondroitin-6-sulphate 
IRS ≤ 100 71 56 15 0.214 - - - - - - - - 
100.0% 78.9% 21.1% - - - - - - 
IRS > 100 53 36 17 - - - - - - 
 100.0% 67.9% 32.1%  - - -  - - -  




4.1.7  Association of chondroitin sulphate staining with clinicopathological 
parameters 
Most pathological parameters such as pathological T stage, extraprostatic 
extension, involvement of seminal vesicles, tumour size and volume, resection margin 
including distal and proximal margin involvement, obturator lymph node metastasis, 
presence of tumour in single/both prostate lobes are only available when patients 
undergo prostatectomies. Gleason grade and sum, lymphovascular invasion, 
perineural invasion, pre-operative PSA and clinical staging are other parameters that 
will be available for all core biopsies and prostatectomies cases. In our cohort of 
study, we have clinicopathological data for most prostatectomy cases (corresponding 
to Gleason sum 6 to 8 tumours) but only Gleason sum, presence of lymphovascular 
invasion and perineural invasion data for the biopsy cases (corresponding to Gleason 
sum 3 to 5 and 8 to 10). (refer to Table 4.1) Also, due to loss of some tissues during 
immunohistochemical processing and the unavailability of some clinicopathological 
data for some cases, the actual number of cases studied could vary and are shown in 
the respective tables. 
Analysis of absolute staining intensities for non-sulphated chondroitin, 
chondroitin-4-sulphate, chondroitin-6-sulphate and chondroitin-2,6-sulphate in both 
prostate adenocarcinoma cells and peritumoural stroma showed significant 
associations with several clinicopathological parameters and known prognostic 
factors.  
Table 4.16 shows that pathological T stage, extraprostatic extension, 
involvement of seminal vesicles, and pre-operative PSA levels were all correlated 
with strong expression of non-sulphated chondroitin in the peritumoural stroma. A 




strong expression of non-sulphated chondroitin in adenocarcinoma cells was also 
associated with involvement of both prostatic lobes. Chondroitin-4-sulphate staining 
in the cytoplasm of the adenocarcinoma cells was also associated with pathological T 
stage, extraprostatic extension and clinical staging. Similarly, a strong expression of 
chondroitin-2,6-sulphate in the cytoplasm of the adenocarcinoma cell and in the 
peritumoural stroma correlated with perineural invasion and seminal vesicle 
involvement respectively.   
Moreover, examination of the percentage of tumour cells stained positively for 
non-sulphated chondroitin revealed correlations with pathological T stage and 
extraprostatic extension. When a higher percentage of peritumoural stroma cells are 
stained positively for chondroitin-6-sulphate, this was associated with pathological T 
stage and extraprostatic extension too. In a similar manner, high percentage of 
adenocarcinoma cells and peritumoural stroma cells stained positively for 
chondroitin-2,6-sulphate was correlated with clinical staging and tumour volume 
respectively (Table 4.17). 
No significant correlations were found when the expression patterns of non-
sulphated chondroitin, chondroitin-4-sulphate, chondroitin-6-sulphate or chondroitin-
2,6-sulphate were analyzed with the other clinicopathological parameters listed in 
Table 4.1 (P >0.05), namely resection margin including distal and proximal margin 
involvement and lymphovascular invasion. Results of all association studies 
performed to determine correlation between chondroitin sulphate staining and all 
clinicopathological parameters (regardless of statistical significance) are shown in 
Appendix II. No correlation with obturator lymph node involvement was performed 
as none of the patients demonstrated metastases to nodes. 




Table 4.16  Association studies of chondroitin sulphate staining intensity with clinicopathological parameters. 
Epitope Stained tissue component Clinicopathological 
parameter 





Non-sulphated chondroitin Adenocarcinoma cells Lobe occurrence     
  Single lobe 11 11 (100.0%) 0 (0.0%) 0.013 
  Both lobes 64 38 (59.4%) 26 (40.6%)  
  Total 75    
       
 Peritumoural stroma Pathological T staging     
  T2a to T2c 39 34 (87.2%) 5 (12.8%) 0.049 
  T3a to T3b 33 22 (66.7%) 11(33.3%)  
  Total 72    
       
  Extraprostatic extension  
  Yes 33 22 (66.7%) 11 (33.3%) 0.049 
  No 39 34 (87.2%) 5 (12.8%)  
  Total 72    
       
  Seminal vesicle involvement   
  Involved 7 3 (42.9%) 4 (57.1%) 0.034 
  Not involved 68 56 (82.4%) 12 (17.6%)  
  Total 75    
       
       
       
       




Non-sulphated chondroitin Peritumoural stroma Pre-op PSA levels     
  ≤ 8ng/ml 21 21 (100.0%) 0 (0.0%) 0.021 
  > 8ng/ml 20 15 (75.0%) 5 (25.0%)  
  Total 41    
       
Chondroitin-4-sulphate Adenocarcinoma cells Extraprostatic extension    
  Yes 35 24 (68.6%) 11 (31.4%) 0.041 
  No 38 34 (89.5%) 4 (10.5%)  
  Total 73    
       
  Pathological T staging     
  T2a to T2c 38 34 (89.5%) 4 (10.5%) 0.041 
  T3a to T3b 35 24 (68.6%) 11 (31.4%)  
  Total 73    
       
  Clinical staging     
  T1a to T1c 36 32 (88.9%) 4 (11.1%) 0.015 
  T2a to T4 7 3 (42.9%) 4 (57.1%)  
  Total 43    
       
Chondroitin-2,6-sulphate Adenocarcinoma cells Perineural invasion     
  Seen 89 65 (73.0%) 24 (27.0%) 0.017 
  Not Seen 52 47 (90.4%) 5 (9.6%)  
  Total 141    
       
       
     




 Peritumoural stroma Seminal vesicle involvement   
  Involved 7 0 (0%) 7 (100.0%) 0.018 
  Not involved 72 34 (47.2%) 38 (52.8%)  
  Total 79    
 




Table 4.17 Association studies of percentage of cells positively stained for different chondroitin sulphate with clinicopathological 
parameters. 
Antigen  Stained tissue component Clinicopathological 
parameter 
Total % of positively 
stained cells ≤50% 
% of positively 
stained cells >50% 
P-value 
Non-sulphated chondroitin Adenocarcinoma cells Pathological T stage     
  T2a to T2c 40 30 (75.0%) 10 (25.0%) 0.05 
  T3a to T3b 33 17 (51.5%) 16 (48.5%)  
  Total 73    
       
  Extraprostatic extension    
  Yes 33 17 (51.5%) 16 (48.5%) 0.05 
  No 40 30 (75.0%) 10 (25.0%)  
  Total 73    
       
Chondroitin-6-sulphate Peritumoural stroma Extraprostatic extension   
  Yes 34 9 (26.5%) 25 (73.5%) 0.004 
  No 35 22 (62.9%) 13 (37.1%)  
  Total 69    
       
  Pathological T staging     
  T2a to T2c 35 22 (62.9%) 13 (37.1%) 0.004 
  T3a to T3b 34 9 (26.5%) 25 (73.5%)  
  Total 69    
       
       
       




Chondroitin-2,6-sulphate Adenocarcinoma cells Clinical staging     
  T1a to T1c 37 25 (67.6%) 12 (32.4%) 0.045 
  T2a to T4 8 2 (25.0%) 6 (75.0%)  
  Total 45    
       
 Peritumoural stroma Tumour volume     
  <4.00 cm3 28 7 (25.0%) 21 (75.0%) 0.025 
  ≥4.00 cm3 29 1 (3.4%) 28 (96.6%)  
  Total 57    




4.2  Gene transcript analysis of chondroitin-sulphate biosynthesis and editing 
genes in prostate cancer cell lines 
Upregulation in the CS/DS biosynthetic and editing enzymes and the 
CSPG/DSPG was observed from the genome wide expression analysis in Chapter 3. 
This was further supported by immunohistochemical staining of the prostate tissue 
sections in which an increased expression of various chondroitin sulphate subtypes in 
prostate adenocarcinoma tissues was seen. Next, to employ a good in vitro model for 
use to investigate some of the functions of these differentially expressed genes, the 
expression of the CS/DS biosynthetic genes and some CSPGs in 3 prostate cell lines, 
RWPE-1, a normal epithelial prostate cell line and LNCaP and PC-3, both of which 
are prostate adenocarcinoma cell lines, were quantified. Both cancer cell lines were 
derived from metastatic sites: LNCaP is from the supraclavicular lymph node, while 
PC-3 is from bone metastasis.  
 Table 4.18 shows the expression fold changes of CS/DS and CSPG/DSPG 
genes in LNCaP and PC-3 as compared to RWPE-1, determined from real-time PCR 
and from microarray study. It can be observed that many of these genes are either 
upregulated or downregulated in the same manner in both cancer cell lines; however, 
some genes are not found to be differentially expressed in the same manner in both 
cancer cell lines.  
 There is about 10 fold upregulation of CSGalNAcT-1 in LNCaP while in PC-3, 
CSGalNAcT-1 is upregulated by about 20 fold. Microarray results revealed an 
upregulation of CSGalNacT-1 gene by 2 fold in the prostate adenocarcinoma tissues. 
This was further verified to be upregulated by 4.3 fold through real-time RT-PCR. 
CSGalNAcT-1 was reported to be responsible for the initiation of CS/DS biosynthesis 
after the formation of the tetrasaccharide linkage region xylose-galactose-galactose-




glucuronic acid. CSGalNAcT-2, which shares similar homology to CSGalNAcT-1 and 
is reported to be involved in the elongation of the CS/DS chain, was not differently 
expressed in prostate adenocarcinoma tissues compared to BPH tissues. We 
hypothesized that the upregulation of CSGalNAcT-1 could result in increased 
expression of the chondroitin sulphate chains in prostate adenocarcinoma and could 
potentially contribute to cancer cell behaviour.  
Similarly, we do not observe a significant change in CSGalNAcT-2 expression 
in PC-3 but there was a downregulation of about 5 fold of CSGalNAcT-2 in LNCaP. 
PC-3 was thus used to further investigate the functions of CSGalNAcT-1 as its 
expression of CSGalNAcT-1 and CSGalNAcT-2 was more similar to the data obtained 











Table 4.18  Expression fold changes of CS/DS biosynthesis and editing enzymes and CSPG/DSPG genes in 1) LNCaP (n=3) and PC-3 (n=3) 
as compared to RWPE-1 (n=3), determined by qPCR and 2) in prostate adenocarcinoma tissues (n=6) compared to BPH tissues (n=6), obtained 
from microarray study. P-values of qPCR were obtained using unpaired T-test. Relative fold changes and p-value shown here for microarray 
study were determined by dCHIP. 
Gene Gene name Prostate Cancer Cell Lines Prostate Adenocarcinoma 
tissues 
LNCaP  PC-3 Microarray Study 
Relative Fold 
Change 
p-value Relative Fold 
Change 
p-value Relative Fold 
Change 
p-value 
XylTI xylosyltransferase I N.D <0.05 N.D <0.05 -1.5 >0.05 
XylTII xylosyltransferase  II 1.40 0.39 1.65 0.26 -1.3 >0.05 
B4GalT7 xylosylprotein beta 1,4-
galactosyltransferase, polypeptide 7 
(galactosyltransferase I) 
2.24 0.01 2.65 0.00 1.0 >0.05 
B3GalT6 UDP-Gal:betaGal beta 1,3-
galactosyltransferase polypeptide 6 
2.94 0.06 3.36 0.08 2.3 <0.05 
B3GAT3 beta-1,3-glucuronyltransferase 3 
(glucuronosyltransferase I) 
5.10 0.00 2.61 0.03 1.0 >0.05 







CSGalNAcT-2 chondroitin sulphate N-
acetylgalactosaminyltransferase 2 
-5.23 0.01 1.11 0.88 1.2 >0.05 
CSGLCA-T chondroitin sulphate 
glucuronyltransferase 
3.17 0.00 2.45 0.04 1.3 >0.05 
CHPF chondroitin polymerising factor 2.18 0.21 1.15 0.83 1.3 >0.05 




CHSY1 chondroitin synthase I -1.75 0.26 -3.90 0.041 1.0 >0.05 
CHSY3 chondroitin synthase 3 N.D <0.05 3.30 0.00 -1.3 >0.05 
 SART2 (DSE) dermatan sulphate epimerase     -1.6 >0.05 
CHST13 carbohydrate (chondroitin 4) 
sulphotransferase 13 
263.8 0.0009 8.13 0.002 -1.0 >0.05 
CHST11 carbohydrate (chondroitin 4) 
sulphotransferase 11 
-4.17 0.331 -1.05 0.64 -1.3 >0.05 
CHST12 carbohydrate (chondroitin 4) 
sulphotransferase 12 
4.99 0.0013 1.12 0.70 -1.5 >0.05 
CHST7 carbohydrate (N-acetylglucosamine 6-
O) sulphotransferase 7 
-1.53 0.25 -2.99 0.06 -1.4 >0.05 
CHST3 carbohydrate (chondroitin 6) 
sulphotransferase 3 
-4.88 0.02 -6.72 0.001 1.1 >0.05 
GALNAC4S-6ST B cell RAG associated protein 0.78 0.24 0.69 0.27 -4.0 <0.05 
CHST14 (D4ST1) carbohydrate (N-acetylgalactosamine 
4-0) sulphotransferase 14 
1.31 0.36 1.95 0.18 -1.3 >0.05 
UST uronyl-2-sulphotransferase 2.13 0.03 0.93 0.78 -1.7 >0.05 
ACAN aggrecan 13.83 0.006 N.D <0.05 -1.13 >0.05 
VCAN versican -296.1 0.0007 -4.72 0.009 -2.73 <0.05 
NCAN neurocan 9.15 0.00 -1.31 0.50 -1.04 >0.05 
CSPG4 chondroitin sulphate proteoglycan 4 -6.98 0.0002 -2.02 0.20 -3.07 >0.05 
CSPG5 chondroitin sulphate proteoglycan 5 
(neuroglycan C) 
141.7 0.0006 5.09 0.010 1.64 >0.05 
SMC3 structural maintenance of 
chromosomes 3 
-22.82 0.0004 -168.1 <0.000
1 
-1.04 >0.05 
N.D refers to not detectable in 45 cycles of real-time PCR




4.3 Functional Analysis of CSGalNAcT-1 in prostate cancer cell, PC-3 
4.3.1 CSGalNAcT-1 is effectively silenced in PC-3 – gene transcript and protein 
levels 
To investigate the functional significance of CSGalNAcT-1 upregulation in 
prostate cancer, the gene was silenced in PC-3 prostate cancer cells using 
Dharmacon’s ON-TARGET PLUS SMARTpool double-stranded siRNA 
oligonucleotides. CSGalNAcT-1 was 90% silenced (Figure 4.13A) and protein levels 
of CSGalNAcT-1 were also reduced by 2.5 fold. (Figure 4.13C, 4.13D) CSGalNAcT-
2, with similar homology to CSGalNAcT-1, was not silenced, indicating that there was 
no unspecific off-target silencing. Using Cy3-conjugated non-targeting siRNA, 
transfection efficiency was observed to be 100% (Figure 4.13B). 
4.3.2 Reduction of CS/DS chains after CSGalNAcT-1 siRNA 
The levels of CS/DS expression in the CSGalNAcT-1 silenced cells (cell 
lysate) were quantified by first measuring the total glycosaminoglycans (GAG) 
content using the Blyscan Assay and then by measuring the total GAG content again 
after chondroitinase AC and chondroitinase B digestion. Chondroitin sulphate was 
significantly decreased by about 37% after CSGalNAcT-1 siRNA treatment. Although 
dermatan sulphate differential expression did not reach statistical significance 
(p=0.05), it was observed that there was a 37% decrease in dermatan sulphate 
expression in the CSGalNAcT-1 silenced cells too (Figure 4.13E). These data are in 
line with the report that CSGalNAcT-1 is important in the CS/DS biosynthetic process 
[Sato et al, 2003]. 




Figure 4.13 CSGalNAcT-1 is effectively silenced and CS/DS expression is reduced. 
[A] CSGalNAcT-1 was 90% silenced in PC-3 prostate cancer cells using double 
stranded siRNA oligonucleotides. CSGalNAcT-2, with similar homology to 
CSGalNAcT-1, was not silenced, indicating that there was no unspecific off-target 
silencing. [B] Transfection efficiency was 100%, using Cy3-tagged non-targeting 
siRNA. [C, D] Protein levels of CSGalNAcT-1 silenced PC-3 were also reduced by 
2.5 fold. [E] Using Blyscan Assay, the total GAG content (of the cell lysate) before 
and after each of chondroitinase AC and chondroitinase ABC treatment were 
qunatified. Chondroitin sulphate was significantly decreased by about 37% after 
CSGalNAcT-1 siRNA treatment. Dermatan sulphate was also decreased by about 37% 
in the CSGalNAcT-1 silenced cells, although this did not reach statistical significance 
(p=0.05). Non-targeting siRNA (n=3); CSGalNAcT-1 siRNA (n=3); ‘*’ represents 
p<0.05; ‘**’ represents p<0.01. Statistical test was done using unpaired T-test. 
Experiment was repeated to confirm results. 
 
 




4.3.3 CSGalNAcT-1 silencing inhibited PC-3 proliferation 
CSGalNAcT-1 silencing in PC-3 revealed that the proliferation of PC-3 was 
inhibited by approximately 10% after 72 hours and by 25% after 96 hours of silencing 
(Figure 4.14A). I questioned whether the decrease in proliferative ability was a result 
of cell cycle arrest and/or due to increased apoptosis.  
4.3.4 Apoptotic analysis of CSGalNAcT-1 silenced PC-3 cells 
Apoptosis assay was also performed at 72 hours by using the Guava Nexin Assay 
which contains 2 dyes, Annexin V-PE and 7-AAD. Annexin V binds with high 
affinity to phosphatidylserine which externalizes to the outer cellular surface in the 
early stages of apoptosis [Vermes et al, 1995]; 7-AAD is a cell impermeant dye and is 
used as an indicator of cell membrane structural integrity, which in late stages of 
apoptosis, there is loss of membrane integrity [Schmidt et al, 1992]. It was found that 
there was about 5% increase in apoptotic cells after CSGalNAcT-1 silencing, of which 
3% increase were in early apoptosis and 2% increase were in late apoptosis (Figure 
4.14B). 
4.3.5 Cell cycle analysis of CSGalNAcT-1 silenced PC-3 cells 
Cell cycle analysis was performed at 72 hours via propidium iodide staining and 
it was observed that there was an arrest in the G1 phase. There were about 3% more 
cells in the G1 phase in the CSGalNAcT-1 silenced group as compared to the non-
targeting siRNA group. Also, there were 3% lesser cells in the S phase of the 
CSGalNAcT-1 silenced group as compared to the non-targeting siRNA group. There 
was no significant difference in the number of cells in the G2/M phase in both 
silenced groups (Figure 4.14C). 
 




4.3.6 CSGalNAcT-1 silencing impeded PC-3 invasion. 
The invasive ability of the CSGalNAcT-1 silenced cells were also investigated 
and we report a significant 35% decrease in the number of CSGalNAcT-1 silenced 
cells that invaded across the Matrigel™, as compared to the number of invaded non-
targeting silenced cells at 72 hours post-transfection (Figure 4.14D). 
4.3.7 CSGalNAcT-1 silencing has no effect on PC-3 adhesion to collagen type I. 
We also determined the adhesive capability of the CSGalNAcT-1 silenced cells 
and report that there was no significant change in the adhesion of CSGalNAcT-1 









Figure 4.14  Effects of CSGAlNAcT-1 silencing on PC-3 cell behaviour. [A] 
CSGalNAcT-1 silencing inhibited proliferation of PC-3 by approximately 10% after 
72 hours post-transfection and by 25% after 96 hours of silencing. [B] CSGalNAcT-1 
silencing results in 5% increase in apoptotic cells at 72 hours post-transfection, of 
which 3% increase were in early apoptosis and 2% increase were in late apoptosis. 
[C] CSGalNAcT-1 silenced PC-3 cells were arrested at the G1 phase. [D] Cell 
invasion was inhibited after silencing CSGalNAcT-1; there were 35% less invaded 
CSGalNAcT-1 silenced cells than non-targeting silenced cells at 72 hours post-
transfection. [E] No significant change was observed in the ability of CSGalNAcT-1 
silenced cells to adhere to collagen type I, as compared to non-targeting silenced cells. 
Non-targeting siRNA (n=3); CSGalNAcT-1 siRNA (n=3); ‘*’ represents p<0.05; ‘**’ 
represents p<0.01; ‘***’ represents p<0.001. Statistical test was done using unpaired 
T-test. 
 




4.3.8 Microarray analysis of CSGalNACT-1 silenced PC-3 cells 
To gain insight into some of the potential mechanisms CSGalNAcT-1 can mediate 
cellular behaviour, a genome-wide expression analysis using Affymetrix Human 
U133 Plus 2 GeneChips was performed. Total RNA was extracted from the non-
targeting siRNA and CSGalNAcT-1 siRNA transfected cells to be used for the 
microarray study. The purity of the RNA was assessed based on A260/A280 while the 
quality of the isolated RNA was checked using the Agilent Bioanalyzer. Quality of 
the RNA was assessed based on the electrophoretic trace of the RNA sample (similar 
to Figure 3.3) and the RNA integrity number (RIN) (Table 4.19).  
Labelled cRNA was synthesized using the Affymetrix one-cycle target 
labeling kit and the labelled cRNA was fragmented prior to hybridization to 
Affymetrix U133 plus2 Genechips. The fragmented cRNA was checked using the 
Agilent Bioanalyzer and the electrophoregrams analyzed, as performed in Section 3.2, 
Figure 3.4.  
Table 4.19  RNA purity and quality of samples used for microarray study 
Samples A260/A280 RIN 
 Mean SD Mean SD 
Non-targeting siRNA (n=3) 2.07 0.02 9.53 0.12 
CSGalNAcT-1 siRNA (n=3) 2.07 0.04 9.30 0.44 




4.3.8.1 Quality control of microarray data 
Staining, washing and scanning of the microarray chips were performed on 
Fluidics Station 450 and the Affymetrix GeneChip Scanner 3000. The presence of 
housekeeping genes, spike control cRNAs, background scaling factor and noise (raw 
Q) were checked to ensure the quality of the assays done. The 3’/5’ ratios for β-actin 
gene lies from 1.1 to 1.51 for all samples. The scaling factors for all the samples are 
within two-fold of each other, the smallest factor being 3.80 while the largest factor is 
5.68, with a mean factor of 5.02. All the spiked in controls were detected as present in 
all arrays; in addition, there was increasing average intensity values from BioB to 
CRE for all samples. Q values for all our samples are similar to one another, with a 
range of 1.0 to 1.2 only. 
4.3.8.2  Differential expression of genes in CSGalNAcT-1 silenced PC-3 
Several softwares such as GCOS, dCHIP and Genespring were used to analyze 
the microarray data. The data was normalized and expression intensities of different 
genes were derived using each of the above software. Genes that were commonly 
identified by the three softwares as differentially expressed in the prostate cancer 
sections by more than or equal to 2 fold change with p<0.05 and, in which more than 
50% of the tumours showed the same change were obtained. From this selection 
criterion across the 3 softwares, 10 genes were found downregulated after 
CSGalNAcT-1 silencing in PC-3 (Table 4.20). 
Real-time polymerase chain reaction (qPCR) was performed on 6 genes and it 
was observed that all 6 of these genes were downregulated in CSGalNAcT-1 silenced 
PC-3 cells, showing 100% correlation with the microarray results. 




Table 4.20  List of genes differentially expressed after CSGalNAcT-1 silencing and their fold changes as determined from microarray study 
and real-time PCR. Non-targeting siRNA (n=3); CSGalNAcT-1 siRNA (n=3). Relative fold change and p-values for microarray study are all 
p<0.05, and obtained from dCHIP. P-values for real-time PCR are performed using unpaired T-test. 












MAPRE-1 microtubule-associated protein, RP/EB family, 
member 1 
22919 Cell cycle -3.48 -3.80 0.001 
RCBTB1 regulator of chromosome condensation (RCC1) 
and BTB (POZ) domain containing protein 1 
55213 Putative adaptor for cullin 3 
E3 ligase 
-2.64 -3.39 0.002 
LIFR Leukemia inhibitory factor receptor 3977 Cell proliferation and 
migration 
-2.35 -1.86 0.008 
HIPK3 Homeodomain interacting protein kinase 3 10114 Apoptosis -3.56 -2.09 0.005 
CPOX coproporphyrinogen oxidase 1371 Heme biosynthetic pathway -2.36 -2.52 0.0003 
ATL3 atlastin GTPase 3 25923 ER and golgi 
morphogenesis 
-2.30 - - 
TPX2 TPX2, microtubule-associated protein homolog 
(Xenopus laevis) 
22974 Cell cycle -2.46 -2.37 0.0001 
FAM96A family with sequence similarity 96, member A 84191 unknown -2.55 - - 
TPPC2 trafficking protein particle complex 2 6399 ER-Golgi transport -2.22 - - 
- CDNA FLJ37302 fis, clone BRAMY2016009 - unknown -2.38 - - 




4.3.9 Cell cycle and apoptotic proteins were downregulated in CSGalNAcT-1 
silenced PC-3 cells 
It was found that the downregulation of CSGalNAcT-1 resulted in the suppression 
of several genes important in microtubule and cell cycle dynamics, such as the 
MAPRE-1 gene which encodes the EB1 proteins and the TPX2 gene. The HIPK3 
gene, important in mediating Fas-associated apoptosis resistance in PC-3 cells, was 
also found to be downregulated through CSGalNAcT-1 silencing. These genes were 
also verified by real-time PCR to be downregulated in CSGalNAcT-1 silenced cells. 
The protein levels of these genes in CSGalNAcT-1 silenced PC-3 cells were next 
investigated. 
 MAPRE-1 was found to be downregulated by 3.5 fold from microarray results 
and downregulated by 3.8 fold from real-time PCR. Using flow cytometry to 
determine the protein expression of the EB1 protein, the median log fluorescence 
intensity for the scrambled siRNA cells is 10.15 and for the CSGalNACT-1 silenced 
cells, is 9.03 at 48 hours. At 72 hours, the median log fluorescence intensity for the 
scrambled siRNA cells is 9.16 and for CSGalNACT-1 silenced cells, is 8.79. This 
correspond to a decrease in the median expression of the protein in CSGalNAcT-1 
silenced cells by about 11% at 48 hours and a difference of 4% at 72 hours.  (Figure 
4.15 and 4.16) 
TPX2 was also found to be downregulated by 2.5 fold from microarray data and 
downregulated by 2.4 fold, as verified by real-time PCR. Similarly, using flow 
cytometry, it was revealed that there was about 30% less CSGalNAcT-1 silenced cells 
that were TPX2 positively stained at 48 hours than the non-targeting control group. At 
48 hours, the median percentage of positively stained scrambled siRNA cells is 94.0% 
while it is 65.5% for TPX2 positively stained-CSGalNAcT-1 silenced cells. The 




expression of TPX2 in both non-targeting and CSGalNAcT-1 silenced cells were 
generally lower at 72 hours than at 48 hours, where the median percentage of 
positively stained scrambled siRNA cells is 38.2% while it is 25.7% for TPX2 
positively stained-CSGalNAcT-1 silenced cells. Nevertheless, it was detected that 
there were 33% less TPX2 positively stained CSGalNAcT-1 silenced cells than 
control cells at 72 hours. (Figure 4.17 and 4.18) 
HIPK3 were also downregulated by 2.5 fold (microarray) and 2.1 fold (qPCR). 
Flow cytometry results showed that the median log expression of HIPK3 expression, 
at 48 hours, for scrambled siRNA cells was 9.27 and for CSGalNAcT-1 silenced cells, 
was 9.03. This translated to a decrease of 3% in CSGalNAcT-1 silenced PC-3 cells. 
This difference was increased to 10% at 72 hours, where the median log expression of 
HIPK3 expression for scrambled siRNA cells was 7.24 and for CSGalNAcT-1 
silenced cells, was 6.46. (Figure 4.19 and 4.20) 




Figure 4.15  CSGalNAcT-1 silencing downregulated MAPRE-1 protein. Non-targeting cells and CSGalNAcT-1 PC-3 cells were fixed and 
stained with MAPRE-1 antibody and an FITC-labeled anti-mouse IgG secondary antibody, and then analyzed via a flow cytometer, at 48 hours 
and 72 hours post transfection. From the overlay diagram at 48 hours, the median of the graph of CSGalNAcT-1 silenced cells (red) was shifted 
to the left of the graph of the non-targeting silenced cells (black line), representing lower expression of the MAPRE-1 protein in the 
CSGalNAcT-1 silenced cells. ‘FSC’ is forward scatter, which is a measure of cellular size. 





Figure 4.16  CSGalNAcT-1 silencing downregulated MAPRE-1 protein by about 11% at 48 hours and 4% at 72 hours. Non-targeting silenced 









































Figure 4.17 CSGalNAcT-1 silencing downregulated TPX2 protein. Non-targeting and CSGalNAcT-1 silenced PC-3 cells were fixed and 
stained with TPX2 antibody and an FITC-labeled anti-mouse IgG secondary antibody, and then analysed via a flow cytometer. The TPX2-
positively stained cells were gated from the negative control cells. From the overlay diagrams, there were a smaller number of TPX-2 positively 
stained CSGalNAcT-1 silenced PC-3 cells (red) compared to the non-targeting silenced cells (black line), representing lower expression of the 
TPX2 protein in the CSGalNAcT-1 silenced cells at 48 hours and 72 hours. ‘FSC’ is forward scatter, which is a measure of cellular size. 





Figure 4.18  CSGalNAcT-1 silencing downregulated TPX-2 protein. There were 30% less TPX2-positive CSGalNAcT-1 silenced cells than the 
non-targeting control group at 48 hours post-transfection; at 72 hours post-transfection, there were 33% less TPX2 positively stained 
CSGalNAcT-1 silenced cells than control cells. Non-targeting silenced PC-3 (n=3); CSGalNaCT-1 silenced PC-3 (n=3). Statistical test was 



























































Figure 4.19 CSGalNAcT-1 silencing downregulated HIPK3 protein. Non-targeting and CSGalNAcT-1 PC-3 cells were fixed and stained with 
HIPK3 antibody and an Alexa-Fluor 488 conjugated anti-rabbit IgG secondary antibody, and then analysed via a flow cytometer, 48 hours and 
72 hours post-transfection. The HIPK3 positively stained cells were gated from the negative control cells. From the overlay diagram at 72 hours, 
the log median fluorescence intensity of the graph of CSGalNAcT-1 silenced cells (red) was shifted to the left of the graph of the non-targeting 
silenced cells (black line), representing lower expression of the HIPK3 protein in the CSGalNAcT-1 silenced cells.  




Figure 4.20 CSGalNAcT-1 silencing downregulated HIPK3 protein. The median log fluorescence intensity of HIPK3 stained positive cells 
was 3% lower in CSGalNAcT-1 silenced PC-3 cells at 48 hours and this difference was increased to 10% at 72 hours Non-targeting silenced PC-














































4.4.1 Increased chondroitin sulphate expression and their potential use as a 
biomarker of prostate cancer progression 
In this study, the expression patterns of different chondroitin sulphate subtypes 
such as non-sulphated chondroitin, chondroitin-4-sulphate, chondroitin-6-sulphate and 
chondroitin-2,6-sulphate in benign prostatic tissue and paired prostate cancer samples 
from corresponding patients were examined. On the whole, chondroitin sulphate 
appears to be more highly expressed in malignant tissues as compared to non-
malignant tissues. However, chondroitin sulphate expression and localization appears 
to alter in different Gleason grades of prostate cancer tissue, with increasing 
expression of chondroitin sulphate in the peritumoural stroma and a concomitant 
decreasing expression of chondroitin sulphate in the cytoplasm of the malignant cells, 
as tumour grade increases.   
The growth promoting effects of chondroitin sulphate has long been reported. 
Back in 1965, Takeuchi J demonstrated that chondroitin sulphate treatment promoted 
the growth of solid Ehrlich ascites tumour in a dose-dependent manner. [Takeuchi J, 
1965] In yet another approach, Denholm et al, 2001, reported inhibition of melanoma 
cells’ proliferation through removing chondroitin sulphate and dermatan sulphate 
chains using chondroitinase AC and chondroitinase B respectively [Denholm et al, 
2001]. Chondroitinase AC, but not chondroitinase B, treatment also enhanced 
apoptosis of melanoma cells. These studies demonstrate the growth promoting and 
apoptosis resistance effects of chondroitin sulphate in tumour biology. 
Chondroitin sulphate may regulate prostate cancer cell behavior and influence 
patient prognosis through several mechanisms. Platelet derived growth factors 
(PDGFs) are involved in regulating proliferation of cancer cells and stimulating 




tumour angiogenesis, and chondroitin-4-sulphate has been shown to enhance PDGF 
action by enhancing signaling of the tyrosine kinase receptors [Fthenou et al, 2006]. 
Indeed, PDGF and its receptor have been reported to be upregulated in prostate 
adenocarcinoma, and expression of PDGF receptor has been shown to mark prostate 
cancer cells with the greatest disposition for bony metastasis [Dolloff et al, 2005; 
Fudge et al, 1994].  
Stromal cell-derived factor-1 (SDF-1) is a chemoattractant for prostate 
carcinoma cells [Cooper et al, 2003]. Chondroitin sulphate has been shown to be 
required for cellular binding of SDF-1 [Netelenbos et al, 2003]. In prostate carcinoma, 
treatment of cancer cells with SDF-1 upregulated expression of αvβ3 integrin 
receptors, resulting in increased cell adhesion and invasion [Sun et al, 2007]. 
Furthermore, SDF-1 has been shown to be critical for spread of prostate cancer, and a 
positive correlation has been reported between SDF-1 signaling and bony metastasis 
[Sun et al, 2005; Taichman et al, 2002].  
Several reports have highlighted the importance chondroitin sulphate plays in 
development as well.  They have demonstrated that chondroitin sulphate is essential 
for cell proliferation, cytokinesis and migration through inhibiting biosynthesis of 
chondroitin by RNA interference, and this may underlie the mechanistic processes 
leading to the association of chondroitin sulphate with adverse pathologic parameters. 
[Mizuguchi et al, 2003; Izumikawa et al, 2004]  
The differing expression of chondroitin sulphate in different tumour grades of 
prostate cancer reflects yet again, that tumours are of different heterogeneous genetic 
makeup.  It was interesting to note that in the prostate adenocarcinoma samples, there 
was a decreasing expression of chondroitin-6-sulphate and non-sulphated chondroitin 




in the adenocarcinoma cells with increasing Gleason grades. Chondroitin-2,6-sulphate 
expression was the highest in the Gleason 6 and 7 grade cancers and the lowest in 
Gleason 8 to 10 grade cancers. In contrast, all chondroitin sulphate subtypes 
expression in the peritumoural stroma was observed to increase with increasing 
Gleason grades, the highest being in the Gleason sum 8 to 10 cancers. Proteoglycans 
and glycosaminoglycans in the tumour stroma have been well-known to play intricate 
and crucial roles in the carcinogenic process, such as growth factor binding, 
disturbances in the collagen fibrillar network that permits neoplastic formation and 
invasion [Iozzo RV, 1999] and matrix degradation via enhancement or inhibition of 
proteolytic enzymes [Hornebeck et al, 2002]. The significance of the spatial and 
temporal expression of the CS/CSPG in prostate adenocarcinoma tissues remains to 
be explored.    
4.4.2 Unraveling the functional significance of CSGalNAcT-1 upregulation in 
prostate cancer 
Next, I was interested to understand the functional relevance of the 
upregulation of chondroitin sulphate in prostate adenocarcinoma. Using the prostate 
cancer cell lines, LNCaP and PC-3 cells as our model of study, the expression of 
genes coding for chondroitin sulphate biosynthetic and modifying enzymes were 
screened by using real-time PCR. This was performed to detect the differential 
expression of genes that could bring about an increased expression of chondroitin 
sulphate in prostate cancer. Many CS/CSPGs synthetic genes were revealed to be 
differentially expressed in the prostate cancer cell lines as compared to the normal 
prostate epithelial cell, RWPE-1. Of interest to this study, I would like to highlight the 
CSGalNAcT-1 gene, which was found to be overexpressed in prostate 




adenocarcinoma tissues from our microarray data (about 2 fold) and in prostate cancer 
cell lines, LNCaP (about 10 fold) and PC-3 (about 20 fold). 
Since CSGalNAcT-1 is necessary for the initiation of CS/DS biosynthesis 
[Sato et al, 2003], the upregulation of the CS chains observed through 
immunohistochemistry could be a ttributed to the increased expression of this gene. 
Silencing CSGalNAcT-1 in PC-3 resulted in decreased expression of the CS/DS 
chains and also resulted in decreased proliferation, increased apoptosis and reduced 
invasion. Interestingly, by using microarray screen again, we have also detected 
previously unknown downstream targets of CSGalNAcT-1 which include the 
microtubule-associated proteins, EB1 encoded by MAPRE-1 and TPX2, as well as 
HIPK3 that is involved in FAS-mediated apoptosis resistance.  
MAPRE-1 codes for the EB1 protein which is a family member of the 
microtubule tip-tracking proteins [Li and Yi, 2001]. EB1 has also been found to 
interact with the cytoplasmic microtubules along their full length with accentuations 
at their tips in interphase and was localised to the centrosomes and the mitotic spindle 
during mitosis [Morrison et al, 1998; Berrueta et al, 1998]. It has been implicated in 
stimulation of growth at the microtubule plus ends which is important for search-
capture of ER-Golgi transport vesicle, in the microtubule capture at the cell cortex 
during cytoskeletal reorientation, at the kinetochores of prometaphase and at the cell 
cortex where astral microtubules can attach [Tirnauer et al, 2002; Rogers et al, 2002; 
Vaughan KT, 2005]. It is an important regulator of microtubule dynamics including 
mitotic spindle formation and proper chromosome segregation [Tirnauer and Bierer, 
2000]. In addition, EB1 has been found to interact with the adenomatous polyposis 
coli (APC) protein, a well-known tumour suppressor gene [Su et al, 1995]. APC and 
EB1 have been reported to function together in mitosis to regulate spindle dynamics 




and chromosome alignment [Green et al, 2005], however, there was a separate study 
reporting that the EB1-APC interaction is not crucial to promoting microtubule net 
growth at the microtubule plus ends [Kita et al, 2006]. In addition, EB1 has been 
reported to promote Aurora B kinase activity through blocking its inactivation by 
protein phosphatase 2A [Sun et al, 2008]. Aurora B kinase, belonging to the Aurora 
kinase family well-known to be implicated in tumourigenesis and are important 
regulators of the cell cycle [Vader and Lens, 2008], is known to be an important 
regulator of kinetochore-microtubule attachments; it is crucial for correction of 
syntelic attachments, and ensuring that the chromosomes are properly bi-orientated 
and will segregate equally in anaphase [Andrews PD, 2005]. Downregulation of the 
EB1 protein could thus result in reduced activity of Aurora B kinase and lead to cell 
cycle arrest.      
Recently, Liu et al have reported that EB1 acts as an oncogene that promotes 
cellular growth and inhibits apoptosis via activation of the beta-catenin/TCF pathway 
[Liu et al, 2009]. In addition, another study conducted by Wang et al also reported the 
promotion of cellular growth in oesophageal squamous cell carcinoma by 
overexpressing EB1, through the beta-catenin/TCF pathway [Wang et al, 2005]. They 
revealed that EB1 disrupted the interaction between APC and beta-catenin. Beta-
catenin/TCF are effector molecules of the Wnt signaling pathway. Beta-catenin can be 
found as a protein complex, being bound with APC, glycogen synthase kinase 3β 
(GSK3β), axin and protein phosphatase 2A (PP2A), a multi-subunit complex. [Hart et 
al, 1998; Ratcliffe et al, 2000] In the presence of Wnt signalling, beta-catenin is 
protected from degradation via the ubiquitin pathway [Aberle et al, 1997] and this 
stabilized beta-catenin enters the nucleus, complexes with the transcription factors of 
the Lef1/TCF family, promotes transcription of downstream targets such as c-myc, c-




jun and cyclin D1 [Shtutman et al, 1999; He et al, 1998]. Our study has further 
confirmed the growth promoting and apoptosis-resistance effects of EB1, as 
downregulation of EB1 also resulted in growth inhibition and increased apoptosis in 
the prostate cancer cells. Even more so, we have demonstrated that CSGalNAcT-1 
could regulate EBl proteins as well; although beta-catenin/TCF, APC, GSK3B, axin, 
c-myc, c-jun, cyclin D1 transcript levels were not differentially changed in our 
microarray data (see Table 4.22), these could represent changes at a post-translational 
level. Alternatively, perhaps CSGalNAcT-1 mediated-EB1 downregulation inhibits 
cell growth and enhance apoptosis via other pathways. Future work is needed to 
confirm how CSGalNAcT-1 mediates EB1 downregulation and also, how EB1 plays a 
role in CSGalNAcT-1 mediated growth inhibition and enhance apoptosis. Possibly, it 
would also be interesting to investigate any possible interactions between chondroitin 
sulphate/dermatan sulphate and or CSGalNAcT-1 interactions with the Wnt signalling 
pathway in prostate tumourigenesis; Wnt-1-induced secreted protein 1 (WISP-1) has 
been reported to bind to decorin and biglycan (dermatan sulphate proteoglycans) 
[Desnoyers et al, 2001] thus regulating their function; Nadanaka et al has also recently 
reported the importance of chondroitin sulphate E structures synthesized by C4ST1in 
Wnt3a signaling [Nadanaka et al, 2008]. 
TPX2 is a microtubule-associated protein important in promoting microtubule 
assembly around chromosomes that is crucial for bipolar spindle formation [Gruss et 
al, 2002]. In Xenopus laevis egg extracts, TPX2 is bound to importins α and β, which 
when RanGTP binds, TPX2 is released and promotes microtubule assembly [Gruss et 
al, 2001; Gruss et al, 2004]. TPX2 also activates Aurora A [Kufer et al, 2002; Eyers et 
al, 2003], a serine/threonine kinase that is important in centrosome maturation, 
centrosome separation and bipolar spindle assembly. Proper localization and function 




of centrosomal components, accurate migration of the centrosomes to define the 2 
poles of the bipolar spindles and the astral microtubules connections with the 
centrosome to the cell cortex to maintain proper bipolarity requires Aurora A kinase 
[Vader and Lens, 2008]. Moreover, Aurora A kinase has also been reported to 
phosphorylate CENP-A which causes the recruitment of Aurora B kinase to the inner 
centromere at prometaphase  [Kunitoku et al, 2003]. 
The endpoint of mitosis is to ensure diploid chromosome number in the 
daughter cell and as such, cell cycle progression is a tightly controlled process that 
involves many checkpoints to ensure proper cell division occurring at high fidelity. 
The microtubule network thus plays an imperative role in the proper segregation of 
cellular contents; we know that EB1 and TPX2 are microtubule-associated proteins, 
which together with their binding partners and downstream players such as the Aurora 
kinases, regulate microtubule dynamics and spindle assembly. Downregulation of 
EB1 and TPX2 could thus result in disruption in cell cycle progression. In our study, 
we have ascertained CSGalNAcT-1 silencing resulted in downregulation of EB1 and 
TPX2 which could perhaps affect the activation of the Aurora kinases and the beta-
catenin/TCF pathway, resulting in decreased proliferative ability yet increased 
apoptotic capacity of the PC-3 cells. 
HIPK3, homeodomain interacting protein kinase 3, is a serine/threonine kinase 
that phosphorylates FADD [Rochat-Steiner et al, 2000] and was found to be elevated 
in Fas-resistant DU145 and PC-3 cells in comparison with more sensitive PPC-1 and 
ALVA31 prostate carcinoma cells [Curtin and Cotter, 2004]. Curtin and Cotter also 
reported that inhibition of HIPK3 significantly reduced FADD phosphorylation and 
increased the sensitivity of DU145 cells to Fas-mediated apoptosis. They also further 
demonstrated that HIPK3 expression is regulated by JNK through the transcription 




factor c-Jun. In our study, we did not detect any differential change in JNK or c-Jun 
expression (see Table 4.14) in the CSGalNAcT-1 silenced PC-3 cells; this could 
possibly indicate 1) a JNK-independent pathway of HIPK3 activation that is mediated 
by the CSGalNAcT-1 and/or CS/DS chains or 2) post-translational modifications of 
JNK. Nevertheless, our findings have shown that CSGalNAcT-1 silencing could 
downregulate HIPK3, rendering the cells more sensitive to apoptosis, consistent with 
our data that there was increased apoptosis after CSGalNAcT- 1 removal.   
CSGalNAcT-1 suppression also reduced PC-3 cells invasiveness through the 
Matrigel in vitro. Leukaemia inhibitory factor receptor (LIFR) has been reported to be 
implicated in carcinogenesis [Grant et al, 2001; Tomida et al, 2000] and in our study, 
have been found to be downregulated after CSGalNAcT-1 silencing. The leukemia 
inhibitory factor receptor (LIF-R) subunit is a component of cell-surface receptor 
complexes for the multifunctional cytokines like leukaemia inhibitory factor (LIF), 
cardiotrophin-1, ciliary neurotrophic factor, and human oncostatin M [Plun-Favreau et 
al, 2003]. LIFR activation by the cytokine LIF has been shown to promote cellular 
proliferation via protein tyrosine kinases, protein kinase C and STAT3 
phosphorylation in pancreatic cancer cells [Kamohara et al, 2007]. In prostate cancer, 
oncostatin M stimulated the growth of 22Rv1 prostate cancer cells through the p38 
MAPK signaling pathway and phosphatidylinositol-3-kinase pathway [Godoy 
Tundidor et al, 2005]. Targets of the p38 MAPK signaling pathway and PI3K 
signaling includes the matrix metalloproteinase family members, which play 
important roles in tumour invasion by degrading extracellular matrix and regulating 
cytokine activities [Shukla et al, 2007; Hsieh et al, 2007]. In our study, CSGalNAcT-1 
silencing suppresses LIFR mRNA and also downregulation of matrix 
metalloproteinase 13 by about 1.6 fold, which could potentially affect the 




invasiveness of the PC-3 cells. In addition, other proteolytic enzymes are found to be 
downregulated after CSGalNAcT-1 silencing, such as carboxypeptidase M (1.6 fold, 
p<0.001) and Sumo1/sentrin specific peptidase 7 (1.6 fold, p<0.01) which although 
relatively not much is known about their effects on invasion currently, might serve to 
effect the aggression of the cancer cells into the surrounding tissue.  
Our present study provides mechanistic insights into how CSGalNAcT-1 could 
attenuate prostate tumour activity by inhibiting proliferation, activating apoptosis and 
inhibiting cell invasion (Figure 4.21). A longer period of study will be useful in 
determining the long term effects of CSGalNAcT-1 silencing in the prostate 
adenocarcinoma cells as from our study, we noticed only small percentages of 
changes in proliferation, apoptosis and EB1, TPX2 and HIPK3 protein levels at 72 
hours. This could possibly be due to the complex synthesis of the CS/DS chains from 
gene transcript level to proteoglycans end-product; moreover, this could be hampered 
by the transient silencing of the CSGalNAcT-1 gene using our methods which will not 
allow us to conduct long-term studies. In addition, future work will also be needed to 
determine exactly the mechanisms by which CSGalNAcT-1 affects cell cycle, elicits 
apoptosis and reduces tumour cell invasion. Since CSGalNAcT-1 is involved in 
chondroitin sulphate synthesis, the question remains if CSGalNAcT-1 elicits signaling 
via chondroitin sulphate chains or by novel non-enzymatic mechanisms that bypasses 
the chondroitin sulphate chains. Nevertheless, this study reveals important tumour-
attenuating properties of the CSGalNaCT-1 and/or the CS/DS chains and could prove 
to be an interesting novel therapeutic target. 
  




Table 4.21 Transcript data of genes possibly involved in CSGalNAcT-1-mediated 
signaling. Relative fold change values are those from dCHIP. P-value of genes listed 
are p >0.05 






















GSK3β glycogen synthase kinase 3 beta  8.91 0.04 8.94 0.006 1.02 
CTNNB1 beta-catenin 5.39 0.11 5.25 0.05 0.90 
APC adenomatous polyposis coli 2.59 0.20 2.11 0.15 0.72 
AXIN1 axin 1  5.43 0.04 5.64 0.11 1.16 
AXIN2 axin 2  5.78 0.11 5.96 0.05 1.13 
PPP2CA 
protein phosphatase 
2 (formerly 2A), 
catalytic subunit, 
alpha isoform  
3.95 0.26 3.94 0.24 0.99 
PPP2CB 
protein phosphatase 
2 (formerly 2A), 
catalytic subunit, 
beta isoform 
10.32 0.02 10.35 0.04 1.02 
PPP2R1A 
protein phosphatase 
2 (formerly 2A), 
regulatory subunit A, 
alpha isoform 
10.14 0.03 10.16 0.05 1.01 
PPP2R1B 
protein phosphatase 
2 (formerly 2A), 
regulatory subunit A, 
beta 
isoform 
8.46 0.02 8.5 0.01 1.03 
PPP2R5A 
protein phosphatase 
2, regulatory subunit 
B', alpha isoform  
8.25 0.05 8.28 0.009 1.02 
PPP2R5B 
protein phosphatase 
2, regulatory subunit 
B', beta isoform 
8.16 0.06 8.16 0.05 1 
PPP2R5C 
protein phosphatase 
2, regulatory subunit 
B', gamma isoform 
3.7 0.21 3.35 0.26 0.78 
PPP2R5D 
protein phosphatase 
2, regulatory subunit 
B', delta isoform 
7.38 0.04 7.3 0.06 0.95 
PPP2R5E 
protein phosphatase 
2, regulatory subunit 
B', epsilon isoform 
8.59 0.02 8.61 0.06 1.01 
AURKB Aurora kinase B 9.4 0.02 9.5 0.06 1.10 




LEF1 lymphoid enhancer-binding factor 1  4.04 0.28 4.50 0.14 1.38 
TCF7 
transcription factor 7 
(T-cell specific, 
HMG-box) 
3.71 0.10 3.89 0.06 1.13 
TCF7L1 
transcription factor 
7-like 1 (T-cell 
specific, HMG-box) 
6.78 0.06 6.97 0.04 1.14 
TCF7L2 
transcription factor 
7-like 2 (T-cell 
specific, HMG-box) 







10.38 0.02 10.34 0.04 0.97 
c-Jun 
v-jun sarcoma virus 
17 oncogene 
homolog (avian) 
6.84 0.02 6.88 0.04 1.00 
CCND1 cyclin D1  10.24 0.03 10.43 0.02 1.14 
AURKA 
serine/threonine 
kinase 6 (aurora 
kinase A) 
10.57 0.01 10.54 0.03 0.98 
CENP-A centromere protein A, 17kDa 10.38 0.01 10.4 0.01 1.00 
FADD 
Fas (TNFRSF6)-
associated via death 
domain 




protein kinase 8 6.52 0.03 6.49 0.13 0.98 
CASP8 caspase 8  6.39 0.003 6.12 0.55 0.83 
CASP3 caspase 3  8.62 0.02 8.61 0.04 0.99 





Figure 4.21 Hypothetical diagram on the mechanisms of CSGalNAcT-1 role in PC-3 cell behaviour. Proposed hypothetical diagram of 
possible pathways CSGalNAcT-1 could be involved in.  In this study, CSGalNAcT-1 has been shown to regulate the MAPRE-1 gene encoding 
EB1 protein. EB1 has been reported to promote cell growth and inhibit apoptosis via the beta-catenin/TCF pathway. Beta-catenin, glycogen 
synthase kinase 3 beta (GSK3B), adenomatous polyposis coli (APC), axin and protein phosphatase 2A (PP2A) can be found as a protein 
complex; in the presence of Wnt signalling, dishevelled (dvl) proteins transduce the signal to inhibit GSK3B, leading to beta-catenin 
accumulation in the cytosol. Beta-catenin enters the nucleus and cooperate with transcription factors of the LEF/TCF family to promote 
transcription of downstream targets such as c-myc, c-jun and cyclin D1. These targets are important factors for cell growth and cell cycle. EB1 
can also protect Aurora kinase B (AURKB) from phosphorylation by PP2A; Aurora kinase B, as well as Aurora kinase A (AURKA), is an 
important mediator of cell cycle. TPX2 was also found to be regulated by CSGalNAcT-1. Crucial for bipolar spindle assembly, TPX2 also 
activates AURKA. AURKA could phosphorylate CENP-A which could promote AURKB to the inner centromere. CSGalNAcT-1 also regulates 
the HIPK3 gene, which phosphorylates Fas-associated via death domain (FADD) and results in Fas-mediated apoptosis resistance. This has been 
reported to be mediated by JNK through c-jun. As such, CSGalNAcT-1 silencing downregulates MAPRE-1/EB1, TPX2 and HIPK3 protein, 
which could impede cell cycle progression, reduce cell growth and promote apoptosis.  




Chapter 5  
Expression and Functional Analysis of Heparan Sulphate in Prostate 
Cancer 
5.1 Expression analysis of heparan sulphate in prostate cancer  
5.1.1 Localization of heparan sulphate in BPH and adenocarcinoma tissues 
Expression analysis of the heparan sulphate was examined in a total of 106 
cases of benign prostatic hyperplastic tissues and 132 cases of prostate 
adenocarcinoma cases, in which 85 of these cases are matched cases (i.e both BPH 
samples and prostate adenocarcinoma tissues were taken from the same patient).    
Using monoclonal antibody 10E4, heparan sulphate was not expressed in the 
benign secretory epithelial cells in about 90.57% of the benign cases. Heparan 
sulphate staining was positive in the periglandular stroma for 93.4% of the benign 
cases, with a range of weak to strong staining. 86.36% of the prostate adenocarcinoma 
tissues also do not express heparan sulphate in the cytoplasm of the cancer cells. 
Peritumoural stroma cells were positively stained for heparan sulphate in about 86.3% 
of the adenocarcinoma tissues, demonstrating weak to strong staining. The expression 
data of heparan sulphate in 106 cases of benign prostatic tissues and 132 cases of 
prostate adenocarcinoma samples are shown in Table 5.1 and Figure 5.1. 
5.1.2 Comparison of heparan sulphate expression in benign prostatic and 
adenocarcinoma tissues 
When staining differences in the means of 85 cases of matched benign and 
prostate adenocarcinoma tissues were compared, no significant changes in staining 
intensity or percentage of cells stained positively for heparan sulphate in the 
adenocarcinoma cells and the peritumoural stroma, as compared to the benign 




epithelial cells and the periglandular stroma, respectively, were observed. (Figure 5.2 
and Table 5.2) 
5.1.3 Comparison of heparan sulphate expression in different grades of 
prostate adenocarcinoma tissues 
Following this, we wanted to determine whether the expression levels of 
heparan sulphate in both the cytoplasm of the prostate adenocarcinoma cells and the 
peritumoural stroma are associated with different tumour grades of prostate 
adenocarcinoma. Due to technical difficulties encountered as a result of different 
batches of antibodies employed for use for the prostate TMAs (Gleason sum 6 and 7) 
and the core biopsies (Gleason sum 3 to 5 and 8 to 10), we compared the 2 extreme 
grades of prostate adenocarcinoma cases only (i.e Gleason sum 3 to 5 versus Gleason 
sum 8 to 10) since immunohistochemical staining was performed at the same time and 
using the same batch of antibodies for this set of tissues.  
 There was very weak mean staining in the cytoplasm of the adenocarcinoma 
tissues of Gleason sum 3 to 5 and 8 to 10, and there was no significant difference 
between the two extreme grades. There was also a very small percentage of 
adenocarcinoma cells positively stained for heparan sulphate in both Gleason sum 3 to 
5 and Gleason sum 8 to 10 groups, and there was no significant difference between 
the two extreme grades either. In addition, no significant difference was also observed 
in the staining intensity, percentage of peritumoural stroma cells positively stained 
and immunoreactivity score, between the Gleason sum 3 to 5 group and Gleason sum 
8 to 10 group (Figure 5.3 and Table 5.3). 




Table 5.1 Expression profiles of 10E4 specific-heparan sulphate epitope in prostate tissues. 
Stained tissue 





Weighted Average Intensity 
(WAI) 
Percentage of cells 
(%) Immunoreactivity Score (IRS) 
≤1 1<I<2 ≥2 ≤50 >50 ≤100 100<IRS<200 ≥200 
Benign 
Secretory 
epithelial cells 106 
96 4 1 5 8 2 9 0 1 
90.57% 3.77% 0.94% 4.72% 7.55% 1.89% 8.49% 0.00% 0.94% 
Periglandular 
Stromal cells 106 
7 37 14 48 32 67 48 23 28 




114 7 2 9 16 2 17 1 0 
86.36% 5.30% 1.52% 6.82% 12.12% 1.52% 12.88% 0.76% 0.00% 
Peritumoural 
Stromal cellsa 131 
18 33 22 58 36 77 51 24 38 
13.74% 25.19% 16.79% 44.27% 27.48% 58.78% 38.93% 18.32% 29.01% 
aOne cancer section had too little stroma cells for analysis. 




Figure 5.1 10E4-specific heparan sulphate epitope staining in prostate tissues. [A] BPH [B] Gleason sum 4 Section [C] Gleason sum 7 section 
[D] Gleason sum 9 section [E] Negative Control ‘Epi’ represents benign epithelial cell, ‘CaP’ represents cancer cells and ‘SM’ represents 
stromal cells.  




Figure 5.2 Comparisons of 10E4-specific heparan sulphate epitope expression in prostate adenocarcinoma samples (n=85) against matched BPH 
samples (n=85). [A] Weighted Average Intensity [B] Percentage of cells positively stained [C] Immunoreactivity Score. Statistical tests were 
performed using paired T-test. 
  




Table 5.2 Mean values of 10E4-specific heparan sulphate epitope staining in prostate adenocarcinoma samples (n=85) versus paired BPH 
samples (n=85). Statistical tests were performed using paired T-test. 
  
  
Weighted Average Intensity Percentage of cells stained  IRS 
Mean SEM P-value Mean SEM p-value Mean SEM P-value 
Epithelial / Cancer cell region 
Benign secretory epithelial 
cells 0.18 0.07 0.092 3.82 1.76 0.199 7.41 3.91 0.609 
Adenocarcinoma cells 0.32 0.08 6.15 1.95 9.53 2.88 
Stromal region 
Periglandular stromal cells 1.59 0.09 0.907 66.29 3.88 0.368 119.70 9.61 0.446 
Peritumoural stromal cells 1.60 0.09 69.79 4.17 128.00 9.84 
 
 




Figure 5.3  Comparisons of 10E4-specific heparan sulphate epitope expression in different Gleason grades of prostate adenocarcinoma 
tissues, in both peritumoural stroma and cytoplasm of cancer cell. Gleason sum 3, 4 & 5 (n=21); Gleason sum 8, 9 & 10 (n=46) [A,D] Weighted 
Average Intensity [B,E] Percentage of cells positively stained [C,F] Immunoreactivity score. Statistical test was performed using unpaired T-test. 
  




Table 5.3  Mean values of 10E4-specific heparan sulphate staining in different grades of prostate adenocarcinoma tissues: Gleason sum 3,4 
& 5 (n=21) vs Gleason sum 8,9 & 10 (n=46). P-values were determined by unpaired T-test. 
Gleason Sum Weighted Average Intensity Percentage of cells positively stained Immunoreactivity Score 
Mean SEM P-value Mean SEM P-value Mean SEM P-value 
Adenocarcinoma          
3,4 & 5 0.48 0.33 0.808 0.19 0.15 0.402 0.95 0.74 0.467 
8, 9 & 10 1.52 0.82  0.15 0.08  2.17 1.07  
          
Peritumoural Stroma         
3,4 & 5 1.64 0.29 0.696 45.24 9.75 0.953 108.10 25.82 0.600 








5.1.4 Association of heparan sulphate staining with clinicopathological 
parameters 
Heparan sulphate staining in the peritumoural stroma was found associated 
with clinical staging (P=0.046). (Table 5.4 and 5.5) No significant correlations were 
found when the expression patterns of heparan sulphate were analyzed with the other 
clinicopathological parameters listed in Table 2 (P >0.05), namely resection margin 
including distal and proximal margin involvement, pathological T staging, 
extraprostatic extension, seminal vesicle involvement, perineural invasion, 
lymphovascular invasion, tumour volume and pre-operative PSA levels. We were 
unable to correlate with obturator lymph node involvement as none of our patients 
demonstrated metastases to nodes. 




Table 5.4  Association studies of 10E4-epitope specific heparan sulphate staining 















Adenocarcinoma  Pathological T staging  
 T2a to T2c 35 31 4 1.000 
  100.0% 88.6% 11.4%  
 T3a to T3c 34 31 3  
  100.0% 91.2% 8.8%  
 Total 69    
      
 Extraprostatic extension  
 Yes 34 31 3 1.000 
  100.0% 91.2% 8.8%  
 No 35 31 4  
  100.0% 88.6% 11.4%  
 Total 69    
      
 Seminal vesicle involvement  
 Involved 7 6 1 0.578 
  100.0% 85.7% 14.3%  
 Uninvolved 65 58 7  
  100.0% 89.2% 10.8%  
 Total 72    
      
 Pre-operative PSA levels  
 ≤8ng/ml 20 17 3 0.695 
  100.0% 85.0% 15.0%  
 >8ng/ml 20 15 5  
  100.0% 75.0% 25.0%  
 Total 40    
      
 Lymphovascular invasion 
 Present  9 9 0 0.584 
  100.0% 100.0% .0%  
 Absent 60 52 8  
  100.0% 86.7% 13.3%  
 Total 69    
      
 Perineural invasion     
 Seen  60 54 6 0.626 
  100.0% 90.0% 10.0%  
 Not seen 13 11 2  
  100.0% 84.6% 15.4%  
 Total 73    
  




 Circumferential resection margin 
 Involved 33 29 4 1.000 
  100.0% 87.9% 12.1%  
 Uninvolved 39 35 4  
  100.0% 89.7% 10.3%  
 Total 72    
      
 Apex margin     
 Involved 34 32 2 0.267 
  100.0% 94.1% 5.9%  
 Uninvolved 38 32 6  
  100.0% 84.2% 15.8%  
 Total 72    
      
 Proximal  margin   
 Involved 8 6 2 0.210 
  100.0% 75.0% 25.0%  
 Uninvolved 65 59 6  
  100.0% 90.8% 9.2%  
 Total 73    
      
 Clinical stage     
 T1a to T1c 33 28 5 0.172 
  100.0% 84.8% 15.2%  
 T3a to T3b 8 5 3  
  100.0% 62.5% 37.5%  
 Total 41    
      
 Lobe occurence      
 Both Lobes 62 55 7 0.584 
  100.0% 88.7% 11.3%  
 Singles Lobe 9 9 0  
  100.0% 100.0% .0%  
 Total 71    
      
 Tumour Volume     
 <4cm3 28 27 1 0.614 
  100.0% 96.4% 3.6%  
 ≥4 cm3 31 28 3  
  100.0% 90.3% 9.7%  
 Total 59    
    
 Maximum tumour dimension   
 <2.5cm 35 32 3 0.711 
  100.0% 91.4% 8.6%  
 ≥2.5cm 37 32 5  
  100.0% 86.5% 13.5%  
 Total 72    
      






Pathological T staging  
 T2a to T2c 34 22 12 0.144 
  100.0% 64.7% 35.3%  
 T3a to T3c 34 15 19  
  100.0% 44.1% 55.9%  
 Total 68    
      
 Extraprostatic extension  
 Yes 34 15 19 0.144 
  100.0% 44.1% 55.9%  
 No 34 22 12  
  100.0% 64.7% 35.3%  
 Total 68    
      
 Seminal vesicle involvement  
 Involved 7 4 3 1.000 
  100.0% 57.1% 42.9%  
 Uninvolved 64 35 29  
  100.0% 54.7% 45.3%  
 Total 71    
      
 Pre-operative PSA levels   
 ≤8ng/ml 19 7 12 0.748 
  100.0% 36.8% 63.2%  
 >8ng/ml 20 9 11  
  100.0% 45.0% 55.0%  
 Total 39    
      
 Lymphovascular invasion   
 Present  9 4 5 0.722 
  100.0% 44.4% 55.6%  
 Absent 59 33 26  
  100.0% 55.9% 44.1%  
 Total 68    
      
 Perineural invasion     
 Seen  60 34 26 0.756 
  100.0% 56.7% 43.3%  
 Not seen 12 6 6  
  100.0% 50.0% 50.0%  
 Total 72    
      
 Circumferential resection margin  
 Involved 33 17 16 0.638 
  100.0% 51.5% 48.5%  
 Uninvolved 38 22 16  
  100.0% 57.9% 42.1%  
 Total 71    




      
 Apex margin     
 Involved 34 18 16 0.637 
  100.0% 52.9% 47.1%  
 Uninvolved 37 22 15  
  100.0% 59.5% 40.5%  
 Total 71    
      
 Proximal  margin   
 Involved 8 5 3 0.725 
  100.0% 62.5% 37.5%  
 Uninvolved 64 35 29  
  100.0% 54.7% 45.3%  
 Total 72    
      
 Clinical stage     
 T1a to T1c 32 12 20 0.250 
  100.0% 37.5% 62.5%  
 T3a to T3b 8 5 3  
  100.0% 62.5% 37.5%  
 Total 40    
      
 Lobe occurence      
 Both Lobes 61 33 28 0.721 
  100.0% 54.1% 45.9%  
 Singles Lobe 9 6 3  
  100.0% 66.7% 33.3%  
 Total 70    
      
 Tumour Volume     
 <4cm3 28 18 10 0.597 
  100.0% 64.3% 35.7%  
 ≥4 cm3 31 17 14  
  100.0% 54.8% 45.2%  
 Total 59    
  
 Maximum tumour dimension 
 <2.5cm 34 21 13 0.341 
  100.0% 61.8% 38.2%  
 ≥2.5cm 37 18 19  
  100.0% 48.6% 51.4%  


























Adenocarcinoma  Pathological T staging  
 T2a to T2c 35 35 0 0.239 
  100.0% 100.0% .0%  
 T3a to T3c 34 32 2  
  100.0% 94.1% 5.9%  
 Total 69    
      
 Extraprostatic extension   
 Yes 34 32 2 0.239 
  100.0% 94.1% 5.9%  
 No 35 35 0  
  100.0% 100.0% .0%  
 Total 69    
      
 Seminal vesicle involvement  
 Involved 7 6 1 0.186 
  100.0% 85.7% 14.3%  
 Uninvolved 65 64 1  
  100.0% 98.5% 1.5%  
 Total 72    
      
 Pre-operative PSA levels  
 ≤8ng/ml 20 20 0 -- 
  100.0% 100.0% 0.0%  
 >8ng/ml 20 20 0  
  100.0% 100.0% 0.0%  
 Total 40    
      
 Lymphovascular invasion  
 Present  9 8 1 0.246 
  100.0% 88.9% 11.1%  
 Absent 60 59 1  
  100.0% 98.3% 1.7%  
 Total 69    
      
 Perineural invasion     
 Seen  60 58 2 1.000 
  100.0% 96.7% 3.3%  
 Not seen 13 13 0  
  100.0% 100.0% 0.0%  
 Total 73    




 Circumferential resection margin 
 Involved 33 32 1 1.000 
  100.0% 97.0% 3.0%  
 Uninvolved 39 38 1  
  100.0% 97.4% 2.6%  
 Total 72    
      
 Apex margin     
 Involved 34 34 0 0.495 
  100.0% 100.0% .0%  
 Uninvolved 38 36 2  
  100.0% 94.7% 5.3%  
 Total 72    
      
 Proximal  margin     
 Involved 8 8 0 1.000 
  100.0% 100.0% .0%  
 Uninvolved 65 63 2  
  100.0% 96.9% 3.1%  
 Total 73    
      
 Clinical stage     
 T1a to T1c 33 33 0 0.195 
  100.0% 100.0% .0%  
 T3a to T3b 8 7 1  
  100.0% 87.5% 12.5%  
 Total 41    
      
 Lobe occurence      
 Both Lobes 62 60 2 1.000 
  100.0% 96.8% 3.2%  
 Singles Lobe 9 9 0  
  100.0% 100.0% .0%  
 Total 71    
      
 Maximum tumour dimension   
 <2.5cm 35 34 1 1.000 
  100.0% 97.1% 2.9%  
 ≥2.5cm 37 36 1  
  100.0% 97.3% 2.7%  
 Total 72    
      
 Tumour Volume     
 <4cm3 28 27 1 1.000 
  100.0% 96.4% 3.6%  
 ≥4 cm3 31 30 1  
  100.0% 96.8% 3.2%  
 Total 59    






Pathological T staging  
 T2a to T2c 34 7 27 0.752 
  100.0% 20.6% 79.4%  
 T3a to T3c 34 5 29  
  100.0% 14.7% 85.3%  
 Total 68    
      
 Extraprostatic extension   
 Yes 34 5 29 0.752 
  100.0% 14.7% 85.3%  
 No 34 7 27  
  100.0% 20.6% 79.4%  
 Total 68    
      
 Seminal vesicle involvement  
 Involved 7 1 6 1.000 
  100.0% 14.3% 85.7%  
 Uninvolved 64 11 53  
  100.0% 17.2% 82.8%  
 Total 71    
      
 Pre-operative PSA levels 
 ≤8ng/ml 19 3 16 0.661 
  100.0% 15.8% 84.2%  
 >8ng/ml 20 2 18  
  100.0% 10.0% 90.0%  
 Total 39    
      
 Lymphovascular invasion 
 Present  9 2 7 0.654 
  100.0% 22.2% 77.8%  
 Absent 59 10 49  
  100.0% 16.9% 83.1%  
 Total 68    
      
 Perineural invasion     
 Seen  60 13 47 0.107 
  100.0% 21.7% 78.3%  
 Not seen 12 0 12  
  100.0% .0% 100.0%  
 Total 72    
      
 Circumferential resection margin 
 Involved 33 6 27 1.000 
  100.0% 18.2% 81.8%  
 Uninvolved 38 7 31  
  100.0% 18.4% 81.6%  
 Total 71    




 Apex margin     
 Involved 34 7 27 0.762 
  100.0% 20.6% 79.4%  
 Uninvolved 37 6 31  
  100.0% 16.2% 83.8%  
 Total 71    
      
 Proximal  margin     
 Involved 8 2 6 0.629 
  100.0% 25.0% 75.0%  
 Uninvolved 64 11 53  
  100.0% 17.2% 82.8%  
 Total 72    
      
 Clinical stage     
 T1a to T1c 32 2 30 0.046 
  100.0% 6.3% 93.8%  
 T3a to T3b 8 3 5  
  100.0% 37.5% 62.5%  
 Total 40    
      
 Lobe occurence      
 Both Lobes 61 11 50 0.670 
  100.0% 18.0% 82.0%  
 Singles Lobe 9 2 7  
  100.0% 22.2% 77.8%  
 Total 70    
      
 Maximum tumour dimension   
 <2.5cm 34 7 27 0.762 
  100.0% 20.6% 79.4%  
 ≥2.5cm 37 6 31  
  100.0% 16.2% 83.8%  
 Total 71    
      
 Tumour Volume     
 <4cm3 28 8 20 0.197 
  100.0% 28.6% 71.4%  
 ≥4 cm3 31 4 27  
  100.0% 12.9% 87.1%  
 Total 59    
  




5.2  Gene transcript analysis of heparan sulphate biosynthesis genes in 
prostate cancer cell lines 
To understand the expression profiles of the enzymes responsible for heparan 
sulphate biosynthesis in the prostate cell lines, RWPE-1, LNCaP and PC-3, 
quantitative real-time polymerase chain reaction (qPCR) was performed using a series 
of primers targeting members of the heparan sulphate biosynthetic pathway. Relative 
fold changes of the heparan sulphate biosynthetic genes differentially expressed in the 
prostate cancer cell lines, LNCaP and PC-3, as compared to the normal prostate 
epithelial cell lines, RWPE-1, are shown in Table 5.6. It was observed that the 
heparan sulphate editing enzymes such as the N-deacetylase/N-sulphotransferases, 
heparan sulphotransferases, sulphatases and heparanases were differentially expressed 
in the prostate adenocarcinoma cell lines. Heparan sulphate proteoglycans such as 
glypican 4 is upregulated in both prostate cancer cell lines, while the other glypican 
family members and perlecan (HSPG2) are not differentially changed in the same 
manner in both cancer cell lines. 
  Amongst the heparan sulphotransferase differentially expressed in the prostate 
cancer cell lines, the HS3ST3A1 and HS6ST2 genes were found to be downregulated 
in both LNCaP and PC-3. From the microarray study performed using human prostate 
adenocarcinoma tissues in Chapter 3, HS3ST3A1 and HS6ST2 were also found to be 
downregulated in prostate adenocarcinoma. As such, these evidences point to a 
potential role of HS3ST3A1 and HS6ST2 in prostate tumour cell behaviour. Silencing 
studies in the normal prostate epithelial cell line, RWPE-1, was performed using 
double-stranded RNA oligonucleotides, to determine whether HS3ST3A1 and HS6ST2 
are potential tumour suppressor genes.  




Table 5.6 Relative fold changes of genes coding for heparan sulphate biosynthesis enzymes differentially expressed [1] in prostate cancer 
cell lines, LNCaP (n=3) and PC-3 (n=3) as compared to normal prostate epithelial cell line, RWPE-1 (n=3). (using β-actin as normalizer); P-
values obtained by performing unpaired T-test and [2] in prostate adenocarcinoma tissues (n=6) compared to BPH tissues (n=6); relative fold 
change and p-values listed is from dCHIP.  
Gene 
Symbol 
Gene Name Prostate cancer cell lines Prostate 
adenocarcinoma 
tissues 
LNCaP PC-3 Microarray Result 
Relative fold 
Change 





EXT1 exostoses (multiple) 1 -1.30 0.347 -1.15 
 
0.761 -1.58 >0.05 
EXT2 exostoses (multiple) 2 -4.17 0.403 -6.25 0.185 -1.22 >0.05 
EXTL1 exostoses (multiple)-like 1 -1.75 0.05 -1.67 0.054 1.06 >0.05 
EXTL2 exostoses (multiple)-like 2 6.77 0.004 -1.27 0.753 1.03 >0.05 
EXTL3 exostoses (multiple)-like 3 4.8 0.001 1.30 0.232 -1.03 >0.05 
NDST1 N-deacetylase/N-sulphotransferase (heparan 
glucosaminyl) 1 
-2.27 0.02 -2.17 0.001 -1.18 >0.05 
NDST2 N-deacetylase/N-sulphotransferase (heparan 
glucosaminyl) 2 
-1.19 0.618 3.40 0.027 1.02 >0.05 
NDST3 N-deacetylase/N-sulphotransferase (heparan 
glucosaminyl) 3 
upregulated b <0.05 upregulated b <0.05 -1.03 >0.05 
NDST4 N-deacetylase/N-sulphotransferase (heparan 
glucosaminyl) 4 
-1.52 0.515 -2.13 0.203 -1.20 >0.05 
PAPSS1 3'-phosphoadenosine 5'-phosphosulphate 
synthase 1 
1.13 0.883 -1.85 0.395 1.17 >0.05 




PAPSS2 3'-phosphoadenosine 5'-phosphosulphate 
synthase 2 
1.42 0.195 1.765 0.063 1.57 >0.05 
HS2ST1 heparan sulphate 2-O-sulphotransferase 1 4.10 0.005 -1.41 0.221 1.27 
 
>0.05 
HS3ST1 heparan sulphate (glucosamine) 3-O-
sulphotransferase 1 
not detectedc <0.05 -3.57 0.001 1.18 >0.05 
HS3ST2 heparan sulphate (glucosamine) 3-O-
sulphotransferase 2 
not detectedc <0.05 -11.1 0.20 2.30 >0.05 
HS3ST3A
1 
heparan sulphate (glucosamine) 3-O-
sulphotransferase 3A1 
-50.00 <0.001 -5.00 0.002 -2.23 <0.05 
HS3ST3B
1 
heparan sulphate (glucosamine) 3-O-
sulphotransferase 3B1 
-33.33 <0.001 -100.0 <0.001 -2.46 <0.05 
HS3ST4 heparan sulphate (glucosamine) 3-O-
sulphotransferase 4 
N.D a 1.06 >0.05 




0.880 352.1 0.01 1.17 >0.05 
HS6ST1 heparan sulphate 6-O-sulphotransferase 1 1.78 0.069 -1.61 0.003 -1.18 >0.05 
HS6ST2 heparan sulphate 6-O-sulphotransferase 2 -11.11 0.003 -2.33 0.007 -3.63 <0.05 
HS6ST3 heparan sulphate 6-O-sulphotransferase 3 upregulation b <0.05 upregulationb <0.05 1.30 >0.05 
SULF1 sulphatase 1 not detectedc <0.05 -45.45 <0.0001 1.08 >0.05 
SULF2A sulphatase 2 isoform variant 1 -111.11 0.001 -1.14 0.706 2.79 <0.05 
SULF2B sulphatase 2 isoform variant 2 -28.57 0.0003 -1.10 0.76  
HPSE heparanase -33.33 0.004 -25.00 <0.0001 1.41 >0.05 
HPSE2 heparanase 2 N.D a -1.39 >0.05 
HSPG2 heparan sulphate proteoglycan 2 -8.33 <0.0001 1.61 0.086 -1.65 >0.05 
GPC1 glypican 1 1.21 0.503 -4.76 0.005 -2.41 >0.05 
GPC2 glypican 2 -1.09 0.669 -3.57 0.0003 -1.06 >0.05 




GPC3 glypican 3 20.0 0.003 -10.87 0.003 -1.49 >0.05 
GPC4 glypican 4 967 0.001 165 0.004 -1.90 >0.05 
GPC5 glypican 5 N.D a -1.35 >0.05 
GPC6 glypican 6 -16.67 0.005 3.72 0.01 -1.21 >0.05 
aExpression not detected in all 3 prostate cell lines within 45 cycles of qPCR 
bExpression not detected in RWPE-1 but detected in LNCaP and PC-3, within 45 cycles of qPCR. 
cExpression not detected within 45 cycles of qPCR.  




5.3 Functional Analysis of HS3ST3A1 in prostate cancer  
5.3.1 HS3ST3A1 is effectively silenced in RWPE-1 
To investigate the functional significance of HS3ST3A1 downregulation in 
prostate cancer, HS3ST3A1 was silenced in normal prostate epithelial cell, RWPE-1, 
using Silencer double-stranded siRNA oligonucleotides from Ambion Technologies, 
accompanied by Oligofectamine as the delivery reagent. HS3ST3A1 was 87% silenced 
as compared to the non-targeting siRNA control. (Figure 5.4A) Transfection 
efficiency was determined to be 100% by using Cy3-conjugated negative control 
siRNA. (Figure 5.4B) Unspecific silencing of HS3ST3B1, a close homolog of 
HS3ST3A1, was checked and found HS3ST3B1 to be unsilenced in HS3ST3A1-
silenced RWPE-1 cells (p=0.2). 
5.3.2 HS3ST3A1 silencing inhibited RWPE-1 proliferation 
Cell proliferation is performed by using the CellTiter 96 AQueous One Solution 
Cell Proliferation Assay (Promega Corporation, Madison, Wisconsin, USA) that 
contains a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] which is 
bioreduced by NADPH or NADH produced by metabolically active cells via 
dehydrogenase enzymes into a colored formazan product. [Barltrop et al, 1991] 
Measurement of absorbance of the formazan product at 490nm [Cory et al, 1991] 
revealed inhibition of cell proliferation by about 37% after silencing HS3ST3A1 in 
RWPE-1 cells, 72 hours post-transfection as compared to non-targeting siRNA 
controls. (Figure 5.4C) 
 
 




5.3.3 HS3ST3A1 silencing inhibited RWPE-1 migration 
Acquisition of migration and invasion ability into the basement membrane and 
extracellular matrix are phenotypes of malignant cells. To investigate whether the 
downregulation of HS3ST3A1 in a normal prostate epithelial cell line would result in 
progression to malignancy, the migratory ability of the RWPE-1 cell line was tested 
after silencing HS3ST3A1, using the transwell migration chamber. It was found that 
migration of RWPE-1 was inhibited by 26% after HS3ST3A1 silencing, at 72 hours 
post transfection, as compared to non-targeting siRNA control. (Figure 5.4D) 
5.3.4 HS3ST3A1 silencing did not affect RWPE-1 adhesion to collagen type I 
Proteoglycans are known to mediate cell-cell adhesion, cell adhesion to 
the basement membrane and extracellular matrix. Such complex adhesion 
capacities are important components of how a malignant cell migrates and 
invades into the surrounding tissue as well. The effects of HS3ST3A1 suppression 
on the adhesion ability of RWPE-1 cells was investigated, and revealed that 
HS3ST3A1 silencing did not affect RWPE-1 adhesion to collagen type I. (Figure 
5.4E) 
  





Figure 5.4 Effects of HS3ST3A1 silencing on RWPE-1 cell behaviour. [A] 
Silencing efficiency of HS3ST3A1 siRNA is 87%, with no unspecific silencing of 
HS3ST3B1. [B] Transfection efficiency is 100%, using Cy3-tagged negative 
control siRNA. [C] HS3ST3A1 inhibited RWPE-1 proliferation. [D] HS3ST3A1 
inhibited RWPE-1 motility. [E] HS3ST3A1 has no effect on RWPE-1 adhesion to 
collagen type I. Non-targeting silenced RWPE-1 (n=3); HS3ST3A1 silenced 
RWPE-1 (n=3). ‘***’ represents p <0.001; Statistical test was performed using 
unpaired T-test.  




5.4 Functional Analysis of HS6ST2 in prostate cancer  
5.4.1 HS6ST2 is effectively silenced in RWPE-1 
To investigate the functional significance of HS6ST2 downregulation in 
prostate cancer, HS6ST2 was silenced in normal prostate epithelial cell, RWPE-1, 
using Silencer double-stranded siRNA oligonucleotides from Ambion Technologies 
and Oligofectamine as the delivery reagent. HS6ST2 was 87% silenced as compared 
to the non-targeting siRNA control. (Figure 5.5A) Transfection efficiency is the same 
as Section 5.3.1 as transfection conditions are exactly the same. Unspecific silencing 
of HS6ST1, an isoform of HS6ST2, was checked and found to be unsilenced (p=0.2). 
Another isoform member, HS6ST3 was found to be inherently expressed at a low 
level/not expressed in normal RWPE-1 cells (not detectable within 45 cycles of 
qPCR) and hence, unspecific silencing of HS6ST3 in HS6ST2-silenced RWPE-1 cells 
were not determined. 
5.4.2 HS6ST2 silencing prevented the proliferation of RWPE-1 cells 
Proteoglycans are known to mediate cell proliferation through binding with 
several growth factors and acting as co-receptors. The downregulation of HS6ST2 in 
prostate cancer cells may allow normal epithelial prostate cells to acquire cancerous 
phenotypes, such as dysregulation in the control of cell proliferation. As such, the 
effects of HS6ST2 silencing in normal prostate epithelial cells, RWPE-1, was 
determined and found that contrary to our hypothesis, HS6ST2 silencing inhibited 








5.4.2 HS6ST2 silencing reduced the migratory ability of RWPE-1 cells 
Next, the migratory ability of the RWPE-1 cell line was tested after silencing 
HS6ST2, using the transwell migration chamber. It was found that migration of 
RWPE-1 was inhibited by 56% after HS6ST2 silencing, at 72 hours post transfection, 
as compared to non-targeting siRNA control (Figure 5.5C). 
5.4.3 HS6ST2 silencing did not affect RWPE-1 adhesion to collagen type I 
Similarly, I wanted to understand whether HS6ST2 is important in the 
adhesion of RWPE-1 cells to the ECM/BM, since adhesion capacities are 
important components in the migration and invasion of malignant cells during 
metastasis as well. It was revealed that HS6ST2 downregulation did not affect the 
adhesion ability of RWPE-1 cells to collagen type I (Figure 5.5D). 




Figure 5.5 Effects of HS6ST2 silencing on RWPE-1 cell behaviour. [A] Silencing efficiency of HS6ST2 is 87%, with no unspecific silencing 
of HS6ST1. HS6ST3 was inherently found to be not expressed/expressed at low levels in RWPE-1 (not detectable within 45 cycles of qPCR), 
hence checking of unspecific silencing of HS6ST3 was not performed. [B] HS6ST2 silencing inhibited RWPE-1 cell proliferation. [C] HS6ST2 
silencing impeded RWPE-1 motility. [D] HS6ST2 silencing did not appear to have any effect on RWPE-1 adhesion to collagen type I. Non-
targeting silenced RWPE-1 (n=3); HS6ST2 silenced RWPE-1 (n=3). ‘***’ represents p <0.001; Statistical test was performed using 
unpaired T-test.  





5.5.1 Utility of 10E4-specific heparan sulphate as a prostate cancer biomarker 
 Heparan sulphates are a group of structurally diverse molecules that can 
participate in many important cellular processes. In this study, monoclonal 10E4, 
which recognizes mixed HS domains containing both N-acetylated and N-sulphated 
disaccharide units were used [van den Born J et al, 2005]. Using this monoclonal 
10E4, it was demonstrated that specific heparan sulphate epitopes recognized by this 
antibody, was not differentially expressed in the prostate adenocarcinoma tissues as 
compared to the benign hyperplastic prostate tissues, both in the cytoplasm of the 
adenocarcinoma cells and the peritumoural stroma. In addition, there were no 
significant differences in 10E4 staining in the low grade cancers (Gleason sum<6) as 
compared to high grade cancers (Gleason sum >8).  
Also, it was demonstrated that strong 10E4 staining is associated with higher 
clinical staging; however, 10E4 is not associated with other clinicopathological 
parameters such as resection margin including distal and proximal margin 
involvement, pathological T staging, extraprostatic extension, seminal vesicle 
involvement, perineural invasion, lymphovascular invasion, tumor volume and pre-
operative PSA levels. 
Comparatively, detection of heparan sulphate staining using 10E4 in prostate 
cancer did not seem to correlate well with clinicopathological parameters as compared 
to chondroitin sulphate staining in prostate cancer. Chondroitin sulphate staining, as 
discussed in Chapter 4, correlated with many parameters of poor outcome, and is a 
potential biomarker of prostate cancer prognosis, and from our study, appears to be a 
better biomarker than the heparan sulphates. Indeed, reports of heparan sulphate 
expression in prostate adenocarcinoma and their potential use as a biomarker of 




prostate cancer prognosis is scarce, as compared to reports on chondroitin sulphate in 
prostate cancer.  
5.5.2 HS3ST3A1 and HS6ST2 are not tumour suppressors in prostate cancer. 
Heparan sulphate can be sulphated at various positions on the N-
acetylglucosamine (C3 position and C6 position) and uronic acid (C2 position). 
Sulphation is performed by different sulphotransferases from mainly 3 different 
families that include heparan sulphate-2-O-sulphotransferases, heparan sulphate-3-O-
sulphotransferases and heparan sulphate-6-O-sulphotransferases. The sulphation 
pattern of the glycosaminoglycans and proteoglycans are important, as they encode 
molecular diversity and elicit different biologies [Gama et al, 2006]. 
There are six family members belonging to the heparan sulphate 3-O-
sulphotransferases. They include HS3ST1, HS3ST2, HS3ST3A1, HS3ST3B1, HS3ST4 
and HS3ST5 [Shworak et al, 1999; Mochizuki et al, 2003]. These proteins are 
comprised of a divergent amino-terminal region and a very homologous carboxyl-
terminal sulphotransferase domain of approximately 260 residues. Southern analyses 
suggest the HS3ST1, HS3ST2, and HS3ST4 genes are single copy while HS3ST3A1 
and HS3ST3B1 genes are each duplicated in humans. Each isoform has different, 
unique substrate specificities from one another [Liu et al, 1999; Xia et al, 2002; Chen 
et al, 2003], thus generating defined saccharide sequences in structurally complex HS 
polysaccharide. 
In my study, I have observed differential expression of the HS-3OST isoforms 
in prostate adenocarcinoma tissues as compared to BPH tissues, as well as in prostate 
cancer cell lines as compared to normal prostate epithelial cell lines. However, the 
same isoform might not necessarily be differentially expressed in the same manner in 
both prostate tissues and prostate cancer cell lines: HS3ST1 is downregulated in 




LNCaP and PC3 but there was no significant change in prostate adenocarcinoma 
tissues, HS3ST2 is suppressed in both LNCaP and PC3 but upregulated in prostate 
adenocarcinoma tissues (albeit no statistical significance) and HS3ST5 is 
downregulated in LNCaP, upregulated in PC3 but not differentially expressed in 
prostate cancer tissues compared to BPH tissues. These could be due to different 
tissue/cell types, as the prostate adenocarcinoma tissues contain a heterogeneous 
mixture of cell populations while the prostate cancer cell lines represent a 
homogenous cell population originating from the epithelial cells of the secretory 
glands. Alternatively, these could also suggest the inherent heterogeneous nature of 
different prostate tumours, with different genetic makeup and instability. HS3ST4 is 
not detectable in prostate cancer cell lines and not differentially expressed in prostate 
cancer tissues compared to BPH tissues. On the other hand, both HS3ST3A1 and 
HS3ST3B1 were consistently found downregulated in prostate adenocarcinoma tissues 
as well as in prostate cancer cell lines. HS3ST3A1 was downregulated by 2.2 fold in 
prostate cancer tissue, 50 fold in LNCaP and 5 fold in PC3 while HS3ST3B1 was 
downregulated by 2.5 fold in cancer tissue, 33 fold in LNCaP and 100 fold in PC3.  
The HS3ST3A1 and HS3ST3B1 are integral membrane proteins, consisting of 
conserved carboxyl-terminal sulphotransferase domain and the divergent amino-
terminal regions. Intriguingly, the entire sulphotransferase domain sequence of the 
HS3ST3B1 cDNA (774 base pairs) was 99.2% identical to the same sulphotransferase 
region of HS3ST3A1 [Liu et al, 1999]. Also, HS3ST3A1 and HS3ST3B1 were reported 
to sulphate and generate identical 3-O-sulphated disaccharides; both enzymes transfer 
sulphate to the 3-OH position of the glucosamine within IdoA2S-GlcNS or IdoA2S-
GlcNH2 [Liu et al, 1999]. Thus, sulphation specificity corresponds to the nearly 
identical sulphotransferase domains and is not perturbed by the unique amino terminal 




regions of each sulphotransferase. As such, the unique amino-terminal regions of 
HS3ST3A1 and HS3ST3B1 may contribute distinctive biologic roles to the nearly 
identical sulphotransferase domains. In fact, the cytoplasmic tail at the amino terminal 
of HS3ST3B1contains a polyproline tract, which are known to form a rigid left-
handed-helix where such motifs are critical elements bound by protein interaction 
modules such as SH3 and WW domains. Protein-protein interactions within the 
amino-terminal regions may regulate the spatial organization or functional interaction 
of the enzymes, thus contributing to the different biologic activities of the different 
enzymes [Feng et al, 1994; Chen et al, 1997; Rau et al, 1995]. Actual delineation of 
the functional significance between HS3ST3A1 and HS3ST3B1 requires future 
investigation. 
Nevertheless, downregulation of both HS3ST3A1 and HS3ST3B1 in the 
prostate adenocarcinoma tissues and in prostate cancer cell lines indicates that 
heparan sulphate sequences containing specific 3-O-sulphated disaccharides coded by 
HS3ST3A1 and HS3ST3B1 are suppressed in prostate cancer, since HS3ST3A1 and 
HS3ST3B1 generate identical 3-O-sulphated disaccharides. This specific disaccharide 
sequence in heparan sulphate or heparan sulphate proteoglycans could be functionally 
important in prostate tumourigenesis, and thus warrants further investigation.  
In addition, it was found that the heparan sulphate 6-O-sulphotransferase 
(HS6ST) members are also dysregulated in prostate adenocarcinoma. HS6ST catalyze 
the transfer of sulphate from 3'-phosphoadenosine 5'-phosphosulphate (PAPS) to 
position 6 of the N-sulphoglucosamine residue of heparan sulphate.  The HS6ST 
family comprised of three isoforms and one alternatively spliced form [Habuchi et al, 
2003]. Individual isoforms showed characteristic preference for the uronic acid 
residue neighboring the N-sulphoglucosamine. [Habuchi et al, 2000] HS6ST1 




predominantly sulphated the 6-OH position of GlcNSO3 in HexA-GlcNSO3 unit. On 
the other hand, HS6ST2 preferably transferred sulphate to the 6-OH position of 
GlcNSO3 in IdoA(2SO4)-GlcNSO3 unit or highly sulphated regions. A splice variant 
of HS6ST2, which is 40 amino acids shorter, termed HS6ST2-S has substrate 
specificity somewhat intermediate between HS6ST1 and HS6ST2 [Habuchi et al, 
2003]. In this study, only HS6ST2 was found downregulated by 3.5 fold in prostate 
adenocarcinoma tissue and suppressed by 11 fold in LNCaP and by 2.3 fold in PC3, 
as compared to BPH tissues and normal prostate epithelial cell, RWPE-1 respectively. 
HS6ST1 and HS6ST3 were both not found differentially expressed in prostate 
adenocarcinoma tissues as compared to BPH tissues, but were found differentially 
expressed in prostate cancer cell lines; HS6ST1 was downregulated by 1.6 fold in PC3 
only and HS6ST3 were found expressed in both prostate cancer cells, LNCaP and 
PC3, while it was not detectable within 45 cycles of amplification through real-time 
PCR in RWPE-1. Again, this could be due to differences in the heterogeneous nature 
of tissue sections and homogeneous cell populations using prostate cancer cell lines, 
as well as possibly due to tumour heterogeneity. Since HS6ST2 expression is 
suppressed in both prostate adenocarcinoma tissues and prostate cancer cell lines, 
HS6ST2 could be a tumour suppressor that allows prostate cancer acquisition after its 
suppression.  
Surprisingly, I discovered that silencing HS3ST3A1 or HS6ST2 in normal 
prostate epithelial cells, RWPE-1, did not appear to acquire cancerous phenotypes; in 
contrary, both HS3ST3A1-silenced RWPE-1 cells  and HS6ST2-silenced RWPE-1 
cells showed decreased proliferative capacity and decreased cell motility. These 
findings demonstrated that HS3ST3A1 and HS6ST2 are not tumour suppressors, but 
are important in normal cellular functions.  




Indeed, several studies have reported on the importance of heparan sulphate in 
mediating cellular processes such as growth and apoptosis. Recently, Kobayashi et al, 
2010, have shown that HS6ST2 inhibition in chick limb region resulted in limb bud 
truncation [Kobayashi et al, 2010].  Todorovicc et al, 2005, have showed that the 
heparan sulphate proteoglycan, syndecan-4, together with matrix proteins and integrin 
receptors, triggers apoptosis in fibroblasts via p53 activation of Bax [Todorovicc et al, 
2005]. These findings explain the importance of heparan sulphate and their 
biosynthetic enzymes in normal cellular function.  
Many regulatory mechanisms appear to control the expression of heparan 
sulphate too. Most recently, Chau et al, 2009, reported that perturbation of p53 
directly influences SULF2, an extracellular heparan sulphate 6-O-endosulphatase that 
regulates growth factor binding to their cognate receptors [Chau et al, 2009].  p53 has 
been reported to directly regulate heparanase expression [Baraz et al, 2006]. These 
studies have revealed that timely expression of heparan sulphate are critical for 
normal functioning of cellular processes, and regulatory mechanisms are in place to 
tightly regulate the expression of these glycosaminoglycans. Although it has not been 
reported on the direct regulation of p53 on HS3ST3A1 and/or HS6ST2, given the 
observation that p53 directs the regulation of many genes including CS/HS modifying 
genes and CSPG/HSPG, it suggests then that perhaps, the biological functions of 
HS/CS and HSPG/CSPG could also be governed by p53.  
Undeniably, the structural diversity of heparan sulphates and their 
proteoglycans encompass a huge array of possible dysregulations in diseases, 
resulting in specific functional repercussions. In prostate cancer, much work can be 
further performed to determine specific HS structures that are differentially expressed 
by utilising different antibodies that recognize different heparan sulphate structures. 




In addition, functional studies investigating the downregulation of HS6ST2 and 
HS3ST3A1 in prostate cancer, as compared to normal prostate cells, can be performed 
by overexpressing these genes in cancer cell lines to determine if they are important in 
regulating tumour cell phenotypes. 




Chapter 6   
Conclusions and Future Work 
6.1 Identification of potential biomarkers in prostate cancer 
Heterogeneity in disease manifestations of prostate cancer, in which some 
prostate cancers never become life threatening while some progress to metastatic 
forms, poses a huge prognostic and treatment challenge. Identifying biomarkers of 
clinical outcome have the potential to greatly improve the management of prostate 
cancer. In this study, genome-wide expression profiles of prostate adenocarcinoma 
tissues were compared against BPH tissues, and it was revealed that 865 genes 
involved in development and differentiation, cell motility, cell proliferation, cellular 
response to stress, homeostasis, cell communication, cell cycle, apoptosis and 
metabolism were aberrantly expressed by at least 2 fold in the cancerous tissues. This 
represents a disarray of genetic networks that could contribute to or arise from the 
cancer cell phenotype. Nonetheless, this gene list provides an excellent avenue to 
investigate the potential application of some of these molecules as biomarkers of 
prostate cancer prognosis, and also to identify potential novel therapeutic targets. 
 Chondroitin sulphate and heparan sulphate are ubiquitously present on the 
cellular surface and in the ECM, and are hence well positioned to elicit many cell-cell, 
cell-ECM signalling mechanisms, regulating important cellular behaviour. Of interest 
to this study is the application of chondroitin sulphate and heparan sulphate as 
possible biomarkers of prostate cancer. Since chondroitin sulphate and heparan 
sulphate are structurally diverse molecules with different sulphate modifications, four 
different chondroitin sulphate subtypes – non-sulphated chondroitin, chondroitin-4-
sulphate, chondroitin-6-sulphate and chondroitin-2,6-sulphate and one heparan 




sulphate epitope that consists of mixed N-sulphated and N-acetylated regions, were 
explored in prostate adenocarcinoma tissues.  
  Non-sulphated chondroitin and chondroitin-4-sulphate were upregulated in 
prostate adenocarcinoma cells as compared to paired benign epithelial secretory cells 
of the benign prostate hyperplastic tissues; in addition, expression of chondroitin-4-
sulphate was downregulated but chondroitin-6-sulphate expression was upregulated in 
peritumoural stroma as compared to periglandular stroma. In addition, we found that 
with increasing tumour grades, there was increasing expression of all chondroitin 
sulphate subtypes in the peritumoural stroma, with the highest expression in high 
grade cancers (Gleason sum >8). These results represent a potential role of 
chondroitin sulphate in prostate tumourigenesis and possibly, spatiotemporal roles 
during prostate cancer progression to malignancy.  
 Heparan sulphate expression was determined in prostate adenocarcinoma 
tissues using the monoclonal 10E4 that recognizes ‘mixed’ N-acetylated and N-
sulphated domains of HS. By using this monoclonal antibody, no significant changes 
in heparan sulphate expression were detected in prostate adenocarcinoma tissues as 
compared to paired benign prostate hyperplastic tissues. Nevertheless, given the huge 
repertoire of heparan sulphate structures, other heparan sulphate epitopes can be 
investigated to determine whether they are differentially expressed in prostate cancer. 
 Association studies between expression of chondroitin sulphate or heparan 
sulphate with clinicopathological parameters was also performed. It was found that 
high expression of non-sulphated chondroitin, chondroitin-4-sulphate, chondroitin-6-
sulphate and chondroitin-2,6-sulphate in the cancer cells and in cancer stroma 
correlated with pathological T stage, extraprostatic extension, perineural invasion, 




seminal vesicle involvement, tumour volume, clinical staging, pre-operative PSA 
levels and occurrence of cancer in both prostate lobes.  All these pathologic 
parameters augur a worse prognosis for patients, and highlight the association of 
chondroitin sulphate expression with conventional adverse predictors. On the other 
hand, heparan sulphate staining as detected by monoclonal 10E4 did correlate with 
only clinical staging, but not with the other parameters. Comparatively, this shows 
that chondroitin sulphate could be a better predictive biomarker than heparan sulphate 
in prostate cancer outcome; however, we could first determine other heparan sulphate 
epitopes expression in prostate cancer and evaluate their use as potential biomarkers 
before reaching a definitive conclusion. 
 To determine if chondroitin sulphate will be a good indicator of prostate 
cancer progression, long term follow up data such as PSA relapse and survival will be 
important. Future work will include data acquisition of such parameters and 
subsequent analysis with the current chondroitin sulphate expression patterns.  
6.2 Establishing the functional significance of CS/HS and their biosynthesis 
enzymes in prostate cancer.  
Identifying new molecular targets could facilitate innovation of novel 
therapies that could halt progression of localized prostate cancer towards metastasis or 
that could target metastatic prostate cancer. From the genome wide expression screen, 
CSGalNAcT-1 was seen to be upregulated in prostate adenocarcinoma tissues. Since 
CSGalNAcT-1 is responsible for the initiation of CS/DS synthesis and a concomitant 
upregulation of chondroitin sulphate expression in prostate cancer tissues was 
observed through immunohistochemistry, I hypothesized that the upregulation of 
CSGalNAcT-1 and its corresponding increase in chondroitin sulphate expression 
could be functionally important in prostate cancer. Prostate cancer cell lines, LNCaP 




and PC3, also demonstrated upregulation of CSGalNAcT-1 as compared to normal 
prostate epithelial cells, RWPE-1. CSGalNAcT-1 silenced PC3 cells showed 
inhibition in proliferation and invasion, increase in apoptosis and cell cycle arrest via 
downregulation of MAPRE-1, TPX2 and HIPK3. These results highlighted 
CSGalNAcT-1 as a pro-tumour protein and revealed CSGalNAcT-1 as a potential 
therapeutic target. Future work however, could be done to investigate whether 
CSGalNAcT-1 elicits cell signalling via direct effects on the downstream genes or it 
was performed via indirect effects, through the CS/DS chains that were reduced in 
expression as a result of CSGalNAcT-1 silencing.  
Heparan sulphate is a multi-faceted molecule contributed by its diverse 
structures, which is facilitated by different sulphate modifications. Heparan sulphate 
sulphotransferase enzymes, HS3ST3A1 and HS6ST2, were shown to be downregulated 
in prostate adenocarcinoma tissues compared to BPH tissues, and also revealed to be 
downregulated in prostate cancer cell lines, LNCaP and PC3, compared to normal 
prostate epithelial cell lines, RWPE-1. The hypothesis that these enzymes could be 
potential tumour suppressors in prostate cancer is made. HS3ST3A1 and HS6ST2 were 
silenced in normal prostate epithelial cells, RWPE-1. HS3ST3A1-silenced RWPE-1 
and HS6ST2-silenced RWPE-1 both showed inhibition in proliferation and motility. 
These results showed that HS3ST3A1 and HS6ST2 are important enzymes in normal 
prostate physiology and also represent that HS3ST3A1 and HS6ST2 are not key 
tumour suppressor genes. However, we cannot disregard the importance of HS3ST3A1 
and HS6ST2 suppression in prostate cancer as they could be functionally important in 
prostate tumour progression only after other anti-cancer signals are lost. Future work 
could include overexpression of HS3ST3A1 and HS6ST2 in prostate cancer cells so as 
to understand the roles of HS6ST2 and HS3ST3A1 in a tumour environment.  




All in, the importance of chondroitin sulphate and heparan sulphate in normal 
prostate physiology and prostate cancer tumourigenesis has been revealed. 
Essentially, the potential role of chondroitin sulphate as a predictive biomarker and 
CSGalNAcT-1 as a novel therapeutic target has been highlighted. Due to the large 
structural and functional repertoire of chondroitin sulphate and heparan sulphate, this 
necessitates the need to elucidate the exact structural entity that is important in 
prostate cancer progression. Certainly, this remains challenging yet promising in the 
field of prostate cancer research. 
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Gene name Gene ID Fold 
change 
AMACR alpha-methylacyl-CoA racemase 23600 23.10 
ZIC2 Zic family member 2 (odd-paired homolog, 
Drosophila) 
7546 21.71 
ELF5 E74-like factor 5 (ets domain transcription 
factor) 
2001 14.62 
PCA3 prostate cancer antigen 3 50652 13.74 
HOXC6 homeobox C6 3223 12.38 
GLYATL1 glycine-N-acyltransferase-like 1 92292 10.13 
IGSF4D immunoglobulin superfamily, member 4D 253559 9.45 
TMEM45B transmembrane protein 45B 120224 8.46 
HIST3H2A histone 3, H2a 92815 8.28 
DLX1 distal-less homeobox 1 1745 7.84 
ALOX15B arachidonate 15-lipoxygenase, type B 247 7.41 
CLDN7 claudin 7 1366 7.21 
AGR2 anterior gradient 2 homolog (Xenopus 
laevis) 
10551 6.77 
NKX2-3 NK2 transcription factor related, locus 3 
(Drosophila) 
159296 6.68 
SPP1 secreted phosphoprotein 1 (osteopontin, 
bone sialoprotein I, early T-lymphocyte 
activation 1) 
6696 6.23 
SLC45A2 solute carrier family 45, member 2 51151 6.02 
PGC progastricsin (pepsinogen C) 5225 5.78 
CLDN3 claudin 3 1365 5.74 
C15orf48 chromosome 15 open reading frame 48 84419 5.62 
ASPN asporin (LRR class 1) 54829 5.58 
HPN hepsin (transmembrane protease, serine 1) 3249 5.46 
SGEF Src homology 3 domain-containing 
guanine nucleotide exchange factor 
26084 5.24 
CGREF1 cell growth regulator with EF-hand domain 
1 
10669 5.17 
TRIM36 tripartite motif-containing 36 55521 5.10 
TRPM4 transient receptor potential cation channel, 
subfamily M, member 4 
54795 5.03 
MAL2 mal, T-cell differentiation protein 2 114569 4.89 
HOXC4 homeobox C4 3221 4.82 
SLC4A4 solute carrier family 4, sodium bicarbonate 
cotransporter, member 4 
8671 4.76 
BAMBI BMP and activin membrane-bound 
inhibitor homolog (Xenopus laevis) 
25805 4.72 
CENPN centromere protein N 55839 4.53 
FASN fatty acid synthase 2194 4.50 
FABP5 fatty acid binding protein 5 (psoriasis-
associated) /// similar to Fatty acid-binding 






associated fatty acid-binding protein 
homolog) (PA-FABP) 




COMP cartilage oligomeric matrix protein 1311 4.44 
GDF15 growth differentiation factor 15 9518 4.44 
AK5 adenylate kinase 5 26289 4.41 
LOC285463 hypothetical protein LOC285463 285463 4.35 
RAB17 RAB17, member RAS oncogene family 64284 4.26 
TRGC2 T cell receptor gamma constant 2 /// T cell 
receptor gamma variable 2 /// T cell 
receptor gamma variable 9 /// TCR gamma 
alternate reading frame protein /// 
hypothetical protein LOC642083 
6967 4.20 
ITGBL1 integrin, beta-like 1 (with EGF-like repeat 
domains) 
9358 4.14 
FBP1 fructose-1,6-bisphosphatase 1 2203 4.14 
MYC v-myc myelocytomatosis viral oncogene 
homolog (avian) 
4609 4.11 
FMO5 flavin containing monooxygenase 5 2330 4.11 
B3GAT1 beta-1,3-glucuronyltransferase 1 
(glucuronosyltransferase P) 
27087 4.03 
SLC43A1 solute carrier family 43, member 1 8501 4.00 
KIAA0114 KIAA0114 57291 3.97 
HK2 hexokinase 2 3099 3.89 
MYO6 myosin VI 4646 3.86 
PPP1R9A protein phosphatase 1, regulatory 
(inhibitor) subunit 9A 
55607 3.86 
GJB1 gap junction protein, beta 1, 32kDa 
(connexin 32, Charcot-Marie-Tooth 
neuropathy, X-linked) 
2705 3.78 
tcag7.216 similar to matrilin 2 precursor 285929 3.73 
HIST1H2A
M 
histone 1, H2am 8336 3.68 
CA13 carbonic anhydrase XIII 377677 3.68 
STX19 syntaxin 19 415117 3.68 
NUDT16P nudix (nucleoside diphosphate linked 
moiety X)-type motif 16 pseudogene 
152195 3.63 
KIAA0984 KIAA0984 protein 23329 3.63 
REPS2 RALBP1 associated Eps domain containing 
2 
9185 3.51 
RRM2 ribonucleotide reductase M2 polypeptide 6241 3.48 
PYCR1 pyrroline-5-carboxylate reductase 1 5831 3.41 
CCDC4 coiled-coil domain containing 4 389206 3.36 
MYRIP myosin VIIA and Rab interacting protein 25924 3.32 
CTNND2 catenin (cadherin-associated protein), delta 
2 (neural plakophilin-related arm-repeat 
protein) 
1501 3.32 






DNAH5 dynein, axonemal, heavy polypeptide 5 1767 3.14 
SLC7A11 solute carrier family 7, (cationic amino acid 
transporter, y+ system) member 11 
23657 3.10 
PLA2G7 phospholipase A2, group VII (platelet-
activating factor acetylhydrolase, plasma) 
/// phospholipase A2, group VII (platelet-
activating factor acetylhydrolase, plasma) 
7941 3.10 
CYP2J2 cytochrome P450, family 2, subfamily J, 
polypeptide 2 
1573 3.07 
FHIT fragile histidine triad gene 2272 3.05 
RAP1GAP RAP1 GTPase activating protein 5909 3.05 
GPR160 G protein-coupled receptor 160 26996 3.05 
STEAP4 STEAP family member 4 79689 3.03 
MPP6 membrane protein, palmitoylated 6 
(MAGUK p55 subfamily member 6) 
51678 3.03 
CHMP4C chromatin modifying protein 4C 92421 3.03 
ZDHHC11 zinc finger, DHHC-type containing 11 79844 3.01 
NEDD4L neural precursor cell expressed, 
developmentally down-regulated 4-like 
23327 2.99 
PDLIM5 PDZ and LIM domain 5 10611 2.99 
TARP T cell receptor gamma constant 2 /// T cell 
receptor gamma variable 2 /// T cell 
receptor gamma variable 9 /// TCR gamma 
alternate reading frame protein /// 
hypothetical protein LOC642083 
445347 2.99 












SIM2 single-minded homolog 2 (Drosophila) 6493 2.81 
ABCC4 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 4 
10257 2.77 
FLJ20021 hypothetical LOC90024 90024 2.75 
MCCC2 methylcrotonoyl-Coenzyme A carboxylase 
2 (beta) 
64087 2.71 
ZNF96 zinc finger protein 96 9753 2.68 
LOC440731 hypothetical LOC440731 440731 2.68 
TLCD1 TLC domain containing 1 116238 2.60 
RIMS1 regulating synaptic membrane exocytosis 1 22999 2.58 
PCSK6 proprotein convertase subtilisin/kexin type 
6 
5046 2.57 
PCDHGA4 protocadherin gamma subfamily A, 4 56111 2.57 
C9orf58 chromosome 9 open reading frame 58 83543 2.57 





AADACL1 arylacetamide deacetylase-like 1 57552 2.55 
MAOA monoamine oxidase A 4128 2.55 
ECT2 epithelial cell transforming sequence 2 
oncogene 
1894 2.53 
SEC24A SEC24 related gene family, member A (S. 
cerevisiae) /// CXYorf1-related protein 
10802 2.53 
ACAD8 acyl-Coenzyme A dehydrogenase family, 
member 8 
27034 2.50 
ELOVL7 ELOVL family member 7, elongation of 
long chain fatty acids (yeast) 
79993 2.50 
RHPN2 rhophilin, Rho GTPase binding protein 2 85415 2.46 
MGC72075 hypothetical protein MGC72075 340277 2.46 
GPR98 G protein-coupled receptor 98 84059 2.46 
HMMR hyaluronan-mediated motility receptor 
(RHAMM) 
3161 2.46 
IL20RA interleukin 20 receptor, alpha 53832 2.43 
SLC27A2 solute carrier family 27 (fatty acid 
transporter), member 2 
11001 2.43 
GOLPH2 golgi phosphoprotein 2 51280 2.43 
ZCCHC6 zinc finger, CCHC domain containing 6 79670 2.43 
RBM35B RNA binding motif protein 35B 80004 2.41 
LOC286189 hypothetical protein LOC286189 286189 2.39 
PCCB propionyl Coenzyme A carboxylase, beta 
polypeptide 
5096 2.38 
TSPAN13 Tetraspanin 13 27075 2.38 
SLC19A1 solute carrier family 19 (folate transporter), 
member 1 
6573 2.38 
SLC19A2 solute carrier family 19 (thiamine 
transporter), member 2 
10560 2.38 
PPAT phosphoribosyl pyrophosphate 
amidotransferase 
5471 2.38 
C9orf65 chromosome 9 open reading frame 65 158471 2.36 
MTAC2D1 membrane targeting (tandem) C2 domain 
containing 1 
123036 2.35 
C2orf37 chromosome 2 open reading frame 37 80067 2.33 
SRPRB signal recognition particle receptor, B 
subunit 
58477 2.33 
LOC389834 hypothetical gene supported by AK123403 
/// hypothetical protein LOC642398 
389834 2.31 
PDIA5 protein disulfide isomerase family A, 
member 5 
10954 2.31 
SLC26A2 solute carrier family 26 (sulfate 
transporter), member 2 
1836 2.30 
TUFT1 tuftelin 1 7286 2.30 
B3GALT6 UDP-Gal:betaGal beta 1,3-
galactosyltransferase polypeptide 6 
126792 2.28 
KM-HN-1 KM-HN-1 protein 256309 2.28 
PSAT1 phosphoserine aminotransferase 1 29968 2.28 
RPL22L1 ribosomal protein L22-like 1 /// similar to 






TMEM144 transmembrane protein 144 55314 2.25 
IGFBP2 insulin-like growth factor binding protein 
2, 36kDa 
3485 2.25 
RAB11FIP1 RAB11 family interacting protein 1 (class 
I) 
80223 2.23 
C1orf97 chromosome 1 open reading frame 97 /// 
chromosome 1 open reading frame 97 
84791 2.22 
ANKRD22 ankyrin repeat domain 22 118932 2.22 
PIGW phosphatidylinositol glycan anchor 
biosynthesis, class W 
284098 2.20 
PVRL3 poliovirus receptor-related 3 25945 2.20 
ZNF30 zinc finger protein 30 90075 2.20 
KIAA1244 KIAA1244 57221 2.20 
SLC12A8 solute carrier family 12 (potassium/chloride 
transporters), member 8 
84561 2.20 
PAOX polyamine oxidase (exo-N4-amino) 196743 2.20 










PNC1 protein 84275 2.19 
C4orf13 Chromosome 4 open reading frame 13 84068 2.19 
LOC401097 Similar to LOC166075 401097 2.17 
ASNS asparagine synthetase 440 2.17 
TSPAN1 tetraspanin 1 10103 2.17 
SLC7A1 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 1 
6541 2.16 






FAM83H family with sequence similarity 83, 
member H 
286077 2.16 
MTHFD2 methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 
10797 2.14 
RIPK2 receptor-interacting serine-threonine kinase 
2 
8767 2.14 
ILDR1 immunoglobulin-like domain containing 
receptor 1 
286676 2.14 
HSD17B4 hydroxysteroid (17-beta) dehydrogenase 4 3295 2.14 
LYPLAL1 lysophospholipase-like 1 127018 2.13 
TRIB3 tribbles homolog 3 (Drosophila) 57761 2.13 
WIPI1 WD repeat domain, phosphoinositide 
interacting 1 
55062 2.13 





DHCR24 24-dehydrocholesterol reductase 1718 2.10 
C7orf24 chromosome 7 open reading frame 24 79017 2.08 
LYPLA1 lysophospholipase I 10434 2.07 
RBM35A RNA binding motif protein 35A 54845 2.07 
RFC5 CS box-containing WD protein 5985 2.06 
JOSD3 Josephin domain containing 3 79101 2.06 
LRRC8E leucine rich repeat containing 8 family, 
member E 
80131 2.06 
LRBA LPS-responsive vesicle trafficking, beach 
and anchor containing 
987 2.06 
KIAA0746 KIAA0746 protein 23231 2.06 
SHRM Transcribed locus 57619 2.04 
PUS7 pseudouridylate synthase 7 homolog (S. 
cerevisiae) 
54517 2.04 
TMTC4 transmembrane and tetratricopeptide repeat 
containing 4 
84899 2.04 
NLN neurolysin (metallopeptidase M3 family) 57486 2.04 
STYK1 serine/threonine/tyrosine kinase 1 55359 2.04 
THSD1 thrombospondin, type I, domain containing 
1 /// thrombospondin, type I, domain 
containing 1 pseudogene 
55901 2.03 
ChGn chondroitin beta1,4 N-
acetylgalactosaminyltransferase 
55790 2.03 
ZDHHC23 zinc finger, DHHC-type containing 23 254887 2.01 
FLJ10357 hypothetical protein FLJ10357 55701 -2.00 
KLHL5 kelch-like 5 (Drosophila) 51088 -2.01 
NLGN4Y neuroligin 4, Y-linked 22829 -2.01 
ZNF532 zinc finger protein 532 55205 -2.01 
VAV3 vav 3 oncogene 10451 -2.03 
TCEA2 transcription elongation factor A (SII), 2 6919 -2.03 
IFI16 interferon, gamma-inducible protein 16 3428 -2.04 
C6orf60 chromosome 6 open reading frame 60 79632 -2.04 
NUDT10 nudix (nucleoside diphosphate linked 
moiety X)-type motif 10 
170685 -2.04 
TCF8 transcription factor 8 (represses interleukin 
2 expression) 
6935 -2.04 
ATP2A2 ATPase, Ca++ transporting, cardiac 
muscle, slow twitch 2 
488 -2.04 
FXYD6 FXYD domain containing ion transport 
regulator 6 
53826 -2.06 
CRISPLD2 cysteine-rich secretory protein LCCL 
domain containing 2 
83716 -2.06 
SERPINB1 serpin peptidase inhibitor, clade B 
(ovalbumin), member 1 
1992 -2.06 
SLC27A3 solute carrier family 27 (fatty acid 
transporter), member 3 
11000 -2.06 
LOC153682 Hypothetical protein LOC644009 153682 -2.06 
MAML2 mastermind-like 2 (Drosophila) 84441 -2.06 
PRG1 proteoglycan 1, secretory granule 5552 -2.06 





TPBG trophoblast glycoprotein 7162 -2.07 
PLEKHH2 pleckstrin homology domain containing, 
family H (with MyTH4 domain) member 2 
130271 -2.07 
SLC8A1 solute carrier family 8 (sodium/calcium 
exchanger), member 1 
6546 -2.07 
ZNF512 zinc finger protein 512 84450 -2.07 
FGFR1 fibroblast growth factor receptor 1 (fms-
related tyrosine kinase 2, Pfeiffer 
syndrome) 
2260 -2.07 
FLJ13197 hypothetical protein FLJ13197 79667 -2.07 
STARD4 START domain containing 4, sterol 
regulated 
134429 -2.07 
RGMB RGM domain family, member B 285704 -2.08 
PPP1R3C protein phosphatase 1, regulatory 
(inhibitor) subunit 3C 
5507 -2.10 
LOC283481 hypothetical protein LOC283481 283481 -2.10 
PELI2 pellino homolog 2 (Drosophila) 57161 -2.10 
PGAP1 GPI deacylase 80055 -2.10 
WNT5B wingless-type MMTV integration site 
family, member 5B /// wingless-type 
MMTV integration site family, member 5B 
81029 -2.10 
EID3 E1A-like inhibitor of differentiation 3 493861 -2.10 
SGCB sarcoglycan, beta (43kDa dystrophin-
associated glycoprotein) 
6443 -2.10 
FAT4 FAT tumor suppressor homolog 4 
(Drosophila) 
79633 -2.10 
CG018 hypothetical gene CG018 90634 -2.10 
DCN decorin 1634 -2.10 
TMEM16A transmembrane protein 16A 55107 -2.11 
PYGM phosphorylase, glycogen; muscle (McArdle 
syndrome, glycogen storage disease type 
V) 
5837 -2.11 
C20orf194 chromosome 20 open reading frame 194 25943 -2.11 
NES nestin 10763 -2.11 
LOC285989 zinc finger protein 789 285989 -2.11 
FGD5 FYVE, RhoGEF and PH domain 
containing 5 
152273 -2.11 
NALP1 NACHT, leucine rich repeat and PYD 
(pyrin domain) containing 1 
22861 -2.11 
GPRASP1 G protein-coupled receptor associated 
sorting protein 1 
9737 -2.11 
GNB5 guanine nucleotide binding protein (G 
protein), beta 5 
10681 -2.13 
SYTL4 synaptotagmin-like 4 (granuphilin-a) 94121 -2.13 
TFPI tissue factor pathway inhibitor (lipoprotein-
associated coagulation inhibitor) 
7035 -2.13 
PGRMC1 progesterone receptor membrane 
component 1 
10857 -2.13 
TUBB6 tubulin, beta 6 84617 -2.13 





subfamily C, member 4 
CUGBP2 CUG triplet repeat, RNA binding protein 2 10659 -2.13 
LAMA4 laminin, alpha 4 3910 -2.13 
ALDH1L2 aldehyde dehydrogenase 1 family, member 
L2 
160428 -2.13 
RASSF5 Ras association (RalGDS/AF-6) domain 
family 5 
83593 -2.14 
ZDHHC15 zinc finger, DHHC-type containing 15 158866 -2.16 
TSC22D3 TSC22 domain family, member 3 1831 -2.16 




PRKAR2B protein kinase, cAMP-dependent, 
regulatory, type II, beta 
5577 -2.16 
C4orf31 chromosome 4 open reading frame 31 79625 -2.16 
C1R complement component 1, r subcomponent 
/// similar to Complement C1r 
subcomponent precursor (Complement 
component 1, r subcomponent) 
715 -2.16 
SERPINE2 serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), 
member 2 
5270 -2.17 
DIXDC1 DIX domain containing 1 85458 -2.17 
CASP1 caspase 1, apoptosis-related cysteine 
peptidase (interleukin 1, beta, convertase) 
834 -2.17 
ARHGEF4 Rho guanine nucleotide exchange factor 
(GEF) 4 
50649 -2.17 
MEIS3P1 Meis1 homolog 3 (mouse) pseudogene 1 4213 -2.17 
FBXL7 F-box and leucine-rich repeat protein 7 23194 -2.17 
C1S complement component 1, s subcomponent 716 -2.19 
BTG2 BTG family, member 2 7832 -2.19 
EVI1 ecotropic viral integration site 1 2122 -2.19 
ITGB1BP2 integrin beta 1 binding protein (melusin) 2 26548 -2.19 
MBNL2 muscleblind-like 2 (Drosophila) 10150 -2.19 
MSN moesin 4478 -2.19 
C7 complement component 7 730 -2.19 
FAM46A family with sequence similarity 46, 
member A 
55603 -2.20 
OR2A20P Olfactory receptor, family 2, subfamily A, 
member 7 
401428 -2.20 
PSCDBP pleckstrin homology, Sec7 and coiled-coil 
domains, binding protein /// pleckstrin 
homology, Sec7 and coiled-coil domains, 
binding protein 
9595 -2.20 
SERPING1 serpin peptidase inhibitor, clade G (C1 
inhibitor), member 1, (angioedema, 
hereditary) 
710 -2.20 
GPM6B glycoprotein M6B 2824 -2.20 
RSNL2 restin-like 2 79745 -2.20 





CD200 CD200 molecule 4345 -2.22 
HEPH hephaestin 9843 -2.22 
PPP1R14A protein phosphatase 1, regulatory 
(inhibitor) subunit 14A 
94274 -2.22 
CPVL carboxypeptidase, vitellogenic-like /// 
carboxypeptidase, vitellogenic-like 
54504 -2.22 
TSPAN2 tetraspanin 2 10100 -2.22 
RASSF6 Ras association (RalGDS/AF-6) domain 
family 6 
166824 -2.22 
DLL1 delta-like 1 (Drosophila) 28514 -2.23 
HS3ST3B1 heparan sulfate (glucosamine) 3-O-
sulfotransferase 3B1 
9953 -2.23 
MAGI2 membrane associated guanylate kinase, 
WW and PDZ domain containing 2 
9863 -2.23 
MYADM myeloid-associated differentiation marker 91663 -2.23 
ITIH5 inter-alpha (globulin) inhibitor H5 80760 -2.23 
BDH2 3-hydroxybutyrate dehydrogenase, type 2 56898 -2.25 
NRP1 neuropilin 1 8829 -2.25 
RAI2 retinoic acid induced 2 10742 -2.25 
PLEKHA6 pleckstrin homology domain containing, 
family A member 6 
22874 -2.25 
HTRA1 HtrA serine peptidase 1 5654 -2.25 
DSC3 desmocollin 3 1825 -2.25 
CCL19 chemokine (C-C motif) ligand 19 6363 -2.25 
BOC Boc homolog (mouse) 91653 -2.27 
LAMB2 laminin, beta 2 (laminin S) 3913 -2.27 
MATN2 matrilin 2 4147 -2.27 
TRPC1 transient receptor potential cation channel, 
subfamily C, member 1 
7220 -2.27 
PCOLCE procollagen C-endopeptidase enhancer 5118 -2.27 
ALDH1A1 aldehyde dehydrogenase 1 family, member 
A1 
216 -2.27 
TRIM6 tripartite motif-containing 6 117854 -2.27 
LDHB lactate dehydrogenase B 3945 -2.27 
ZNF423 zinc finger protein 423 23090 -2.27 
SELENBP1 selenium binding protein 1 /// selenium 
binding protein 1 
8991 -2.27 
SELM selenoprotein M 140606 -2.27 
SRPX sushi-repeat-containing protein, X-linked 8406 -2.28 
LOC619208 hypothetical protein LOC619208 619208 -2.28 
TIMP1 TIMP metallopeptidase inhibitor 1 7076 -2.28 
ANG angiogenin, ribonuclease, RNase A family, 
5 /// ribonuclease, RNase A family, 4 
283 -2.28 
HMGCLL1 3-hydroxymethyl-3-methylglutaryl-
Coenzyme A lyase-like 1 
54511 -2.28 
FOXF1 forkhead box F1 2294 -2.28 
GPR124 G protein-coupled receptor 124 25960 -2.28 
GALNTL1 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-









SLMAP sarcolemma associated protein 7871 -2.28 
MXRA7 matrix-remodelling associated 7 439921 -2.28 
EPHA4 EPH receptor A4 2043 -2.30 
IL8 interleukin 8 3576 -2.30 
PAK1 p21/Cdc42/Rac1-activated kinase 1 (STE20 
homolog, yeast) 
5058 -2.30 
DKK3 dickkopf homolog 3 (Xenopus laevis) 27122 -2.31 
LOC493869 similar to RIKEN cDNA 2310016C16 493869 -2.31 
GRK5 G protein-coupled receptor kinase 5 2869 -2.31 
EHBP1L1 hypothetical protein MGC15523 /// EH 
domain binding protein 1-like 1 
254102 -2.31 
TTMB TTMB protein 399474 -2.33 
PARD6G par-6 partitioning defective 6 homolog 
gamma (C. elegans) 
84552 -2.33 
TWIST2 twist homolog 2 (Drosophila) 117581 -2.33 
ACTN1 actinin, alpha 1 87 -2.33 
EFHA2 EF-hand domain family, member A2 286097 -2.33 
ADCY5 adenylate cyclase 5 111 -2.33 
APCDD1 adenomatosis polyposis coli down-
regulated 1 
147495 -2.33 
ANK2 ankyrin 2, neuronal 287 -2.33 
IFITM3 interferon induced transmembrane protein 
3 (1-8U) 
10410 -2.35 
MSRB3 methionine sulfoxide reductase B3 253827 -2.35 
LTBP3 latent transforming growth factor beta 




hypothetical protein DKFZP761M1511 54492 -2.35 
ARMCX2 armadillo repeat containing, X-linked 2 9823 -2.35 
ACAA2 acetyl-Coenzyme A acyltransferase 2 
(mitochondrial 3-oxoacyl-Coenzyme A 
thiolase) 
10449 -2.35 
FLJ21963 FLJ21963 protein 79611 -2.35 
IFITM2 interferon induced transmembrane protein 
2 (1-8D) 
10581 -2.35 
BTG3 BTG family, member 3 10950 -2.36 
HDAC9 histone deacetylase 9 9734 -2.36 
BHLHB2 basic helix-loop-helix domain containing, 
class B, 2 
8553 -2.36 
EFNB3 ephrin-B3 1949 -2.36 
BACH2 BTB and CNC homology 1, basic leucine 
zipper transcription factor 2 /// BTB and 
CNC homology 1, basic leucine zipper 
transcription factor 2 
60468 -2.36 
NDN necdin homolog (mouse) 4692 -2.36 
KNTC2 kinetochore associated 2 10403 -2.36 





ICAM2 intercellular adhesion molecule 2 3384 -2.36 
C14orf78 chromosome 14 open reading frame 78 113146 -2.36 
PDGFC platelet derived growth factor C 56034 -2.38 
KCNE3 potassium voltage-gated channel, Isk-
related family, member 3 
10008 -2.38 
GNAZ guanine nucleotide binding protein (G 
protein), alpha z polypeptide 
2781 -2.38 
KIAA1713 KIAA1713 80816 -2.38 
GBP3 guanylate binding protein 3 2635 -2.38 
MID1 midline 1 (Opitz/BBB syndrome) 4281 -2.38 
BIN1 bridging integrator 1 274 -2.39 
CAPG capping protein (actin filament), gelsolin-
like 
822 -2.39 
TRAF3IP2 TRAF3 interacting protein 2 10758 -2.39 
LOC399959 hypothetical gene supported by BX647608 399959 -2.39 
RP1-
93H18.5 
hypothetical protein LOC441168 441168 -2.39 
TP53INP2 tumor protein p53 inducible nuclear protein 
2 
58476 -2.39 
S100A6 S100 calcium binding protein A6 
(calcyclin) 
6277 -2.39 
PLEKHO1 pleckstrin homology domain containing, 
family O member 1 
51177 -2.39 
ISL1 ISL1 transcription factor, 
LIM/homeodomain, (islet-1) 
3670 -2.39 
RGS13 regulator of G-protein signalling 13 6003 -2.39 
CFL2 cofilin 2 (muscle) /// cofilin 2 (muscle) 1073 -2.41 
SLC40A1 solute carrier family 40 (iron-regulated 
transporter), member 1 
30061 -2.41 
LRFN5 leucine rich repeat and fibronectin type III 
domain containing 5 
145581 -2.41 
PLEKHC1 pleckstrin homology domain containing, 
family C (with FERM domain) member 1 
10979 -2.41 
tcag7.981 juxtaposed with another zinc finger gene 1 221895 -2.41 
FZD7 frizzled homolog 7 (Drosophila) 8324 -2.41 
FBXO32 F-box protein 32 114907 -2.43 
PTGIS prostaglandin I2 (prostacyclin) synthase /// 
prostaglandin I2 (prostacyclin) synthase 
5740 -2.43 
JAM3 junctional adhesion molecule 3 83700 -2.43 
EVA1 epithelial V-like antigen 1 10205 -2.43 
C9orf26 chromosome 9 open reading frame 26 (NF-
HEV) 
90865 -2.43 
FLJ39155 EGF-like, fibronectin type III and laminin 
G domains 
133584 -2.43 
DMD dystrophin (muscular dystrophy, Duchenne 
and Becker types) 
1756 -2.43 
CAV1 caveolin 1, caveolae protein, 22kDa 857 -2.43 
ADD3 adducin 3 (gamma) 120 -2.45 







MXRA6 Tensin 1 /// Tensin 1 54589 -2.45 
ITGB8 integrin, beta 8 3696 -2.45 
LOC203274 hypothetical protein LOC203274 203274 -2.45 
IRAK1BP1 interleukin-1 receptor-associated kinase 1 
binding protein 1 
134728 -2.45 
CKMT2 creatine kinase, mitochondrial 2 
(sarcomeric) 
1160 -2.45 
MCAM melanoma cell adhesion molecule 4162 -2.46 
C9orf3 chromosome 9 open reading frame 3 84909 -2.46 
DSCR1L2 ESTs 11123 -2.46 
HLF hepatic leukemia factor 3131 -2.46 
MEIS1 Meis1, myeloid ecotropic viral integration 
site 1 homolog (mouse) 
4211 -2.46 
TLE2 transducin-like enhancer of split 2 (E(sp1) 
homolog, Drosophila) 
7089 -2.46 
GBP2 guanylate binding protein 2, interferon-
inducible /// guanylate binding protein 2, 
interferon-inducible 
2634 -2.46 
HS3ST3A1 heparan sulfate (glucosamine) 3-O-
sulfotransferase 3A1 
9955 -2.46 
VIM vimentin 7431 -2.46 
IER3 immediate early response 3 8870 -2.48 
SPON1 spondin 1, extracellular matrix protein 10418 -2.48 
TMEM16E ESTs 203859 -2.48 
MEST mesoderm specific transcript homolog 
(mouse) 
4232 -2.48 
PROCR protein C receptor, endothelial (EPCR) 10544 -2.48 
EMP3 epithelial membrane protein 3 2014 -2.48 
CCR2 chemokine (C-C motif) receptor 2 /// 
chemokine (C-C motif) receptor 2 
1231 -2.48 
NT5DC2 5'-nucleotidase domain containing 2 64943 -2.48 
LOC283070 hypothetical protein LOC283070 283070 -2.48 
SPOCK3 sparc/osteonectin, cwcv and kazal-like 
domains proteoglycan (testican) 3 
50859 -2.48 
FZD2 frizzled homolog 2 (Drosophila) 2535 -2.48 
BNC2 basonuclin 2 54796 -2.48 
RBPMS RNA binding protein with multiple splicing 11030 -2.50 
OLFML1 olfactomedin-like 1 283298 -2.50 
PPP1R12B protein phosphatase 1, regulatory 
(inhibitor) subunit 12B 
4660 -2.50 
BVES blood vessel epicardial substance 11149 -2.50 
COL18A1 collagen, type XVIII, alpha 1 80781 -2.50 
DUSP6 dual specificity phosphatase 6 1848 -2.50 
GAS1 growth arrest-specific 1 2619 -2.51 
LGALS3BP lectin, galactoside-binding, soluble, 3 
binding protein 
3959 -2.51 
C16orf45 chromosome 16 open reading frame 45 89927 -2.53 
CDC42EP3 CDC42 effector protein (Rho GTPase 
binding) 3 
10602 -2.53 





CAP2 CAP, adenylate cyclase-associated protein, 
2 (yeast) 
10486 -2.53 
EPB41L3 erythrocyte membrane protein band 4.1-
like 3 
23136 -2.53 
HEY1 hairy/enhancer-of-split related with YRPW 
motif 1 
23462 -2.55 
ASB2 ankyrin repeat and SOCS box-containing 2 51676 -2.55 
RRAS related RAS viral (r-ras) oncogene 
homolog 
6237 -2.55 
INMT indolethylamine N-methyltransferase 11185 -2.57 
PCDH18 protocadherin 18 54510 -2.57 
RND3 Rho family GTPase 3 390 -2.57 
LAMP3 lysosomal-associated membrane protein 3 27074 -2.57 
SERPINA7 Nik related kinase 6906 -2.57 
CARD15 Transcribed locus, weakly similar to 
XP_520634.1 PREDICTED: similar to 
naked cuticle homolog 1; naked cuticle-1; 
Dvl-binding protein [Pan troglodytes] 
64127 -2.57 
MRGPRF MAS-related GPR, member F 219928 -2.57 
FLJ10847 hypothetical protein FLJ10847 55244 -2.58 
ISYNA1 myo-inositol 1-phosphate synthase A1 51477 -2.58 
MT1X metallothionein 1X 4501 -2.58 
TLR3 toll-like receptor 3 7098 -2.58 
SVIL supervillin 6840 -2.58 
EDNRA endothelin receptor type A 1909 -2.58 
SCRN1 secernin 1 9805 -2.58 
LOC402560 hypothetical LOC402560 402560 -2.60 
DNALI1 dynein, axonemal, light intermediate 
polypeptide 1 
7802 -2.60 
CHRM1 cholinergic receptor, muscarinic 1 1128 -2.60 
PRKCB1 protein kinase C, beta 1 5579 -2.60 
FEZ1 fasciculation and elongation protein zeta 1 
(zygin I) 
9638 -2.60 
NAV2 neuron navigator 2 89797 -2.60 
C21orf63 chromosome 21 open reading frame 63 59271 -2.60 
EYA4 ESTs 2070 -2.60 
NT5E 5'-nucleotidase, ecto (CD73) 4907 -2.60 
GNG2 guanine nucleotide binding protein (G 
protein), gamma 2 
54331 -2.60 
LARGE like-glycosyltransferase 9215 -2.62 
PDE8B phosphodiesterase 8B 8622 -2.62 
RBP7 retinol binding protein 7, cellular 116362 -2.62 
FOXC1 forkhead box C1 2296 -2.62 
NID1 nidogen 1 4811 -2.62 
PDZRN4 PDZ domain containing RING finger 4 29951 -2.62 
SYNGR1 synaptogyrin 1 9145 -2.62 
AKAP7 A kinase (PRKA) anchor protein 7 9465 -2.62 
AMT aminomethyltransferase 275 -2.64 
INPP1 inositol polyphosphate-1-phosphatase 3628 -2.64 





PLCL2 phospholipase C-like 2 23228 -2.64 
SORBS1 sorbin and SH3 domain containing 1 10580 -2.64 
STOM stomatin 2040 -2.64 
MMP2 matrix metallopeptidase 2 (gelatinase A, 
72kDa gelatinase, 72kDa type IV 
collagenase) 
4313 -2.66 
SERPINB9 serpin peptidase inhibitor, clade B 
(ovalbumin), member 9 
5272 -2.66 
PALMD palmdelphin 54873 -2.66 
TMEM16D transmembrane protein 16D 121601 -2.66 
DACH1 dachshund homolog 1 (Drosophila) 1602 -2.68 
Gcom1 GRINL1A combined protein 145781 -2.68 
SPATA18 spermatogenesis associated 18 homolog 
(rat) 
132671 -2.68 
HOXB2 homeobox B2 3212 -2.68 
PTPLA protein tyrosine phosphatase-like (proline 
instead of catalytic arginine), member A 
9200 -2.68 
DDIT4L DNA-damage-inducible transcript 4-like 115265 -2.68 
CPA3 carboxypeptidase A3 (mast cell) 1359 -2.68 
GMNN geminin, DNA replication inhibitor 51053 -2.68 
CX3CL1 chemokine (C-X3-C motif) ligand 1 6376 -2.69 
MGC39900 hypothetical protein MGC39900 286527 -2.69 
AYTL1 acyltransferase like 1 54947 -2.69 
MET met proto-oncogene (hepatocyte growth 
factor receptor) 
4233 -2.69 
NHS Nance-Horan syndrome (congenital 
cataracts and dental anomalies) 
4810 -2.71 
S100A8 S100 calcium binding protein A8 
(calgranulin A) 
6279 -2.71 
SEMA6D sema domain, transmembrane domain 
(TM), and cytoplasmic domain, 
(semaphorin) 6D 
80031 -2.71 
NEU1 FYN oncogene related to SRC, FGR, YES 
/// sialidase 1 (lysosomal sialidase) 
4758 -2.71 
EFEMP2 EGF-containing fibulin-like extracellular 
matrix protein 2 
30008 -2.71 
ST5 suppression of tumorigenicity 5 6764 -2.73 
METTL7A methyltransferase like 7A 25840 -2.73 
FAM92A1 family with sequence similarity 92, 
member A1 
137392 -2.73 
TUBA1 tubulin, alpha 1 7277 -2.73 
AKR1B1 aldo-keto reductase family 1, member B1 
(aldose reductase) 
231 -2.73 
CSPG2 chondroitin sulfate proteoglycan 2 
(versican) 
1462 -2.73 
GSTP1 glutathione S-transferase pi 2950 -2.73 
OGN osteoglycin (osteoinductive factor, 
mimecan) 
4969 -2.73 
LRRC34 leucine rich repeat containing 34 151827 -2.75 






GSTM3 glutathione S-transferase M3 (brain) 2947 -2.75 
ROBO1 roundabout, axon guidance receptor, 
homolog 1 (Drosophila) 
6091 -2.75 
FCGRT Fc fragment of IgG, receptor, transporter, 
alpha 
2217 -2.77 
SULF2 sulfatase 2 55959 -2.77 
TCF7L1 transcription factor 7-like 1 (T-cell specific, 
HMG-box) /// transcription factor 7-like 1 
(T-cell specific, HMG-box) 
83439 -2.77 
PTGS2 prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and 
cyclooxygenase) 
5743 -2.77 
PRICKLE2 prickle-like 2 (Drosophila) 166336 -2.77 
C1orf165 chromosome 1 open reading frame 165 79656 -2.79 
BMP5 bone morphogenetic protein 5 653 -2.79 
LMO4 LIM domain only 4 8543 -2.79 
IFITM1 interferon induced transmembrane protein 
1 (9-27) 
8519 -2.81 
NID2 nidogen 2 (osteonidogen) 22795 -2.81 
PDE4A phosphodiesterase 4A, cAMP-specific 
(phosphodiesterase E2 dunce homolog, 
Drosophila) 
5141 -2.81 
RGC32 response gene to complement 32 28984 -2.81 
RBM24 RNA binding motif protein 24 221662 -2.81 
FLNA filamin A, alpha (actin binding protein 280) 2316 -2.81 
TMEM158 transmembrane protein 158 25907 -2.81 
GPX7 glutathione peroxidase 7 2882 -2.83 
RNASE4 ribonuclease, RNase A family, 4 6038 -2.83 
COL4A3 collagen, type IV, alpha 3 (Goodpasture 
antigen) 
1285 -2.83 
PRSS16 protease, serine, 16 (thymus) 10279 -2.83 
PDE5A phosphodiesterase 5A, cGMP-specific 8654 -2.83 
FLRT2 fibronectin leucine rich transmembrane 
protein 2 
23768 -2.85 
EDG2 endothelial differentiation, 
lysophosphatidic acid G-protein-coupled 
receptor, 2 
1902 -2.85 
RBMS3 RNA binding motif, single stranded 
interacting protein 
27303 -2.85 
SDC1 syndecan 1 6382 -2.85 
CTTNBP2 cortactin binding protein 2 83992 -2.85 
JPH4 junctophilin 4 84502 -2.85 
PRTFDC1 phosphoribosyl transferase domain 
containing 1 
56952 -2.85 
C6orf32 chromosome 6 open reading frame 32 9750 -2.87 
OLFML3 olfactomedin-like 3 56944 -2.87 
TBC1D1 TBC1 (tre-2/USP6, BUB2, cdc16) domain 
family, member 1 
23216 -2.87 





family member 2 
SLCO3A1 solute carrier organic anion transporter 
family, member 3A1 
28232 -2.87 
TGFBR3 transforming growth factor, beta receptor 
III (betaglycan, 300kDa) 
7049 -2.87 
CXorf6 chromosome X open reading frame 6 10046 -2.87 
FER1L3 fer-1-like 3, myoferlin (C. elegans) 26509 -2.89 
R7BP R7 binding protein 401190 -2.89 
COL6A2 collagen, type VI, alpha 2 1292 -2.89 
TRHDE thyrotropin-releasing hormone degrading 
enzyme 
29953 -2.89 
EFHC2 EF-hand domain (C-terminal) containing 2 80258 -2.89 
FLJ32363 FLJ32363 protein 375444 -2.89 
TRIM22 tripartite motif-containing 22 10346 -2.89 
NPAL3 NIPA-like domain containing 3 57185 -2.89 
UBD ubiquitin D 10537 -2.91 
APOBEC3
G 
apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like 3G 
60489 -2.91 
RAB9B RAB9B, member RAS oncogene family 51209 -2.91 





WFDC1 WAP four-disulfide core domain 1 58189 -2.93 
APOD apolipoprotein D 347 -2.95 
HHIP hedgehog interacting protein 64399 -2.95 
TRIP6 thyroid hormone receptor interactor 6 7205 -2.95 
CAV2 caveolin 2 858 -2.95 
DES desmin /// family with sequence similarity 
48, member A 
1674 -2.95 
AOC3 amine oxidase, copper containing 3 
(vascular adhesion protein 1) 
8639 -2.95 
AOX1 aldehyde oxidase 1 316 -2.95 
BST2 bone marrow stromal cell antigen 2 684 -2.97 
PLK2 polo-like kinase 2 (Drosophila) 10769 -2.97 
RBP1 retinol binding protein 1, cellular 5947 -2.97 
TMLHE trimethyllysine hydroxylase, epsilon 55217 -2.97 
ADAMTS9 ADAM metallopeptidase with 
thrombospondin type 1 motif, 9 
56999 -2.97 
PPAP2B phosphatidic acid phosphatase type 2B 8613 -2.97 
CRYAB crystallin, alpha B 1410 -2.99 
BMP4 bone morphogenetic protein 4 652 -2.99 
TSHZ3 teashirt family zinc finger 3 57616 -2.99 
C20orf100 chromosome 20 open reading frame 100 84969 -2.99 
ECRG4 chromosome 2 open reading frame 40 84417 -2.99 
ZNF711 zinc finger protein 711 7552 -3.01 
S100A4 S100 calcium binding protein A4 (calcium 
protein, calvasculin, metastasin, murine 
placental homolog) 
6275 -3.01 






ARL4C ADP-ribosylation factor-like 4C 10123 -3.01 
HSD11B1 hydroxysteroid (11-beta) dehydrogenase 1 3290 -3.01 
THSD4 thrombospondin, type I, domain containing 
4 
79875 -3.03 
DMN desmuslin 23336 -3.03 
EMILIN1 elastin microfibril interfacer 1 11117 -3.03 
LPHN2 latrophilin 2 23266 -3.03 
SYNPO2 synaptopodin 2 171024 -3.05 
ST6GAL2 ESTs 84620 -3.05 
C3 complement component 3 /// similar to 
Complement C3 precursor 
718 -3.05 
SERTAD4 SERTA domain containing 4 56256 -3.05 
CYBA cytochrome b-245, alpha polypeptide 1535 -3.05 
CPM carboxypeptidase M 1368 -3.07 
GPR126 G protein-coupled receptor 126 57211 -3.07 
JUB jub, ajuba homolog (Xenopus laevis) 84962 -3.10 
EBI2 Epstein-Barr virus induced gene 2 
(lymphocyte-specific G protein-coupled 
receptor) 
1880 -3.10 
C20orf42 chromosome 20 open reading frame 42 55612 -3.10 
KIAA1462 KIAA1462 57608 -3.10 
SMTN smoothelin 6525 -3.10 




PTGDS prostaglandin D2 synthase 21kDa (brain) 5730 -3.12 
ARHGAP20 Rho GTPase activating protein 20 57569 -3.12 
C13orf21 chromosome 13 open reading frame 21 387923 -3.14 
CSRP1 cysteine and glycine-rich protein 1 1465 -3.14 
TF transferrin 7018 -3.14 
COX7A1 cytochrome c oxidase subunit VIIa 
polypeptide 1 (muscle) 
1346 -3.16 
TBX5 T-box 5 6910 -3.16 
LOC130576 hypothetical protein LOC130576 130576 -3.16 
G0S2 G0/G1switch 2 50486 -3.16 
LTBP4 latent transforming growth factor beta 
binding protein 4 
8425 -3.16 
DBNDD2 dysbindin (dystrobrevin binding protein 1) 
domain containing 2 
55861 -3.16 
GMPR guanosine monophosphate reductase /// 
guanosine monophosphate reductase 
2766 -3.18 
CCDC8 coiled-coil domain containing 8 83987 -3.18 
CXCL12 chemokine (C-X-C motif) ligand 12 
(stromal cell-derived factor 1) 
6387 -3.18 
KLHL14 kelch-like 14 (Drosophila) 57565 -3.18 
WNT4 wingless-type MMTV integration site 
family, member 4 /// wingless-type MMTV 
integration site family, member 4 
54361 -3.18 





PLP2 proteolipid protein 2 (colonic epithelium-
enriched) 
5355 -3.20 
CDO1 cysteine dioxygenase, type I 1036 -3.20 
HOXD10 homeobox D10 3236 -3.23 
ANXA6 annexin A6 309 -3.25 
NAV3 neuron navigator 3 89795 -3.25 
FOXQ1 forkhead box Q1 94234 -3.25 
C1orf106 chromosome 1 open reading frame 106 55765 -3.25 
ZNF179 zinc finger protein 179 7732 -3.25 
CCL2 chemokine (C-C motif) ligand 2 6347 -3.25 
ACTG2 actin, gamma 2, smooth muscle, enteric 72 -3.27 
PNMA1 paraneoplastic antigen MA1 9240 -3.29 
SOX7 SRY (sex determining region Y)-box 7 83595 -3.29 
F10 coagulation factor X 2159 -3.29 
TGFB1I1 transforming growth factor beta 1 induced 
transcript 1 
7041 -3.29 
STOX2 storkhead box 2 56977 -3.32 
RNF175 ring finger protein 175 285533 -3.32 
BIC BIC transcript 114614 -3.34 
LDB3 LIM domain binding 3 11155 -3.34 
PYCARD PYD and CARD domain containing 29108 -3.34 
NPTX2 neuronal pentraxin II 4885 -3.34 
PTN pleiotrophin (heparin binding growth factor 
8, neurite growth-promoting factor 1) /// 
pleiotrophin (heparin binding growth factor 
8, neurite growth-promoting factor 1) 
5764 -3.36 
PIP5K1B phosphatidylinositol-4-phosphate 5-kinase, 
type I, beta 
8395 -3.36 
SCN4B sodium channel, voltage-gated, type IV, 
beta 
6330 -3.39 
ABCA8 ATP-binding cassette, sub-family A 
(ABC1), member 8 
10351 -3.39 
FOXF2 forkhead box F2 2295 -3.39 
CNN1 calponin 1, basic, smooth muscle 1264 -3.41 
HSPB8 heat shock 22kDa protein 8 26353 -3.41 
ANKRD35 ankyrin repeat domain 35 148741 -3.41 
IGFBP6 insulin-like growth factor binding protein 6 3489 -3.41 
IGJ Immunoglobulin J polypeptide, linker 
protein for immunoglobulin alpha and mu 
polypeptides 
3512 -3.41 
TSLP thymic stromal lymphopoietin 85480 -3.41 
PRKCA protein kinase C, alpha 5578 -3.43 
ODZ2 odz, odd Oz/ten-m homolog 2 (Drosophila) 57451 -3.43 
CHN1 chimerin (chimaerin) 1 1123 -3.43 
FLJ10159 hypothetical protein FLJ10159 55084 -3.43 
PCDH9 protocadherin 9 5101 -3.43 
STARD8 START domain containing 8 9754 -3.46 
ITM2C integral membrane protein 2C /// integral 
membrane protein 2C 
81618 -3.46 







KIAA0980 protein 22981 -3.46 
CYP4X1 cytochrome P450, family 4, subfamily X, 
polypeptide 1 
260293 -3.46 
ANXA1 annexin A1 301 -3.46 
LOC285382 hypothetical gene supported by AK091454 285382 -3.48 
C11orf70 chromosome 11 open reading frame 70 /// 
chromosome 11 open reading frame 70 
85016 -3.48 
LOC284244 hypothetical protein LOC284244 284244 -3.48 
CLIC6 chloride intracellular channel 6 54102 -3.48 
ZNF185 zinc finger protein 185 (LIM domain) 7739 -3.48 
LOC387882 hypothetical protein 387882 -3.48 
RAB34 RAB34, member RAS oncogene family 83871 -3.51 
ALS2CR4 amyotrophic lateral sclerosis 2 (juvenile) 
chromosome region, candidate 4 
65062 -3.51 
LMOD1 leiomodin 1 (smooth muscle) 25802 -3.51 
FRMD6 FERM domain containing 6 122786 -3.51 
FAM107A family with sequence similarity 107, 
member A 
11170 -3.53 
ATRNL1 attractin-like 1 26033 -3.53 
ACTC actin, alpha, cardiac muscle 1 70 -3.56 
CHRDL1 chordin-like 1 91851 -3.56 
MAB21L1 mab-21-like 1 (C. elegans) 4081 -3.56 
LOC143381 hypothetical protein LOC143381 143381 -3.58 
CDCA7 cell division cycle associated 7 /// cell 
division cycle associated 7 
83879 -3.58 
C14orf159 chromosome 14 open reading frame 159 80017 -3.58 
LOH11CR2
A 
loss of heterozygosity, 11, chromosomal 
region 2, gene A 
4013 -3.58 
PGF placental growth factor, vascular 
endothelial growth factor-related protein 
5228 -3.61 
GPRC5B G protein-coupled receptor, family C, 
group 5, member B 
51704 -3.61 
KIAA1644 KIAA1644 protein 85352 -3.61 
CX3CR1 chemokine (C-X3-C motif) receptor 1 1524 -3.63 
HS6ST2 heparan sulfate 6-O-sulfotransferase 2 90161 -3.63 
SPRY2 sprouty homolog 2 (Drosophila) 10253 -3.63 
CKM creatine kinase, muscle 1158 -3.63 
VAMP5 vesicle-associated membrane protein 5 
(myobrevin) 
10791 -3.66 
TNFRSF19 tumor necrosis factor receptor superfamily, 
member 19 
55504 -3.66 
ANGPT1 angiopoietin 1 284 -3.68 
PLAC9 placenta-specific 9 219348 -3.68 
PAK3 p21 (CDKN1A)-activated kinase 3 5063 -3.68 
TMEM61 transmembrane protein 61 199964 -3.68 
TCEAL2 transcription elongation factor A (SII)-like 
2 
140597 -3.68 
MYOCD myocardin 93649 -3.71 






POU2AF1 POU domain, class 2, associating factor 1 5450 -3.73 
ARMCX1 armadillo repeat containing, X-linked 1 51309 -3.73 
SLC22A17 solute carrier family 22 (organic cation 
transporter), member 17 
51310 -3.76 
SNCAIP synuclein, alpha interacting protein 
(synphilin) 
9627 -3.76 
GPR161 G protein-coupled receptor 161 23432 -3.78 
EYA1 eyes absent homolog 1 (Drosophila) 2138 -3.81 
COCH coagulation factor C homolog, cochlin 
(Limulus polyphemus) 
1690 -3.81 
PGM5 phosphoglucomutase 5 5239 -3.84 
B3GALT2 UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 2 
8707 -3.84 
TCF21 transcription factor 21 6943 -3.84 
P2RY5 purinergic receptor P2Y, G-protein 
coupled, 5 
10161 -3.86 
EDG3 endothelial differentiation, sphingolipid G-
protein-coupled receptor, 3 
1903 -3.86 
CPLX3 lectin, mannose-binding, 1 like /// 
complexin 3 
594855 -3.86 
SFRP1 secreted frizzled-related protein 1 6422 -3.89 
MCC mutated in colorectal cancers 4163 -3.89 
RSPO3 R-spondin 3 homolog (Xenopus laevis) 84870 -3.89 
TRO trophinin /// trophinin 7216 -3.89 
FLJ25076 similar to CG4502-PA 134111 -3.89 
VIT vitrin 5212 -3.92 
PHLDA1 pleckstrin homology-like domain, family 
A, member 1 
22822 -3.92 
FHL2 four and a half LIM domains 2 2274 -3.92 
ATP1B1 ATPase, Na+/K+ transporting, beta 1 
polypeptide 
481 -3.94 
FST follistatin 10468 -3.94 
MT1M metallothionein 1M 4499 -3.94 
PTGER3 prostaglandin E receptor 3 (subtype EP3) 5733 -3.94 
PLAC8 placenta-specific 8 51316 -3.94 
FHOD3 formin homology 2 domain containing 3 80206 -3.94 
RARRES1 retinoic acid receptor responder (tazarotene 
induced) 1 
5918 -3.94 
STAC SH3 and cysteine rich domain 6769 -3.97 
ZNF655 zinc finger protein 655 79027 -4.00 
GALNAC4S
-6ST 
B cell RAG associated protein 51363 -4.03 
TMEM35 transmembrane protein 35 59353 -4.03 
EPHB1 EPH receptor B1 2047 -4.03 
FLJ20920 hypothetical protein FLJ20920 80221 -4.06 
CFB complement factor B 629 -4.06 
CCDC85A coiled-coil domain containing 85A 114800 -4.06 
VSNL1 visinin-like 1 7447 -4.06 






ETV5 ets variant gene 5 (ets-related molecule) 2119 -4.08 
MCF2 MCF.2 cell line derived transforming 
sequence 
4168 -4.08 
NDP Norrie disease (pseudoglioma) 4693 -4.14 
TPM2 tropomyosin 2 (beta) 7169 -4.17 
KCNAB1 potassium voltage-gated channel, shaker-
related subfamily, beta member 1 
7881 -4.17 
SNAI2 snail homolog 2 (Drosophila) 6591 -4.23 
RARRES2 retinoic acid receptor responder (tazarotene 
induced) 2 
5919 -4.23 
TAGLN transgelin 6876 -4.29 
MEIS2 Meis1, myeloid ecotropic viral integration 
site 1 homolog 2 (mouse) 
4212 -4.29 
GPX3 glutathione peroxidase 3 (plasma) 2878 -4.32 
S100A16 S100 calcium binding protein A16 140576 -4.35 
PENK proenkephalin 5179 -4.35 
SLITRK6 SLIT and NTRK-like family, member 6 84189 -4.38 
COL27A1 collagen, type XXVII, alpha 1 85301 -4.38 
GJA1 gap junction protein, alpha 1, 43kDa 
(connexin 43) 
2697 -4.41 
CHST2 carbohydrate (N-acetylglucosamine-6-O) 
sulfotransferase 2 
9435 -4.41 
LOC390940 similar to R28379_1 390940 -4.44 
LOC255480 hypothetical protein LOC255480 255480 -4.44 
LRP4 low density lipoprotein receptor-related 
protein 4 
4038 -4.44 
SERPINF1 serpin peptidase inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium derived 
factor), member 1 
5176 -4.44 
IHPK3 inositol hexaphosphate kinase 3 117283 -4.44 
CSRP2 cysteine and glycine-rich protein 2 1466 -4.50 
EMILIN3 elastin microfibril interfacer 3 90187 -4.53 
ZNF662 zinc finger protein 662 389114 -4.53 
LRRN3 leucine rich repeat neuronal 3 54674 -4.56 
DEPDC7 DEP domain containing 7 91614 -4.56 
ASPA aspartoacylase (Canavan disease) 443 -4.59 
RP11-
393H10.2 
hypothetical protein FLJ14503 256714 -4.59 
FAIM2 Fas apoptotic inhibitory molecule 2 23017 -4.63 
SLC16A5 solute carrier family 16, member 5 
(monocarboxylic acid transporter 6) 
9121 -4.63 
ALDH1A2 aldehyde dehydrogenase 1 family, member 
A2 
8854 -4.63 
LCN2 lipocalin 2 (oncogene 24p3) 3934 -4.63 
JPH2 junctophilin 2 57158 -4.66 
CLU clusterin 1191 -4.66 
ZNF204 zinc finger protein 204 7754 -4.66 
COL13A1 collagen, type XIII, alpha 1 1305 -4.66 





FLJ10781 hypothetical protein FLJ10781 55228 -4.69 
PLCL1 phospholipase C-like 1 5334 -4.76 
SCRG1 scrapie responsive protein 1 11341 -4.76 
FGFR2 fibroblast growth factor receptor 2 
(bacteria-expressed kinase, keratinocyte 
growth factor receptor, craniofacial 
dysostosis 1, Crouzon syndrome, Pfeiffer 
syndrome, Jackson-Weiss syndrome) 
2263 -4.79 
KCNJ8 potassium inwardly-rectifying channel, 
subfamily J, member 8 
3764 -4.79 
ANGPTL1 angiopoietin-like 1 9068 -4.79 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) 
polypeptide 
477 -4.82 
LEPREL1 leprecan-like 1 55214 -4.89 







GABRP gamma-aminobutyric acid (GABA) A 
receptor, pi 
2568 -4.89 
KCTD14 potassium channel tetramerisation domain 
containing 14 
65987 -4.92 
MYL9 myosin, light polypeptide 9, regulatory 10398 -4.92 
EFS embryonal Fyn-associated substrate 10278 -4.96 
EDG8 endothelial differentiation, sphingolipid G-
protein-coupled receptor, 8 
53637 -4.96 
D4S234E DNA segment on chromosome 4 (unique) 
234 expressed sequence 
27065 -4.96 
CXCL1 chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating activity, 
alpha) 
2919 -4.96 
FAM19A1 family with sequence similarity 19 
(chemokine (C-C motif)-like), member A1 
407738 -4.96 
KRT17 keratin 17 3872 -4.99 
CXorf57 chromosome X open reading frame 57 55086 -4.99 
PIGR polymeric immunoglobulin receptor 5284 -5.03 
MAGED4 melanoma antigen family D, 4 /// 
melanoma antigen family D, 4 /// similar to 
melanoma antigen family D, 4 isoform 1 /// 
similar to melanoma antigen family D, 4 
isoform 1 
81557 -5.06 
TNC tenascin C (hexabrachion) 3371 -5.10 
IGSF1 immunoglobulin superfamily, member 1 3547 -5.10 
ROR2 receptor tyrosine kinase-like orphan 
receptor 2 
4920 -5.10 
CP ceruloplasmin (ferroxidase) 1356 -5.10 
TGFB3 transforming growth factor, beta 3 7043 -5.17 
POPDC2 popeye domain containing 2 64091 -5.21 
PLN phospholamban 5350 -5.21 






ELMOD1 ELMO/CED-12 domain containing 1 55531 -5.31 
ATP8B4 ATPase, Class I, type 8B, member 4 79895 -5.35 
COL4A6 collagen, type IV, alpha 6 1288 -5.35 
PAGE4 P antigen family, member 4 (prostate 
associated) 
9506 -5.35 
NTN4 netrin 4 59277 -5.39 
C9orf125 chromosome 9 open reading frame 125 /// 
chromosome 9 open reading frame 125 
84302 -5.50 
CITED1 Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 1 
4435 -5.58 
KCNMB1 potassium large conductance calcium-
activated channel, subfamily M, beta 
member 1 
3779 -5.58 
LOC284837 hypothetical protein LOC284837 284837 -5.66 
CHI3L2 chitinase 3-like 2 /// chitinase 3-like 2 1117 -5.70 
PTCHD1 patched domain containing 1 139411 -5.70 
FLRT3 fibronectin leucine rich transmembrane 
protein 3 
23767 -5.74 
TRIM29 tripartite motif-containing 29 23650 -5.78 
PPARGC1A peroxisome proliferative activated receptor, 
gamma, coactivator 1, alpha 
10891 -5.86 
IQCA IQ motif containing with AAA domain 79781 -5.86 
DPYS dihydropyrimidinase 1807 -5.94 
SMOC1 SPARC related modular calcium binding 1 64093 -5.98 
MGC13057 hypothetical protein MGC13057 84281 -6.11 
ANKRD38 ankyrin repeat domain 38 163782 -6.15 
NELL2 NEL-like 2 (chicken) /// NEL-like 2 
(chicken) 
4753 -6.32 
ABCC3 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 3 
8714 -6.36 
SMARCD3 SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, 
subfamily d, member 3 
6604 -6.45 
CXCL6 chemokine (C-X-C motif) ligand 6 
(granulocyte chemotactic protein 2) 
6372 -6.50 
SERPINB5 serpin peptidase inhibitor, clade B 
(ovalbumin), member 5 
5268 -6.59 
CPXM carboxypeptidase X (M14 family), member 
1 
56265 -6.59 
SP8 Sp8 transcription factor 221833 -6.59 
CFC1 cripto, FRL-1, cryptic family 1 /// similar to 
cryptic 
55997 -6.68 
WNK4 WNK lysine deficient protein kinase 4 65266 -6.92 
DMKN dermokine 93099 -7.06 
FBLN1 fibulin 1 2192 -7.16 
ORM2 orosomucoid 1 /// orosomucoid 2 5005 -7.21 
LSAMP limbic system-associated membrane protein 4045 -7.26 
CPA6 carboxypeptidase A6 57094 -7.46 





COL9A1 collagen, type IX, alpha 1 1297 -7.78 
SV2B synaptic vesicle glycoprotein 2B 9899 -7.84 
SRD5A2 steroid-5-alpha-reductase, alpha 
polypeptide 2 (3-oxo-5 alpha-steroid delta 
4-dehydrogenase alpha 2) 
6716 -7.84 
SCGB1A1 secretoglobin, family 1A, member 1 
(uteroglobin) 
7356 -7.89 
ITGB6 clone LNG06541, highly similar to IR200 3694 -8.11 
RNF165 ring finger protein 165 494470 -8.22 
GATA3 GATA binding protein 3 2625 -8.28 
GPR87 G protein-coupled receptor 87 53836 -8.34 
KRT222P keratin 222 pseudogene 125113 -8.82 
CDH3 cadherin 3, type 1, P-cadherin (placental) 1001 -9.06 
SLITRK5 SLIT and NTRK-like family, member 5 26050 -9.25 
BCL11A B-cell CLL/lymphoma 11A (zinc finger 
protein) 
53335 -9.45 
FZD10 frizzled homolog 10 (Drosophila) 11211 -9.58 
WFDC2 WAP four-disulfide core domain 2 10406 -9.78 
LIX1 Lix1 homolog (mouse) 167410 -9.85 
VILL villin-like 50853 -9.92 
LAMB3 laminin, beta 3 3914 -9.99 
KCNJ15 potassium inwardly-rectifying channel, 
subfamily J, member 15 
3772 -10.13 
CCK cholecystokinin 885 -10.78 
CAPN6 calpain 6 827 -10.93 
H19 H19, imprinted maternally expressed 
untranslated mRNA 
283120 -11.24 
CHST9 carbohydrate (N-acetylgalactosamine 4-0) 
sulfotransferase 9 
83539 -11.39 
NEFH neurofilament, heavy polypeptide 200kDa 4744 -11.88 
BEX1 brain expressed, X-linked 1 55859 -12.04 
LOC572558 hypothetical locus LOC572558 572558 -12.13 
MMP7 matrix metallopeptidase 7 (matrilysin, 
uterine) 
4316 -12.13 
KRT23 keratin 23 (histone deacetylase inducible) 25984 -12.38 
DUOX1 dual oxidase 1 53905 -13.18 
RNF128 ring finger protein 128 79589 -13.45 




SLC2A5 solute carrier family 2 (facilitated 




KIAA1210 protein 57481 -17.75 
LOC92196 similar to death-associated protein 92196 -19.16 
NEFL neurofilament, light polypeptide 68kDa 4747 -19.16 
SOX2 SRY (sex determining region Y)-box 2 6657 -19.56 
SCUBE2 signal peptide, CUB domain, EGF-like 2 57758 -20.25 







CYP4B1 cytochrome P450, family 4, subfamily B, 
polypeptide 1 
1580 -22.47 
CXCL13 chemokine (C-X-C motif) ligand 13 (B-cell 
chemoattractant) 
10563 -25.11 
EDN3 endothelin 3 1908 -25.63 
CYP3A5 cytochrome P450, family 3, subfamily A, 
polypeptide 5 
1577 -25.81 
ABP1 amiloride binding protein 1 (amine oxidase 
(copper-containing)) 
26 -27.86 
KRT15 keratin 15 3866 -32.90 
TP73L tumor protein p73-like 8626 -33.36 
SLC14A1 solute carrier family 14 (urea transporter), 
member 1 (Kidd blood group) 
6563 -34.30 
WIF1 WNT inhibitory factor 1 11197 -36.76 
























Adenocarcinoma  Pathological T staging
 T2a to T2c 40 28 12 0.225 
  100.0 70.0% 30.0%  
 T3a to T3c 33 18 15  
  100.0 54.5% 45.5%  
 Total 73    
      
 Extraprostatic extension 
 Yes 33 18 15 0.225 
  100.0 54.5% 45.5%  
 No 40 28 12  
  100.0 70.0% 30.0%  
 Total 73    
      
 Seminal vesicle involvement 
 Involved 7 2 5 0.090 
  100.0 28.6% 71.4%  
 Uninvolved 69 47 22  
  100.0 68.1% 31.9%  
 Total 76    
      
 Pre-operative PSA levels 
 ≤8ng/ml 22 15 7 1.000 
  100.0 68.2% 31.8%  
 >8ng/ml 20 14 6  
  100.0 70.0% 30.0%  
 Total 42    
      
 Lymphovascular invasion 
 Present  16 10 6 0.372 
  100.0 62.5% 37.5%  
 Absent 120 89 31  
  100.0 74.2% 25.8%  
 Total 136    








 Perineural invasion 
 Seen  88 58 30 0.125 
  100.0 65.9% 34.1%  
 Not seen 53 42 11  
  100.0 79.2% 20.8%  
 Total 141    
      
 Circumferential resection margin 
 Involved 35 23 12 1.000 
  100.0 65.7% 34.3%  
 Uninvolved 41 27 14  
  100.0 65.9% 34.1%  
 Total 76    
      
 Apex margin 
 Involved 34 20 14 0.470 
  100.0 58.8% 41.2%  
 Uninvolved 42 29 13  
  100.0 69.0% 31.0%  
 Total 76    
      
 Proximal  margin 
 Involved 9 3 6 0.059 
  100.0 33.3% 66.7%  
 Uninvolved 68 47 21  
  100.0 69.1% 30.9%  
 Total 77    
      
 Clinical stage     
 T1a to T1c 36 26 10 0.676 
  100.0 72.2% 27.8%  
 T3a to T3b 8 5 3  
  100.0 62.5% 37.5%  
 Total 44    
      
 Lobe occurence      
 Both Lobes 64 38 26 0.013 
  100.0 59.4% 40.6%  
 Singles Lobe 11 11 0  
  100.0 100.0% .0%  
 Total 75    
      
 Maximum tumour dimension 
 <2.5cm 39 29 10 0.093 
  100.0 74.4% 25.6%  
 ≥2.5cm 37 20 17  
  100.0 54.1% 45.9%  
 Total 76    





      
 Tumour Volume     
 <4cm3 31 23 8 1.000 
  100.0 74.2% 25.8%  
 ≥4 cm3 29 22 7  
  100.0 75.9% 24.1%  
 Total 60    
      
Peritumoural 
Stroma 
Pathological T staging 
T2a to T2c 39 34 5 0.049 
  100.0 87.2% 12.8%  
 T3a to T3c 33 22 11  
  100.0 66.7% 33.3%  
 Total 72    
      
 Extraprostatic extension 
 Yes 33 22 11 0.049 
  100.0 66.7% 33.3%  
 No 39 34 5  
  100.0 87.2% 12.8%  
 Total 72    
      
 Seminal vesicle involvement 
 Involved 7 3 4 0.034 
  100.0 42.9% 57.1%  
 Uninvolved 68 56 12  
  100.0 82.4% 17.6%  
 Total 75    
      
 Pre-operative PSA levels 
 ≤8ng/ml 21 21 0 0.021 
  100.0 100.0% .0%  
 >8ng/ml 20 15 5  
  100.0 75.0% 25.0%  
 Total 41    
      
 Lymphovascular invasion 
 Present  16 12 4 0.776 
  100.0 75.0% 25.0%  
 Absent 120 83 37  
  100.0 69.2% 30.8%  
 Total 136    










 Perineural invasion 
 Seen  88 58 30 0.125 
  100.0 65.9% 34.1%  
 Not seen 53 42 11  
  100.0 79.2% 20.8%  
 Total 133    
      
 Circumferential resection margin 
 Involved 35 25 10 0.171 
  100.0 71.4% 28.6%  
 Uninvolved 40 34 6  
  100.0 85.0% 15.0%  
 Total 75    
      
 Apex margin     
 Involved 34 24 10 0.160 
  100.0 70.6% 29.4%  
 Uninvolved 41 35 6  
  100.0 85.4% 14.6%  
 Total 75    
      
 Proximal  margin 
 Involved 9 7 2 1.000 
  100.0 77.8% 22.2%  
 Uninvolved 67 53 14  
  100.0 79.1% 20.9%  
 Total 76    
      
 Clinical stage     
 T1a to T1c 35 30 5 0.565 
  100.0 85.7% 14.3%  
 T3a to T3b 8 8 0  
  100.0 100.0% .0%  
 Total 43    
      
 Lobe occurence      
 Both Lobes 63 49 14 1.000 
  100.0 77.8% 22.2%  
 Singles Lobe 11 9 2  
  100.0 81.8% 18.2%  
 Total 74    
      
 Maximum tumour dimension 
 <2.5cm 38 32 6 0.271 
  100.0 84.2% 15.8%  
 ≥2.5cm 37 27 10  
  100.0 73.0% 27.0%  
 Total 75    





 Tumour Volume     
 <4cm3 31 27 4 0.204 
  100.0 87.1% 12.9%  
 ≥4 cm3 29 21 8  
  100.0 72.4% 27.6%  






Section 1B  Association of percentage of cells positively stained for non-

















Adenocarcinoma  Pathological T staging
 T2a to T2c 40 30 10 0.050 
  100.0% 75.0% 25.0%  
 T3a to T3c 33 17 16  
  100.0% 51.5% 48.5%  
 Total 73    
      
 Extraprostatic extension 
 Yes 33 17 16 0.050 
  100.0% 51.5% 48.5%  
 No 40 30 10  
  100.0% 75.0% 25.0%  
 Total 73    
      
 Seminal vesicle involvement 
 Involved 7 3 4 0.238 
  100.0% 42.9% 57.1%  
 Uninvolved 69 46 23  
  100.0% 66.7% 33.3%  
 Total 139    
      
 Pre-operative PSA levels 
 ≤8ng/ml 22 10 12 0.758 
  100.0% 45.5% 54.5%  
 >8ng/ml 20 11 9  
  100.0% 55.0% 45.0%  
 Total 42    
      
 Lymphovascular invasion 
 Present  16 10 6 0.365 
  100.0% 62.5% 37.5%  
 Absent 120 90 30  
  100.0% 75.0% 25.0%  
 Total 136    









 Perineural invasion 
 Seen  88 64 24 1.000 
  100.0% 72.7% 27.3%  
 Not seen 53 38 15  
  100.0% 71.7% 28.3%  
 Total 133    
      
 Circumferential resection margin 
 Involved 35 23 12 1.000 
  100.0% 65.7% 34.3%  
 Uninvolved 41 27 14  
  100.0% 65.9% 34.1%  
 Total 76    
      
 Apex margin     
 Involved 34 22 12 1.000 
  100.0% 64.7% 35.3%  
 Uninvolved 42 27 15  
  100.0% 64.3% 35.7%  
 Total 76    
      
 Proximal  margin 
 Involved 9 4 5 0.264 
  100.0% 44.4% 55.6%  
 Uninvolved 68 46 22  
  100.0% 67.6% 32.4%  
 Total 77    
      
 Clinical stage     
 T1a to T1c 36 18 18 0.701 
  100.0% 50.0% 50.0%  
 T3a to T3b 8 5 3  
  100.0% 62.5% 37.5%  
 Total 44    
      
 Lobe occurence      
 Both Lobes 64 41 23 0738 
  100.0% 64.1% 35.9%  
 Singles Lobe 11 8 3  
  100.0% 72.7% 27.3%  
 Total 75    
      
 Maximum tumour dimension 
 <2.5cm 39 27 12 0.473 
  100.0% 69.2% 30.8%  
 ≥2.5cm 37 22 15  
  100.0% 59.5% 40.5%  
 Total 76    





 Tumour Volume     
 <4cm3 31 23 8 0.408 
  100.0% 74.2% 25.8%  
 ≥4 cm3 29 18 11  
  100.0% 62.1% 37.9%  
 Total 60    
      
Peritumoural 
Stroma 
Pathological T staging 
T2a to T2c 39 31 8 0.188 
  100.0% 79.5% 20.5%  
 T3a to T3c 33 21 12  
  100.0% 63.6% 36.4%  
 Total 72    
      
 Extraprostatic extension 
 Yes 33 21 12 0.188 
  100.0% 63.6% 36.4%  
 No 39 31 8  
  100.0% 79.5% 20.5%  
 Total 72    
      
 Seminal vesicle involvement 
 Involved 7 3 4 0.077 
  100.0% 42.9% 57.1%  
 Uninvolved 68 52 16  
  100.0% 76.5% 23.5%  
 Total 75    
      
 Pre-operative PSA levels 
 ≤8ng/ml 21 20 1 0.184 
  100.0% 95.2% 4.8%  
 >8ng/ml 20 16 4  
  100.0% 80.0% 20.0%  
 Total 41    
      
 Lymphovascular invasion 
 Present  16 9 7 0.582 
  100.0% 56.3% 43.8%  
 Absent 120 78 42  
  100.0% 65.0% 35.0%  
 Total 136    
      
 Perineural invasion     
 Seen  88 57 31 1.000 
  100.0% 64.8% 35.2%  
 Not seen 53 35 18  
  100.0% 66.0% 34.0%  
 Total 141    





 Circumferential     
 Involved 35 26 9 1.000 
  100.0% 74.3% 25.7%  
 Uninvolved 40 30 10  
  100.0% 75.0% 25.0%  
 Total 75    
      
 Apex margin     
 Involved 34 26 8 0.611 
  100.0% 76.5% 23.5%  
 Uninvolved 41 29 12  
  100.0% 70.7% 29.3%  
 Total 75    
      
 Proximal  margin 
 Involved 9 7 2 1.000 
  100.0% 77.8% 22.2%  
 Uninvolved 67 49 18  
  100.0% 73.1% 26.9%  
 Total 76    
      
 Clinical stage     
 T1a to T1c 35 31 4 0.308 
  100.0% 88.6% 11.4%  
 T3a to T3b 8 6 2  
  100.0% 75.0% 25.0%  
 Total 43    
      
 Lobe occurence      
 Both Lobes 63 46 17 1.000 
  100.0% 73.0% 27.0%  
 Singles Lobe 11 8 3  
  100.0% 72.7% 27.3%  
 Total 74    
      
 Maximum tumour dimension 
 <2.5cm 38 27 11 0.795 
  100.0% 71.1% 28.9%  
 ≥2.5cm 37 28 9  
  100.0% 75.7% 24.3%  
 Total 75    
      
 Tumour Volume     
 <4cm3 31 24 7 0.769 
  100.0% 77.4% 22.6%  
 ≥4 cm3 29 21 8  
  100.0% 72.4% 27.6%  






















Adenocarcinoma  Pathological T staging
 T2a to T2c 38 34 4 0.041 
  100.0% 89.5% 10.5%  
 T3a to T3c 35 24 11  
  100.0% 68.6% 31.4%  
 Total 73    
      
 Extraprostatic extension 
 Yes 35 24 11 0.041 
  100.0% (68.6%) (31.4%)  
 No 38 34 4  
  100.0% (89.5%) (10.5%)  
 Total 73    
      
 Seminal vesicle involvement 
 Involved 8 5 3 0.188 
  100.0% 62.5% 37.5%  
 Uninvolved 68 56 12  
  100.0% 82.4% 17.6%  
 Total 76    
      
 Pre-operative PSA levels 
 ≤8ng/ml 21 16 5 0.697 
  100.0% 76.2% 23.8%  
 >8ng/ml 21 18 3  
  100.0% 85.7% 14.3%  
 Total 42    
      
 Lymphovascular invasion 
 Present  17 15 2 0.681 
  100.0% 88.2% 11.8%  
 Absent 122 110 12  
  100.0% 90.2% 9.8%  
 Total 139    
      
      
      
      
      





 Perineural invasion     
 Seen  90 75 15 0.001 
  100.0% 83.3% 16.7%  
 Not seen 54 54 0  
  100.0% 100.0% .0%  
 Total 144    
      
 Circumferential resection margin 
 Involved 35 27 8 0.574 
  100.0% 77.1% 22.9%  
 Uninvolved 41 34 7  
  100.0% 82.9% 17.1%  
 Total 76    
      
 Apex margin     
 Involved 35 29 6 1.000 
  100.0% 82.9% 17.1%  
 Uninvolved 41 33 8  
  100.0% 80.5% 19.5%  
 Total 76    
      
 Proximal  margin     
 Involved 9 7 2 1.000 
  100.0% 77.8% 22.2%  
 Uninvolved 68 55 13  
  100.0% 80.9% 19.1%  
 Total 77    
      
 Clinical stage     
 T1a to T1c 36 32 4 0.015 
  100.0% 88.9% 11.1%  
 T3a to T3b 7 3 4  
  100.0% 42.9% 57.1%  
 Total 43    
      
 Lobe occurence      
 Both Lobes 65 52 13 0.677 
  100.0% 80.0% 20.0%  
 Singles Lobe 10 9 1  
  100.0% 90.0% 10.0%  
 Total 75    
      
 Maximum tumour dimension 
 <2.5cm 38 32 6 0.565 
  100.0% 84.2% 15.8%  
 ≥2.5cm 38 29 9  
  100.0% 76.3% 23.7%  
 Total 76    





 Tumour Volume     
 <4cm3 29 23 6 0.748 
  100.0% 79.3% 20.7%  
 ≥4 cm3 30 25 5  
  100.0% 83.3% 16.7%  
 Total 59    
      
Peritumoural 
Stroma 
Pathological T staging 
T2a to T2c 38 31 7 0.574 
  100.0% 81.6% 18.4%  
 T3a to T3c 35 26 9  
  100.0% 74.3% 25.7%  
 Total 73    
      
 Extraprostatic extension 
 Yes 35 26 9 0.574 
  100.0% 74.3% 25.7%  
 No 38 31 7  
  100.0% 81.6% 18.4%  
 Total 73    
      
 Seminal vesicle involvement 
 Involved 8 5  3  0.354 
  100.0% 62.5% 37.5%  
 Uninvolved 68 55  13   
  100.0% 80.9% 19.1%  
 Total 76    
      
 Pre-operative PSA levels 
 ≤8ng/ml 21 18 3 1.000 
  100.0% 85.7% 14.3%  
 >8ng/ml 21 18 3  
  100.0% 85.7% 14.3%  
 Total 42    
      
 Lymphovascular invasion 
 Present  17 10 7 0.402 
  100.0% 58.8% 41.2%  
 Absent 122 86 36  
  100.0% 70.5% 29.5%  
 Total 139    
      
 Perineural invasion     
 Seen  90 62 28 1.000 
  100.0% 68.9% 31.1%  
 Not seen 54 38 16  
  100.0% 70.4% 29.6%  
 Total 144    





 Circumferential resection margin 
 Involved 35 26 9 0.407 
  100.0% 74.3% 25.7%  
 Uninvolved 41 34 7  
  100.0% 82.9% 17.1%  
 Total 76    
      
 Apex margin     
 Involved 35 25 10 0.166 
  100.0% 71.4% 28.6%  
 Uninvolved 41 35 6  
  100.0% 85.4% 14.6%  
 Total 76    
      
 Proximal  margin 
 Involved 9 8 1 0.675 
  100.0% 88.9% 11.1%  
 Uninvolved 68 53 15  
  100.0% 77.9% 22.1%  
 Total 77    
      
 Clinical stage     
 T1a to T1c 36 30 6 0.567 
  100.0% 83.3% 16.7%  
 T3a to T3b 7 7 0  
  100.0% 100.0% .0%  
 Total 43    
      
 Lobe occurence      
 Both Lobes 65 50 15 0.679 
  100.0% 76.9% 23.1%  
 Singles Lobe 10 9 1  
  100.0% 90.0% 10.0%  
 Total 75    
      
 Maximum tumour dimension 
 <2.5cm 38 33 5 0.158 
  100.0% 86.8% 13.2%  
 ≥2.5cm 38 27 11  
  100.0% 71.1% 28.9%  
 Total 76    
      
 Tumour Volume     
 <4cm3 29 25 4 0.506 
  100.0% 86.2% 13.8%  
 ≥4 cm3 30 23 7  
  100.0% 76.7% 23.3%  





Section 2B  Association of percentage of cells positively stained for 

















Adenocarcinoma  Pathological T staging
 T2a to T2c 38 30 8 0.076 
  100.0% 78.9% 21.1%  
 T3a to T3c 35 20 15  
  100.0% 57.1% 42.9%  
 Total 73    
      
 Extraprostatic extension 
 Yes 35 20 15 0.076 
  100.0% 57.1% 42.9%  
 No 38 30 8  
  100.0% 78.9% 21.1%  
 Total     
  73    
 Seminal vesicle involvement 
 Involved 8 3 5 0.050 
  100.0% 37.5% 62.5%  
 Uninvolved 68 50 18  
  100.0% 73.5% 26.5%  
 Total 76    
      
 Pre-operative PSA levels 
 ≤8ng/ml 21 13 8 0.505 
  100.0% 61.9% 38.1%  
 >8ng/ml 21 16 5  
  100.0% 76.2% 23.8%  
 Total 42    
      
 Lymphovascular invasion 
 Present  17 11 6 0.024 
  100.0% 64.7% 35.3%  
 Absent 122 107 15  
  100.0% 87.7% 12.3%  
 Total 139    
      
      
      
      





 Perineural invasion     
 Seen  90 71 19 0.035 
  100.0% 78.9% 21.1%  
 Not seen 54 50 4  
  100.0% 92.6% 7.4%  
 Total 144    
      
 Circumferential resection margin 
 Involved 35 24 11 0.800 
  100.0% 68.6% 31.4%  
 Uninvolved 41 30 11  
  100.0% 73.2% 26.8%  
 Total 76    
      
 Apex margin     
 Involved 35 25 10 0.807 
  100.0% 71.4% 28.6%  
 Uninvolved 41 28 13  
  100.0% 68.3% 31.7%  
 Total 76    
      
 Proximal  margin     
 Involved 9 6 3 1.000 
  100.0% 66.7% 33.3%  
 Uninvolved 68 48 20  
  100.0% 70.6% 29.4%  
 Total 77    
      
 Clinical stage     
 T1a to T1c 36 27 9 0.172 
  100.0% 75.0% 25.0%  
 T3a to T3b 7 3 4  
  100.0% 42.9% 57.1%  
 Total 43    
      
 Lobe occurence      
 Both Lobes 65 47 18 0.467 
  100.0% 72.3% 27.7%  
 Singles Lobe 10 6 4  
  100.0% 60.0% 40.0%  
 Total 75    
      
 Maximum tumour dimension 
 <2.5cm 38 26 12 1.000 
  100.0% 68.4% 31.6%  
 ≥2.5cm 38 27 11  
  100.0% 71.1% 28.9%  
 Total 76    





 Tumour Volume     
 <4cm3 29 20 9 0.567 
  100.0% 69.0% 31.0%  
 ≥4 cm3 30 23 7  
  100.0% 76.7% 23.3%  
 Total 59    
      
Peritumoural 
Stroma 
Pathological T staging 
T2a to T2c 38 12 26 0.804 
  100.0% 31.6% 68.4%  
 T3a to T3c 35 10 25  
  100.0% 28.6% 71.4%  
 Total 73    
      
 Extraprostatic extension 
 Yes 35 10 25 0.804 
  100.0% 28.6% 71.4%  
 No 38 12 26  
  100.0% 31.6% 68.4%  
 Total 73    
      
 Seminal vesicle involvement 
 Involved 8 1 7 0.423 
  100.0% 12.5% 87.5%  
 Uninvolved 68 23 45  
  100.0% 33.8% 66.2%  
 Total 76    
      
 Pre-operative PSA levels 
 ≤8ng/ml 21 9 12 1.000 
  100.0% 42.9% 57.1%  
 >8ng/ml 21 8 13  
  100.0% 38.1% 61.9%  
 Total 42    
      
 Lymphovascular invasion 
 Present  17 6 11 0.128 
  100.0% 35.3% 64.7%  
 Absent 122 68 54  
  100.0% 55.7% 44.3%  
 Total 139    
      
 Perineural invasion     
 Seen  90 40 50 0.025 
  100.0% 44.4% 55.6%  
 Not seen 54 35 19  
  100.0% 64.8% 35.2%  
 Total 144    





 Circumferential resection margin 
 Involved 35 9 26 0.234 
  100.0% 25.7% 74.3%  
 Uninvolved 41 16 25  
  100.0% 39.0% 61.0%  
 Total 76    
      
 Apex margin     
 Involved 35 12 23 1.000
  100.0% 34.3% 65.7%  
 Uninvolved 41 13 28  
  100.0% 31.7% 68.3%  
 Total 76    
      
 Proximal  margin     
 Involved 9 2 7 0.710 
  100.0% 22.2% 77.8%  
 Uninvolved 68 23 45  
  100.0% 33.8% 66.2%  
 Total 77    
      
 Clinical stage     
 T1a to T1c 36 14 22 1.000 
  100.0% 38.9% 61.1%  
 T3a to T3b 7 3 4  
  100.0% 42.9% 57.1%  
 Total 43    
      
 Lobe occurence      
 Both Lobes 65 19 46 0.484 
  100.0% 29.2% 70.8%  
 Singles Lobe 10 4 6  
  100.0% 40.0% 60.0%  
 Total 75    
      
 Maximum tumour dimension 
 <2.5cm 38 16 22 0.083 
  100.0% 42.1% 57.9%  
 ≥2.5cm 38 8 30  
  100.0% 21.1% 78.9%  
 Total 76    
      
 Tumour Volume     
 <4cm3 29 13 16 0.288 
  100.0% 44.8% 55.2%  
 ≥4 cm3 30 9 21  
  100.0% 30.0% 70.0%  






















Adenocarcinoma  Pathological T staging  
 T2a to T2c 36 34 2 1.000 
  100.0% 94.4% 5.6%  
 T3a to T3c 34 33 1  
  100.0% 97.1% 2.9%  
 Total 70    
      
 Extraprostatic extension    
 Yes 34 33 1 1.000 
  100.0% 97.1% 2.9%  
 No 36 34 2  
  100.0% 94.4% 5.6%  
 Total 70    
      
 Seminal vesicle involvement    
 Involved 7 7 0 1.000 
  100.0% 100.0% .0%  
 Uninvolved 66 63 3  
  100.0% 95.5% 4.5%  
 Total 73    
      
 Pre-operative PSA levels    
 ≤8ng/ml 21 20 1 1.000 
  100.0% 95.2% 4.8%  
 >8ng/ml 20 19 1  
  100.0% 95.0% 5.0%  
 Total 41    
      
 Lymphovascular invasion   
 Present  16 16 0 0.211 
  100.0% 100.0% .0%  
 Absent 106 92 14  
  100.0% 86.8% 13.2%  
 Total 122    
      
      
      
      
      





 Perineural invasion     
 Seen  82 77 5 0.034 
  100.0% 93.9% 6.1%  
 Not seen 45 36 9  
  100.0% 80.0% 20.0%  
 Total 127    
      
 Circumferential resection margin   
 Involved 32 30 2 0.581 
  100.0% 93.8% 6.3%  
 Uninvolved 40 39 1  
  100.0% 97.5% 2.5%  
 Total 72    
      
 Apex margin     
 Involved 34 31 3 0.100 
  100.0% 91.2% 8.8%  
 Uninvolved 38 38 0  
  100.0% 100.0% .0%  
 Total 72    
      
 Proximal  margin     
 Involved 9 8 1 0.330 
  100.0% 88.9% 11.1%  
 Uninvolved 64 62 2  
  100.0% 96.9% 3.1%  
 Total 73    
      
 Clinical stage     
 T1a to T1c 34 32 2 1.000 
  100.0% 94.1% 5.9%  
 T3a to T3b 8 8 0  
  100.0% 100.0% .0%  
 Total 42    
      
 Lobe occurence      
 Both Lobes 61 59 2 0.370 
  100.0% 96.7% 3.3%  
 Singles Lobe 10 9 1  
  100.0% 90.0% 10.0%  
 Total 71    
      
 Maximum tumour dimension   
 <2.5cm 34 32 2 0.599 
  100.0% 94.1% 5.9%  
 ≥2.5cm 38 37 1  
  100.0% 97.4% 2.6%  
 Total 72    





 Tumour Volume     
 <4cm3 27 26 1 0.482 
  100.0% 96.3% 3.7%  
 ≥4 cm3 29 29 0  
  100.0% 100.0% .0%  
 Total 56    
      
Peritumoural 
Stroma 
Pathological T staging   
T2a to T2c 35 31 4 1.000 
  100.0% 88.6% 11.4%  
 T3a to T3c 34 30 4  
  100.0% 88.2% 11.8%  
 Total 69    
      
 Extraprostatic extension   
 Yes 34 30 4 1.000 
  100.0% 88.2% 11.8%  
 No 35 31 4  
  100.0% 88.6% 11.4%  
 Total 69    
      
 Seminal vesicle involvement   
 Involved 7 7 0 1.000 
  100.0% 100.0% .0%  
 Uninvolved 65 57 8  
  100.0% 87.7% 12.3%  
 Total 135    
      
 Pre-operative PSA levels   
 ≤8ng/ml 20 19 1 0.605 
  100.0% 95.0% 5.0%  
 >8ng/ml 20 17 3  
  100.0% 85.0% 15.0%  
 Total 40    
      
 Lymphovascular invasion   
 Present  16 11 5 0.590 
  100.0% 68.8% 31.3%  
 Absent 105 63 42  
  100.0% 60.0% 40.0%  
 Total 121    
      
 Perineural invasion     
 Seen  82 58 24 0.007 
  100.0% 70.7% 29.3%  
 Not seen 44 20 24  
  100.0% 45.5% 54.5%  
 Total 126    





 Circumferential resection margin   
 Involved 32 30 2 0.281 
  100.0% 93.8% 6.3%  
 Uninvolved 39 33 6  
  100.0% 84.6% 15.4%  
 Total 71    
      
 Apex margin     
 Involved 34 30 4 1.000 
  100.0% 88.2% 11.8%  
 Uninvolved 37 33 4  
  100.0% 89.2% 10.8%  
 Total 71    
      
 Proximal  margin     
 Involved 9 9 0 0.584 
  100.0% 100.0% .0%  
 Uninvolved 63 55 8  
  100.0% 87.3% 12.7%  
 Total 72    
      
 Clinical stage     
 T1a to T1c 33 30 3 1.000 
  100.0% 90.9% 9.1%  
 T3a to T3b 8 7 1  
  100.0% 87.5% 12.5%  
 Total 41    
      
 Lobe occurence      
 Both Lobes 60 53 7 1.000 
  100.0% 88.3% 11.7%  
 Singles Lobe 10 9 1  
  100.0% 90.0% 10.0%  
 Total 70    
      
 Maximum tumour dimension    
 <2.5cm 33 28 5 0.459 
  100.0% 84.8% 15.2%  
 ≥2.5cm 38 35 3  
  100.0% 92.1% 7.9%  
 Total 72    
      
 Tumour Volume     
 <4cm3 27 25 2 0.671 
  100.0% 92.6% 7.4%  
 ≥4 cm3 29 25 4  
  100.0% 86.2% 13.8%  






Section 3B Association of percentage of cells with positive chondroitin-6-

















Adenocarcinoma  Pathological T staging  
 T2a to T2c 36 11 25 0.794 
  100.0% 30.6% 69.4%  
 T3a to T3c 34 9 25  
  100.0% 26.5% 73.5%  
 Total 70    
      
 Extraprostatic extension  
 Yes 34 9 25 0.794 
  100.0% 26.5% 73.5%  
 No 36 11 25  
  100.0% 30.6% 69.4%  
 Total 70    
      
 Seminal vesicle involvement  
 Involved 7 3 4 0.671 
  100.0% 42.9% 57.1%  
 Uninvolved 66 20 46  
  100.0% 30.3% 69.7%  
 Total 73    
      
 Pre-operative PSA levels  
 ≤8ng/ml 21 7 14 1.000 
  100.0% 33.3% 66.7%  
 >8ng/ml 20 7 13  
  100.0% 35.0% 65.0%  
 Total 41    
      
 Lymphovascular invasion  
 Present  16 9 7 1.000 
  100.0% 56.3% 43.8%  
 Absent 106 62 44  
  100.0% 58.5% 41.5%  
 Total 116    
      
      
      
      





 Perineural invasion  
 Seen  82 42 40 0.134 
  100.0% 51.2% 48.8%  
 Not seen 45 30 15  
  100.0% 66.7% 33.3%  
 Total 127    
      
 Circumferential resection margin 
 Involved 32 12 20 0.448 
  100.0% 37.5% 62.5%  
 Uninvolved 40 11 29  
  100.0% 27.5% 72.5%  
 Total 72    
      
 Apex margin     
 Involved 34 7 27 0.124 
  100.0% 20.6% 79.4%  
 Uninvolved 38 15 23  
  100.0% 39.5% 60.5%  
 Total 72    
      
 Proximal  margin     
 Involved 9 3 6 1.000 
  100.0% 33.3% 66.7%  
 Uninvolved 64 20 44  
  100.0% 31.3% 68.8%  
 Total 73    
      
 Clinical stage     
 T1a to T1c 34 12 22 0.697 
  100.0% 35.3% 64.7%  
 T3a to T3b 8 2 6  
  100.0% 25.0% 75.0%  
 Total 42    
      
 Lobe occurence      
 Both Lobes 61 19 42 1.000 
  100.0% 31.1% 68.9%  
 Singles Lobe 10 3 7  
  100.0% 30.0% 70.0%  
 Total 71    
      
 Maximum tumour dimension  
 <2.5cm 34 9 25 0.610 
  100.0% 26.5% 73.5%  
 ≥2.5cm 38 13 25  
  100.0% 34.2% 65.8%  
 Total 72    





 Tumour Volume  
 <4cm3 27 8 19 0.580 
  100.0% 29.6% 70.4%  
 ≥4 cm3 29 11 18  
  100.0% 37.9% 62.1%  
 Total 56    
      
Peritumoural 
Stroma 
Pathological T staging 
T2a to T2c 35 22  13  0.004 
  100.0% 62.9% 37.1%  
 T3a to T3c 34 9  25   
  100.0% 26.5% 73.5%  
 Total 69    
      
 Extraprostatic extension 
 Yes 34 9  25  0.004 
  100.0% 26.5% 73.5%  
 No 35 22  13   
  100.0% 62.9% 37.1%  
 Total 69    
      
 Seminal vesicle involvement  
 Involved 7 2 5 0.442 
  100.0% 28.6% 71.4%  
 Uninvolved 65 31 34  
  100.0% 47.7% 52.3%  
 Total 72    
      
 Pre-operative PSA levels   
 ≤8ng/ml 20 10 10 0.751 
  100.0% 50.0% 50.0%  
 >8ng/ml 20 8 12  
  100.0% 40.0% 60.0%  
 Total 40    
      
 Lymphovascular invasion  
 Present  16 6 10 1.000 
  100.0% 37.5% 62.5%  
 Absent 105 41 64  
  100.0% 39.0% 61.0%  
 Total 121    
      
 Perineural invasion     
 Seen  82 30 52 0.184 
  100.0% 36.6% 63.4%  
 Not seen 44 22 22  
  100.0% 50.0% 50.0%  
 Total 126    





 Circumferential resection margin
 Involved 32 11 21 0.094 
  100.0% 34.4% 65.6%  
 Uninvolved 39 22 17  
  100.0% 56.4% 43.6%  
 Total 71    
      
 Apex margin     
 Involved 34 14 20 0.635 
  100.0% 41.2% 58.8%  
 Uninvolved 37 18 19  
  100.0% 48.6% 51.4%  
 Total 71    
      
 Proximal  margin     
 Involved 9 2 7 0.166 
  100.0% 22.2% 77.8%  
 Uninvolved 63 31 32  
  100.0% 49.2% 50.8%  
 Total 72    
      
 Clinical stage     
 T1a to T1c 33 17 16 0.059 
  100.0% 51.5% 48.5%  
 T3a to T3b 8 1 7  
  100.0% 12.5% 87.5%  
 Total 41    
      
 Lobe occurence      
 Both Lobes 60 27 33 1.000 
  100.0% 45.0% 55.0%  
 Singles Lobe 10 6 4  
  100.0% 60.0% 40.0%  
 Total 70    
      
 Maximum tumour dimension  
 <2.5cm 33 17 16 0.480 
  100.0% 51.5% 48.5%  
 ≥2.5cm 38 16 22  
  100.0% 42.1% 57.9%  
 Total 71    
      
 Tumour volume     
 <4cm3 27 17 10 0.119 
  100.0% 63.0% 37.0%  
 ≥4 cm3 29 12 17  
  100.0% 41.4% 58.6%  






Section 4A Association of chondroitin-2,6-sulphate staining intensity with all 















Adenocarcinoma  Pathological T staging  
 T2a to T2c 38 26 12 0.228 
  100.0% 68.4% 31.6%  
 T3a to T3c 34 18 16  
  100.0% 52.9% 47.1%  
 Total 72    
      
 Extraprostatic extension   
 Yes 34 18 16 0.228 
  100.0% 52.9% 47.1%  
 No 38 26 12  
  100.0% 68.4% 31.6%  
 Total 72    
      
 Seminal vesicle involvement   
 Involved 7 3 4 0.413 
  100.0% 42.9% 57.1%  
 Uninvolved 68 44 24  
  100.0% 64.7% 35.3%  
 Total 75    
      
 Pre-operative PSA levels   
 ≤8ng/ml 22 14 8 0.760 
  100.0% 63.6% 36.4%  
 >8ng/ml 21 12 9  
  100.0% 57.1% 42.9%  
 Total 43    
      
 Lymphovascular invasion   
 Present  18 14 4 0.757 
  100.0% 77.8% 22.2%  
 Absent 118 95 23  
  100.0% 80.5% 19.5%  
 Total     
      
      
      
      
      





 Perineural invasion     
 Seen  89 65  24  0.017 
  100.0% 73.0% 27.0%  
 Not seen 52 47  5   
  100.0% 90.4% 9.6%  
 Total 141    
      
 Circumferential resection margin  
 Involved 35 22 13 0.817 
  100.0% 62.9% 37.1%  
 Uninvolved 40 24 16  
  100.0% 60.0% 40.0%  
 Total 75    
      
 Apex margin     
 Involved 35 20 15 0.635 
  100.0% 57.1% 42.9%  
 Uninvolved 40 26 14  
  100.0% 65.0% 35.0%  
 Total 75    
      
 Proximal  margin     
 Involved 9 5 4 0.725 
  100.0% 55.6% 44.4%  
 Uninvolved 67 42 25  
  100.0% 62.7% 37.3%  
 Total 76    
      
 Clinical stage     
 T1a to T1c 37 25 12 0.226 
  100.0% 67.6% 32.4%  
 T3a to T3b 8 3 5  
  100.0% 37.5% 62.5%  
 Total 45    
      
 Lobe occurence      
 Both Lobes 64 37 27 0.079 
  100.0% 57.8% 42.2%  
 Singles Lobe 10 9 1  
  100.0% 90.0% 10.0%  
 Total 74    
      
 Maximum tumour dimension   
 <2.5cm 37 25 12 0.345 
  100.0% 67.6% 32.4%  
 ≥2.5cm 38 21 17  
  100.0% 55.3% 44.7%  
 Total 75    





 Tumour Volume     
 <4cm3 28 20 8 0.576 
  100.0% 71.4% 28.6%  
 ≥4 cm3 29 18 11  
  100.0% 62.1% 37.9%  
 Total 57    
      
Peritumoural 
Stroma 
Pathological T staging   
T2a to T2c 40 16 24 1.000 
 100.0% 40.0% 60.0%  
 T3a to T3c 34 14 20  
  100.0% 41.2% 58.8%  
 Total 74    
      
 Extraprostatic extension  
 Yes 36 16 20 0.817 
  100.0% 44.4% 55.6%  
 No 40 16 24  
  100.0% 40.0% 60.0%  
 Total 76    
      
 Seminal vesicle involvement   
 Involved 7 0  7  0.018 
  100.0% 0% 100.0%  
 Uninvolved 72 34  38   
  100.0% 47.2% 52.8%  
 Total 79    
      
 Pre-operative PSA levels   
 ≤8ng/ml 22 11 11 0.763 
  100.0% 50.0% 50.0%  
 >8ng/ml 22 9 13  
  100.0% 40.9% 59.1%  
 Total 44    
      
 Lymphovascular invasion   
 Present  18 9 9 0.298 
  100.0% 50.0% 50.0%  
 Absent 118 42 76  
  100.0% 35.6% 64.4%  
 Total 136    
      
 Perineural invasion     
 Seen  89 35 54 0.858 
  100.0% 39.3% 60.7%  
 Not seen 52 19 33  
  100.0% 36.5% 63.5%  
 Total 141    





 Circumferential resection margin   
 Involved 36 17 19 0.499 
  100.0% 47.2% 52.8%  
 Uninvolved 44 17 27  
  100.0% 38.6% 61.4%  
 Total 80    
      
 Apex margin     
 Involved 37 15 22 0.822 
  100.0% 40.5% 59.5%  
 Uninvolved 43 19 24  
  100.0% 44.2% 55.8%  
 Total 80    
      
 Proximal  margin     
 Involved 10 4 6 1.000 
  100.0% 40.0% 60.0%  
 Uninvolved 71 31 40  
  100.0% 43.7% 56.3%  
 Total 81    
      
 Clinical stage     
 T1a to T1c 38 18 20 0.710 
  100.0% 47.4% 52.6%  
 T3a to T3b 8 3 5  
  100.0% 37.5% 62.5%  
 Total 46    
      
 Lobe occurence      
 Both Lobes 67 26 41 0.344 
  100.0% 38.8% 61.2%  
 Singles Lobe 11 6 5  
  100.0% 54.5% 45.5%  
 Total 78    
      
 Maximum tumour dimension   
 <2.5cm 39 18 21 0.490 
  100.0% 46.2% 53.8%  
 ≥2.5cm 38 14 24  
  100.0% 36.8% 63.2%  
 Total 77    
      
 Tumour Volume     
 <4cm3 30 16 14 0.299 
  100.0% 53.3% 46.7%  
 ≥4 cm3 29 11 18  
  100.0% 37.9% 62.1%  
 Total 59    





Section 4B Association of percentage of cells positively stained for 

















Adenocarcinoma  Pathological T staging  
 T2a to T2c 38 28 10 0.087 
  100.0% 73.7% 26.3%  
 T3a to T3c 34 18 16  
  100.0% 52.9% 47.1%  
 Total 72    
      
 Extraprostatic extension  
 Yes 34 18 16 0.087 
  100.0% 52.9% 47.1%  
 No 38 28 10  
  100.0% 73.7% 26.3%  
 Total 72    
      
 Seminal vesicle involvement  
 Involved 7 3 4 0.227 
  100.0% 42.9% 57.1%  
 Uninvolved 68 46 22  
  100.0% 67.6% 32.4%  
 Total 75    
      
 Pre-operative PSA levels   
 ≤8ng/ml 22 13 9 1.000 
  100.0% 59.1% 40.9%  
 >8ng/ml 21 12 9  
  100.0% 57.1% 42.9%  
 Total 43    
      
 Lymphovascular invasion   
 Present  18 12 6 0.091 
  100.0% 66.7% 33.3%  
 Absent 118 100 18  
  100.0% 84.7% 15.3%  
 Total 136    
      
      
      
      





 Perineural invasion     
 Seen  89 71 18 0.367 
  100.0% 79.8% 20.2%  
 Not seen 52 45 7  
  100.0% 86.5% 13.5%  
 Total 141    
      
 Circumferential resection margin   
 Involved 35 23 12 1.000 
  100.0% 65.7% 34.3%  
 Uninvolved 40 26 14  
  100.0% 65.0% 35.0%  
 Total 75    
      
 Apex margin     
 Involved 35 24 11 0.633 
  100.0% 68.6% 31.4%  
 Uninvolved 40 25 15  
  100.0% 62.5% 37.5%  
 Total 75    
      
 Proximal  margin     
 Involved 9 7 2 0.710 
  100.0% 77.8% 22.2%  
 Uninvolved 67 43 24  
  100.0% 64.2% 35.8%  
 Total 76    
      
 Clinical stage     
 T1a to T1c 37 25 12 0.045 
  100.0% 67.6% 32.4%  
 T3a to T3b 8 2 6  
  100.0% 25.0% 75.0%  
 Total 45    
      
 Lobe occurence      
 Both Lobes 64 43 21 0.725 
  100.0% 67.2% 32.8%  
 Singles Lobe 10 6 4  
  100.0% 60.0% 40.0%  
 Total 74    
      
 Maximum tumour dimension   
 <2.5cm 37 24 13 1.000 
  100.0% 64.9% 35.1%  
 ≥2.5cm 38 25 13  
  100.0% 65.8% 34.2%  
 Total 75    





 Tumour Volume     
 <4cm3 28 20 8 1.000 
  100.0% 71.4% 28.6%  
 ≥4 cm3 29 20 9  
  100.0% 69.0% 31.0%  
 Total 57    
      
Peritumoural 
Stroma 
Pathological T staging   
T2a to T2c 38 8 30 0.090 
  100.0% 21.1% 78.9%  
 T3a to T3c 34 2 32  
  100.0% 5.9% 94.1%  
 Total 72    
      
 Extraprostatic extension  
 Yes 34 2 32 0.090 
  100.0% 5.9% 94.1%  
 No 38 8 30  
  100.0% 21.1% 78.9%  
 Total 72    
      
 Seminal vesicle involvement  
 Involved 7 0 7 0.584 
  100.0% .0% 100.0%  
 Uninvolved 68 10 58  
  100.0% 14.7% 85.3%  
 Total 75    
      
 Pre-operative PSA levels   
 ≤8ng/ml 22 4 18 0.345 
  100.0% 18.2% 81.8%  
 >8ng/ml 21 1 20  
  100.0% 4.8% 95.2%  
 Total 43    
      
 Lymphovascular invasion  
 Present  18 1 17 0.466 
  100.0% 5.6% 94.4%  
 Absent 118 17 101  
  100.0% 14.4% 85.6%  
 Total 136    
      
 Perineural invasion     
 Seen  89 10 79 0.318 
  100.0% 11.2% 88.8%  
 Not seen 52 9 43  
  100.0% 17.3% 82.7%  
 Total 141    





 Circumferential resection margin 
 Involved 35 3 32 0.203 
  100.0% 8.6% 91.4%  
 Uninvolved 40 8 32  
  100.0% 20.0% 80.0%  
 Total 75    
      
 Apex margin     
 Involved 35 6 29 0.746 
  100.0% 17.1% 82.9%  
 Uninvolved 40 5 35  
  100.0% 12.5% 87.5%  
 Total 75    
      
 Proximal  margin     
 Involved 9 1 8 1.000 
  100.0% 11.1% 88.9%  
 Uninvolved 67 10 57  
  100.0% 14.9% 85.1%  
 Total 76    
      
 Clinical stage     
 T1a to T1c 37 4 33 1.000 
  100.0% 10.8% 89.2%  
 T3a to T3b 8 1 7  
  100.0% 12.5% 87.5%  
 Total 45    
      
 Lobe occurence      
 Both Lobes 64 9 55 1.000 
  100.0% 14.1% 85.9%  
 Singles Lobe 10 1 9  
  100.0% 10.0% 90.0%  
 Total 74    
      
 Maximum tumour dimension 
 <2.5cm 37 8 29 0.113 
  100.0% 21.6% 78.4%  
 ≥2.5cm 38 3 35  
  100.0% 7.9% 92.1%  
 Total 75    
      
 Tumour Volume     
 <4cm3 28 7 21 0.025 
  100.0% 25.0% 75.0%  
 ≥4 cm3 29 1 28  
  100.0% 3.4% 96.6%  
 Total 57    
 
